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ABSTRACT 
The Endoplasmic Reticulum is the cellular organelle primarily responsible for producing 
proteins on the secretory pathway, a pathway important in the production of 
biopharmaceuticals. One of the requirements for the successful production of a functional 
protein is correct folding of the polypeptide sequence. During conditions such as viral 
infection, mutant protein expression and cell differentiation the endoplasmic reticulum is 
placed under conditions of stress. IRE1 is a protein kinase and endoribonuclease, which along 
with PERK and ATF6, forms part of the Unfolded Protein Response, the system by which the 
cell deals with the stress caused by a high protein load. IRE1 is capable of increasing the 
protein folding capacity of the ER, by upregulating chaperone proteins and reducing the load 
by attenuating translation, (protective response). This action is mediated by splicing of the 
mRNA coding for the bZIP transcription factor XBP-1.  IRE1 is also capable of causing 
apoptotic responses via TRAF2 (cell injuring response) resulting in the activation of JNK and 
NFκB. In this study, using site directed mutagenesis a panel of IRE1 mutants was produced 
and screened for alterations to the protective and cell injuring responses. Of these the D711A 
mutant was shown in mouse embryonic fibroblasts to retain endoribonuclease activity, and to 
display an attenuated cell injuring response. When this mutant was applied to an industrial 
CHO cell line it appeared to exhibit an increase in biopharmaceutical productivity over the 
wild type IRE1, indicating its potential for use in the biopharmaceutical cell lines.  
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1. INTRODUCTION 
 
In the decades since the first biopharmaceuticals were produced, demand for protein-based 
products such as antibodies and clotting factors has increased dramatically. This increase is 
compounded by the large doses which are required for many recently licensed therapeutic 
biopharmaceuticals, most notably those of humanised monoclonal antibodies. 
Biomanufacturing capacity has begun to expand to accommodate the shortfall, but demand is 
already beginning to outstrip production (Butler 2005; Schroder 2008). As opposed to 
traditional drugs and therapies which often involve inserting a foreign agent into the body 
with all the potential side effects that can result from upsetting the homeostasis of the 
organism, biopharmaceuticals often consist of an endogenous protein, and may represent a 
much less invasive method for restoring homeostasis in a disease state. Many 
biopharmaceuticals are already licensed by regulatory authorities and more are currently in 
development or clinical trials.  
 
Output remains one of the greatest challenges in biopharmaceutical research – generally 
speaking and with some exceptions which will be covered later, cells and organisms did not 
evolve to produce the levels of secreted protein required for industrial biomanufacture – 
indeed, systems exist to prevent just such a situation, often evolved to prevent co-opting of 
protein production systems by viral agents, for example the RNaseL protein which switches 
off protein production in virally infected cells (Floyd-Smith, Slattery et al. 1981) Secretory 
output of the cell is well controlled by complex interactomes of kinases, regulatory proteins 
and regulatory elements that can either help the cell cope with high loads of protein – by 
upregulating chaperone systems which guide proteins through the secretory pathway and 
control degradation of proteins, or which can simply sacrifice the cell which is overproducing 
- by inducing autophagy, caspase cascades and apoptosis. Collectively, these systems are 
referred to as the unfolded protein response (UPR).  
 
There is potential, therefore in biopharmaceutical research to attempt to circumvent the 
unfolded protein response or to control its workings and outputs. Indeed, some investigation 
has already been carried out along these lines (Borth, Mattanovich et al. 2005; Tigges and 
Fussenegger 2006; Becker, Florin et al. 2008; Ku, Ng et al. 2008). However, these 
approaches, although effective, often represent simple brute-force overexpression of 
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chaperones, rather than a more controlled and targeted system, using the UPR’s own 
mechanisms. How could this control potentially be exercised? By using one of the most 
evolutionarily ancient UPR mechanisms, conserved in eukaryotes from yeast to humans – 
IRE1. 
 
Part 1.1 of this introductory section will describe the factors involved in industrial 
biopharmaceutical protein production, covering the stresses, bottlenecks and requirements 
and some of the cell lines that have been used to produce biopharmaceuticals. It will also 
make reference to the other great challenge in industrial biopharmaceutical production – cell 
viability and the control of apoptosis. Part 1.2 will cover the main components and systems of 
the unfolded protein response in growth, disease and differentiation, with reference to how 
these workings can affect the cell cycle, development and growth in cells, and some of the 
endogenous producers of biopharmaceuticals – antibody expressing immune cells. Part 1.3 
will focus on IRE1 itself - detailing how the structure and behaviour of this serine-threonine 
kinase/endoribonuclease is linked to its dual functions of chaperone regulation and apoptosis, 
both important factors in the production of biopharmaceutical proteins. Part 1.4 will discuss 
how chemical genetic approaches using the kinase inhibitor 4-Amino-1-tert-butyl-3-(1′-
naphthylmethyl)pyrazolo[3,4-d]pyrimidine (1NM-PP1) have both elucidated the structural 
components of IRE1 and given a potential mechanism for control of its downstream effects. 
Part five will outline the aims of this project, with reference to the desired scientific and 
industrially important outcomes. 
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1.1. Industrial Protein Biomanufacture: Selection, Synthesis and Secretion 
 
Figure 1.1 – Timeline for biopharmaceutical production. 
 
 
 
Industrial synthesis of proteins is one of the most useful techniques for the manufacture of 
medical proteins for clinical treatment, such as clotting factors and insulin. In 2005 there 
were up to 30 licenced biopharmaceuticals, including recombinant proteins, chimeric or 
humanised monoclonal antibodies (e.g. Herceptin) and nucleic acid based products. Industrial 
proteins can be produced in a variety of different host cells, such as bacteria, plants, yeasts 
and mammalian cells. The earliest licensed biopharmaceutical, human recombinant insulin 
(Humulin) produced by Genentech in 1982, was originally grown in E.coli, however, this 
organism cannot produce the post-translational modifications required for true eukaryotic cell 
protein production (Butler 2005). Therefore, mammalian cells are usually the most desirable 
host, because they are more likely to ensure correct protein folding and to ensure that the 
correct post-translational modifications are performed on the human protein product. 
Furthermore, mammalian cells are more suitable for meeting regulatory requirements due to 
the large knowledge base available on them. As a result, around 60-70% (Wurm 2004) of all 
recombinant industrial proteins are produced in mammalian cell lines such as Chinese 
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hamster ovary (CHO) cells and human embryonic kidney (HEK) cells, which are known to 
produce yields of up to 5g/L of product (Butler 2005). Important requirements for a cell line 
to be used include – high efficiency of transfection, ability to adapt to serum free medium and 
ability to adapt to scaling up to bioreactor volumes (Baldi, Hacker et al. 2007). Over the past 
decades, a number of different cell lines have been employed by the biopharmaceutical 
industry in production:  The most commonly used are HEK293, CHO and NS0 – with the 
most frequent being CHO cells.  
 
CHO 
 
The CHO cell line was originally studied because its lower chromosome number allowed for 
easy examination of chromosomal and genetic changes (Tjio and Puck 1958), a fact that is 
still useful today in examining apoptotic changes in the industrial cell lines. A variant of the 
CHOK1 cell line from the Puck lab was then produced in 1980 by Urlaub and Chasin with a 
mutant in the DHFR gene, which codes for a protein that reduces folic acid to tetrahydrofolic 
acid. This mutant rendered it unable to survive without supplementation of derivatives of 
tetrahydrofolic acid such as glycine, purine nucleotides and thymidylate (Urlaub and Chasin 
1980). Even at this early stage, however, some of the mutants were found to be able to revert 
to a DHFR producing state (Urlaub and Chasin 1980). CHO cell lines used in transient gene 
expression include K1 and DHFR mutant DG44 as they are well adapted for both laboratory 
and industrial production, and well studied. They are therefore useful for drug development 
and are the cell line of choice for industrial production. Several monoclonal antibody lines 
are produced using CHO cells, as they are particularly able to produce high protein titres(de 
la Cruz Edmonds, Tellers et al. 2006). 
 
The Biopharmaceutical Process 
 
Once the most suitable cell line has been selected, a considerable amount of effort goes into 
the selection and production of this product before the biopharmaceutical product can be 
harvested. Development of a medical biopharmaceutical protein product usually requires the 
following:  
 
1) The gene of interest, along with the appropriate promoter and transcription sequences, are 
stably transferred into the cell line, along with another gene, such as dihydrofolate reductase, 
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which allows the cell line to be selected for, often with the use of a metabolite which prevents 
growth of the cells which do not have the additional genes.  
2) After selection, those cells which have the required genes are moved to larger cultures to 
scale up production of the clones.  
3) The clones are examined to ascertain which are the best producers of the protein. These 
clones are selected for cultivation, seeking the one cell line with the best production and 
growth characteristics (Wurm 2004). 
 
Each stage of this process has its own issues and areas for improvement, and the 
biopharmaceuticals industry has developed and is in the process of developing strategies for 
overcoming them. The following sections will deal with these issues and strategies in more 
detail, addressing where in each area genetic and process modifications have been used to 
help improve product yield. Finally, this section will deal with recent advances in modifying 
the unfolded protein response in industrial cell lines and the potential for further work in this 
field.  
 
1.1.1 Transfection 
 
In order to induce an industrial cell line to produce a biopharmaceutical, the gene coding for 
the product is normally transfected into the cell, usually in order that it may stably integrate 
into the host cell genome. Integration usually occurs at a random point in the host cell 
genome, and selection procedures are required to find a clone which is producing the 
biopharmaceutical at commercially viable levels (see later section on selection of high 
producers). Improvements can be made to the yield of the recombinant protein by: increasing 
the strength of the promoter associated with the gene; adding introns to the coding sequence, 
or modifying it; using a weak promoter for the selection gene as opposed to a strong promoter 
for the gene of interest to augment gene amplification (although this may reduce the 
efficiency of selection); linearisation of plasmids; altering the sequence to assure the gene is 
not affected by the position of its site of integration, such as by the insertion of boundary 
elements around the gene of interest to negate the transcriptional influences of nearby 
sequences (Wurm 2004). For most, large scale production of biopharmaceuticals where the 
cell line is to be used over a long period of time to produce a large amount of product for 
commercial and medical use, a stable cell line is the most suitable system. However, stable 
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integration into the host cell genome often takes months of production and characterisation, a 
large investment of time and resources – for some applications is it possible to use large-scale 
transient transfection. Transient transfection of biopharmaceuticals is particularly useful to 
identify proteins for clinical trials or academic research, where a wide range of lead 
compounds, such as secretory, membrane or intracellular recombinant proteins, or variants of 
the same protein, must be produced quickly in mammalian cells, in order to enter screening 
and to identify the best candidate, or where a non-commercial, but still substantial level of 
protein (10-100 mgs) is required to be produced. This approach may take days or weeks, 
rather than months and therefore is suitable for these requirements. Productivity of stable 
transfections, however, still remains at five times that of transient transfections, and cell 
densities at 3-5 times greater (Wurm 2004). Transgenic expression also requires a lot of 
DNA, >1ug of DNA per ml of culture(Baldi, Hacker et al. 2007),  making DNA a significant 
contributor to the cost of this method. Indeed, any significant increase in the efficiency of 
DNA transfer could reduce the costs involved in transient transfections. DNA preparation 
therefore requires a high yield of usable DNA without any endotoxin, LPS, RNA or other 
contaminants from bacterial preparation removed (Stadler, Lemmens et al. 2004). 
 
Transfection with recombinant protein DNA usually involves chemical methods of inserting 
DNA into the cell, as physical methods such as electroporation or microinjection do not work 
well with large scale transfection. Frequently used chemical methods include 
polyethyleneimines (PEI), cationic lipids and calcium phosphate. PEIs produce high yields of 
IgG, but have cytotoxic effects and are not biodegradable. Cationic lipids are expensive to 
produce and have therefore been little used in large scale transfection (Baldi, Hacker et al. 
2007). Calcium phosphate gives high transfection efficiencies and is inexpensive, but the 
methodology is time-sensitive, reducing the scale upon which it can be performed (Meissner, 
Pick et al. 2001).  
1.1.2 Selection and Characterisation of High Producers 
 
Once the host cell has been transfected with recombinant DNA, the selection process begins 
to find the transfected clone with the highest production of the recombinant DNA. Why is it 
necessary to select for the highest producers of biopharmaceuticals? Obviously  a higher 
yield of any product, biopharmaceutical or otherwise is economically and medically 
desirable, but in the case of one biopharmaceutical, monoclonal antibody (mAb), this is 
32 
 
particularly important – the medical efficacy of this product is dependent upon very high 
doses (Dinnis and James 2005). Direct modifications to the antibody itself can improve the 
affinity of the molecule, for example, producing chimeric antibodies, antibodies containing 
the variable region, containing the murine complementarity defining regions, from mouse to 
retain specificity and the human constant region to reduce immunogenicity, and increase the 
half life of the product in vivo (Butler 2005). However, it is still necessary to select for the 
highest producing clone – this is done with a selectable marker, usually something which 
allows the host cell to grow where it would not otherwise do so, such as an antibiotic 
resistance gene to allow growth in an antibiotic supplemented medium, or where the host cell 
is deficient in a gene for a nutrient, such as the DG4 DHFR deficient CHO mutant mentioned 
above, growth in a medium which is not supplemented with the required nutrient. The 
biopharmaceutical production gene, driven by a strong viral promoter (Butler 2005), is 
transfected into the host cell in the form of a linearised plasmid along with a gene such as 
dihydrofolate reductase (DHFR) or glutamine synthase (GS). Selection pressure is then 
applied with an inhibitor of the enzyme (methotrexate (MTX) in the case of DHFR, 
methionine sulfoximine (MSX) in the case of GS). This selects for those cells into the 
genomes of which the plasmid has stably integrated, producing higher copy numbers of the 
inserted plasmid (Gasser, Simonsen et al. 1982; Bebbington, Renner et al. 1992). The GS 
system (de la Cruz Edmonds, Tellers et al. 2006) combines both inhibitor and metabolite 
approaches – the transfected plasmid contains the glutamine synthase gene which produces 
glutamine, allowing the host cell to be grown in glutamine free medium. Selection is then 
further applied by addition of MSX, producing clones with a stronger expression both of GS 
and the biopharmaceutical product.  It also does not require mutant host cells as the DHFR 
system does, is faster, and produces less toxic ammonia as a byproduct (de la Cruz Edmonds, 
Tellers et al. 2006). This system also functions well in NS0 cells, as these do not have 
endogenous glutamine synthase. Site of integration is particularly important with stable cell 
lines, and can affect gene silencing during repeated cultures. This is thought to be due to the 
heterochromatin structure in the area in which the gene is integrated (see later sections on the 
UPR and epigenetics). Positional effects can cause differences in stability and expression. 
These differences may be offset by vector design, incorporating flanking areas/boundary 
elements which can insulate genes from positional effects. Matrix or Scaffold elements can 
also be included that force the chromatin to remain open and transcribable and resist 
silencing, regardless of location within the chromosome (Kim, Kim et al. 2004). 
 
33 
 
Once the selection marker has been applied, the cell line goes through many passages to 
mimick production culture generation numbers. To assess the stability of transfection, this is 
performed with and without selectable markers, or with variable selection marker 
concentration and seeding density as yields may reduce when high copy number is not 
selected for (de la Cruz Edmonds, Tellers et al. 2006). Regular assessments are made of the 
transfected clones, including viability counts and doubling times. Biopharmaceutical 
production can be directly assessed by methods such as ELISA, HPLC and glycosylation 
forms (see later) by LCMS. FACS analysis can be performed where a cell surface marker will 
indicate transfection(de la Cruz Edmonds, Tellers et al. 2006). 
 
1.1.3 Culture Media and Nutrients 
 
Most biopharmaceutical media have been adapted from those developed for research 
cell culture, e.g. Eagle’s Minimum Essential Medium and Dulbecco’s Modified Eagle’s 
Medium (DMEM) which were developed in 1959-1969 for mammalian cell culture (Eagle 
1959; Morton 1970). Media also exist that have been specially formulated for particular cell 
lines, such as CD-CHO (Invitrogen) (Gorfien, Dzimian et al. 1998; Fike, Dadey et al. 2001). 
Certain media types can also be used for transfection of DNA into cells (Baldi, Hacker et al. 
2007).  Medium is perhaps one of the simplest factors in biopharmaceutical production to 
control and optimise as nutrients and cofactors, and selective agents such as drugs, chemicals 
and growth factors can be added or removed. It is also possible to optimise media by using 
different media at each manufacturing phase (Wurm 2004). It can take 3-4 days to maximise 
production at 10^6 cells per ml, during which time the medium in the culture vessel may have 
accumulated toxic byproducts such as ammonia or vital nutrients may have been depleted, 
therefore medium is regularly supplemented by batch feeding of predicted concentrations of 
nutrients. pH is controlled, and carbon substrates are kept to stable levels in order to control 
production of  toxic byproducts, such as lactate, prolonging the production phase (Butler 
2005). In research cell culture, medium is usually supplemented with animal serum, for 
example foetal calf serum. Animal-derived serum is well supplied with hormones, growth 
factors and thus an excellent supplement for cell growth. Furthermore, serum albumin acts as 
a buffer against pH and shearing effects in shaken cultures. However, the constituents of 
animal derived media may vary greatly, making it difficult to maintain the consistency 
required for biopharmaceutical manufacture, potential contamination, by agents such as the 
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prion responsible for bovine spongiform encephalopathy (BSE), and possible interference 
with protein processing, it is necessary to reduce or remove all animal derived materials in 
production medium. Serum-free medium is therefore usually used in protein biomanufacture 
and effective substitutes for the growth factors in serum must be produced. Producer cell 
lines have specific requirements for these nutrients and even different CHO clones can vary, 
and therefore variations on a basic medium recipe tend to be used to optimise cell lines, and 
metabolic analysis on the resulting depletions used to build up a picture of what supplements 
are required, such as protein hydrolysates (Sung, Lim et al. 2004). Microarray analysis can 
also be used to assess what expression changes are occurring in response to deficiencies in 
medium and predict what nutrients and ligands are required at a genetic level(Butler 2005).  
The production of proteins is important at all stages of nutrient processing – proteins 
to transport nutrients into the cell, proteins to transport and adjust the lipids that build the cell 
membranes themselves, protein enzymes to convert and metabolise nutrients into useful 
forms. Therefore the unfolded protein response plays a role in feeding these proteins into 
these systems. The cells of eukaryotic organisms are protected to some extent from the 
stressful environmental changes that single-celled yeasts are exposed to, with the circulatory 
systems of large multicellular organisms ensuring suitable levels of carbon and nitrogen 
sources, and no requirements for controlling meiosis in response to nutrient levels, although 
the control of cell membrane composition and phosphoinositides is still a requirement. The 
unfolded protein response remains part of nutrient regulation in these cells, taking on other 
specialized roles, such as control of lipid membrane formation, and although it may not 
regulate responses to carbon sources, in humans, the UPR is involved in the regulation of 
glucose levels via insulin secretion.   
1.1.4 Controlling Apoptosis 
 
A high cell density and long term cell viability is necessary for high protein output, 
and therefore control of apoptosis is necessary to preserve this viability. In cell culture, 
apoptosis can be caused by nutrient depletion, toxic metabolite production, shear forces from 
mixing, or hypoxia due to insufficient gas distribution. However, it is only of any use to alter 
apoptosis when this is the limiting factor in the cell culture and product titre, and therefore 
reducing apoptosis is of most use over long cultures where medium may be depleted and cells 
are more likely to go into death phase, or for cells under many apoptotically insulting 
conditions (Arden and Betenbaugh 2004). It is particularly necessary to inhibit apoptotis if 
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adding cytotoxic increasers of cell productivity (Dinnis and James 2005). Cell death in 
culture may occur by apoptosis or necrosis. Necrosis results from physical damage to cells, 
for example as may occur due to shear forces in a stirred-tank bioreactor, and causes swelling 
and rupture – as a result, careful control of the shear forces applied during growth in a 
bioreactor can reduce this effect. Apoptosis results from a stimulus, either internal or 
external, that causes a cellular cascade resulting in programmed cell death. Apoptotic bodies 
form containing the packaged cellular material, which are absorbed by the surrounding cells 
in an organism. Unfortunately, this apoptotic material may build up in cultured cells, having a 
detrimental effect (Mastrangelo and Betenbaugh 1998). Apoptosis can be detected in a 
variety of ways. DNA fragmentation assays can be used to assess the integrity of the genome.  
Western blots for caspase 3 and other apoptosis related proteases will indicate the level of 
apoptotic cascades. Cell integrity can be assessed by labelling cell membranes with annexin 
V or staining DNA with propidium iodide or ethidium bromide to indicate where the DNA is 
located and show chromatin condensation. Flow cytometry can be used to detect changes to 
the plasma membrane, cell size and shape, and propidium iodide/annexin V staining. 
However, these assays are sensitive but not specific as they may not differentiate between 
apoptosis and necrosis (Arden and Betenbaugh 2004). There are three main pathways by 
which a cell can undergo the induction of apoptosis – mitochondrially mediated, cell surface 
receptor mediated and ER stress mediated (Arden and Betenbaugh 2004).  
The mitochondrial pathway is based on the membrane potential of the mitochondria, 
and is associated with the Bcl-2 family of proteins which control the balance of mitochondrial 
apoptosis. Bcl proteins come in three forms  –  antiapoptotic Bcl proteins, which are 
homologous to Bcl-2, apoptotic proteins which have BH1 homology domains, and apoptotic 
proteins only containing the BH3 domain. Pro apoptotic proteins such as Bak and Bax, in 
response to apoptotic stimuli, such as toxin exposure or DNA damage, move into the 
mitochondrial membrane, and their structure is altered so as to compromise the mitochondrial 
membrane potential(Harris and Thompson 2000). This causes the release of cytochrome C 
from the mitochondria, which is pro-apoptotic and promotes the conversion of procaspase 9, 
which  is formed into the apoptosome with Apaf-1, and is proteolysed into caspase 9. Bcl 
proteins counteract apoptosis by binding to proapoptotic proteins, by retaining the balance of 
the mitochondrial membrane and by preventing release of the apoptotic factors from the 
mitochondria (Adams and Cory 2002).  
The receptor mediated pathway is mediated via TNF (tumour necrosis factor)-type 
receptors. When activated, these receptors recruit a death protein, FADD (Fas-Associated 
36 
 
protein with Death Domain) to their cytoplasmic tails - FADD activates pro-caspase 8 into 
caspase 8, which activates Bak and Bax via Bid and causes mitochondrial apoptosis, and 
caspase activation. Caspase 8,9 and 12 are initiators from the cell surface, mitochondrial and 
ER pathway, which trigger effector caspases 3,6, and 7 which finalise the cell death 
programme (Chandler, Cohen et al. 1998; Ashkenazi 2002). 
The ER related pathway is triggered by blocking of glycosylation and disulphide bond 
formation and by release of calcium from the ER as well as defects in protein secretory 
transport to the golgi (Oyadomari, Koizumi et al. 2002).  
Large buildups of unfolded protein can cause oxidative stress, with all the associated 
damage caused by reactive oxygen species, such as DNA damage. Around 25% of all ROS is 
formed during disulphide bond formation and protein folding in the ER controlled by the 
Ero1-PDI (protein disulphide isomerise) oxidation chain (Tu and Weissman 2004). Apoptotic 
effects of CHOP induced by cigarette-smoke in bronchial cells can be counteracted by 
overexpression of BiP/GRP78 and by antioxidant free-radical scavengers, indicating the role 
of the unfolded protein response in dealing with oxidative stress (Tagawa, Hiramatsu et al. 
2008). 
 
Once apoptosis has been assessed and found to be a limiting factor, control can be attempted. 
Apoptosis can be controlled extracellularly, by adjusting the environment the producer cells 
are in, particularly the culture medium and intracellularly, by making genetic changes to the 
cell line itself. One of the issues with removing serum from the culture medium is that serum 
contributes anti-apoptotic factors to culture medium, making serum free-medium apoptotic 
(Zanghi, Fussenegger et al. 1999). Expensive anti-apoptotic supplements such as growth 
factors like insulin, IGF and transferrin (Sunstrom, Gay et al. 2000; Jones, Nivitchanyong et 
al. 2005), caspase inhibitors (although these only block certain apoptosis pathways, and still 
leave cells vulnerable to mitochondrial induced cell death, see later) or the anti-apoptotic 
peptide Suramin (Zanghi, Renner et al. 2000) must then be added to counteract this. 
Unfortunately Suramin can only protect cells from apoptosis during the death phase, 
indicating the need for further research on the anti-apoptotic components of serum. Control of 
nutrients can also be control of apoptosis – glutamine, which is usually supplemented into 
cell culture medium, suppresses the DNA damage inducible gene gadd153 (Abcouwer, 
Schwarz et al. 1999) . Galactose is important for post-translational modification, but will also 
reduce apoptosis if fed in to the culture medium. Some amino acids (e.g. glycine, asparagine, 
threonine) can also act as a buffer against damage from carbon dioxide, osmolarity and 
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nutrient depletion (Mendonca, Arrozio et al. 2002) (Sanfeliu and Stephanopoulos 1999; 
deZengotita, Abston et al. 2002; Lengwehasatit and Dickson 2002). Intracellular control of 
apoptosis usually involves genetic strategies either using endogenous cell mechanisms or 
hijacking viral methods for preventing apoptosis during infection. Bcl family proteins are 
anti-apoptotic, therefore, unsurprisingly, transfection with these reduces apoptosis in cell 
culture (Mastrangelo, Hardwick et al. 2000). Bcl family proteins can also be engineered so as 
to remove their ability to be cleaved by caspases during apoptosis and therefore to remove 
their antiapoptotic activity or trigger their degradation. This results in higher, longer lasting 
Bcl2 activity. Bcl-X1 can be used in a similar fashion, but this mutant is less stable than the 
Bcl2 variant (Figueroa, Sauerwald et al. 2003; Arden and Betenbaugh 2004). Caspase 
inhibitors such as XIAP (X-linked inhibitor of apoptosis protein) and CrmA (cytokine 
response modifier A) can interrupt the chain of caspase activation that leads to apoptosis. The 
anti-apoptotic effect of XIAP can be enhanced by removing its RING domain which is pro-
apoptotic. Proapototic proteins can be engineered to be dominant negative or ineffective, for 
example, caspase 9 can be engineered to bind but not cleave its downstream substrates 
(Sauerwald, Betenbaugh et al. 2002; Sauerwald, Oyler et al. 2003). Caspase mutants cannot 
inhibit the mitochondrial pathways, however. Instead,the pro-apoptotic protein Bax can be 
prevented from reaching the mitochondrial membrane by humanin, a short peptide (Guo, 
Zhai et al. 2003), or cells can be selected with a particularly high mitochondrial membrane 
which are less susceptible to apoptosis by this pathway (Follstad, Wang et al. 2002). Many 
types of virus prevent apoptosis of cells they have infected by maintaining mitochondrial 
membrane integrity and affecting Bcl family members such as VDAC and cyclophilin D. 
Viral homologues of Bcl2, e.g bhrf-2 from Epstein Barr virus can be used to supplement the 
cells own Bcl2 and shift the balance away from apoptosis(Jung, Cote et al. 2002; Boya, 
Roumier et al. 2003). 
 
1.1.5 Post-Translational Modifications 
 
In any review of biopharmaceutical production, particularly one relating to the unfolded 
protein response, it is necessary to address the optimization of post-translational 
modifications. In an organism, post-translational modifications such as glycosylation increase 
the solubility of a protein, act as a shield against other proteins, and can stabilise a protein’s 
conformation, as well as acting as a marker of protein folding status (Schröder 2010). As 
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already stated, mammalian cells are used for biopharmaceuticals because of their ability to 
confer the correct post-translational additions to a protein product (Wurm 2004)  – these 
additions can make a crucial difference to the biological activity, bioavailability and 
immunogenicity of a biopharmaceutical. Biologically active post-translational modifications 
include glycosylation, galactosylation, sialylation, sulphation, fatty acylation, 
glycophosphatidylinositol anchoring,  methyl- and acetylation. Galactosylation and 
sialylation  are often incomplete (Butler 2005). The particular glycoforms attached to each 
site are heterogenous, forming a pool of glycoforms for each product. Expression of 
glycosylation enzymes in the Golgi affects the level of each glycoform. Sialyation varies in 
structure across species, CHO forms being closer to human than mouse or ungulate, but still 
restricted in a manner which affects human EPO production/formation. These affect 
immunogenicity, with some glycoforms from different species being highly immunogenic in 
humans (Jenkins, Parekh et al. 1996; Baker, Rendall et al. 2001). Control of glycosylation 
can potentially also improve consistency and produce more pharmacologically active 
glycoforms. Proteins can be engineered for longer half lives or greater efficacy by altering the 
glycan structures or knocking out the enzymes, e.g. altering antibodies for greater affinity for 
their target (Shinkawa, Nakamura et al. 2003).  Glycosylation will also vary according to cell 
cycle stage and amount of protein throughput. It is difficult to control the exact glycoforms 
obtained in animal cell cultures, and because a consistent glycosylation profile is required for 
recombinant protein products, this represents a significant issue. Depletion of glucose and 
glutamine may reduce the amount of glycosylation and sialylation, altering the profile as 
these nutrients run out in the medium, and alterations in pH, temperature, oxygen, ammonia 
can affect the glycosylation profile by changing enzyme activity and glycan branching. It is 
possible to control the conditions which lead to the glycosylation profile of a product, as 
levels of nutrients such as glutamine and albumin, levels of dissolved CO2  and enzymes such 
as sialidase and glycosidase have been shown to affect type and number of post-translational 
modifications (Borys, Linzer et al. 1993; Andersen and Goochee 1994; Yang and Butler 
2000).  
1.1.6 Exit from the Endoplasmic Reticulum 
 
Once the conditions of the bioreactor are controlled appropriately and the correct medium 
and supplements added to the cell culture medium for growth, production and post-
translational modification, one more thing limits the production of a biopharmaceutical - exit 
39 
 
from the secretory pathway from translation at the endoplasmic reticulum, through the Golgi, 
to secretion into the medium for harvesting (Schroeder 2008).  
The size and capacity of the endoplasmic reticulum can be a limiting factor upon the 
protein production. Therefore, there is a requirement for cellular control systems to regulate 
this. In yeast, there are two forms of ER, perinuclear and cortical, which are passed on to 
daughter cells by slightly differing mechanisms. Perinuclear, as its name suggests, is 
transferred along with the nucleus, whereas cortical ER is attached at the bud site and passed 
on during budding. Inheritance of cortical ER is dependent upon  an ER associated 
chaperone-like protein, Aux1p possessing an Hsp40-type J- Domain, although this domain 
does not appear to be required for the localization of the ER (Du, Pypaert et al. 2001; Barr 
2002). The unfolded protein response is generally thought to be a controlling factor in the 
expansion and accommodation of ER capacity by membrane control (Menzel, Vogel et al. 
1997) and vesicular budding of the ER in yeast (Sato, Sato et al. 2002), although it may not 
be necessary for initial formation of the ER (Koning, Larson et al. 2002), and the fact that 
membrane expansion alone can deal with unfolded protein stress (Schuck, Prinz et al. 2009) 
indicates that increase in the capacity of the ER may be an independent means for the cell to 
deal with unfolded protein stress without activating the more detrimental areas of the UPR, 
such as the apoptotic responses of the IRE1 arm. However, in mammals silencing of the 
ATF6 arm of the UPR almost completely removes ER proliferation in response to unfolded 
protein stress, indicating the necessity at least for the transcriptional arm of the UPR 
(Maiuolo, Bulotta et al. 2011).  
Spliced XBP-1 is not only capable of regulating antibody production - expansion of 
the capacity of the ER by a ectopic expression of XBP-1 improved expression of a number of 
secreted proteins in CHO cells (Tigges and Fussenegger 2006). Overexpression of the active 
(spliced), as opposed to the inactive (unspliced) form of XBP-1 in CHO cells was able to 
increase the production of recombinant monoclonal erythropoetin transiently transfected into 
a cell line which the secretory capacity of the cell line was the limiting factor in the protein 
yields. Addition of this transcription factor to erythropoetin producing CHO cell lines caused 
an 2.5-fold increase in titres of the protein, and approximately 2-fold in NS0 cells (Ku, Ng et 
al. 2008). Similar experiments with monoclonal antibodies and interferon γ did not yield an 
increase, however. This was thought to be due to the rate limiting step of these products 
occurring before the secretory pathway, for example during translation. When CHOKI cells 
which had reached maximal erythropoeitin production capacity, overexpressed spliced XBP-
1 allowed them to produce a greater yield, indicating the secretory capacity of host cells must 
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be at its maximum before addition of spliced XBP-1 can help alleviate it. Similar results were 
observed in NS0 cells (Ku, Ng et al. 2008). CHO cells seem to downregulate their XBP-1 as 
they are selected for monoclonal antibody overexpression, as analysis of XBP-1 protein and 
XBP-1 mRNA indicated a reduction in expression. Thus, lower expression of XBP-1 may be 
an indicator of well adapted cell line to monoclonal antibody production over a long period of 
time in cell culture (Becker, Florin et al. 2009). That simple overexpression of chaperones 
may not necessarily be the best approach, as overexpression of BiP was not successful at 
increasing monoclonal antibody yields in mammalian cells (Borth, Mattanovich et al. 2005). 
Indeed, tissue plasminogen activator (TPA) yields were actually increased by a reduction in 
BiP levels (Dorner, Krane et al. 1988). Furthermore, high levels of spliced XBP-1 decreases 
CHO cell survival over time after transfection, and thus clones overexpressing XBP-1 are 
likely to be unsuitable for use in selection procedures and unstable over many passages 
(Becker, Florin et al. 2008). XBP-1 spliced stable clones had lower productivities and lower 
survival, and therefore were selected against in clonal selection procedures. XBP-1 spliced 
transfected cells had seven times lower colony counts as opposed to mock transfected cells 
and prolonged XBP-1 induction showed apoptotic effects in annexin V stain assay. This can 
be counteracted by co-expressing the anti-apoptotic protein X-Linked inhibitor of apoptosis 
(XIAP), which alleviated the effects of XBP-1 alone on colony counts in CHO cells. Indeed, 
coexpression of XIAP and XBP-1 increased colony counts further, rescuing the XBP-1 
reduction, and reducing apoptosis. XBP-1 expression increased the yields of monoclonal IgG 
40%, but XBP-1 + XIAP increased it further, by 100% (Becker, Florin et al. 2009). By this, it 
can be seen that combining overexpression of XBP-1 with an anti-apoptotic protein not only 
alleviates the effects of XBP-1, but actually increases yields. One of the proteins involved in 
the unfolded protein response is capable of both of these actions – IRE1.  
 
1.2. The Unfolded Protein Response: Adapting Protein Production 
 
The ER is involved in translocating, manufacturing, storing, folding, and post-translational 
modification of proteins (Mellman and Warren 2000).  Saturation of the protein processing 
mechanisms of the ER and build-up of unfolded, misfolded and non-functional proteins, and 
over-expression of proteins  puts the endoplasmic reticulum under stress, causing 
perturbations of ER homeostasis, difficulties in membrane assembly and integrity, loss of 
secretory proteins due to insufficient processing and release, and the induction of apoptotic 
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pathways and responses, as well as a build-up of reactive oxygen species generated during 
the formation of disulphide bonds. This saturation can be induced by a range of conditions. 
Metabolic imbalances such as a lack of glucose may cause it via signalling cascades. 
Mutations in genes which code for secretory or transmembrane proteins which fold in the 
endoplasmic reticulum may prevent proper folding from occurring, thus saturating the folding 
machinery. Certain pathogens, such as Hepatitis C, may, by hijacking the protein production 
machinery overload it and cause buildup. Saturation can also be induced experimentally, by 
blocking of the SERCA calcium pump to perturb calcium homeostasis, preventing proper 
glycosylation occurring, or by inducing reductive stress which prevents disulphide bonds 
forming properly (Kaufman 2002). ER homeostasis may be perturbed as part of the 
physiological process whereby a cell specialises into competency for secretion, for example 
in the cases of antibody-secreting plasma cells, or insulin-secreting pancreatic cells 
(Rutkowski and Kaufman 2004).   
In the previous section, 1.1.6 Exit from the Endoplasmic Reticulum, brief reference 
was made to the unfolded protein response and its role in protein secretion. This section will 
aim to elaborate upon the information given so far in greater detail, illustrating how the 
control mechanisms in the endoplasmic reticulum affect not only protein throughput, but the 
whole function of the cell, from early development through to apoptosis.  
 
1.2.1. Structure of the Unfolded Protein Response 
 
Quality control and folding pathways must function in tandem to ensure cell surface 
and secreted proteins can be kept at functional levels, as minor problems in protein folding 
may cause rejection of the nascent protein. This control is achieved by a number of signalling 
pathways and feedback loops, referred to as the unfolded protein response (UPR). The 
existence of the unfolded protein response was indicated when it was discovered that some 
pharmacological agents and mutations could change the levels of chaperones that reside in 
the ER (Kozutsumi, Segal et al. 1988).  
 
1.2.1.2 Detection of Endoplasmic Reticulum Stress 
 
The eukaryotic UPR reduces ER stress caused by a high protein load by three 
methods, the first two of which seek to rectify the imbalances caused by ER stress. The first 
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involves reducing the amount of protein load being produced and entering the ER by  
transiently inhibiting translation of proteins and their transfer into the ER to reduce the 
amount of proteins that require folding; The second is a longer term adaptation – increasing 
the cell’s ability to fold the excess of polypeptides, by activating UPR genes which make up 
protein folding machinery, such as chaperones and oxidating and reducing enzymes, thus 
increasing the protein folding capacity; (Ron and Walter 2007) and increasing the production 
of proteins which degrade misfolded polypeptide, which may be stalling the folding 
machinery (Mori 2000) and by increasing phospholipid production and expanding the ER 
volume (Cox, Chapman et al. 1997). The third mechanism is not rectifying – it involves 
inducing cell death, usually by apoptotically shutting down persistently ER stressed cells, 
which may be malfunctioning due to genetic errors, or infected by a virus which is co-opting 
the protein production machinery(Ron and Walter 2007). However, before these systems can 
be activated, the presence of a high load of protein must be detected. This detection is 
achieved by sensors facing the ER lumen wherein the load will first form, which can then 
send signals to effectors which transfer the unfolded protein signal to other parts of the cell. 
All eukaryotes have some kind of basic unfolded protein response, ranging from yeast with 
the most simple to the expanded systems of the higher eukaryotes.  
Current opinion differs as to the mechanism by which these signals are detected and 
to the transmembrane effectors which transduce the signal into a response in eukaryotes. One 
model (Bertolotti 2000; Oikawa, Kimata et al. 2009) suggests that in an unstressed state 
where protein load is non-detrimental, BiP exists constitutively bound to the effector proteins. 
When the ER receives a high load of unfolded protein, as described earlier, these unfolded 
proteins will present many exposed hydrophobic residues to the ER lumen, some of which 
will sequester BiP from the effectors by competing for BiP’s hydrophobic binding pocket 
with the sensors. This sequestering leaves areas of these proteins exposed, allowing them to 
aggregate and form oligomers, and be modified into their active forms. Artificial 
overexpression of BiP ensures there are sufficient levels to occupy all sites on the effectors 
and the unfolded protein load, and reverses this activation (Bertolotti 2000) However, a BiP 
dissociation-incompetent mutant was still capable of dimerising in yeast (Oikawa, Kimata et 
al. 2005; Ron and Walter 2007), indicating that this model may not completely account for 
the detection mechanisms. Another model (Credle, Finer-Moore et al. 2005) suggests that at 
least one of the transducers possesses an area in the ER facing domain which forms a 
structure similar to the peptide binding groove of the major histocompatibility complexes, 
(MHC) and therefore may be capable of directly binding unfolded protein peptides, and 
43 
 
sensing unfolded proteins in this manner, as mutations of residues facing into this domain 
impairs proper function of the transducer. However, this binding groove may not necessarily 
be accessible in all eukaryotes, and the residues in question may simply be necessary for 
oligomerisation (Zhou, Liu et al. 2006). It is also possible that a hybrid mechanism of the two 
systems may exist in yeast, with BiP dissociation as a primary response to low levels of ER 
stress followed by oligomerisation as a secondary and more consequential reaction in terms 
of downstream gene expression and apoptotic effects, to prolonged and severe unfolded 
protein loads (Pincus, Chevalier et al. 2010).  
 
Figure 1.2 – Pathways of the unfolded protein response (from (Schroder 2008)).  
 
 
1.2.1.3 Activation of the Unfolded Protein Response 
 
The ER contains proteins whose primary function is to sense misfolding and instigate the 
expression of genes which alter the folding ability of the cell. It is these proteins which are 
responsible for the downstream effects that interference with ER homeostasis has upon gene 
expression, metabolism, apoptosis and intracellular signalling (Rutkowski and Kaufman 
2004). The more complex the eukaryotic organism, the more complex the unfolded protein 
response it activates. Simple unicellular organisms such as the yeasts only express the most 
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highly conserved sensor, Ire1 (Nikawa and Yamashita 1992; Cox, Shamu et al. 1993; Mori, 
Ma et al. 1993; Tirasophon, Welihinda et al. 1998; Saloheimo, Valkonen et al. 2003; Guerfal, 
Ryckaert et al. 2010)and some of the salient points of its activation also appear to be 
conserved across eukaryotes, such as apparent clustering or formation of multimers for the 
second stage of activation (Korennykh, Egea et al. 2009; Li, Korennykh et al.). The simple 
multicellular organism C. elegans expresses a single isoform of each of three sensors, ire-1 
pek-1 and atf-6 (Shen, Ellis et al. 2001; Calfon, Zeng et al. 2002; Shen, Ellis et al. 2005). 
Higher eukaryotes such as mammals diverge further, expressing distinct isoforms of IRE1, 
PERK and ATF6 with apparently differing expression patterns and roles, such as IRE1α and -
β and ATF6 α and β (Bertolotti 2001). All three sensors share BiP as a negative regulator, 
which prevents oligomerisation in IRE1 (Bertolotti 2000; Okamura, Kimata et al. 2000), and 
translocation to the Golgi in ATF6 by masking the localization signals (Shen, Chen et al. 
2002). Furthermore, IRE1 and PERK have interchangeable ER luminal domains, indicating 
they share a common mechanism of activation (Bertolotti 2000; Kohno). Each sensor induces 
a set of specific downstream cascades that together reduce the protein load upon, and increase 
the folding capacity of, the ER.  
 
ATF6 
 
 ATF6 (activating transcription factor 6) in higher eukaryotes exists in two isoforms, α 
and β. ATF6 exists as an ER-localised glycosylated type II transmembrane protein 90KDa 
long (Haze, Yoshida et al. 1999). This precursor is retained in the ER lumen by interaction 
with BiP (Shen, Chen et al. 2002) until activation by contact with unfolded protein, or 
experimental overexpression, but not heat shock, (Yoshida, Haze et al. 1998)causes it to 
translocate to the Golgi complex. In the Golgi it is cleaved into a 50kDa proteolysed 
cytoplasmic active bZIP transcription factor by site 1 protease (S1P) and site 2 protease 
(S2P), proteases previously known to be involved in response to cholesterol deprivation 
(Sakai, Duncan et al. 1996). Of the two proteases, the cleavage event is dependent upon S2P 
but can proceed partially without S1P and requires the two processing motifs, RxxL and 
asparagine/proline (Ye, Rawson et al. 2000). The 50kDa domain is released by proteolysis 
which reveals a basic region which may function as a nuclear localization sequence(Haze, 
Okada et al. 2001). 50kDa ATF6  accumulates in the nucleus where it binds, with the general 
transcription factor NF-Y as a cofactor (Roy, Li et al. 1996) to the CCAAT and CCACG 
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sections of a CCAAT-N9-CCACG element and a similar motif on its complementary 
sequence, the motif TGACGTG(G/A) (Wang, Shen et al. 2000), in the promoters of ER 
targets such as BiP/GRP78, GRP94, XBP-1 and calreticulin. This upregulates these genes to 
allow transcriptional alleviation of ER stress (Yoshida, Haze et al. 1998; Li, Baumeister et al. 
2000). Via XBP-1, ATF6 and IRE1 activation are linked together to form a co-ordinated 
transcriptional response to ER stress (Lee, Tirasophon et al. 2002). ATF6β is a similar 
glycosylated type II transmembrane protein, related to the cAMP response binding element, 
and with significant homology to, but slightly longer, than the α isoform at 110 kDa (Haze, 
Okada et al. 2001). It is cleaved in the same manner as the α isoform, into a 60kDa active 
form and may act in concert with it to activate ER stress response genes (Haze, Okada et al. 
2001). However, it has a lower transcriptional activity than the α isoform and opinion differs 
as to whether this places it functionally in opposition to it, as the β isoform competes for 
binding sites may act as a repressor for ATF6 transcriptional induction of the α isoform either 
as a homodimer or heterodimerically  (Thuerauf, Morrison et al. 2004). However, Yoshida et 
al  find no alteration of ATF6α responses in ATF6β -/- mouse cells, contraindicating this 
(Yoshida, Okada et al. 2000). ATF6 turnover is approximately two hours, allowing it to 
quickly replenish itself after ER insult, although insult with tunicamycin logically results in 
an unglycosylated form (Haze, Yoshida et al. 1999). Glycosylation is particularly important 
to the function of ATF6β, which possesses five N-linked glycosylation sites upon which its 
cleavage, activation and repressor effects depend. Unglycosylated β loses repressor effect, 
whereas unglycosylated α has enhanced activity, suggesting a role for ATF6 in sensing an 
overload of the post-translational modification systems of the endoplasmic reticulum (Guan, 
Wang et al. 2009). 
 
PERK 
 
  PERK (PKR-like endoplasmic reticulum kinase) is an ER localised type I 
transmembrane ER-resident protein encoded for by the EIF2AK3 gene involved in 
translational control via phosphorylation of eIF-2α (eukarotic initiation factor 2α) (Shi, An et 
al. 1999). eIF-2α facilitates translation in a GTP-dependent manner, by transferring Met-
tRNA to the 40S ribosomal subunit, initiating translation, and hydrolyzing GTP to GDP, 
which causes the release of the eIF-2α-GDP complex from the ribosome. eIF-2α-GDP must 
then be reconverted to eIF-2α-GTP, a function which is performed by eIF-2B. 
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Phosphorylation at serine 51, contained within a sequence highly conserved across 
eukaryotes, produces a non-functional form of eIF-2α with a higher affinity for eIF-2B than 
the unphosphorylated. As peIF-2α increases, it sequesters away the pool of available eIF-2B, 
preventing the resynthesis of eIF-2α-GTP, and the formation of eIF-2 complexes which can 
initiate translation and induce the assembly of the 80s ribosome (de Haro, Mendez et al. 
1996; Kimball 1999; Shi, An et al. 1999). Various eIF-2α  kinases exist which respond to 
cellular stresses by prevent translation in response to stimuli such as PKR (protein kinase R) 
which responds to viral double-stranded RNA by preventing translation (Thomis and Samuel 
1992; Barber, Wambach et al. 1993) and HRI (heme-regulated eIF-2α kinase) which reduces 
translation in response to heme to control protein production in developing erythroid cells 
(Chen and London 1995). PERK functions to couple this translational attenuation response 
with unfolded protein stress and to allow a direct shutoff of the causative protein load. 
PERK’s different method of activation to that of the other eIF2 α kinases  is marked by a 
divergent 550-residue flanking sequence (Shi, Vattem et al. 1998). PERK dimerises (Liu, 
Schroder et al. 2000) and becomes autophosphorylated in its kinase domain (Harding, Zhang 
et al. 1999) in response to unfolded protein.  This activation is most likely triggered by 
dissociation of the GRP78/BiP chaperone from PERK’s ER luminal domain, and this 
detection mechanism is so similar to that of IRE1a that their two luminal domains can be 
interchanged whilst retaining function, indicating conservation of endoplasmic reticulum 
detection function (Liu, Schroder et al. 2000).  Once active, it phosphorylates eIF-2α at serine 
51 as described above. Downregulation of protein synthesis is a pro-survival response to 
unfolded protein stress, as it reduces the load of protein which requires processing by the ER. 
Therefore, PERK fulfils the function of an ER-resident mechanism for controlling protein 
synthesis, and its long half life (~13h) (Bertolotti 2000) allows continuous functioning. This 
is consistent with a translational response to long-lived ER stress as opposed to the 
transcriptional response to short-lived stress induced by ATF6. PERK is also capable of 
responding to hypoxic stress which can be induced by high loads of unfolded protein via 
activating transcription factor 4 (ATF4), a regulator of the unfolded protein response and 
nuclear factor 2 (Nrf2), an important factor in cellular response to hypoxia. In hypoxic 
conditions, PERK induces more efficient translation of mRNA coding for ATF4, which, like 
BiP and other genes necessary for hypoxic responses, does not suffer hypoxic 
downregulation.   (Harding, Novoa et al. 2000; He, Gong et al. 2001; Koumenis, Naczki et al. 
2002; Blais, Filipenko et al. 2004). ATF4 is then thought to form a leucine zipper dimer with 
Nrf2 to induce a host of cytoprotective proteins such as NAD(P)H quinone oxidoreductase 1 
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and glutathione S-transferases (Venugopal and Jaiswal 1996; Hayes, Chanas et al. 2000). 
Nrf2 deletion mutants exhibit decreased survival following ER stress insult, and perk
-/-
 cells 
have impaired Nrf2 nuclear import, indicating PERK’s importance in this signalling pathway 
(Cullinan, Zhang et al. 2003).  After ER stress has caused shutoff of general protein synthesis 
via eIF-2α phosphorylation, it must be restarted again to begin coping with protein loads – 
this function is thought to be performed by Growth arrest and DNA damage-inducible protein 
34 (GADD34), which appears to upregulate BiP and CHOP expression in a eIF-2α 
independent manner in response to ER stress stimuli (Kojima, Takeuchi et al. 2003). 
 
IRE1 
 
Inositol requiring 1 (IRE1), like PERK is an ER localized transmembrane protein first 
discovered in yeast to be required for growth in the absence of inositol (Cox, Shamu et al. 
1993; Mori, Ma et al. 1993) and possessing both a serine/threonine kinase domain and an 
RNase domain resembling that of RNase L (Tirasophon, Welihinda et al. 1998). It is the 
evolutionarily oldest endoplasmic reticulum stress sensor, existing in most eukaryotes from 
yeast to humans (but not some protozoans), and the only ER stress sensor in yeast . In 
eukaryotes, there are two IRE1 homologues, IRE1α (Tirasophon, Welihinda et al. 1998), 
which is ubiquitous and required for embryogenesis (ireα-/- embryos die during gestation 
(Urano, Bertolotti et al. 2000)) required for protection against unfolded protein stress, and 
IRE1β (Wang, Harding et al. 1998) which is localized to the gastrointestinal tract and 
protective against inflammatory bowel disease (Bertolotti 2000). The ER luminal domain of 
IRE1, thought to be responsible for detection of unfolded protein levels, possesses two 
specialized areas, a dimerisation domain (Zhou, Liu et al. 2006) and a peptide binding groove 
similar to that of the major histocompatibility complex (Credle, Finer-Moore et al. 2005).  As 
with PERK, the kinase domain of IRE1 becomes autophosphorylated (Shamu and Walter 
1996) after di- or oligomerisation (Korennykh, Egea et al. 2009). This activity may be 
responsible for IRE1’s ability to induce apoptosis, as the cytoplasmic domain of IRE1 was 
found to bind to the TRAF domain of TRAF2. Once this binding has occurred TRAF2 then 
induces phosphorylation of c-Jun N-terminal kinase (JNK), resulting in the activation of this 
apoptotic pathway by an indirect mechanism involving coupling of plasma membrane 
receptors to JNK (Urano 2000). In mammals, the RNase domain of IRE1 is responsible for 
non-spliceosomal removal of a 26 base conserved intron from the mRNA of the bZip 
48 
 
transcription factor XBP-1, whose active protein product XBP-1(s) then induces the 
transcription of a variety of endoplasmic reticulum stress-related targets (see “XBP-1”, later) 
(Calfon, Zeng et al. 2002). In yeast, this splicing is performed instead on the mRNA of the 
transcription factor Hac1p (Gonzalez, Sidrauski et al. 1999).  The structure and function of 
IRE1 will be covered in more detail in section 1.3 of this introduction.  
1.2.1.4 Alleviation of Endoplasmic Reticulum Stress 
 
Once the high load of unfolded proteins has been detected and has caused the activation of 
one of the sensors PERK, IRE1 or ATF6, the message is then transduced by the downstream 
activities of these sensors. This response may be translational control, general suppression of 
translation by phosphorylation of eIF-2α or increase of the translational targets of PERK such 
as ATF4, or it may be transcriptional, involving the upregulation of ER stress response genes 
by ATF6 and XBP-1 in response to IRE1 activation. These responses are protective, helping 
the cell deal with or at least reducing the unfolded protein load, but both PERK and IRE1 are 
also capable of inducing apoptotic responses via CHOP and JNK respectively – this 
inflammatory activity will be covered below in the section on the detrimental effects of the 
unfolded protein response. As opposed to yeast in which all unfolded protein responses are 
controlled by Ire1p, mammalian systems with their multiple sensors IRE1, PERK and ATF6 
appear to have more redundancy. This may indicate in mammalian cells the IRE1 arm is 
specialised for protein output, (for example, in plasma cells) indicating the importance of this 
for industrial protein synthesis. Protective alleviation of endoplasmic reticulum stress can be 
performed using several mechanisms – activation of ERSE promoter-driven genes to increase 
the folding capacity of the cell, and endoplasmic reticulum associated degradation (ERAD) 
which targets excess proteins for degradation.    
ERSE Promoters 
 
ATF6 and XBP-1 are bZip transcription factors activated by the unfolded protein response to 
upregulate endoplasmic reticulum stress-induced genes. These make up the transcriptional 
response component of the unfolded protein response by binding to  ERSE/URPE promoters, 
which are cis-acting elements located in the promoter regions upstream of UPR target genes, 
including chaperones such as BiP and ERAD components. In yeast, the unfolded protein 
response element (UPRE) is required for induction of the KAR2 gene which codes for Kar2p, 
the yeast homologue of the chaperone BiP (Mori, Sant et al. 1992; Kohno, Normington et al. 
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1993). The UPRE contains the consensus sequence (CAGCGTG), which is required for its 
function(Mori, Kawahara et al. 1996). In mammalian DNA multiple response elements 
(Wooden, Li et al. 1991) control the unfolded protein response; endoplasmic reticulum 
response element (ERSE) I and II, and the unfolded protein response element UPRE 
(Yamamoto, Sato et al. 2007). ERSE I and II function as binding sites for the bZIP domain of 
spliced XBP-1,  causing transcription of genes involved in the response to ER stress, such as 
GRP78, GRP94, and ERP72. The ERSE element contains a consensus sequence CCAATN9-
CCACG, which is present in the promoters of and sufficient for the induction of GRP78/BiP, 
GRP94 and calreticulin, with the CCAAT component binding the general transcription factor 
NF-Y and the CCACG ATF6/XBP-1 and conferring specificity for the UPR (Roy and Lee 
1995; Roy, Li et al. 1996; Yoshida, Haze et al. 1998). The UPRE element has a longer 
consensus sequence - TGACGTGG/A, and binds XBP-1 more strongly than ATF6. (Wang, 
Shen et al. 2000; Yoshida, Matsui et al. 2001; Yoshida, Matsui et al. 2003). The ERSE II 
element has the consensus sequence ATTGG-N-CCACG and was found in the Herp gene, 
(Kokame, Kato et al. 2001)  and can bind both ATF6 in an NF-Y dependent manner and 
XBP-1 [Yamamoto2004].  
 
XBP-1  
 
XBP-1 (X-box binding protein 1) is a basic leucine zipper transcription factor first 
characterised in B cells (Liou, Boothby et al. 1990), which is a functional homologue of the 
yeast transcription factor Hac1p. In yeast, Hac1p mRNA is cleaved at two particular splice 
junctions by Ire1p and splices both sites independently, thus excising an intron. tRNA ligase 
then joins the 5' and 3' exon ends to form the spliced mRNA (Gonzalez, Sidrauski et al. 
1999). The unspliced form of Hac1p mRNA cannot be translated due to internal base pairing 
(Ruegsegger, Leber et al. 2001), whereas the spliced form of Hac1p mRNA is translated 
more efficiently and may produce a more stable protein which is resistant to ubiquitin-
dependent degradation (Cox and Walter 1996). Hac1p activation is required for activation of 
UPR target genes in yeast (Casagrande, Stern et al. 2000)  
In mammalian cells, IRE1 performs a similar cleavage and intron removal upon the 
XBP-1 mRNA, upon which activation of the UPR is dependent. A 26 nucleotide sequence  is 
excised from the XBP-1 mRNA (Calfon, Zeng et al. 2002). The predicted structure of the 
areas at the boundaries of the excised section forms two stem loops of seven base pairs, much 
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like the stem loop in the sequence which is cleaved in HAC1(Calfon, Zeng et al. 2002).  The 
sequences left when the 26bp are excised are predicted to form interactions with each other, 
thus closing the gap left by the excision. Removal of the intron causes a shift in the reading 
frame into the 3’ UTR thus giving a protein 54KDa long instead of 33KDa (Calfon, Zeng et 
al. 2002). Both the spliced and unspliced variants of the mRNA are capable of producing a 
protein, the two proteins having differing C-termini, and the new terminus conferred upon the 
spliced variant allowing it to function as a transcription factor (Lee, Tirasophon et al. 2002).  
The basic leucine zipper domain and the transactivation domain of the spliced form are close 
enough to each other to allow functioning, without reducing the stability of the protein (Lee, 
Iwakoshi et al. 2003). Spliced XBP-1 is capable of activating a series of genes under the 
control of the endoplasmic reticulum response element with a far greater effect than the 
unspliced form (Iwakoshi, Lee et al. 2003; Yoshida, Matsui et al. 2003). Unlike in yeast, 
where the unspliced form of Hac1p mRNA is unable to produce a protein due to its secondary 
structure, (Ruegsegger, Leber et al. 2001) the unspliced form of XBP-1 mRNA can be 
translated, but its protein product is expressed only at low levels in a cell undergoing ER 
stress(Lee, Iwakoshi et al. 2003). The unspliced isoform negatively regulates the spliced form 
by binding to it and sequestering it away from the nucleus and targeting it for degradation. 
(Yoshida, Oku et al. 2006). Induction by ATF6 (a similar basic leucine zipper protein with a 
transmembrane domain which is also required for the UPR) is also required to produce 
sufficient levels of the XBP-1 mRNA to activate the unfolded protein response (Wang, Shen 
et al. 2000). These functions are conserved across eukaryotes – in C. elegans, where the 
excised intron from xbp-1 mRNA is 23 bases long, silencing of the xbp-1 gene abolishes the 
UPR [Shen2001] and the use of an interfering RNAi against the xbp-1 gene, as with the ire1 
gene blocks expression and tunicamycin-induced upregulation of the C. elegans homologues 
of BiP, hsp-3 and hsp-4 (Calfon, Zeng et al. 2002). 
ERAD 
 
Another method in addition to the upregulation of chaperone foldases, which the cell can use 
to deal with ER stress due to a high protein load is ER-associated degradation (ERAD). This 
pathway utilises many of the same chaperone and ubiquitin conjugating, proteins, but instead 
of increasing the folding capacity of the endoplasmic reticulum, it aims to reduce the burden 
of unfolded or misfolded proteins by recognising these proteins and causing them to be 
targeted for degradation(Vashist and Ng 2004). Lectins such as Yos9p and lectin-like 
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chaperones such as calnexin and calreticulin play a role in this recognition, as does BiP. 
Proteins such as Der1p and Sec61p may remove misfolded proteins from the ER by forming 
pores, and target them for destruction by polyubiquitylation of their lysine residues (Kincaid 
and Cooper 2007). A third model suggests that a transcription factor, CREB-H  can gauge the 
functioning of the unfolded protein degradation machinery by acting as a suicide probe, being 
cleaved during ER stress into a form which can affect transcription (Bailey, Barreca et al. 
2007). EDEM, an ER mannosidase causes proteasomal degradation of misfolded 
proteins(Yoshida, Matsui et al. 2003). 
 
1.3. IRE1: Structure and Function 
 
Having illustrated the roles and significance of the arms of the unfolded protein response, and 
their relation to industrial protein biosynthesis, particularly in the areas of secretion, protein 
throughput and apoptosis, this introduction will now focus on one particular area of the 
unfolded protein response, the most evolutionarily ancient one – the IRE1 axis, in particular 
how its structure, component parts, macromolecular behaviour, and function relate to its 
downstream effects.  
 
Mammalian IRE1 is a type 1 transmembrane serine/threonine protein kinase (Tirasophon, 
Welihinda et al. 1998). The yeast orthologue, Ire1p was sequenced by Nikawa and Yamashita 
in 1992 (Nikawa and Yamashita 1992), who discovered the gene for a membrane spanning 
protein with similarity to protein kinases (Hanks, Quinn et al. 1988) while studying myo-
inositol yeast auxotrophs, and found that is was required for inositol prototrophy. Cox and 
Shamu (Cox, Shamu et al. 1993) elucidated its function and link to the unfolded protein 
response whilst screening for the effector that triggered the activation of the unfolded protein 
response element to upregulate BiP and PDI. They found that rapid cell death occurred on 
treatment with β-mercaptoethanol or tunicamycin, both ER-stress inducers in ire1Δ mutants. 
Ire1p is a necessary component of the unfolded protein response in this organism, sensing the 
levels of unfolded protein induced stress in the lumen of the endoplasmic reticulum and 
transmitting this information to the nucleus in a kinase activity-dependent manner, by way of 
the cleavage of an intron from the mRNA encoding the protein Hac1p (Mori, Sant et al. 1992; 
Cox and Walter 1996) in a unusual non-spliceosomal fashion similar to pre t-RNA splicing 
(Gonzalez, Sidrauski et al. 1999). This increases the levels of Hac1p, a transcription factor 
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which binds to a regulatory sequence in the promoters of genes coding for ER resident 
proteins known as the UPRE (unfolded protein response element).  Human IRE1 was cloned 
using degenerate oligonucleotide primers based upon the highly conserved kinase VII 
subdomain from S. cerevisiae to screen for a human homolog of the Ire1p gene (Tirasophon, 
Welihinda et al. 1998). This homolog was found by Northern blot to be ubiquitously 
expressed in many human tissues and  by generation of mutants in the putative kinase domain 
and mRNA studies using S. cerevisiae derived Hac1p mRNA, to have both kinase and 
endonuclease activity, in common with its S. cerevisiae homolog. Loss of kinase activity was 
found to result in a blocking or reduction in the unfolded protein response, however a loss of 
endoribonuclease activity induced by point mutation in the RNAase domain was not found to 
induce a concurrent loss of kinase activity (Tirasophon, Welihinda et al. 1998). 
1.3.1 Isoforms 
 
Two genes coding for two human IRE1 proteins exist, IRE1α which is expressed 
ubiquitously, and IRE1β, which is localised to the highly secreting epithelial cells of the 
gastro-intestinal tract.  ire1β-/- mice were found to be more susceptible to inflammatory bowel 
disease induced by dextran sodium sulphate (Bertolotti 2001) indicating a role for IRE1β in 
inflammatory signalling. IRE1β’s cleavage effects on RNAs appear to overlap, but not match 
with IRE1α’s. Both isoforms are capable of splicing XBP-1 mRNA, and both are capable of 
upregulating BiP (Tirasophon 2000; Bertolotti 2001) but IRE1α’s other targets include 
particular endoplasmic reticulum-located mRNAs such as biogenesis of lysosome-related 
organelles complex-1, subunit 1 (Blos1), and scavenger receptor class A, member 3 (Scara3) 
(Hollien and Weissman 2006; Hollien, Lin et al. 2009) indicating that IRE1α’s activities 
appear to remain firmly associated directly with the endoplasmic reticulum stress responses. 
IRE1β however, is a little more promiscuous in function – among its effects are translational 
repression of by cleaving the 28s ribosomal RNA (Iwawaki, Hosoda et al. 2001) and although 
IRE1β shares an ability to downregulate expression levels of some ER-localised mRNAs, this 
function does not appear to be dependent upon 28s ribosome cleavage (Nakamura, Tsuru et 
al. 2010).  Logically given IRE1β’s localisation in gastrointestinal tract cells, and given the 
effect of lipotoxicity and overnutrition on IRE1 signalling, it also appears to play some role in 
regulating fat transport by decreasing levels of microsomal triglyceride transfer protein 
mRNA, which contributes to the assembly of dietary-fat transporting chylomicrons. These 
divergent functions may account for some of the two IRE1 isoforms apparently opposing 
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effects – in Xenopus laevis embyros loss of IRE1β was detrimental to mesoderm formation, 
whereas loss of the IRE1α-XBP-1 pathway appears to promote it (Yuan, Cao et al. 2008).  
1.3.2 Domain Structures 
 
IRE1 is an unusual protein in that it has both functional kinase and endoribonuclease 
activities within the same cytosolic effector domain, and it is this compartmentalised 
structure that contributes to its divergent effects and  therefore its usefulness as the target of 
investigation into the possibility of using the endoplasmic reticulum stress responses to 
improve biopharmaceutical production levels. The structure of IRE1 comprises the following: 
an ER luminal domain on the N-terminus, responsible for sensing ER stress (Credle, Finer-
Moore et al. 2005; Zhou, Liu et al. 2006); a transmembrane domain, and a protein 
kinase/endoribonuclease domain thought to be located in the cytosol (Lee 2008). This section 
will discuss the particular structures of each part of the IRE1 protein and how they contribute 
to the functions of the protein as a whole.  
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Figure 1.3 – One potential ribbon structure of the N-luminal/N-terminal and cytosolic/C-
terminal domains of human IRE1, from Zhou et al (Zhou, Liu et al. 2006) and Lee et al (Lee 
2008) respectively showing two monomers interfaced together. The C-terminal ends of the 
two monomers of the N-luminal domains (top) would connect to the transmembrane sections 
of the monomers (red lines). From this point they would connect with the top of the cytosolic 
domains (bottom). ADP is shown bound to the kinase domain.  
 
 
 
 
 
 
  
Figure 1.4 – Oligomerised IRE1 multimer structure from (Korennykh, Egea 
et al. 2009). In this structure, rather than spanning the membrane, multiple 
IRE1 units assemble with their RNAse domains facing outwards.  
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1.3.2.1 Luminal Domain 
 
The luminal domain of IRE1 functions as its sensor of the presence of unfolded proteins – the 
precise mechanisms by which the luminal domain transmits a signal to the effector 
cytoplasmic domains is uncertain – this will be covered in more detail in the following 
section 1.3.3 “Clustering and Activation Mechanisms”.  The luminal domains of IRE1α and β 
bear structural resemblance to the Activin/TGF-β serine-threonine kinases (Hanks and Hunter 
1995) and functional resemblance to receptor tyrosine kinases, although unlike tyrosine 
kinases they have no known endogenous small molecule ligand. There appears to be 
considerable function conservation cross-species in the luminal domains of the of the IRE1 – 
domains from C. elegans ire1, human IRE1α and murine IRE1β can each be combined in 
chimera with the yeast cytoplasmic domain to produce functional unfolded protein response 
signalling transducers (Liu, Li et al. 2005). The structures of the luminal domain give 
indications as to how it detects unfolded proteins, but no clear answer as to how, or to what 
extent these structure contribute to function. Di/oligomerisation of the luminal domains  
appears to occur in response to dissociation of BiP (Bertolotti 2000) and at a dimerisation 
interface whose structure, hydrogen bonding and hydrophobic interactions are shared by 
PERK.  A conserved area in the luminal domain of IRE1 is required for this 
di/oligomerisation, particularly lysine and aspartate residues (K121 and D123 in IRE1-alpha) 
which if mutated, will disrupt hydrogen bonding within the beta sheets which form the 
interface (Zhou, Liu et al. 2006). At the dimerisation interface, a central groove is formed 
roughly resembling that of the antigen binding domains of the major histocompatibility 
complexes. The groove is formed of α-helices mounted on a triangular β-sheet floor (Credle, 
Finer-Moore et al. 2005; Zhou, Liu et al. 2006) and contains conserved amino acid side-
chains required to contribute to induction of the UPR – binding of unfolded protein to this 
groove was proposed to cause an alteration in the orientation of the IRE1 dimer which 
activates its cytoplasmic functions (Credle, Finer-Moore et al. 2005; Zhou, Liu et al. 2006). 
However, the association of unfolded protein is unlikely to be the sole activator in human 
IRE1, for several reasons: 
1) Purified luminal domain forms dimers in vitro in the absence of unfolded protein.   
2) The MHC-like groove is narrower in the human IRE1 isoform than in the yeast, 
reducing the likelihood of peptide binding. α-helices in the groove contain glutamine 
resides which span the groove stabilising the dimerisation interface to the detriment of 
peptide access to it.   
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3) The orientation of the dimer in the ER membrane is unsuitable for the formation of 
peptide-IRE1 oligomers (Zhou, Liu et al. 2006). 
Given the complex kinetics of interaction between BiP and IRE1 (Pincus, Chevalier et al. 
2010) it is more likely that a complex interaction of unfolded protein, BiP association and 
disassociation with both unfolded protein and IRE1, and auto-dimerisation/ oligomerisation 
of IRE1 contribute to the picture of mammalian unfolded protein detection under different 
conditions, and that yeast mechanisms may differ from those of higher eukaryotes.  
 
1.3.2.2 Kinase Domain 
 
 
The kinase domain of IRE1 is thought to be both a direct functional effector, activating its 
downstream apoptotic functions, (Urano 2000) and a facilitator for the conformational 
changes that induce activity of the RNAse domain (Sidrauski and Walter 1997).  IRE1’s 
activation loop and structural features conform to those of a transmembrane serine/threonine 
kinase, but it has no known close relatives among the kinases  (Hanks, Quinn et al. 1988; 
Hanks and Hunter 1995). Ire1 is an atypical kinase in more than structure. Currently the only 
known target of IRE1’s phosphorylation is itself. Activation of the kinase domain is 
dependent upon autophosphorylation of associated  IRE1 multimers (Shamu and Walter 
1996; Papa, C. et al. 2003). Single IRE1 kinase domains consist of a bilobal fold typical of 
the protein kinases comprised of an N-terminal lobe and a larger C-terminal lobe with the 
activation loop flexibly sited in the groove between the two (See Figure 1.5). The N-terminal 
lobe of IRE1 comprises a twisted 5-strand anti-parallel beta sheet (orange, top of panel B) 
flanked by a single alpha helix (pink, top right of panel B). The C-lobe consists of two paired 
beta strands and eleven alpha helices (Lee, Scapa et al. 2008).  
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Figure 1.5 – A) Simplified protein kinase structure (after (Huse and Kuriyan 2002)) B) 
Structure of IRE1 kinase domain from PDB entry for (Lee, Scapa et al. 2008), IRE1 with 
ADP situated in nucleotide pocket.  N-terminal lobe (upper section), C-terminal lobe (lower 
section), Activation loop (circled). 
 
A 
 
 
B 
 
 
 
Dimerisation of IRE1 is thought to be induced by bound adenine nucleotides causing a 
conformational change which activates the RNase domain (Sidrauski and Walter 1997; Lee 
2008). The precise nature of the conformational changes is as yet unknown. Crystal structures 
have been produced indicating at least two conformations, an early “face to face” 
dephosphorylated conformation of kinase domains that would permit trans-
autophosphorylation (Ali, Bagratuni et al. 2011) and a “back to back” conformation in which 
dimerisation interfaces are aligned forming an active dimeric RNase domain capable of 
binding XBP-1 mRNA (Lee, Scapa et al. 2008). The fine structure of the IRE1 kinase pocket 
itself will be covered in more detail in the section below “The IRE1 Kinase Pocket” 
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1.3.2.3 RNase Domain 
 
The RNase domain of IRE1 confers upon the protein its main marker of function – XBP-1 
splicing (Calfon, Zeng et al. 2002).  It is a 132 residue globular domain located C-terminally 
from the kinase domain (Lee, Scapa et al. 2008) and thought to be located in the cytosol in 
order to access the XBP-1 mRNAs which preferentially locate  there (Uemura, Oku et al. 
2009). The RNase domain consists of eight alpha helices, and is highly ordered in crystal 
structure apart from a short sequence (residue 1036-1041 in (Lee, Scapa et al. 2008)) between 
helices 3 and 4. The domain is held in a set orientation against the C-lobe of the kinase 
domain by a set of hydrophobic residues, and a dimerisation interface permits the formation 
of dimers forming a surface suitable for mRNA binding.  
 
Figure 1.6 - RNase domain of IRE1 showing C-terminal nuclease/mRNA binding surface 
(Lee, Scapa et al. 2008). 
 
 
 
The RNase domain of IRE1 (Figure 1.6) shares close homology with RNaseL, a component 
of  the interferon response to viral infection which degrades single-stranded RNA in response 
to viral infection at UU and UA nucleotides and inhibits viral protein synthesis (Tirasophon 
2000). Like IRE1’s change in response to unfolded protein/kinase activation, RNase L 
undergoes a conformational change in response to activation by the antiviral 2',5'-
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oligoadenylate (2-5A) system, which permits interaction with eukaryotic polypeptide chain 
release factor 3 (eRF3)  and localises RNaseL to the mRNA target (Floyd-Smith, Slattery et 
al. 1981; Bisbal and Silverman 2007). Both proteins also require dimerisation to be activated 
(Dong and Silverman 1995; Shamu and Walter 1996), but RNaseL has no protein kinase 
activity (Floyd-Smith, Slattery et al. 1981), however, like IRE1, its RNase function is 
dependent upon the structural support of the kinase domain between its N-terminal ligand 
sensor and effector domain (Dong, Xu et al. 1994; Lee 2008).  An analysis of the protein 
sequence of human IRE1α using the NCBI conserved domains database also reveals 
similarity of its RNase domain to the PUB/PUG domain 
(http://www.ncbi.nlm.nih.gov/Structure/cdd/cdd.shtml).  The PUB/PUG domain is a 
sequence motif in the N-terminal region of the yeast protein Png1p, a cytoplasmic peptide:N-
glycanase which may be involved in proteasomal degradation of misfolded glycoproteins 
exported to the cytoplasm. The proteasomal domain is predicted to have four alpha helices 
and be highly conserved, and contain a UBA or UBX domain, present in many enzymes 
within the ubiquitin degradation pathway (Doerks, Copley et al. 2002; Suzuki and Lennarz 
2003).  This homology may indicate common ancestral proteins involved in several arms of 
the unfolded protein response.   Although IRE1 has no endogenous small molecule ligand 
activator, pharmacological agents have been found which modify its activity. The flavonol 
quercetin can bind in the dimer interface of the RNase domain to act as an agonist and a 
cofactor for ADP binding on activation (Wiseman, Zhang et al. 2010). Antagonists of IRE1 
activation include a range of salicylaldehyde analogs such as 3-ethoxy-5,6-
dibromosalicylaldehyde which inhibited cleavage of XBP-1 stem-loop RNase. The 
salicylaldehyde analogues were selective for IRE1 with no effect on RNaseL, indicating the 
diversity of activation between the two related proteins (Volkmann, Lucas et al. 2011).  
 
1.3.3 Clustering and Activation Mechanisms 
 
The precise nature of activation of IRE1 and the nature of the relationship between domain 
structures, conformation al changes, and interactions with other effectors is still uncertain – 
this section will deal with current knowledge regarding the mechanisms of IRE1 activation in 
response to unfolded protein.  
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Interaction with BiP 
 
The interaction between IRE1 and BiP is known to be a major contributory factor to the 
induction of response to unfolded protein stress (Bertolotti 2000), as upregulation of BiP is 
one of the earliest responses to ER stress. GRP78, also known as BiP (heavy chain binding 
protein), an Hsp70-like chaperone, was identified early on as being upregulated in response 
to the presence of unfolded protein (Kohno, Normington et al. 1993).  In its ADP bound state 
it has a high affinity for unfolded protein and a low affinity when bound to ATP. ATP 
hydrolysis therefore results in a switch to the high affinity state. BiP then binds to unfolded or 
misfolded proteins, stabilising and helping them achieve the correct conformation (Wei and 
Hendershot 1995). The BiP binding/dissociation does not appear to be an absolute 
requirement for IRE1 activation in yeast – the BiP binding site is not located in the regions of 
the luminal domain of yeast IRE1 upon which activation is dependent. Deletion of the BiP 
binding site hypersensitised yeast IRE1 to ethanol and temperature stress whilst leaving its 
ER stress responses inactive (Kimata, Oikawa et al. 2004). Mammalian IRE1, however, 
becomes “leaky”, displaying increased basal activation and overexpression, with its BiP 
binding site deleted (Oikawa, Kimata et al. 2009).  It is likely therefore that the activation of 
mammalian IRE1 requires a complex dynamic interaction between BiP, and the different 
states of the IRE1 monomer/multimer complexes, with BiP binding to IRE1 providing a 
buffer insulating IRE1 from activating immediately in the presence of unfolded protein, and 
deactivating it rapidly when unfolded protein levels fall again, thus modulating the activity of  
IRE1 to when unfolded protein levels are high enough to require it (Pincus, Chevalier et al. 
2010).  
Interaction with Unfolded Protein 
 
Based upon the dynamics of interaction and response of IRE1 to the removal of BiP binding 
sites activation of mammalian IRE1 could therefore be considered mainly BiP-dependent and 
activation of yeast unfolded protein/ligand dependent (Liu, Schroder et al. 2000). The 
differences between the protein accessible (yeast) and glutamine-blocked (mammalian) 
(Zhou, Liu et al. 2006).  MHC-like peptide binding groove would also indicate a greater role 
for direct activation by unfolded protein. Binding studies using the ER luminal domain of 
yeast IRE1 appear to confirm this, indicating preferential binding of the luminal area to 
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peptides with basic and hydrophobic residues, activation upon peptide binding, and loss of 
activation when amino acids within the peptide binding groove were mutated (Gardner and 
Walter 2011). 
Clustering 
 
Trans-autophosphorylation of IRE1 is required for activation (Shamu and Walter 1996), 
indicating that some degree of interaction  between IRE1 monomers is a requirement for 
triggering the unfolded protein response via IRE1. Elucidation of the crystal structure and 
mutational analyses revealed the following characteristics of the N-terminus: IRE1 must at 
least dimerise, if not oligomerise, (Kimata, Ishiwata-Kimata et al. 2007; Korennykh, Egea et 
al. 2009) Dimerisation then may site the opposing kinase sites of each IRE1 monomer in a 
position suitable for trans-autophosphorylation, causing a conformational change whose 
mechanism is not yet fully understood in the enzyme which shifts the position of the C-
terminal lobe and places the nucleotide binding loop in a position to allow mRNA binding. 
However, the extent and complexity of the interactions required appears to go beyond simple 
dimerisation. In a radiolabelled XBP1-like substrate assay on mammalian IRE1, cleavage of 
the substrate mRNA displayed a Hill co-efficient of 3.4, indicating the formation of tetramers 
or larger species to initiate XBP-1 splicing, and ultracentrifugation of activated IRE1 
indicates multimers of a size consistent with formation of oct- and decamers (Li, Korennykh 
et al. 2010).  Under conditions of ER stress in association with unfolded protein, yeast IRE1 
can be visualised by immunofluorence microscopy forming visible puncta, which associate 
and disassociate quickly in wild-type IRE1, a phenomenon that would not be detectable with 
simple dimerisation. These puncta occur even in kinase-dead (K702A) mutants, indicating 
clustering occurs pre- or during autophosphorylation, and post-BiP dissociation, placing the 
clustering shortly after initial ER stress detection (Kimata, Ishiwata-Kimata et al. 2007).  
Preventing of this clustering by altering the IRE1 dimerisation interface, for example by 
mutation of a lysine (K121) toa larger tyrosine residue in the luminal interface attenuates 
splicing and also prevents foci clustering after two hours of ER stress induction with 
tunicamycin (Li, Korennykh et al. 2010) and  reduces UPR signalling at the centres formed 
by the clustering, preventing recruitment of Hac1 to Ire1(Aragon, van Anken et al. 2009). 
The crystal structure of clustered yeast IRE1 indicates the formation of a helical rod 
comprised of 14 molecules of IRE1 per helical turn. This structure exhibits outward-facing 
RNase domains competent for Hac1 binding (Korennykh, Egea et al. 2009). An alternative 
62 
 
crystal structure of human IRE1 (Figure 1.4) bound to ADP exhibits a potential earlier 
intermediate form of the multimer – a “face-to-face” orientation where the activation loop of 
kinase domains are in proximity to each other potentially permitting autophosphorylation – 
when the nucleotide binds, the interaction between the monomers of IRE1 is strengthened,  
allowing the activation loops to be accessed for phosphorylation. Conformational changes 
forming a β-sheet within the helices of the kinase domain then allow shift to the the “back-to-
back” conformation which permits RNase domains to be sited in a manner competent for 
splicing (Ali, Bagratuni et al. 2011).  
Activation/Deactivation 
 
If activation mechanisms differ between yeast and mammalian systems, then it appears that 
the mechanisms of activation downstream of this are similar across the eukaryotes : ER stress 
causes oligomerisation of IRE1, mediated by the peptide-binding structures of the luminal 
domain in yeast, in the plane of the ER membrane which sites IRE1 in a manner that permits 
trans-autophosphorylation and the onset of RNase activity. In conditions of prolonged stress 
in HEK293 cells, however, IRE1 appears to become incapacitated, possibly to bias against 
the activation of apoptotic cascades(Lin, Li et al. 2007; Li, Korennykh et al. 2010), even if 
the stress has not been relieved. This incapacitation is characterized by dissociation of 
clustering over the 6-8 hours after stress induction, dephosphorylation beginning at four 
hours and declining at six and reductions in XBP-1 splicing correlating with the de-
clustering(Li, Korennykh et al. 2010). This deactivation could be considered a natural 
consequence of the formation of multimers - once free IRE1 molecules have been trapped 
within the higher-order structures, they lose the steric freedom to activate and de-activate – as 
the structures increase in size, so the number of IRE1 monomers that are removed from the 
free pool increases(Pincus, Chevalier et al. 2010).  The deactivation mechanism may be 
mediated  by a fully functioning kinase domain. In yeast, a kinase defective IRE1 mutant 
showed an  inability to properly deactivate in a reporter assay, accumulating the reporter 
product long after the wild type had deactivated , causing  continuous ER stress and 
impairing cell survival(Rubio, Pincus et al. 2011). Phosphorylation and de-phosphorylation 
then are likely to be required for both assembly and disassembly of the IRE1 multimer and 
therefore homeostatic adaptation to ER stress.  
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1.3.4 Downstream Effects 
 
Figure 1.7 – IRE1 interactions and resultant downstream effects.  Outcomes to the left of the 
diagram are survival oriented, to the right favour apoptosis.  
 
 
 
Under normal levels of ER stress, IRE1 protects the cell and ensures survival by halting 
transcription, upregulating the expression of proteins which will help it deal with the 
increased protein load and the ER stress that follows, activating the genes that increase its 
capacity to fold proteins, or to remove misfolded proteins and thus preventing the build-up of 
toxic reactive oxygen species produced during disulphide bond formation and reducing 
unfolded proteins with exposed residues and other harmful side effects of high unprocessed 
protein levels (Figure 1.7, left-hand side). Since ER stress occurs within the compartment of 
the ER membrane and upregulating of the necessary genes must occur in the nucleus, IRE1 is 
required to transduce the signal of ER stress from one to the other.  Human IRE1 performs 
this function via downstream signalling and the upregulation of XBP-1, which then triggers 
activation of the endoplasmic reticulum stress response element (ERSE) promoter, which 
alters the expression of folding machinery such as foldases and chaperone proteins. However, 
under extended ER stress, IRE1’s signalling activity switches to more detrimental 
downstream effects – effecting a general translational downregulation by degrading ER-
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located  mRNAs, and triggering apoptosis via the JNK pathways (Figure 1.7, right-hand 
side).  
IRE1 Dependent mRNA Decay 
 
Part of the unfolded protein response involves the control of translational throughput in order 
to alleviate the protein load upon the ER. Although in higher eukaryotes the PERK pathway 
can regulate translation via control of phospho-eIF2α, this results in a generalised 
downregulation of translation, rather than a targeted ER downregulation. There is a potential 
role then for an ER targeted translational downregulation. Both IRE1 alpha and beta isoforms 
have been seen to exhibit effects on targets other than the classic XBP-1 splicing pathway – 
IRE1α controls its own mRNA levels in response to overexpression(Tirasophon 2000), can 
reduce levels of protectin/complement defense 59 (Oikawa, Tokuda et al. 2007) and regulate 
levels of insulin mRNA (Lipson, Ghosh et al. 2008). IRE1β also controls levels of the 
microsomal triglyceride transfer protein (Iqbal, Dai et al. 2008). Furthermore, in insect cells 
IRE1 was found to degrade particular ER localised mRNAs associated with particularly 
complex folding products (Hollien and Weissman 2006), results which were then confirmed 
in mammalian fibroblasts.  This IRE1 dependent mRNA decay may clear ribosomes ready to 
produce UPR proteins to alleviate stress, and appears to be more pronounced in the insect 
over mammalian cell (Hollien, Lin et al. 2009).  It is dependent upon the presence of the 
RNase domain, and kinase activity independent suggesting a similar mechanism to that of 
XBP-1 splicing via the dimerised RNase surface (Hollien, Lin et al. 2009).  Conversely, Han 
et al suggest that pharmacological activation of XBP-1 splicing by kinase inhibitors that 
prevent autophosphorylation could push the activity of IRE1 towards the XBP-1 splicing 
rather than the mRNA decay pathway, indicating that there is a role of kinase activity in 
regulating the switch between these two outcomes (Han, Lerner et al. 2009). 
IRE1 Dependent Apoptosis 
 
As has been shown, IRE1 is capable of activating the protective arm of the unfolded protein 
response and increasing the ER output of proteins. When the levels of unfolded and 
misfolded protein and the damage from reactive oxygen species generated during the 
formation of disulphide bonds become too high for the cell to safely deal with, components of 
the UPR can respond appropriately; IRE1 may bring about cell injuring and cell death 
responses via pro-apoptotic proteins such as JNK and CHOP, (Schroeder 2008) a 19 kDa, 
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pro-apoptotic transcription factor normally induced under conditions of stress such as glucose 
starvation (Carlson, Fawcett et al. 1993). Within the unfolded protein response, CHOP 
initiates cell death responses to overloading of the endoplasmic reticulum, (Wang, Harding et 
al. 1998).  One of the earliest proteins in the apoptotic pathway of IRE1 is TRAF2 (TNF 
Receptor Associated Factor 2), normally associated with the transduction of cytokine signals 
from membranes to the activation of JNK. TRAF2 consists of an N-terminal ring finger 
domain, a section of five zinc finger domains (the central intermediate domain), and a highly 
conserved TRAF domain at the C-terminal end, common to all TRAF proteins. JNK 
activation by TRAF2 can be induced by IRE1 when TRAF2 interacts with IRE1. TRAF2 
binds to the cytosolic domain of IRE1 (Urano 2000). This allows TRAF2 to form a signalling 
complex with IKK, (I-κB kinase complex) a complex consisting of a heteromer of IKK1 and 
IKK2; and ASK1 (apoptosis signal-regulating kinase), a MAP3 kinase, leading to MKK4 and 
7 phosphorylating JNK and MKK3 and 6 to activate the p38 signalling cascade. JNK (c-Jun 
N-terminal kinase), is activated by phosphorylation of tyrosine and threonine residues in its 
activation loop, which allows it to activate transcription factors by phosphorylation of their 
activation domains.  This action allows the upregulation of genes involved in apoptosis. JNK 
also causes the release of apoptotic proteins such as BIM from the cytoskeleton (Lei and 
Davis 2003). The Bax/Bak type pro- apoptotic proteins have a both a direct effect upon IRE1 
function, and an indirect one via their regulatory effect on intracellular calcium. The pro-
apoptotic  proteins BAX and BAK control ER calcium levels which will induce the unfolded 
protein response when perturbed (Wajant 2003). These proteins have been shown to associate 
directly with IRE1 to modulate the UPR – mice lacking both BAX and BAK were 
particularly vulnerable to tunicamycin treatment and had reduced XBP-1 levels/expression of 
XBP-1 target genes. (Hetz 2006).  Bax Inhibitor -1 (BI-1) (Xu and Reed 1998) , an inhibitor 
of  Bax-induced apoptosis also inhibits XBP-1 splicing by suppressing IRE1 activity 
(Lisbona, Rojas-Rivera et al. 2009).  
 In addition to its apoptotic effects, JNK is capable of mediating insulin resistance via 
phosphorylation of IRS-1 (insulin reception substrate) at serine 307, which prevents tyrosine 
phosphorylation by the  activated insulin receptor of this protein (Hirosumi, Tuncman et al. 
2002). Phosphorylated IRS initiates the phosphatidylinositol 3-kinase pathway (PI3K), which 
activates Akt and causes PI3K to be translocated to the plasma membrane, where it increases 
glucose transport and levels of the glucose transporting protein GLUT4 (Chang, Chiang et al. 
2004). Glucose transport stimulates glucose metabolism and glycogen synthesis. p38 is a 
mitogen activated protein kinase (MAPK) which is activated by the phosphorylation of 
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tyrosine and threonine residues and induces the transcription of apoptotic genes in a similar 
way to JNK.The TRAF2-ASK1-IKK complex also induces serine phosphorylation, 
ubiquitinylation and degradation by the proteosome of  IκB releasing Nuclear factor kappa B 
(NF- κB), which is then capable of translocating to the nucleus and inducing apoptosis and 
inflammation. This pathway can also be activated by PERK via eIF2α.  IRE1-induced JNK 
signalling is also involved in insulin resistance and type II diabetes. Changes in glucose 
uptake and lipidaemia associated with overnutrition, obesity and a lack of exercise result in 
ER stress which then causes JNK to mediate insulin resistance, resulting in impaired glucose 
homeostasis and insulin signalling. Furthermore, the IRE1 JNK axis was found to be the 
transducer of ER-stress induced autophagy in neuroblastoma cells, and cells with impaired 
autophagic responses were more vulnerable to ER stress, indicating a role for autophagy 
upregulation in response to a requirement for degradation of unfolded protein (Ogata, Hino et 
al. 2006). In mammalian cells, the very presence of IRE1 appears to be cytoprotective – 
artificially extended IRE1 signalling prolonged survival of cells, counteracting the 
detrimental effect of PERK signalling that normally persists after IRE1 has been inactivated 
(Lin, Li et al. 2007). However, this role of a counterpoint to PERK-dependent translational 
arrest is already performed by GADD34, as detailed above in the section on PERK . Ligand- 
rather than protein-activated investigations used to separate IRE1 signalling from PERK 
signalling showed that extended PERK signalling was anti-proliferative and pro-apoptotic, 
whereas IRE1 signalling encouraged proliferation, indicating differential contributions to the 
apoptotic decision (Lin, Li et al. 2009).  
Although increasing of the protective responses may not necessarily help in diseases 
where the problem lies in the loss of function of a protein not reaching its intended 
destination, upregulation of the chaperones required for proper folding can help deal with the 
load. Dissection of the apoptotic, inflammatory and insulin-resistance causing pathways of 
the UPR from the protective pathways could also offer insight into the mechanisms involved, 
and possibly help treat some of the diseases where the majority of the damage is caused by 
cell death and inflammatory responses (Ozcan, Cao et al. 2004).  The following section will 
examine the functional components of the IRE1 kinase pocket in greater detail and propose a 
method whereby this dissection could be carried out.  
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1.4. The IRE1 Kinase Pocket: Application of chemical genetics to a protein kinase. 
 1.4.1 Protein kinases and the IRE1 Kinase Pocket 
 
Figure 1.8 - Schematic of IRE1 showing kinase pocket with ATP molecule. Dashed lines 
indicate the order in which the relevant sections fall in the sequence of the protein. Residues 
marked (e.g. K907/K855) of interest to this study are shown with both alpha and beta 
isoforms, where the first (K907) is the alpha isoform and the second (K855) the beta isoform. 
Black arrows indicate donation of phosphates to phosphorylate serine and threonine resides 
on the activation loop.  
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Phosphorylation of proteins is a major modification that controls many cellular processes 
(Adams 2001) – it is performed by protein kinases in an ATP , and usually a magnesium or 
other divalent metal ion dependent manner, transferring a phosphoryl group from ATP to the 
hydroxyl group of tyrosine, serine or threonine, dependent upon the type, tyrosine kinase or 
serine/threonine kinase. Rare kinases exist which can phosphorylate both. (Ben-David, 
68 
 
Letwin et al. 1991; Rossomando, Wu et al. 1992). In the case of kinases such as IRE1, serine 
residues in the activation loop are phosphorylated by ATP, causing the activation loop to 
refold into connection with positively charged residues in the RD pocket. Phosphorylatable 
regions are recognized by residue motifs around the phosphorylation site (Adams 2001). 
Protein kinases share a conserved 200-250 amino-acid core (Hanks, Quinn et al. 1988) and 
kinase domains are present in 2% of eukaryotic genes (Rubin, Yandell et al. 2000). The 
structure of protein kinases is highly conserved across the proteome, and a functional kinase 
enzyme will consist of a number of conserved functional residues and motifs. Of these 
motifs, the following are to be examined during this project (see Figure 1.8 above for 
locations):   
 
1) The magnesium binding loop: This motif marks the N-terminal anchor end of the 
activation segment of the protein kinase and forms part of the β9 sheet which joins the 
magnesium binding loop to the activation segment. It consists of a short tripeptide sequence, 
DFG. The aspartate residue in this motif chelates a positively charged magnesium ion which 
then positions the phosphates of ATP correctly for cleavage.  (Zhou and Adams 1997) which 
appears in the conserved DFG motif (Huse and Kuriyan 2002).  Yeast with this residue 
mutated do not survive (Gibbs and Zoller 1991). Protein kinases also possess an activation 
loop which alters in conformation when phosphorylated and may allow access to substrate 
pockets (Hubbard, Wei et al. 1994; Hubbard 1997; Mohammadi, McMahon et al. 1997) In 
insulin receptor kinase (IRK) this results in a conformational change that positions the DFG 
motif in the active site (Hubbard, Mohammadi et al. 1998).  In human IRE1 α /β 
D711A/D659A forms the beginning of the conserved Asp-Phe-Gly motif (D711Aα 
/D659Aβ) and prevents chelation of the magnesium ion for MgATP (Hubbard, Mohammadi 
et al. 1998). In yeast this mutant is reduced to 4% of activity (Mori, Ma et al. 1993) and 
suffers viability loss without losing nucleotide binding (Chawla, Chakrabarti et al.). As of the 
time of writing, it has not as yet been studied in a mammalian system. 
 
2) A positively charged lysine in the β3 helix, which orientates the α and β phosphates of 
the ATP molecule and may also stabilise the α and β phosphates, helping with 
phosphotransfer without reacting itself or altering binding of ATP. This lysine residue is 
situated on the smaller, N-lobe of the kinase and deep inside the ATP binding cleft.  K->R 
substitutionof this residue in ERK2 produces an impaired protein with no changes toATP 
binding (Carrera, Alexandrov et al. 1993; Robinson, Harkins et al. 1996). In human IRE1 α 
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/β, the K599A/K547A where the lysine residue has been altered to the smaller, uncharged 
residue alanine, is thought to produce a kinase-defective and RNase defective IRE1incapable 
of splicing XBP-1 or activating the unfolded protein response (Tirasophon, Welihinda et al. 
1998; Tirasophon 2000; Iwawaki, Hosoda et al. 2001; Lee, Tirasophon et al. 2002; Urano, 
Calfon et al. 2002; Kaneko, Niinuma et al. 2003; Imagawa, Hosoda et al. 2008; Han, Lerner 
et al. 2009; Lin, Li et al. 2009; Oikawa, Kimata et al. 2009; Uemura, Oku et al. 2009; 
Nakamura, Tsuru et al. 2010; Mao, Shao et al. 2011; Kato, Nakajima et al.).  Mutation to 
arginine (K599R /K547R) which is a mutation conserving the positive charge of the amino 
acid resulted in an incomplete loss of function (Mori, Ma et al. 1993; Shamu and Walter 
1996).   
 
3) A large hydrophobic residue in the β5 sheet which forms a pocket accepting 
the adenine of ATP (Huse and Kuriyan 2002; Nolen, Taylor et al. 2004; Lee 2008). This 
conserved residue is known as the “gatekeeper” (Bishop, Ubersax et al. 2000),  is usually 
large and hydrophobic or polar aligns with the nucleotide portion of ATP masks a 
hydrophobic pocket next to the ATP binding area. Mutations of this residue reduce affinity 
for ATP, but not in a manner than significantly affects binding given normal cellular ATP 
concentrations (Shah, Liu et al. 1997).  Alteration of the site to admit a larger ATP analogue 
produces an analogue sensitized kinase (as-Kinase).  These can be used to investigate the role 
of the kinase by rendering them activable by the pharmacological agent of the analogue, 
however, this methodology is limited by issues such as potential reduction or removal of 
kinase activity due to removal of the gatekeeper residue, an unsuitable gatekeeper residue, 
competition with ATP or the properties of the enlarged analogue itself (Zhang, Kenski et al. 
2005; Hodgson and Schroder). I642A/G and L590A/G are the equivalent mutations of the 
hydrophobic “gatekeeper” residue in human IRE1 α and β that analogue sensitise the IRE1 
protein into which an enlarged ATP analogue such as 1NM-PP1, which was used in (Papa, C. 
et al. 2003) (see below) can fit.  K907A, like K599A has been used as a RNase defective 
control, as it cannot bind the XBP-1 mRNA and has no splicing activity, although it can 
cross-phosphorylate the K599A mutant (Tirasophon 2000). K855A also does not splice in 
mammalian cells (Imagawa, Hosoda et al. 2008) 
A combination of a kinase dead/reduced mutations and an analogue sensitised mutant 
should result in a variant of IRE1 whose RNAse domain can be activated by an ATP 
analogue whilst its kinase domain cannot. In order to fully characterise the possible 
combinations and increase the chances of producing a variant which splices XBP-1 mRNA 
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but does not cause JNK phosphorylation via TRAF 2, a range of kinase dead and analogue 
sensitised mutants in combination were produced.  Given the mutations exhibiting dissective 
effects upon IRE1 function,  a screen of kinase pocket mutants can be performed in a model 
mammalian system to predict their effect upon industrial cell line productivity, and to allow 
the selection of a suitable mutant to be tested in an industrial cell line – therefore, the  
mutants detailed above will be produced in this study and screened for their effect on markers 
of IRE1 function such as XBP-1 splicing and JNK activation, and upon viability and 
resistance to ER stress. Should a suitable mutant be found, this mutant will be progressed 
onto examination in a suitable producer cell line as provided by our industrial collaborator, 
Lonza Biologics. 
1.4.2 Application of an ATP Analogue to IRE1 
 
In the case of IRE1, it has been demonstrated that alteration of the kinase site in combination 
with small molecule chemical genetics (Elphick, Lee et al. 2007) can provide insight into 
how its kinase function activates its RNAse function. In yeast, mutation of Leu
745 
, a highly 
conserved residue located in the ATP binding site of Ire1p to alanine or glycine was predicted 
to be able to sensitise this site to binding of 1NM-PP1. The large leucine residue normally 
extends into the ATP binding site allowing binding of the substrate. Replacement with an 
amino acid with a smaller side chain is thought to produce a pocket into which the large side 
chain of 1NM-PP1 can fit [Bishop1998]. The L-> A mutation shows a 40% decrease in 
activity, the L-> G a >90% decrease. Addition of 1NM-PP1 to the L->A mutant did not 
inhibit, but rather partially rescued the RNase activity. In the case of the L->G mutant, 
activity was restored almost to wild type levels. These effects were specific for 1NM-PP1, 
and did not require the kinase activity of Ire1p to be functional, as the effect of 1NM-PP1 
remained even when a further mutation (K599A) which normally renders IRE1 kinase-dead 
was introduced. The requirement for serine trans-phosphorylation can also be bypassed by 
1NM-PP1. Splicing of Hac1 mRNA and upregulation of UPR associated genes does still 
occur in the sensitised mutants, but requires 1NM-PP1 as a cofactor. This indicates that 
RNase activity is being regulated independently of phosphorylation (Papa, C. et al. 2003). 
IRE1 mutants in which phosphorylation has been bypassed whilst retaining kinase pocket 
occupancy in this way exhibit altered characteristics - this modulation of IRE1 activity by 
1NM-PP1 appears to be pro-survival(Han, Upton et al. 2008). Furthermore, 1NM-PP1 
activated IRE1 with the I642G mutant did not induce IRE1 dependent mRNA degradation, 
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unless ER stress was applied (Hollien, Lin et al. 2009). These characteristics indicate the 
potential usefulness of this system, either using 1NM-PP1, or by producing mutants that 
mimick this ability without the ATP analogue to improve viability in industrial cell growth, 
and indicate the possibility of dissecting other individual components of IRE1 function one 
from the other in manner which is useful for improving viability and cell mass in industrial 
biopharmaceutical manufacture.  
 
 
Figure 1.9- ATP and 1-NM-PP1. 
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1.5. Project Aims 
 
1. To dissect the activities of IRE1 involved in protective signalling pathways via XBP-1 
from the activites involved in inflammatory and apoptotic responses.  
 
Since XBP-1 splicing is dependent upon the RNase function of IRE1 and JNK activation has 
been hypothesised to be dependent upon its kinase function (Urano 2000),  a mutant such as 
the one described above sensitised to 1NM-PP1, which is able to bypass the kinase function 
of IRE1 could be capable of splicing XBP-1 in the presence of a small molecule activator, but 
unable to trigger the apoptotic pathways.  
 
 Mutations will be made in residues which evidence suggests are involved in 
ATP binding, binding of magnesium ions and RNase activity in an attempt to 
produce an analogue-sensitised human mutant which can be induced by 1NM-
PP1.  
 Where possible, both the alpha and beta isoforms of human IRE1 will be used 
as the two forms differ in distribution and effects.   
 Plasmids containing mutated IRE1 will be re-introduced into ire1α-/- mouse 
embryonic fibroblasts.   
 Expression of the mutant IRE1 will be assessed to ensure levels are similar to 
that of the wild type.  
  Splicing of XBP-1 RNA will be assessed by RT-PCR, and JNK activation via 
TRAF2 will be assessed by Western blot. 
  Kinase activity will be assessed by the most appropriate method, e.g. Western 
blot, phosphorylation assays.  
 Viability will be assessed by cell counts or photography. 
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2. Ascertain whether industrial protein yields in an industrial cell line can be increased by 
addition of these mutants.  
 
 These cell lines will need their own endogenous IRE1 to be knocked down, 
possibly by siRNAs, to eliminate the confounding effects of endogenous wild-
type IRE1 on the mutant IRE1 forms. 
 If it is possible to produce a mutant with increased protective and reduced or 
inactive apoptotic activity, it will be attempted to repeat the analyses used in 
the MEF system in CHO cell lines used for industrial protein synthesis.  
 The effect of these mutants on cell productivities will be assessed by the 
appropriate industrial method.  
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2.  MATERIALS 
2.1 Chemicals and solutions  
 
De-ionised/MilliQ/Sterile Water 
 
Where water, de-ionised or otherwise sterilised water is referred to in these solutions, this was 
produced by the MilliQ water purifier to a total organic carbon level of less than 3.0 parts per 
billion. 
 
Autoclaving 
 
Autoclaving was performed at 121°C for 20 min at 1 atmosphere.  
 
Bacto-Tryptone/Yeast Extract/NZ Amine 
 
Where these are used individually, they are as follows: 
 
Tryptone – OXOID, Code: L42  
(Bacto-) Yeast Extract – BD, Code: 212750 
N-Z Amine A – Fluka, Code: C0626-500G 
 
Where they are used for LB agar plates, a combined LB agar mixture from Formedium was 
used –  LB Agar (Lennox) (Code: LBX0302) 
 
Table 2.1- Solutions for Microbiology 
 
30% (v/v) glycerol 189 g glycerol 
Add H2O to ~400 ml, mix well by stirring.  
Add H2O to 500 ml and autoclave. 
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LB broth, Lennox 
 
10 g/l tryptone 
  5 g/l yeast extract 
  5 g/l NaCl 
Add 1l H2O. 
LB agar, Lennox + 50 
µg/ml ampicillin 
10 g/l tryptone 
  5 g/l yeast extract 
  5 g/l NaCl 
15 g/l agar 
Add 1l H2O. Autoclave. 
Add 1ml 50 mg/ml ampicillin after cooling to <50°C. 
LB agar, Lennox + 50 
µg/ml ampicillin + 
10µg/ml tetracycline 
10 g/l tryptone 
  5 g/l yeast extract 
  5 g/l NaCl 
15 g/l agar 
50 µg/ml ampicillin 
Add 1l H2O. Autoclave. 
Add 1ml 50 mg/ml ampicillin 
LB agar, Lennox + 50 
µg/ml ampicillin + 
80µg/ml X-Gal + 500µM 
IPTG 
3.3g/l  tryptone 
1.6 g/l yeast extract 
1.6 g/l NaCl 
5 g/l agar 
300ml DI H2O 
1.5ml 0.1M IPTG 
300μl 80mg/ml X-Gal 
300μl 50mg/ml Ampicillin after cooling to <50°C. 
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NZY+ Broth 10g NZ amine 
5g yeast extract 
5g NaCl 
Add 950ml H2O. Adjust to pH7.5 with NaOH. Autoclave. 
Add 12.5ml filter sterilised 1M MgCl2, 
12.5ml filter sterilised 1M MgSO4, 
Make up to 1l with H2O. 
Autoclave 
Add 10ml filter sterilised 2M glucose 
S.O.C. Medium 2g bacto-tryptone 
0.5g yeast extract 
0.05g NaCl 
0.0186g KCl 
Autoclave. Add 90ml H2O. 
Add 1ml filter sterilised 1M MgCl2 
Make up to 100ml with H2O. 
Autoclave 
Add 1ml filter sterilised 2M D-glucose 
1x TSS 1 g tryptone 
5 g yeast extract 
0.5 g NaCl 
100g  polyethylene glycol 3350 
5ml DMSO 
5ml 1M MgCl2 
Adjust pH to 6.5 with HCl 
Make up to 100ml  
Filter sterilise. 
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Table 2.2 - Solutions for DNA Work 
1 x GTE (50 mM D-
Glucose, 25 mM 
Tris·HCl (pH 8.0), 10 
mM EDTA ) 
2.50 ml 1 M D-Glucose  
1.25 ml 1 M Tris·HCl (pH 8.0) 
1.00 ml 0.5 M EDTA 
50 ml H2O 
10x DNA gel electro-
phoresis sample loading 
buffer 
10 g Ficoll 400 
125 mg bromophenol blue 
10 ml 0.5 M EDTA (pH 8.0) 
Add H2O to ~ 35 ml.  
Dissolve. Add H2O to 45 ml. Autoclave. 
Add 5 ml 10% (w/v) SDS. 
2 mM dNTPs 910 μl H2O 
10 μl 100 mM Tris•HCl (pH 8.0) 
20 μl 100 mM dATP 
20 μl 100 mM dCTP 
20 μl 100 mM dGTP 
20 μl 100 mM dTTP 
10 mg/ml ethidium 
bromide 
Supplier: Sigma-Aldrich, Gillingham, UK 
Hybridization solution
  
 5 ml 20 x SSC, 
 2 ml 10% (w/v) SDS 
1 ml 100 x Denhardt’s solution 
Prewarm at 42°C. 
Prewarm 10 ml formamide to 42°C. 
Immediately before use boil 2 ml 1 mg/ml salmon sperm 
DNA for 5 min, then place for 30 s on an ice-H2O bath. 
Add denatured salmon sperm DNA to the aqueous 
premix, and mix. Mix aqueous premix and formamide for 
use. 
0.2 N NaOH + 1% (w/v) 
SDS 
4 g NaOH 
5 g SDS 
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Dissolve in ~450 ml H2O, add H2O to 500 ml. Store in a 
polyethylene bottle. 
10mg/ml RNase A 10mg RNase A 
Dissolve in 1ml of 1xTE 
8x SYBR Green (from Molecular Probes/Invitrogen, Paisley, UK) 
10,000 x Stock in DMSO   
Dilute 1:1250 to 8x 
50x TAE 242 g Tris 
57.1 ml HOAc 
37.2 g Na2EDTA•2H2O 
Add H2O to 1 l pH ~ 8.5 
10x TE (pH 8.0) 400 ml 1 M Tris•HCl (pH 8.0) 
80 ml 0.5 M EDTA 
Add H2O to 4 l 
Autoclave 
0.1M Sodium Citrate 
/10% Ethanol (v/v) 
1.47g Sodium Citrate  
45ml H2O 
5ml 100% Ethanol 
1M Sodium Hydroxide 2g  NaOH 
50ml H2O 
20 x SSC (for southern 
blot) 
175.32 g NaCl  
 88.23 g Na3•citrate•2 H2O  
Add H2O to 1 l. 
Add 1 ml DEPC treated H2O. Autoclave. 
 
Table 2.3 - Solutions for RNA Work (all preparation equipment baked to remove RNases or 
purchased clean) 
 
DEPC-H2O 1 ml DEPC 
1l sterile H2O 
Autoclave. 
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6 x RNA sample 
loading buffer 
63 g glycerol 
250 mg bromophenol blue  
10 ml 100 mM Na3PO4 (pH 7.0) 
Add DEPC-H2O to 100 ml. 
Add 100 μl DEPC treated H2O. 
Autoclave. 
2 mM dNTPs 910 μl DEPC treated H2O  
10 μl 100 mM Tris•HCl (pH 8.0) in DEPC treated water. 
20 μl 100 mM dATP 
20 μl 100 mM dCTP 
20 μl 100 mM dGTP 
20 μl 100 mM dTTP 
dNTP-UTPs  
 
36.5 μl DEPC treated H2O 
1 μl 100 mM Tris•HCl (pH 8.0) in DEPC treated water. 
10 μl 100 mM dATP 
10 μl 100 mM dCTP 
10 μl 100 mM dGTP 
2.5 μl 100 mM dTTP 
20µl 100mM dUTP 
 
 
 
Table 2.4 - Solutions for Protein Work 
 
2x Assay Buffer (β -
galactosidase assay) 
177 ml 0.4 M Na2HPO4 
 23 ml 0.4 M NaH2PO4 
 0.8 ml 1 M MgCl2 
  2.8 ml  β-mercaptoethanol 
532 mg 2-nitrophenyl-β-D-
galactopyranoside 
Add H2O to 400 ml and mix.   
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E. coli Positive Control 
(Escherichia coli ) Whole 
Cell Lysate (ab5395) 
Supplier: Abcam, Cambridge, UK 
Electrotransfer buffer 4.20 g NaHCO3 
1.59 g Na2CO3  
ELISA coating buffer (0.05 
M sodium carbonate, pH 
9.6) 
1.59g Na2CO3   
2.93g  NaHCO3   
0.2g  NaN3 
Dissolve in 900ml H2O. 
Adjust to pH9.6 +/- 0.02 using 10N HCl or 
NaOH.  
Make up to 1l with H2O 
ELISA wash buffer (pH 7.2) 
 
5.844 g NaCl    
1.153 g  Na2HPO4              
0.258 g   NaH2HPO4
.
H2O   
3.722 g  EDTA    
0.2 ml Tween 20   
10.0 ml butanol   
Dissolve in 900ml of H2O 
Adjust pH to 7.2+/- 0.02 
H2O to 1 L 
ELISA blocking buffer 
 
250.0 ml coating buffer   
1.25 g  casein (Sigma Aldrich, Gillingham, 
UK – Code: C3400)  
ELISA sample/conjugate 
buffer 
 
6.05 g Tris   
2.92 g NaCl    
1.0g casein  
0.1 ml Tween 20   
H2O to 500 ml 
ELISA stop solution 68ml conc. H2SO4 
Add to 432ml of H2O slowly on ice. 
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PBS 8.0 g NaCl 
  0.2 g KCl 
14.4 g Na2HPO4 
  0.2 g KH2PO4 
Add 1L H2O 
PBST 8.0 g NaCl 
  0.2 g KCl 
14.4 g Na2HPO4 
  0.2 g KH2PO4 
Add 900ml H2O  
Add 1ml Tween 20 
Add H2O up to 1l 
PBST + 5% (w/v) skim milk 
powder 
8.0 g NaCl 
  0.2 g KCl 
14.4 g Na2HPO4 
  0.2 g KH2PO4 
Add 900ml H2O  
Add 1ml Tween 20 
Add 50g skimmed milk powder before use 
Add H2O up to 1l 
PBST + 5% (w/v) bovine 
serum albumin 
8.0 g NaCl 
  0.2 g KCl 
14.4 g Na2HPO4 
  0.2 g KH2PO4 
Add 900ml H2O  
Add 1ml Tween 20 
Add 50g bovine serum albumin before use 
Add H2O up to 1l   
0.5% (w/v) Ponceau S, 1% 
(v/v) HOAc 
1.25 g Ponceau S  
Dissolve in 2.5 ml HOAc.  
Add H2O to 250 ml. 
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5 x Reporter lysis buffer  From Promega, Southampton, UK. 
Catalogue number  E3971. Dilute 1:5 in 
water for 1x working solution. 
RIPA buffer 0.5 ml 1M Tris·HCl pH 8.0 
0.3 ml 5 M NaCl 
0.1 ml Triton X-100 
0.5 ml 10% (w/v) sodium deoxycholate 
0.1 ml 10% (w/v) SDS 
Add H2O to 10 ml 
10x semi-dry transfer buffer 73.19g glycine 
60.6 Tris-Base 
Add DI H2O to 500ml DI  
1x semi-dry transfer Buffer 50ml 10x Semi-dry transfer buffer 
25ml methanol 
Add DI H2O to 500ml DI 
TBST 24.2 g Tris 
80g NaCl 
1ml Tween 20 
Add H2O to 1l  
Adjust pH to ~ 7.6 with 10N HCl 
10x TBS/casein (Lonza 
Wash Buffer) 
12g Tris 
45g NaCl 
5g casein 
Add 450ml H2O. 
Adjust to pH 8.2+/-0.1 with HCl 
Make up to 500ml 
TBSTriton + Casein (Lonza 
Blocking Buffer) 
2.4g Tris base 
9.0g NaCl 
0.5ml TritonX 100 
5.0g Casein  
Add 950ml H2O  
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Adjust to pH 7.6 with HCl  
Make up to 1l 
6 x SDS-PAGE sample 
buffer 
3.50 ml 1 M Tris·HCl 
3.78 g glycerol 
1.00 g SDS 
500 μl 10 g/l bromophenol blue 
200 μl β-mercaptoethanol 
Add H2O to 10 ml. 
10 x SDS-PAGE running 
buffer 
144.13 g glycine 
 30.03 g Tris 
 10.00 g SDS 
Add H2O to ~ 900 ml, stir until completely 
dissolved, then add H2O to 1l.  
 
Table 2.5 - Solutions for Tissue Culture 
20mM 1NM-PP1 
 (1-(1,1-dimethylethyl)-
3-(1-
naphthalenylmethyl)-1H-
pyrazolo[3,4-
d]pyrimidin-4-amine) 
6.62g 1NM-PP1 
Dissolve in 1ml DMSO 
20mM Bn-PP1 
(3-Benzyl-1-tert-butyl-
1H-pyrazolo[3,4-
d]pyrimidin-4-ylamine.) 
5.62g Bn-PP1 
Dissolve in 1ml DMSO 
20mM Ph-PP1 5.34g Ph-PP1 
Dissolve in 1ml DMSO 
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1M DTT 1.54g DTT 
Dissolve in 10ml of H2O  
Filter sterilise. 
100mM thapsigargin 1mg thapsigargin, dissolve in 1ml of DMSO 
Dilute into 15ml DMSO.  
Use at 500nM-1µM 
10mg/ml tunicamycin 10mg tunicamycin, dissolve in 1ml DMSO  
Use at 0.1-2.0 µg/ml  
25mM Stock MSX 
(methionine 
sulphoximine) 
250mg MSX 
55ml DMSO 
Dilute in medium 1:1000 for 25µM working use. 
10mg/ml blasticidin Supplier: Melford Laboratories, Ipswich, UK 
50mg/ml hygromycin Supplier: Merck, Middlesex, UK 
20mg/ml zeocin Supplier: Melford Laboratories, Ipswich, UK 
10mg/ml tetracycline. 100 mg tetracycline  
Dissolve in ~9 ml EtOH.  
Add EtOH to 10 ml. 
Filter sterilise. 
Trypan blue 0.4% (v/v)  Supplier: Sigma-Aldrich, Gillingham, UK 
 
 
Table 2.6 - Cell Culture Media and Reagents 
Medium Supplier Cat No 
Dulbecco’s Modified Eagle’s Medium 
with Pyruvate (Dulbecco and Freeman 
1959) 
Sigma-Aldrich, Gillingham, 
UK 
 D6546 
Dulbecco’s Modified Eagle’s Medium 
without pyruvate (Dulbecco and 
Freeman 1959) 
Sigma-Aldrich, Gillingham, 
UK 
D5671 
Dulbecco’s PBS Sigma-Aldrich, Gillingham, 
UK 
D5652 
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Fetal Bovine Serum Sigma-Aldrich, Gillingham, 
UK 
F7524 
L-Glutamine Sigma-Aldrich, Gillingham, 
UK 
G7513 
0.25% Trypsin-EDTA GIBCO/Invitrogen, Paisley, 
UK 
25200-056 
CD-CHO (Gorfien, Dzimian et al. 1998) Invitrogen, Paisley, UK 10743-029 
 
Opti-Mem Invitrogen, Paisley, UK 11058021 
 
 
 
Table 2.7 – Restriction Enzymes 
Enzyme  Source Enzyme  Source 
AflII 
 
New England 
Biolabs, Hitchin, UK 
NheI 
 
Fermentas, 
Cambridge, UK 
AgeI New England 
Biolabs, Hitchin, UK 
NruI 
 
Roche Applied 
Science,  Burgess 
Hill, UK 
AvrII 
 
Roche Applied 
Science,  Burgess 
Hill, UK 
PdiI 
 
Fermentas, 
Cambridge, UK 
BglII 
 
Fermentas, 
Cambridge, UK 
PvuI 
 
Roche Applied 
Science,  Burgess 
Hill, UK 
BsiWI 
 
Roche Applied 
Science,  Burgess 
Hill, UK 
PvuII Roche Applied 
Science,  Burgess 
Hill, UK 
BssHI 
 
Roche Applied 
Science,  Burgess 
Hill, UK 
PstI New England 
Biolabs, Hitchin, UK 
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BstZ17I 
 
New England 
Biolabs, Hitchin, UK 
SacI New England 
Biolabs, Hitchin, UK 
ClaI 
 
Fermentas, 
Cambridge, UK 
SalI 
 
New England 
Biolabs, Hitchin, UK 
DraI 
 
Fermentas, 
Cambridge, UK 
SbfI 
 
New England 
Biolabs, Hitchin, UK 
EagI 
 
New England 
Biolabs, Hitchin, UK 
ScaI 
 
Fermentas, 
Cambridge, UK 
EcoRI  
 
Fermentas, 
Cambridge, UK 
SmaI 
 
Fermentas, 
Cambridge, UK 
EcoRV Fermentas, 
Cambridge, UK 
SnaBI 
 
New England 
Biolabs, Hitchin, UK 
HindIII  
 
Fermentas, 
Cambridge, UK 
SpeI 
 
New England 
Biolabs, Hitchin, UK 
HpaI 
 
Source: Roche 
Applied Science,  
Burgess Hill, UK 
SphI 
 
New England 
Biolabs, Hitchin, UK 
KasI 
 
New England 
Biolabs, Hitchin, UK 
StuI 
 
Fermentas, 
Cambridge, UK 
KpnI 
 
Fermentas, 
Cambridge, UK 
XbaI Fermentas, 
Cambridge, UK 
MluI 
 
Fermentas, 
Cambridge, UK 
XhoI 
 
Roche Applied 
Science,  Burgess 
Hill, UK 
MscI Fermentas, 
Cambridge, UK 
XmaI New England 
Biolabs, Hitchin, UK 
NgoMIV Promega, 
Southampton, UK. 
ZraI Fermentas, 
Cambridge, UK 
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Table 2.8 – Other Enzymes 
Enzyme Source 
Accuprime Taq Invitrogen, Paisley UK 
β-galactosidase (1U/μl )  Promega, Southampton, UK 
Calf Intestinal Alkaline 
Phosphatase 
Fermentas, Cambridge, UK 
GoTaq Polymerase Promega, Southampton UK. 
Hotstar Taq DNA polymerase Qiagen, Crawley, UK 
illustra Hot Start Master Mix 
(Taq) 
GE Healthcare, Chalfont St. Giles, UK 
Lambda phosphatase Sigma-Aldrich, Gillingham, UK 
Pfu Polymerase Promega, Southampton, UK. 
Phusion Polymerase Finnzymes/ New England Biolabs, Hitchin, UK 
Superscript III reverse 
transcriptase 
Invitrogen, Paisley UK 
T4 DNA Ligase Promega, Southampton, UK. 
T4 DNA Ligase Roche Applied Science,  Burgess Hill, UK 
Uracil DNA Glycosylase New England Biolabs, Hitchin, UK 
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2.2 Oligodeoxynucleotide Primers 
 
Table 2.9 - Codes for Degenerate Primers 
Letter Includes 
R  Either Purine (A or G) 
Y  Either Pyrimidine (C or T) 
M  Adenine or Cytosine (A or C)  
K  Guanine or Thymine (G or T) 
S Guanine or Cytosine (G or C) 
W Adenine or Thymine (A or T) 
H Anything but Guanine (A,T or C) 
D  Anything but Cytosine (A,T or G) 
B  Anything but Adenine (C,T or G) 
V  Anything but Thymine (A,C or G) 
N  Any base (A,T,G or C) 
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Table 2.10 - Restriction enzymes used to screen for mutated clones. 
pEDΔC-hIRE1α pCAG-hIRE1β 
Mutant  Enzyme Mutant  Enzyme 
I642A 
I642G 
D711A 
K599R 
EagI 
NgoMIV 
EcoRV 
EcoRI 
L590A 
L590G 
D659A 
K547R 
K855A 
HindIII 
NheI 
HindIII 
NgoMIV 
AflI 
 
Table 2.11 – Oligodeoxynucleotide Primers 
Code 
(where 
available) 
Purpose Primer 
Mutagenesis codon change. Restriction site codon change. Underlining – Restriction site – see Table 2.10 for relevant enzyme and sources.  
H8207 K599R Forward  CAACCGCGACGTGGCCGTGAGGAGAATTCTCCCCGAGTG 
H8227 K599R Reverse  CACTCGGGGAGAATTCTCCTCACGGCCACGTCGCGGTTG  
H8212 K547R Forward  CGGGCAGTGGCTGTCCGCCGGCTCCTCCGCGAGTGCT 
H8232 K547R Reverse  AGCACTCGCGGAGGAGCCGGCGGACAGCCACTGCCCG 
H8204 I642A Forward   GGCAATTCCAGTACATTGCGGCCGAGCTGTGTGCAGCCACCC  
H8224 I642A Reverse   GGGTGGCTGCACACAGCTCGGCCGCAATGTACTGGAATTGCC  
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H8208 L590A Forward   CAGTTCCACTACATTGCCGCGGAGCTCTGCCGGGCAAGCTTGCAG 
H8228 L590A Reverse   CTGCAAGCTTGCCCGGCAGAGCTCCGCGGCAATGTAGTGGAACTG 
H8205 I642G Forward  GCAATTCCAGTACATTGCCGGCGAGCTGTGTGCAGCC   
H8225 I642G Reverse  GGCTGCACACAGCTCGCCGGCAATGTACTGGAATTGC  
H8209 L590G Forward  CAGTTCCACTACATTGCCGGGGAGCTCTGCCGGGCAAGCTTGCAG, 
H8229 L590G Reverse  CTGCAAGCTTGCCCGGCAGAGCTCCCCGGCAATGTAGTGGAACTG 
H8206 D711A Forward  CAAGGCCATGATATCCGCCTTTGGCCTCTGCAAGAAGCTGGC   
H8226 D711A Reverse  GCCAGCTTCTTGCAGAGGCCAAAGGCGGATATCATGGCCTTG  
H8210 D659A Forward  GGTGCTCTCAGCCTTCGGCCTCTGCAAGAAGCTTCCTGCT 
H8230 D659A Reverse  AGCAGGAAGCTTCTTGCAGAGGCCGAAGGCTGAGAGCACC 
H8211 K855A Forward  GCGAGACCTCTTAAGAGCTGTGAGGAACGCGAAGCACCACTACAGGGAGC 
H8231 K855A Reverse  GCTCCCTGTAGTGGTGCTTCGCGTTCCTCACAGCTCTTAAGAGGTCTCGC 
H8341 
IRE1a Activation Loop -
BstZ17I End 
TACGCTTGGAAGCAAGAATAATGAA 
H8397 
IRE1a Activation Loop -
BstZ17I End -2 overhang 
CAG CCT GTA TAC GCT TGG AAG CAA GAA TAA TGA A 
H8364 
IRE1a Activation Loop -Aloop-
Reverse 
CACCCCAGCTCGGCGGGCCAAAGCGTGTCTGCCCACTGCCAGCTT 
H8364 
IRE1a Activation Loop -Aloop-
Reverse-2 
CACCCCAGCTCGGCG GGCGAAAGCGTGTCTGCCCACTGCCAGCTT 
H8343 IRE1a Activation Loop -Aloop- AGACACGC TTCGCCCGCCGAGCTGGGGTGCCTGGCACAGAAGGC 
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Forward 
H8344 
IRE1a Activation Loop -SnaBI 
End 
GTAGTAAAAGACGCAGCCTGC 
H8398 
IRE1a Activation Loop -SnaBI 
End- 3 overhang 
AGA GAT TAC GTA GTA AAA GAC GCA GCC TGC  
H8345 
IRE1b Activation Loop -KpnI 
End 
CCCCTGGTACCTGCAGACACTGCT 
H8347 
IRE1b Activation Loop -
Aloop-Forward 
 CGCTGTGCCTTCGCCCTCCACGCCGGCATCCCCGGCACGGAAGGC 
H8346 
IRE1b Activation Loop -
Aloop-Reverse 
GATGCCGGCGTGGAGGGCGAAGGCACAGCGGCCAGCAGGCAGCTT 
 
H8348 
IRE1b Activation Loop -BglII 
End 
GGA AAA AGA TCT CAG TGG TAT TTG 
IRE1 Vector Sequencing 
Code Name/Purpose AAGAGGCTGCTCTGTTCTGG 
H8033 hIRE1α sequencing 1 CGTGACCTACAGGGAACTGG 
H8034 hIRE1α sequencing 2 CGTGGTGAAGATGGACTGG 
H8035 hIRE1α sequencing 3 CTCATATCCATGCCCAATGC 
H8036 hIRE1α sequencing 4 ACCAGCGTGGTGATAGTTGG 
H8037 hIRE1α sequencing 5 CATCGGGAAAATGTGATTCC 
H8038 hIRE1α sequencing 6 TTTGTGTCCAATGGTGATGG 
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H8039 hIRE1α sequencing 7 GGACAGGCTCAATCAAATGG 
H8040 hIRE1α sequencing 8 TGCTTCCAAGCGTATACAGG 
H8041 hIRE1α sequencing 9 ATGCCACACAGATGGTCTCC 
H8042 hIRE1β sequencing 1 CAGTGACTGGCTGGAGAAGG 
H8043 hIRE1β sequencing 2 GAGTGGTGCTCTCAGACTTCG 
H8044 hIRE1β sequencing 3 CAGAGTCCCTCAAAGCAAGC 
H8045 hIRE1β sequencing 4 AGTCTCAGGAGAGCGAGAGG 
H8046 hIRE1β sequencing 5 TCACCTGGGAAATACATGAGC 
H8047 hIRE1β sequencing 6 CACCTTGGATGGAAGTCTCC 
H8048 hIRE1β sequencing 7 TCCAGGAACTGATGATGAACC 
H8049 hIRE1β sequencing 8 GCCCTTCTCATCACACTCC 
H8050 hIRE1β sequencing 9 GTCGAGAGGTTTTCCGATCC 
H8155 hIRE1α-pED∆c sequencing 1 GGACAGGCTCAATCAAATGG 
H8156 hIRE1α-pED∆c sequencing 2 GTTCCTGGAGTCCTCACTGC 
H8157 hIRE1β-pCAG sequencing 1 CAAGGGAGCGCTCTGTCC 
H8158 hIRE1β-pCAG sequencing 2 TGCTGGGTCAGAGAGAAAGG 
H8159 hIRE1β-pCAG sequencing 3 GGAGAAGCAGCAGGAGACC 
H8160 hIRE1β-pCAG sequencing 4 ATAGTCCCGCCCCTAACTCC 
H8192 hIRE1α-pED∆c sequencing 5 CTCTGCTCCCCTCCTAAAGC 
H1893 hIRE1α-pED∆c sequencing 6 GCACAGATTTGGGACAAAGG 
H8194 hIRE1β-pCAG sequencing 5 TTGTTATCCGCTCACAATTCC 
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H8195 hIRE1β-pCAG sequencing 6 ATTCGGCTTATCGATTGAGG 
H8213 hIRE1α-pED∆c sequencing 7 ACTTTTCGGGGAAATGTGC 
H8214 hIRE1α-pED∆c sequencing 8 TTTTTGGCGAGCTCGAATTA 
H8219 hIRE1β-pCAG sequencing 7 GCCCTCTCGCACGATTACCA 
H8220 hIRE1β-pCAG sequencing 8 CTGCGAGGGGAACAAAGG 
H8221 hIRE1β-pCAG sequencing 9 GCACGCAGCCTTTGTTCC 
H8222 hIRE1β-pCAG sequencing 10 GGAGATGGGGAGAGTGAAGC 
H8223 hIRE1β-pCAG sequencing 11 TCACAGAAAAGCATCTTACGG 
H8261 hIRE1β-pCAG sequencing 12 TCACAGAAAAGCATCTTACGG 
H8262 hIRE1β-pCAG sequencing 13 AGTTCGCCAGTTAATAGTTTGC 
H8276 hIRE1α-pED∆c sequencing 9 AGGTCGACTCTAGAACCATGC 
CHO IRE1a Sequencing 
 A-102   GCCGGTCCGCTTGSWNACNGCRTG 
 A-85 CGGACCGGCTCCATHAARTGGAC   
 A130 CCCGGGTCTTGGTGTCRTACATNGT 
 A49 GACGTGCTGTGGATCCARAAYTAYGC 
 A41 CCCCCTCCATGGTGCAYGARGGNGT 
 A143 TTGGGGAAGGGGTACTTCCAYTTNGT 
 A20 GAAGAGGTCCTTCGAGGARGTNATHAA 
 A163 CGGACAGAGGGGTCTCRTGRTGGNCC 
 A1 GAAGATCCAGCTGCTGCARCARCARCA 
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 A173 CGTGGGCCAGCTTCTCYTCNACRTC 
 B74 CGTGTACAAGGGCATGTTYGAYAAYMG 
 B102 GTCTCCTCGTCCTCGTCRTCNKGYTC 
 B61 CACCAGACCACCTCCGGNYTNGCNCA 
 B121 GAAGTCCTTCTGCTCCACRTAYTCYTG 
 B50 GTGCCCGGCACCGARGGNTGGAT 
 B135 TGATCCTGCCGTGGGCRTTNGGCAT 
 B28 AAGCAGCTGCAGTTCTTYCARGAYGT 
 B161 CCAGCTGCCTCACGATNGGNCCRTC 
 B18   CATGCGGAACAAGAAGCAYCAYTAYMG 
 B182 TCGTGCCGGCACARYTCCATNGC 
H8430 B-186 CTGGGGCTCGGTGGGYTCRTGVMA 
H8431 B-168 ATGGCCCGCAGCARRTCNCKNAC 
 5’1 TTCCCAACGTACAGGGTAGG 
 5’2 TGTGCATCACCTTTCTCAGG 
 5’3 CGTACAGGGTAGGCGTTAGC 
 5’4 GGGGTGATCACACACTCTCC 
 5’5 GTCCAGGGTCAAACTTGAGG 
 3’1 CATCGGGAAAATGTGATTCC 
 3’2 GCTAACGCCTACCCTGTACG 
 3’3 CTTCATGTCTGGGGAAGTGG 
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 3’4 GAAGTATCCGTTCCCCAAGG 
 3’5 GGAGAGATTCCCCAACAACC 
 Luminal1 TTCCCAACGTACAGGGTAGG 
 Luminal2 GCTCTTGGCCTCTGTCTCC 
 Luminal 3 CCCAACGTACAGGGTAGGC 
H8410 347Luminal01 GCTCTTCCACGTGTGTTGG 
H8411 407Lumina01 AGGCCTTCGTTGTTTTTGC 
H8412 2605Kinase01 AGTTCTTCCAGGACGTGAGC 
H8413 2665Kinase01 GATCGTGAGGCAGCTGGA 
H8424 372Luminal GACTGCCATCATTGGGATCT 
H8425 317Luminal CCTGCAGGACTGGATCTTCT 
H8426 2627Kinase AAGCAGCTCCAGTTCTTCCA 
H8427 2624Kinase AGCAGCTCCAGTTCTTCCAG 
H8432 2970Kinase CAGCCACGAGAGACTCTTCC 
H8433 2910Kinase GCTACTTCACGTCTCGCTTCC 
H8455 CHOIRE1180bpF ACTGCCTGAAACCCTGTTGT 
H8456 CHOIRE1180bpR ACAACAGGGTTTCAGGCAGT 
H8457 CHOIRE1500bpF TGACTGGAGAGAAGCAGCAG 
H8458 CHOIRE1500bpR TCTCCAGTCAGGAGGTCGAT 
H8459 CHOIRE12000bpF CTTCGAGAATCAGACGAGCA 
H8460 CHOIRE12000bpR GATTCTCGAAGCAGCTGGAC 
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H8461 CHOIRE12500bpF AGGACGTCATTGCTCGTGA 
H8462 CHOIRE12500bpR TGGGGATCCATAGCAATCAT 
H8463 CHOIRE13000bpF TGGAGCTCTGCAGACATGAG 
H8464 CHOIRE13000bpR TCATGTCTGCAGAGCTCCAT 
H8465 CHOIRE13500bpF AGCAAGAGCACCCTCTGCT 
H8466 CHOIRE13500bpR TTCTAGCAGAGGGTGCTCTTG 
H8467 CHOIRE13900bpF GTGGAGAGGCTCAGAACCAG 
H8468 CHOIRE13900bpR CTGGTTCTGAGCCTCTCCAC 
H8469 CHOIRE13endbpF AAGGCCCTGGGGGTAGAGAG 
H8470 CHOIRE13endbpR CTCTCTACCCCCAGGGCCTT 
T-RACE Primers 
H8414 T-RACE Adapter A (poly-A 
tail) AUCUCGAGUUCGCGCCGGAUCCTTTTTTTTTTTTTTTTTTTTTTTTTVN 
H8415 T-RACE Adapter B (5' Cap) AUAUGCACUGCCGCGUCUGAGGGGGGGG 
H8416 T-RACE Primer A CUCGAGUUCGCGCCGGAUC 
H8417 T-RACE Primer B AUAUGCACUGCCGCGUCUGA 
H8418 5' T-RACE Primer ATATGCACTGCCGCGTCTGA 
H8419 3' T-RACE Primer CTCGAGTTCGCGCCGGATC 
RT-PCR Primers 
H7961 Mouse Forward   GATCCTGACGAGGTTCCAGA 
H7962 Mouse Reverse  ACAGGGTCCAACTTGTCCAG 
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H8395 Mouse Gene Specific Primer CTAGCAGACTCTGGGGAAGG 
H7994 Mouse Actin Forward AGCCATGTACGTAGCCATCC 
H7995 Mouse Actin Reverse CTCTCAGCTGTGGTGGTGAA 
 CHO XBP-1 Forward 1 ACTACTGAAGAGGCTCCAGA 
H8420 CHO XBP-1 Forward 2 CTGAAGAGGCTCCAGAGACG 
H8421 CHO XBP-1 Forward 3 CCAAGGGAAATGGAGTAAGG 
 CHO XBP-1 Reverse 1 ACAGGGTCCAACTTGTCCAG 
H8422 CHO XBP-1 Reverse 2 TCCATGGGAAGATGTTCTGG 
H8423 CHO XBP-1 Reverse 3 GTCCAGAATGCCCAAAAGG 
H8451 CHO Gene Specific Primer 2 ATTGGCAGACTCTGGGGATGGA 
 CHO Actin Forward AGCTGAGAGGGAAATTGTGCG 
 CHO Actin Reverse GCAACGGAACCGCTC 
qPCR Primers 
 CHO XBP-1 Splice Junction  -1  GCTGAGTCCGCAGCAGGTGC 
H8452 CHO XBP-1 Splice Junction  -2 CTGAGTCCGCAGCAGGTG 
H8453 CHO XBP-1 Splice Junction  -3 GCTGAGTCCGCAGCAGGT- 
H8454 CHO XBP-1 Splice Junction  -4 GTCCGCAGCAGGTGCAGGCC 
 CHO XBP-1 Intron GCACTCAGACTACGTGCACC 
 CHO Actin Forward AGCTGAGAGGGAAATTGTGCG 
 CHO Actin Reverse GCAACGGAACCGCTC 
 CHO IRE1 F  AAGGTCCCCAGACAGATGG 
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 CHO IRE1 R CCAGATGAATCCAGAAACTCG 
H8440 CHOIRE1F3 CTTCATGTCTGGGGAAGTGG 
H8441 CHOIRE1R2 GCTCAGGGGGTAAGTGATGA 
H8442 CHOIRE1R3 CATGCTCAGGGGGTAAGTGA 
H8439 CHOIRE1F2 CGCATCACCAAGTGGAAGTA 
Vector Sequencing  and Other Primers 
 SacI to Multiclone Site I CGTGTACGGTGGGAGGTC 
 SacI to Multiclone Site II CAT GACCTTATGGGACTTTCC 
H8428 SacI to Multiclone Site III CAAAATCAACGGGACTTTCC 
H8429 SacI to Multiclone Site IV GGATAGCGGTTTGACTCACG 
 PvuII to Multiclone Site  TTGCATACTTCTGCCTGCTG 
 Avr to Multiclone Site GTAAATTCCTTGCGGCTTTG 
 U6 Promoter + Multiclone Site 
Short F 
 CTAGGTTAAAATGGACTATCATATGTCATATGCTTACCGTAACTTGAAAG 
TATTTCGATTTCTTGGCTTTATATATCTTG 
 U6 Promoter + Multiclone Site 
Long F 
TGGAAAGGACGAACACCGACCGGTCCCGGGGCGCGCTCGCGACGTACGGGAA 
TTCCTCGAGGGCGCCGTTAACCAG 
 U6 Promoter + Multiclone Site 
Long R 
CTGGTTAACGGCGCCCTCGAGGAATTCCGTACGTCGCGAGCGCGCCCCGGG 
ACCGGTCGGCGGTGTTCGTCCTTTCCACAAGA 
 U6 Promoter + Multiclone Site 
Short R 
TATATAAAGCCAAGAAATCGAAATACTTTCAAGTTACGGTAAGCATATGACA 
TATGATAGTCCATTTTAAC 
 Multiclone Site for CMV F AGCTCACCGGTCCCGGGGCGCGCTCGCGACGTACGGAATTCCTCGAGGGCG 
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CCGTTAACCAG 
 Multiclone Site for CMV R CTGGTTAACGGCGCCCTCGAGGAATTCCGTACGTCGCGAGCGCGC 
CCCGGGACCGGTG 
H8475 T7 Sequencing Primer for 
pGEM Vector 
TAATACGACTCACTATAGGGCGA 
H8476 SP6 Sequencing Primer for 
pGEM Vector 
ATTTAGGTGACACTATAGAATACT 
 
 M13 R CAGGAAACAGCTATGACC 
 M13 F TGTAAAACGACGGCCAGT 
 Random Hexamers From Promega, Southampton, UK. 
 Oligo(dT)20  From Promega, Southampton, UK. 
 
 lacZ Probe F GACGTCTCGTTGCTGCATAA 
 lacZ Probe R CAGCAGCAGACCATTTTCAA 
    
2.3 Plasmids 
 
Plasmids were subjected to restriction digest and bioinformatic analysis, and sequenced by DBS Genomics, Durham to produce maps for use in 
restriction enzyme analyses and site directed mutagenesis.  
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Table 2.12 – Plasmids 
Name Source Reference Origin/Derivation  
IRE1 Expression Vectors 
pEDΔC 
pEDΔC-hIRE1α,  
pEDΔC-hIRE1α-K599A, 
pEDΔC-hIRE1α-K907A 
R. Kaufman, 
University of 
Michigan, USA.  
 
(Kaufman1991)(Kaufman, 
Davies et al. 1991) 
(Tirasophon1998, 
2000)(Tirasophon, 
Welihinda et al. 1998; 
Tirasophon 2000) 
pEDΔC-hIRE1α derived from pED plasmid  
by inserting a 3.5kb  hIRE1α XbaI-EcoRI 
cDNA into the XbaI site. Mutagenesis as 
described in. pEDΔC-hIRE1α-K599A and  
pEDΔC-hIRE1α-K907A derived from 
pEDΔC-hIRE1α. 
 
pEDΔC-hIRE1α-
K599A/I642A 
pEDΔC-hIRE1α-
K599A/I642G 
pEDΔC-hIRE1α-K599R 
pEDΔC-hIRE1α-
K599R/I642A 
pEDΔC-hIRE1α-
K599R/I642G 
pEDΔC-hIRE1α-D711A 
pEDΔC-hIRE1α-
D711A/I642A 
Produced in this 
study. 
None Produced from pEDΔC-hIRE1α or  pEDΔC-
hIRE1α-K599A in this study by site-directed 
mutagenesis using QuikChange® II XL Site-
Directed Mutagenesis Kit (see Commercially 
Available Kits, below) 
(See Chapter 1) 
 
 101 
 
Name Source Reference Origin/Derivation  
pEDΔC-hIRE1α-
D711A/I642G 
pCAG 
pCAG-hIRE1β 
pCAG-hIRE1β-K547A 
pCAG-hIRE1β-HA 
pCAG-hIRE1β-HA-K547A 
K. Kohno, Nara 
Institute of Science 
and Technology, 
Japan 
(Iwawaki, Hosoda et al. 
2001) 
Derived from the pCAGGS plasmid by 
inserting a 2.9kb hIRE1β EcoRI-EcoRI cDNA 
into the EcoRI site 
 
 
pCAG-hIRE1β-
K547A/L590A 
pCAG-hIRE1β-HA-
K547A/L590A 
pCAG-hIRE1β-
K547A/L590G 
pCAG-hIRE1β-HA-
K547A/L590G 
pCAG-hIRE1β-K547R 
pCAG-hIRE1β-HA-K547R 
pCAG-hIRE1β-
K547R/L590A 
pCAG-hIRE1β-HA-
Produced in this 
study. 
None Produced from pCAG-hIRE1β 
or  pCAG-hIRE1β-K547A 
by excising hIRE1β with EcoRI and 
subcloning into EcoRI site of puc18 and site-
directed mutagenesis using QuikChange® II 
XL Site-Directed Mutagenesis Kit (see 
Commercially Available Kits, below). HA tags 
cloned as described in “Cloning of IRE1α and 
IRE1β mutant plasmids” 
(See Chapter 1) 
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Name Source Reference Origin/Derivation  
K547R/L590A 
pCAG-hIRE1β-
K547R/L590G 
pCAG-hIRE1β-HA-
K547R/L590G 
pCAG-hIRE1β-D659A 
pCAG-hIRE1β-HA-D659A 
pCAG-hIRE1β-
D659A/L590A 
pCAG-hIRE1β-HA-
D659A/L590A 
pCAG-hIRE1β-
D659A/L590G 
pCAG-hIRE1β-HA-
D659A/L590G 
pCAG-hIRE1β-K855A 
pCAG-hIRE1β-HA-K855A 
pTK-HSV-BP2-hIRE1α Produced in this 
study. 
None Derived from pDJB134 by removing the CREB-H 
gene with SpeI and XbaI and replacing with 
hIRE1α cut from pEDΔC-hIRE1α with SpeI and 
XbaI 
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Name Source Reference Origin/Derivation  
pTKRG-hIRE1b Produced in this 
study. 
None Derived from pCAG-hIRE1β by excising the 
chicken beta actin promoter with SalI and XbaI 
and cloning in the thymidine kinase promoter and 
intron cut from pDJB134 with SalI and NheI. 
Lonza Plasmids 
pEE12.4-replacement Donated by Lonza Biologics, Slough, UK 
pEE12.4-U6 
pEE12.4-U6-4- 
pEE12.4-U6-sh01 
pEE12.4-U6-egfp 
Produced in this 
study. 
None Derived from pEE12.4 by cutting CMV promoter 
out with AvrII and PvuII cloning U6 promoter 
sequence from (Lin, Yang et al. 2004) combined 
with polylinker sequence (see Chapter 4.7). 
shRNA sequences were then cloned in with AgeI 
and NruI (See Chapter 4.8)  
Other 
puc18 Standard cloning 
vector kept in lab  
(Yanisch-Perron, Vieira et 
al. 1985) 
 
pUC18-hIRE1β Produced in this 
study. 
None Derived from pCAG-hIRE1β and pUC18 vector 
by excising hIRE1β with EcoRI and inserting into 
the EcoRI site of the multi-cloning site of pUC18 
pDJB134 Gift from Marie Curie 
Research Insitute, 
(Bailey, Barreca et al. 
2007) 
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Name Source Reference Origin/Derivation  
Surrey  
Invitrogen Plasmids for Stable Cell Line Production – T-Rex System (See “Commercially Available Kits”, below) 
pcDNA/lac/Zeo Purchased from Invitrogen, Paisley UK 
pcDNA6⁄TR 
pcDNA5-FRT-TO 
pOG44 
pcDNA5-FRT-TO-hIRE1α 
pcDNA5-FRT-TO-hIRE1α-K599A 
pcDNA5-FRT-TO-hIRE1α-K599R 
pcDNA5-FRT-TO-hIRE1α-D711A 
pcDNA5-FRT-TO-hIRE1α-I642G 
pcDNA5-FRT-TO-hIRE1α-
D711A/I642G 
pcDNA5-FRT-TO-hIRE1α-
K599A/I642G 
pcDNA5-FRT-TO-hIRE1α-
K599R/I642G 
Produced in this 
study. 
None Produced by collaborator S. Sestak, Bratislava 
from  pcDNA5-FRT-TO by Cloning the 1,071 bp 
SalI-PspOMI fragment from pEDΔC-hIRE1α into 
XhoI + PspOMI digested pcDNA5/FRT/TO to 
produce pcDNA5/FRT/TO-hIRE1α-N’. The 
2,679bp PspOMI fragment from pEDΔC-hIR and 
each mutant pEDΔC plasmid into 
pcDNA5/FRT/TO-hIRE1α-N’. 
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Figure 2. 1 - pEDΔc-hIRE1α 
Figure 2. 2 – pCAG-hIRE1β 
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Figure 2. 3 - pCAG-hIRE1β-HA 
Figure 2. 4 – pTK-HSV-BP2-hIRE1α 
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Figure 2. 5 – p TKRG-hIRE1β  
 
Figure 2. 6 – pEE12.4  
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 Figure 2. 7 – pEE12.4-U6 
 
Figure 2. 8 – pUC18 
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Figure 2. 9- pUC18-hIRE1β 
 
Figure 2. 10 – pDJB134 
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Figure 2. 11 – pcDNA5/FRT/TO-hIRE1α 
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2.4 Antibodies  
 
Table 2.13 - Antibodies 
Name Type  Source Catalogue 
No. 
Lot No. 
Anti-eIF2α Primary Santa Cruz 
Biotechnology Inc/ 
Insight 
Biotechnology Ltd, 
Wembley, UK 
sc-11386 G1309 
Anti-GAPDH Primary Sigma-Aldrich, 
Gillingham, UK 
G8795 028K4859 
Anti-HA 
 
Primary Sigma-Aldrich, 
Gillingham, UK 
H8908-2ml 118K4800 
Anti-human IgG 
kappa HRP 
conjugate 
ELISA 
Conjugate 
US 
Biological/Stratech 
Scientific, 
Newmarket, UK 
11903-37P L10073010 
Anti-IRE1α Primary Abcam, 
Cambridge, UK 
ab37073 870410 
Anti-IRE1α Primary Cell Signalling 
Technology/ New 
England Biolabs, 
Hitchin, UK 
3294S 4 
Anti-IRE1α Primary Sigma-Aldrich, 
Gillingham, UK 
I6785 128K4827 
Anti-IRE1α 
phospho serine 
724 
Primary Abcam, Cambridge, 
UK 
ab481187 GR1571-2 
Anti-IRE1α 
phospho serine 
724 
Primary Novus Biologicals, 
Novus Europe, 
Cambridge, UK 
NB100-
2323H 
I 
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Anti-IRE1β Primary Prestige 
Antibodies/ Sigma-
Aldrich, 
Gillingham, UK 
HPA016558 R06214 
Anti-JNK 
(TJNK) 
 
Primary Cell Signalling 
Technology/ New 
England Biolabs, 
Hitchin, UK 
9258 6 
Anti-PARP Primary Cell Signalling 
Technology/ New 
England Biolabs, 
Hitchin, UK 
9542 9 
Anti-peIF2α Primary Cell Signalling 
Technology/ New 
England Biolabs, 
Hitchin, UK 
9721 10 
 
Anti-Phospho-
JNK (PJNK) 
Primary Cell Signalling 
Technology/ New 
England Biolabs, 
Hitchin, UK 
492515 11 
Anti-Rabbit IgG Secondary Cell Signalling 
Technology/New 
England Biolabs, 
Hitchin, UK 
7074 17,18 
Donkey Anti-
Rabbit 
Secondary ThermoFisher  
Scientific, 
Loughborough, UK 
31458 117095904 
 
 
Fab2 goat anti-
human IgG Fc 
(product 
number). 
ELISA 
Coating  
Jackson 
Immunoresearch 
Labs Inc/Stratech 
Scientific, 
Newmarket, UK 
109 – 006 – 
098 
97700 
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Goat Anti-
Mouse 
Secondary ThermoFisher  
Scientific, 
Loughborough, UK 
31432 HF1010102 
 
2.5 Chemically Competent E. coli Cells 
 
Name Source 
XL10-Gold 
(Genotype - TetrD(mcrA)183 D(mcrCB-
hsdSMR-mrr)173 endA1 supE44 thi-1 
recA1 gyrA96 relA1 lac Hte [F´ proAB 
lacIqZDM15 Tn10 
(Tetr) Amy Camr]) 
Produced in-lab (see Preparation of 
Chemically Competent E. coli, below) 
XL-2 Blue 
(Genotype - endA1 gyrA96(nal
R
) thi-1 
recA1 relA1 lac glnV44 F'[ ::Tn10 
proAB
+
 lacI
q
 Δ(lacZ)M15 Amy CmR] 
hsdR17(rK
-
 mK
+
)) 
Stratagene/Agilent Technologies 
Wokingham, UK – Cat No. #20024 
One shot TOP10 chemically competent 
cells (Genotype - F- mcrA (mrr-hsdRMS-
mcrBC) 80lacZM15 lacX74 recA1 ara139 
(ara-leu)7697 galU galK rpsL (Str
R
) endA1 
nupG>) 
Invitrogen Life Technologies Ltd, Paisley, 
UK – Cat No. C4040 
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2.6 Cell Lines 
 
Table 2.14 - Cell Lines 
Cell line Source/Reference 
ire1α -/- mouse 
embryonic fibroblasts 
 
From  R. Kaufman of the University of Michigan (Lee, 
Tirasophon et al. 2002). 
traf2 
-/-
 mouse 
embryonic fibroblasts 
 
From T. Mak, of the Campbell Family Institute for Breast 
Cancer Research, (Yeh, Shahinian et al. 1997). 
Wild type mouse 
embryonic fibroblasts 
From T. Mak, of the Campbell Family Institute for Breast 
Cancer Research, (Yeh, Shahinian et al. 1997). 
CHO Cell Line  33 From Lonza Biologics, Slough, UK (Porter, Racher et al. 2010) 
 CHO Cell Line  41 From Lonza Biologics, Slough, UK (Porter, Racher et al. 2010) 
 CHO Cell Line  42  From Lonza Biologics, Slough, UK (Porter, Racher et al. 2010) 
CHO Cell Line  137  From Lonza Biologics, Slough, UK (Porter, Racher et al. 2010) 
CHO Cell Line  159 From Lonza Biologics, Slough, UK (Porter, Racher et al. 2010) 
CHO Cell Line  Null From Lonza Biologics, Slough, UK (Porter, Racher et al. 2010) 
CHO Cell Line  Host. From Lonza Biologics, Slough, UK (Porter, Racher et al. 2010) 
T-Rex™ -293 Purchase from Invitrogen, Paisley UK 
Flp-In™ 293 
- Fv2e-C’hIRE1 
Invitrogen, Paisley UK. (Cat no. R75007) Stably transfected 
with C-Terminal human IRE1 chimerically fused to a Fv2e 
dimerisation domain by David Cox, Durham University. 
Flp-In™ 
-CHO 
Invitrogen, Paisley UK (Cat no. R758-07). 
 
2.7 Commercially Available Kits 
 
Table 2.15 - Commercially Available Kits 
Name Purpose Source Protocol 
Version 
DC Protein Assay Protein Biorad, Hemel LIT448 Rev D 
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quantification Hempstead, UK 
 
ECL Plus 
Western Blotting 
Detection 
Reagents 
Western blot 
luminescence 
detection 
Amersham Biosciences/ 
GE Healthcare, Chalfont 
St. Giles, UK 
RPN2132PL 
Rev-B, 2002 
 
 
EndoFree Plasmid 
Maxi Kit 
 
Large volume 
DNA preparation 
Qiagen, Crawley, UK Third Edition, 
November 
2005 
EZ-RNA kit  
 
 
 
RNA Harvesting Geneflow Ltd., Fradley, 
UK. 
Dec 2003 
RNA Easy Kit RNA Preparation Qiagen, Crawley, UK Fourth 
Edition, 
September 
2010 
Miniprep Kit Large volume 
DNA preparation 
Qiagen, Crawley, UK Second 
Edition, Dec 
2006 
FirstChoice® 
RLM-RACE Kit 
 
 
 
RACE  Applied 
Biosystems/Ambion, 
Foster City, CA, USA  
P/N 1700M 
Revision C, 
Revision 
Date: March 
21, 2008 
First Strand cDNA 
Synthesis Kit 
 
Reverse 
transcription of 
cDNA from RNA 
Invitrogen, Paisley, UK 18080400.pps 
8-Oct 2004 
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Flp-In  T-REx 
 Core Kit 
 
pcDNA™ 
5/FRT/TO expression 
vector 
Generating stable 
cell lines 
Invitrogen, Paisley, UK Version D 
111110 
25-0366 
 
Version G 
11 November 
2010 
25-0368 
 
GenElute™ Gel 
Extraction Kit 
Purification of 
DNA from 
agarose gels. 
Sigma-Aldrich, 
Gillingham, UK 
SM/MAM 
7/03 
GenElute
™
 HP 
Plasmid Midiprep Kit 
Preparation of 
Plasmid DNA 
from E. coli. 
Sigma-Aldrich, 
Gillingham, UK  
01911-502620 
0019 
GenElute™ PCR 
Clean-Up Kit 
Purifying DNA. Sigma-Aldrich, 
Gillingham, UK 
CP/JWM 8/04 
Gigaprep Kit Large volume 
DNA preparation 
Qiagen, Crawley, UK May 2002 
jetPRIME™ 
 
Transfection Polyplus Transfection, 
Illkirch, France  
4/12 CPT 114 
vF May 2011 
Lipofectamine 2000 
 
Transfection Invitrogen, Paisley, UK Rev Date: 11 
July 2006 
Neon® Transfection 
System  
Electroporation Invitrogen, Paisley, UK   MP-100 
Rev.M.03.51-
11/07 
pGEM Easy T Vector Cloning of PCR 
products 
Promega, Southampton, 
UK. 
 Revision 2/09 
QIAquick PCR 
Purification Kit 
Purifying DNA. Qiagen, Crawley, UK March 2008 
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QuikChange® II XL 
Site-Directed 
Mutagenesis Kit 
Mutagenesis Agilent Technologies, 
Wokingham, UK 
200521-12 
Revision B 
Rediprime™ II DNA 
Labeling System 
 
Southern blotting 
(Probe labelling).  
GE Healthcare, Chalfont 
St. Giles, UK  
RPN1633PC 
Rev C 04-
2008 
RNasein RNase inhibitor Promega, Southampton, 
UK.  
See First 
Strand 
Synthesis 
protocol. 
TOPO TA Cloning 
kit 
Cloning of PCR 
products 
Invitrogen, Paisley, UK   Version O  
10 April 2006  
25-0276 
3,3’, 5,5’ 
tetramethylbenzidine 
(TMB) Liquid 
Substrate System 
ELISA  Sigma-Aldrich, 
Gillingham, UK  
alc 10/99 
 
2.8 Specialist Equipment 
 
Item Code Manufacturer 
Mr Frosty Cryo Freezing 5100-0001 Nalgene/ ThermoFisher  Scientific, 
Loughborough. 
6 well plates  
24 well plates 
96 well plates 
83.1839.300 
83.1836.300 
83.1835.300 
Sarstedt, Leicester, UK 
 
25cm
2
 flask  (Adherent) 
25cm
2
 flask  (Suspension) 
75cm
2
 flask (Adherent) 
75cm
2
 flask (Suspension) 
83.1810.002 
83.1810.500 
83.1813.002 
83.1813.500 
Sarstedt, Leicester, UK 
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75cm
2
 flask (Adherent) 
75cm
2
 flask (Suspension) 
83.1812.002 
83.1812.500 
PVDF membrane, pore size 
0.45 μm 
RPN303F GE Healthcare, Chalfont St. Giles, 
UK 
Kodak BioMax MS Z363049 ThermoFisher  Scientific, 
Loughborough, UK 
96 well Maxisorp ELISA 
plates 
475094 Nunc/ThermoFisher  Scientific, 
Loughborough, UK 
Abgene adhesive plate seals AB-0580 ThermoFisher  Scientific, 
Loughborough, UK 
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3. METHODS 
 
3.1 Cell Culture 
 
All cells were incubated at 37°C with 5% (v/v) CO2 at 95% humidity. Appropriate antibiotics 
were added to medium as required in stable cell line production. 
3.1.1 Revival 
Cryovials containing cells were stored either in -140°C freezer or liquid nitrogen cryostorage 
vessels. The cryovial was removed  from storage and  incubated at room temperature for approx 
1 min and  then warmed in a 37
o
 C water bath for 1-2 min, submerging only 2/3 of the vial into 
the water bath to prevent contamination and shaking  continuously, but gently, until the cells 
were completely thawed. The cryovial was wiped dry with a tissue and then cleaned with 70% 
(v/v) ethanol before introduction into the tissue culture hood.  Using a 2ml pipette, the contents 
of the cryovial was pipetted drop by drop into a 50ml falcon tube. 10-50ml of the appropriate 
culture medium, pre-warmed was pipette onto the cells, which were then centrifuged at 110 g, 5 
min, RT, to collect them on the bottom of the tube. The supernatant was aspirated and replaced 
with 5-10ml of appropriate fresh pre-warmed medium and mixed gently. The cell suspension 
was then transferred to a 25 cm
2
 vented flask and incubated. Cells were checked daily to 
monitor their growth.  
3.1.2 Cryopreservation 
Table 3. 1- Cryopreservation media 
Cell Types Medium 
ire1α -/-, traf2 -/-, wild type MEFS,  Flp-
In™ -293- Fv2e-C’hIRE1 HEK293s, Flp-
In™-CHO  
90% FBS, 10% DMSO 
CHO Cell Lines 33, 41, 42, 137, 159, 
Null, Host (serum-free adapted lines). 
90% CD-CHO, 10% DMSO 
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1ml of the appropriate cryopreservation medium for the cell type was prepared and placed on 
ice.  A cryovial labeled with the cell line, date and passage number was prepared. Where 
adherent cells were being frozen, they were removed from the flask surface with Trypsin-
EDTA. Cells were counted with an Improved Neubauer haemocytometer, centrifuged and 
resuspended in the appropriate cryopreservation medium to give a concentration of 2-4·10
6
 
cells/ml. 1ml of cell suspension was pipetted into each vial. The cells were frozen at a slow 
cooling rate by placing them in the Mr Frosty Cryo Freezing Container (see “Specialist 
Equipment”) with 100% isopropyl alcohol (250 ml) added. The Cryo Freezing Container was 
then placed into a -80°C freezer for a minimum of 4 h and a maximum of 24 h. The individual 
vials were transferred to either a -140°C freezer or liquid nitrogen for long-term storage.  
3.1.3 Trypsinisation 
When passage was required, (cell confluence of >90% in flask) the medium was aspirated and 
replaced with 5ml of Dulbecco’s PBS and washed. The PBS was then aspirated  cells were 
trypsinised for >1 min with 0.25% with 1ml Trypsin-EDTA (See “Cell Culture Media and 
Reagents”, above) and incubated for 1 min at 37°C. Trypsinisation was halted with an equal 
volume of the appropriate medium for the cell line (as above, “Table 2.6 - Cell Culture 
Media”). 
3.1.4 MEF Culture  
ire1α-/- MEF cell lines were cultured in Dulbecco’s Modified Eagle’s Medium with 110 mg/l 
pyruvate, and with 10%(v/v)  foetal calf serum and 2mM L-glutamine. Wild type and traf2
-/-
 
MEF cell lines were cultured in Dulbecco’s Modified Eagle’s Medium with 10% (v/v) foetal 
calf serum and 2mM L-glutamine. Appropriate antibiotics were added to medium as required in 
stable cell line production.  
3.1.5 CHO Culture 
CHO cells were cultured in CD-CHO medium supplemented with 25 µM MSX . Flp-In™-CHO 
were cultured in Dulbecco’s Modified Eagle’s Medium without pyruvate, and with 10% foetal 
calf serum and 2mM L-glutamine added.  If suspension CHO cells grown in CD-CHO were 
required to be made adherent for purposes of transfection, they were transferred to adherent 
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flasks and cultured in Dulbecco’s Modified Eagle’s Medium without pyruvate, containing 10% 
foetal calf serum and 2mM L-glutamine and trypsinisation was as described above. 
3.1.6 HEK293 Culture  
HEK293 cells were cultured as MEFs, but were grown in Dulbecco’s Modified Eagle’s 
Medium with 10%(v/v)  foetal calf serum and 2mM L-glutamine.  
3.1.7 Stable Cell Line Production 
Stable cell lines production was performed according to the protocol in the Invitrogen “Flp-In  
T-REx Core Kit” Manual.  
 
3.1.7.1 Antibiotic Tolerance 
 
ire1α-/- MEFs were exposed to varying concentrations of zeocin, blasticidin or hygromycin by 
addition to their growth medium and incubated for 14 days and the viable cells counted to 
ascertain a concentration of antibiotic that was not immediately lethal, but that killed all non-
stably transfected cells within 14 days.   
 
3.1.7.2 Transfection with pFRT/lac/Zeo or pcDNA6⁄TR 
 
As recommended in Flp-In™ manual, the pFRT/lac/Zeo or pcDNA6/TR  plasmid was 
linearised by digestion with the restriction enzyme ScaI or BtZ17I/Bst1107I respectively. The 
digestion reaction was run on a gel and purified using the GenElute™ Gel Extraction Kit. 2ug 
of the linearised pFRT/lac/Zeo or pcDNA6/TR plasmid was then transfected into ire1α-/- cells 
using an electroporator and the cells were grown for 24 hours to recover from transfection. The 
medium was then removed, the cells washed, and replaced with medium containing 10µg/ml 
zeocin or blasticidin respectively. The stably transfected cells were incubated for 14 days with 
zeocin until colonies of stably transfected cells began to form, and then grown until the colonies 
approached confluence and would normally have been passaged.  
 
3.1.7.3 Storage of Stable Clones 
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Frozen stocks of the mixed population of transfectants were made as described in Materials and 
Methods – “Cell Culture – Cryopreservation” and one passage was continued for limited 
dilution cloning using 96 well plates (See “Specialist Equipment”) as described in Materials 
and Methods – “Limited Dilution Cloning”. 
 
 
3.1.7.4 Co-Transfection with pcDNA5-FRT-TO-hIRE1α/ pOG44 
 
Clone 4,3 was used for the final cell line production and transfection as it exhibited the best 
response in the tet-repressor function assay above. As recommended by the Flp-In manual, 
1x10
6 
cells from the line 4,3 were electrotransfected with 2µg of the required pcDNA5-FRT-
TO-hIRE1α construct and 20µg of pOG44 (1:10). Cells were grown for 24 hours to allow 
recovery from transfection before application of hygromycin medium. A lower dose of 25 
µg/ml was applied for the first 24 hours after recovery to allow the cells to acclimatise to the 
hygromycin, as during the production of other cell lines in our laboratory by David Cox, it had 
been found that this increased the likelihood of successfully gaining viable clones. After this 
period, the full selection concentration of 100ug/ml was applied. After six days of this 
treatment all non-transfected cells and colonies of stably transfected cells were growing. Frozen 
stocks of the transfectants were made as described in Materials and Methods – “Cell Culture – 
Cryopreservation” and one passage was continued for characterisation in the following chapter. 
 
3.1.8 Transfection - Electroporation 
Mouse embryonic fibroblasts were grown in a 75cm
2
 flask (See “Specialist Equipment”) until 
confluent at a density of 9x10
6
 cells. The cells were washed with PBS and trypsinised with 1ml 
trypsin-EDTA  and incubated for 1 min at 37°C. Trypsinisation was halted with an equal 
volume of medium (as above, “Cell Culture”) and the solution was aspirated and centrifuged at 
110 g for 2 min. The medium was removed and the cells were resuspended in PBS and counted 
with an Improved Neubauer haemocytometer.  1x10
6
 cells were removed per transfection, 
centrifuged at 110 g for 2 min and the PBS removed. Cells were resuspended in Buffer R and 
transiently transfected according to the Digital Biotech (Seoul, Korea)/Invitrogen Microporator 
protocol (Protocol Reference: MP-100 Rev.M.03.51-11/07) with 0.2-8µg of plasmid DNA 
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using the Digital Biotech Microporator MP-100. Transfected cells were immediately transferred 
into medium and grown at 37°C. 
3.1.9 Transfection – Jetprime 
HEK293 cells were seeded at 0.05-0.2x10
6
 cells per 0.5-2ml of appropriate growth medium 
into either 6-well or 24-well plates (See “Specialist Equipment”) as required and grown for 24 h 
or until confluent at a density of 60-80% at time of transfection. 0.25-2µg of DNA, 0.5-4μl of 
jetPRIME™ (DNA:Jetprime ratio 1:2) and 50-200μl of jetPRIME™ buffer per transfection 
were mixed to produce  the reaction mixture and mixed by vortexing, then centrifuged briefly at 
14000g. The reaction was incubated for 10 min at room temperature.  The reaction mix was 
added to the cells with growth medium drop by drop and gently rocked from side to side to mix. 
Cells were incubated at 37°C for 4h and then the medium replaced. Analyses were performed 
24h after transfection.  
3.1.10 Transfection - Lipofectamine 
CHO cells were seeded at 0.15x10
6
  per 0.5ml of appropriate growth medium into 24-well 
plates as required and grown for 24 h at 37°C or until confluent at a density of 60-80% at time 
of transfection. Before transfection, seeding medium was replaced with 800μl fresh prewarmed 
medium and incubated at 37°C for at least 30 min. During the incubation, DNA and 
lipofectamine was prepared. 2ug of DNA per transfection was mixed with 100μl of Optimem 
(See “Cell Culture Media”, above) and incubated for 5 min. 5μl of Lipofectamine were mixed 
with 100μl of Optimem and incubated for 5 min. After the 5 min incubations, the two mixtures 
were combined and the Optimem-DNA-Lipofectamine incubated together for 20 min. The cell 
culture medium was removed from the cells and replaced with the Lipofectamine mixture and 
incubated for 2-3 days, or until the appropriate amount of time for the time course conducted 
had elapsed.  
3.1.11 Induction of endoplasmic reticulum stress with tunicamycin, thapsigargin or DTT 
Endoplasmic reticulum stress was induced by treatment with 100nM-1uM thapsigargin, 100ng-
1µg/ml tunicamycin (Calbiochem/VWR, Lutterworth, UK) or 10mM DTT (Sigma Aldrich, 
Gillingham, UK). Medium was removed from cells and replaced with medium containing the 
 124 
 
ER stressor. Cells were incubated at 37°C for 1-2hr or whichever time was appropriate for the 
experimental time course.  
3.1.12 Assessment of Transfection Efficiency/Cell Death 
Transfection efficiency was assessed by GFP fluorescence by eye, and living versus dead cells 
were stained with trypan blue 0.4% (v/v) (see “Cell Culture Media and Reagents”) and counted 
with an Improved Neubauer haemocytometer.    
3.1.13 Limited dilution cloning 
Limited dilution cloning was performed according to the methodologies in papers by Coller and 
Lefkovits (Lefkovits 1979; Coller and Coller 1986).  Cells were transfected with 2ug of the 
DNA to be stably integrated and grown under the appropriate antibiotic selection conditions for 
>14 days in order to remove all transiently transfected cells. At least three vials of the mixed 
transfection were frozen for a back-up stock according to the above protocols. Sufficient cells 
of the mixed population were grown for the cloning (~1x10
6
) and trypsinised where required to 
remove them from culture vessels. Cells were diluted to a concentration of either 10, 3 or 1 
cells per 50μl of the appropriate growth medium. Three 96 well cloning plates were set up, one 
for each dilution. 50μl of each dilution were dispensed into the appropriate 96-well plate and 
grown for at least 14 days or until it was clear whether or not cells were growing in each 
individual well.  The percentage of wells with growth was assessed and the probability of their 
arising from single clones assessed according to Table 3. 2 below. If no plates had <10% of 
wells containing cells, the experiment was repeated with lower dilutions, 1 cell/well, 0.3 
cells/well and 0.1 cells/well. If less than 10% of wells exhibited growth, each well colony was 
trypsinised and removed from its well and subcultured into a 24 well plate. Once confluence 
was achieved in a 24 well plate, the cell cultures were scaled up to larger plates as required until 
sufficient cells had been achieved for freezing stocks. At least three vials of each clone were 
frozen and those exhibiting the best growth characteristics selected for further testing.  
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Table 3. 2 - Probability that wells showing growth have arisen from one (1/R), two (2/R), three 
(3/R), four (4/R) or five (5/R) stably transfected cells. 
Wells showing 
growth [%] 
Mean no. of transfected 
cells/well at inoculation 
1/R 2/R 3/R 4/R 5/R 
1 0.01 0.995 0.004    
5 0.05 0.975 0.024    
10 0.10 0.950 0.047 0.001   
15 0.16 0.922 0.073 0.003   
20 0.22 0.894 0.099 0.007   
25 0.29 0.861 0.124 0.012   
30 0.35 0.835 0.146 0.017 0.001  
35 0.43 0.800 0.172 0.024 0.002  
40 0.51 0.766 0.195 0.033 0.004  
45 0.61 0.725 0.221 0.044 0.006  
50 0.69 0.694 0.239 0.055 0.009 0.001 
55 0.80 0.652 0.261 0.069 0.013 0.002 
60 0.91 0.613 0.278 0.084 0.019 0.003 
65 1.05 0.565 0.296 0.103 0.027 0.005 
70 1.20 0.517 0.310 0.124 0.037 0.008 
75 1.39 0.461 0.320 0.148 0.051 0.014 
80 1.61 0.402 0.329 0.179 0.069 0.022 
 
3.2 Bacterial culture 
  
3.2.1 Chemical transformation of E. coli 
 
Table 3. 3 – Protocol Details for Chemical Transformation 
Cell Type Tube 
Size 
Cell Volume Heat Shock 
for 
Incubation 
on ice  
Culture Medium 
XL-10 
Gold 
14ml 100 µl 90s 5min 900µl LB with 20 
mM D-glucose 
XL-2 Blue 1.5ml 50 µl + 1μl of β- 30s 2min 0.9ml of NZY+ 
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Ultracompe
-tent Cells 
mercaptoethanol broth preheated to 
42ºC 
TOP10 1.5ml 50 µl 30s 2min 250μl of S.O.C. 
medium pre-warmed 
to room temperature 
 
Standard Protocol 
 
Competent cells were removed from a -80ºC freezer and immediately put on ice where they 
were allowed to thaw. Up to 5µl of DNA was added to the appropriate size of tube for the cell 
type (see Table) and put on ice. Once competent cells were thawed, they were mixed carefully 
by swirling every 2 min. The appropriate volume (see Table 3. 3 – Protocol Details for 
Chemical Transformation , above) of competent cells were carefully added to the DNA, 
pipetting slowly to avoid the production of bubbles/over-agitation of the cells, and mixed 
briefly by flipping, then incubated on ice for 30 min. At the end of the incubation period tubes 
were placed into a rack and heat shocked in a 42ºC waterbath for the appropriate number of 
seconds without moving the tubes, and then placed on ice for X mins as listed in the table 
above. X µl of the appropriate culture medium was added to each tube and incubated at 37ºC 
with shaking at ~250 rpm for 1h. 200 µl cell suspension was plated onto LB-ampicillin 100 
µg/ml agar plates. Plates were incubated in a 37ºC incubator overnight. 
The following solutions were used as controls for transformation: 5 µl water (negative control) 
to determine if contamination of materials gives rise to undesired colonies and 1 µl pUC18 at 
10ng/μl (positive control) to ensure success of transformations.  
3.2.2 Revival of E. coli cultures 
A cryotube containing frozen stock was removed from the -80°C freezer and placed on dry ice. 
The frozen cell suspension was scraped with a pipette tip to loosen some ice (~10-20 µl) and 
streaked onto an LB-ampicillin agar (100 µg/ml) plate. The plate was incubated in a 37ºC 
incubator overnight. 
3.2.3 Growth of E. coli cultures 
LB-broth was added to sterile Erlenmeyer flasks at least twice as big as the intended culture 
volume while working close to the flame of a Bunsen burner. Ampicillin was added to the broth 
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to a final concentration of 100 µg/ml. The broth was then inoculated with a single E. coli 
colony from a LB-agar plate or a fresh saturated overnight culture was diluted 1:100 into the 
new medium, after washing three times with 1ml sterile H2O. Cultures were incubated with 
with shaking at 225 – 250 rpm at 37ºC overnight. 
3.2.4 Production of frozen E. coli stocks. 
1ml of 30% (v/v) glycerol was pipetted into each of two labelled cryotubes. E. coli cultures 
grown as described above were resuspended by vortexing and 1ml was added to each cryotube. 
The cryotubes were then mixed by inverting and flash-frozen by immersion in liquid nitrogen. 
Cryotubes were stored in a -80°C freezer until required for revival. 
 
3.2.5 Preparation of chemically competent E. coli. 
4 ml of LB broth was inoculated with one colony of E. coli cells from a fresh LB agar plate and 
grown >16 h at 37°C with shaking at 225 rpm. The overnight culture was diluted 1:100 into LB 
broth and incubated at 37°C with shaking at 225 rpm. After ~1 h, the absorbance at 600nm of 
the culture was measured every 15 - 30 min until it reached 0.3 – 0.4 A600 nm. The culture was 
transferred to a centrifuge tube precooled on ice and centrifuged for 10 min at 1,000 g and 4°C 
to collect the cells. The supernatant was decanted off, and the cells resuspended by gentle 
shaking and resuspended in 1/10 of the original culture volume of ice-cold 1 x TSS. Cells were 
aliquoted at 500µl into ice-cold 1.5 ml microcentrifuge tubes and snap-frozen  in liquid 
nitrogen. Cells were stored at -70°C. 
3.3 Protocols for preparation/use of DNA 
 
3.3.1 Preparation of DNA from E.coli culture by mini/midi/maxi/gigaprep and ethanol 
precipitation of nucleic acids 
 
3.3.1.1 Plasmid Miniprep 
 
4ml of LB broth with 100μg/ml ampicillin was inoculated with one colony E. coli cells as 
described in “Growth of E. coli cultures”. 1ml of the fresh overnight culture was transferred 
into a 1.5 ml microcentrifuge tube. The remainder of the culture was stored at 4°C. The cells 
 128 
 
were collected by centrifugation for 1 min at 14,000 g at room temperature and the supernatant 
removed. The cells were centrifuged at 14,000 g again to collect the remaining supernatant 
which was aspirated. The cell pellet was resuspended in 100 μl 1xGTE and mixed by pipetting 
up and down, then incubated at room temperature for 5 min. 200 μl 0.2 N NaOH, 1% (w/v) 
SDS was added to lyse the cells. It was then agitated gently by inverting the tubes 4-6 times to 
prevent nicking of genomic DNA. The solution was then incubated on ice for 3-5 min. Then the 
reaction was neutralised by addition of 150 μl ice-cold 5 M KOAc (pH 4.8), and mixed gently 
by inverting the tube 4-6 times. The solution was incubated 5 min on ice, centrifuged for 5 min 
at 14,000 g, 4°C and the supernatant transferred into a new microcentrifuge tube, ensuring not 
to remove any flocculent material with it. The supernatant was centrifuged again at 14,000 g, 
4°C to remove any remaining flocculent material. The remaining supernatant was removed and 
transferred into a new microcentrifuge tube, and mixed with 800μl of 100% ethanol by 
inverting the tube 2-3 times. The mixture was incubated at room temperature for 2 min, then 
centrifuged for 1 min at 14,000 g. The supernatant was removed and discarded, and replaced 
with 1 ml of 70%(v/v) EtOH. The solution was centrifuged for 1 min at 14,000 g, RT (18-
24°C), and the supernatant removed and discarded. The remaining pellet was centrifuged again 
for 10-15 s at 14,000 g at room temperature and the remaining ethanol supernatant removed. 
The DNA pellets were air-dried for no more than 5 min at room temperature to prevent over-
drying. Dry pellets were resuspended in 33μl of 1x TE (pH8.0), with 0.3 mg/ml RNase A and 
incubated at 4°C until dissolved for up to 30 min. DNA was quantified on a Molecular Devices 
Spectramax Spectrophotometer and the concentration confirmed by DNA gel electrophoresis. 
 
3.3.1.2 Plasmid Midi/Maxi/Gigaprep 
 
Preparation of DNA from the appropriate volume of culture in LB-ampicillin medium was 
performed according to the instructions in the Sigma/Qiagen Kits listed above in 
“Commercially Available Kits”. If further concentration of DNA was required, the following 
protocol was followed: 
 
0.1 Volume of 3 M NaOAc (pH 5.2) was added to the nucleic acid sample in a 1.5 ml 
microcentrifuge tube and mixed well. Based on the new volume of the sample 2.5 volumes of 
EtOH at -20ºC were added to the sample and mixed well. The precipitations were incubated for 
≥ 30 min at -70ºC or ≥ 1 h at -20ºC. Then the nucleic acid precipitate was sedimented by 
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centrifugation at 15,000 g, 4ºC for 30 min. The supernatant was aspirated and 1 ml 70% (v/v) 
EtOH was added. The nucleic acid precipitate was sedimented again by centrifugation at 15,000 
g, 4ºC for 10 min and the supernatant aspirated. The solution was centrifuged for 10-20 s at 
15,000 g, room temperature and the remaining liquid aspirated. Then the pellet was air-dried by 
incubating the open tubes for 5 min at room temperature. 10-50 µl of TE (pH 8.0) was added 
and samples were placed at 4ºC to dissolve nucleic acid.  DNA was quantified on a Molecular 
Devices Spectramax Spectrophotometer and confirmed by DNA gel electrophoresis. 
 
3.3.2 DNA agarose gel electrophoresis 
 
An adequate volume of TAE was prepared to fill the electrophoresis tank and to prepare the gel. 
0.3-1.5g of of electrophoresis-grade agarose, dependent upon gel size was placed into an 
Erlenmeyer flask and dissolved in 30-150 ml TAE to produce a 0.9%(w/v), 1%(w/v) or 2% 
(w/v) agarose gel. The agarose was dissolved in a microwave oven at the highest power setting 
for 1 – 5 min, swirling every ~30 to 60 s to ensure even mixing and to avoid boiling over of the 
agarose solution. The agarose solution was allowed to cool to below 40°C, and ethidium 
bromide was added to 0.5 µg/ml to the agarose solution, and mixed. The gel casting platform 
was sealed at the open ends with masking tape. The dissolved agarose was poured in and a gel 
comb inserted. After the gel had solidified, walls were removed from the open ends of the gel 
platform and the gel comb withdrawn. The gel casting platform containing the set gel was 
placed into the electrophoresis tank. Sufficient electrophoresis buffer to cover the gel to a depth 
of about 1 mm was added. The required amount of DNA diluted 1:10 in 1:9 DNA loading 
buffer (1μl DNA, 1μl loading buffer, 9μl water) was added to the wells using a pipette. A DNA 
ladder marker (1Kbp DNA Ladder, Promega, Southampton, UK Code: G5711) was added to 
the first well of each gel at the same proportions as the DNA/Buffer/Water mix. Field strengths 
of 1-1.5V/cm were applied to the gel. Once the DNA had migrated to the required distance 
(judged by migration of the loading dye), the DNA was visualized under a UV transilluminator  
using UV light at 302nm for DNA bands.  
 
3.3.3 Polymerase chain reaction (PCR) for insert construction 
 
The following components were combined in a 100 µl PCR tube. 
 
1.25  units of Pfu Polymerase  
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3 µl 25 mM MgCl2 
5 µl 2 mM dNTP 
1µM of primer 1 
1µM of primer 2 
1 µl of template DNA at 0.5 µg 
5 µl of 10x Pfu polymerase buffer. 
H2O to 50 µl 
and subjected to the following conditions in the thermocycler: 
 
Table 3. 4 - Thermocycler conditions for PCR for insert construction 
Temperature Time No. of Cycles 
95°C 2 min 1 
95°C 30 s 35 
 60.5°C 30 s 
72°C 2 min 39 s 
72°C 5 min 1 
4°C ∞ 1 
 
3.3.4 Cloning of PCR products with cloning vectors pGEM Easy T and TOPO TA cloning kit 
 
In all cases, see “Oligodeoxynucleotide Primers” for sequences of vector primers 
The Promega pGEM Easy-T Vector was used according to the protocol listed above 
(“Commercially Available Kits”).  PCR products requiring cloning were separated on an 
agarose gel, excised and purified from the gel using the GenElute™ Gel Extraction Kit (ibid.) 
then DNA concentration was measured using the Molecular Devices Spectramax 
Spectrophotometer. The DNA was used in the following ligation reaction. 
3μl PCR Product 
5μl 2x Rapid ligation buffer 
1μl pGEM Easy-T Vector (50ng) 
1μl T4 DNA Ligase (at 1-3u/µl) 
The reaction was incubated >16h at 4°C. 5μl of the reaction mixture was chemically 
transformed into E. coli cells according to the protocol above (3.1.1. “Chemical Transformation 
of E. coli”) and plated on to LB agar  + 50 µg/ml ampicillin + 80µg/ml X-Gal + 500µM IPTG 
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plates.  Blue/white colonies were counted, and white colonies selected using a pipette tip for 
colony PCR. The following mix was prepared: 
 
10μl 5x Promega GoTaq Buffer 
5μl 2mM dNTPs 
0.5μl T7 Sequencing Primer for pGEM Vector at 100µM 
0.5 μl SP6 Sequencing Primer for pGEM Vector 100µM 
0.5μl Promega GoTaq Polymerase 
3μl 25mM MgCl 
Sterile H20 to 50μl  
 
White colonies selected were briefly dipped in the PCR mix and then placed in 4ml of LB broth 
+ 50 µg/ml ampicillin and grown >16 h at 37°C with shaking at 225 rpm.  Inoculated PCR 
mixtures were subjected to the following PCR protocol. 
 
Table 3. 5 - Thermocycler conditions for cloning vector PCR 
Temperature Time No. of Cycles 
94°C 2 min 1 
94°C 15 s 30 
 55°C 15 s 
72°C 1 min 
4°C Until required 1 
 
PCR products were run on a 1% (w/v) agarose gel (3.2.2 DNA agarose gel electrophoresis) and 
those producing a band of a correct length compared the original PCR product were selected for 
DNA preparation by miniprep (3.2.1 “Preparation from E.coli culture...of nucleic acids”) and 
sequencing. 
 
The TOPO TA cloning vector was used according to the protocol listed above (“Commercially 
Available Kits”).  PCR products requiring cloning were separated on an agarose gel, excised 
and purified from the gel using the GenElute™ Gel Extraction Kit (ibid.). The DNA 
concentration and purity was measured using the Molecular Devices Spectramax 
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Spectrophotometer (OD at 260nm, OD260/OD280 ratio). The DNA was used in the following 
ligation reaction: 
4μl PCR Product 
1μl Salt solution (1.2 M NaCl, 0.06 M MgCl2). 
1μl TOPO Vector (10 ng/µl plasmid DNA in: 50% glycerol, 50 mM Tris-HCl pH 7.4 (at 25°C), 
1 mM EDTA, 1 mM DTT, 0.1% Triton X-100, 100 µg/mL BSA, phenol red) 
 
Chemical transformation, into TOP10 Chemically competent E. coli cells, colony selection and 
colony PCR, and agarose gel run of products was performed as above. Colony PCR used the 
following PCR mix and PCR conditions as above.  
 
5μl 10x Accuprime PCR BufferI 
0.5μl Primer M13 R 100µM 
0.5 μl Primer M13 F 100µM 
0.2μl (1unit) Accuprime Taq 
42.μl H20 (to 50μl)  
 
3.3.5 Restriction enzyme digestion 
 
Restriction enzyme digest was performed according to the appropriate protocols recommended 
by the manufacturer. If cleanup was required after the enzymatic digest, it was either purified 
with a GenElute™ PCR Clean-Up Kit or the reaction was run on an agarose gel as described 
above and purified from the gel using a GenElute™ Gel Extraction Kit. 
 
3.3.6 10μl reaction (Small volume, for test digests) 
 
Xμl 100ng-1µg DNA 
1μl 10x restriction enzyme buffer 
1μl restriction enzyme at 10units/µl 
H2O to 10μl 
 
3.3.7 50μl Reaction (Large volume for harvesting digest products) 
 
Xμl 10-50ug DNA 
 133 
 
5μl 10x restriction enzyme buffer 
10units/1μl-50units/5μl Restriction Enzyme (Recommended amounts not exceeded in case of 
star activity) 
H2O to 50μl 
 
Digestion is 1hr-Overnight depending on whether enzymes suffered from star activity/loss of 
specificity upon too long a digest.   
 
3.3.8 Dephosphorylation of DNA 5’ termini with calf intestinal alkaline phosphatase (CIAP). 
 
The following components were combined in a 100 µl PCR tube: 
1-10 µg of DNA 
5 µl CIAP reaction buffer 
1 µl 0.01U/µl CIAP 
H2O to 50 µl 
and mixed well by flipping the tube. Tubes were briefly centrifuged in a microcentrifuge to 
collect all liquid at the bottom of the tube, and incubated at 37°C for 30 min. After the 
incubation, an additional 1 µl 0.01U/µl of CIAP was added and the sample was incubated  for 
another 30 min at 37°C. 
 
3.3.9 DNA ligation with T4 DNA ligase 
 
3.3.9.1 Standard method 
 
The following components were combined in a 100 µl PCR tube: 
 
33-50 ng of vector DNA 
Insert DNA at a 1:1 or 1:3 molar ratio, calculated as follows: 
((ng vector)x(kb size of insert))/(kb size of vector)) x (molar ratio of (insert/vector)) = (ng 
insert) 
e.g. ((50ng)x(0.5kb))/(6kb)) x (3/1) = (12.5ng insert) 
2 µl of T4 DNA ligase buffer 
1 µl of T4 DNA ligase  
H2O to 20 µl 
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and mixed well by flipping the tube. Tubes were briefly centrifuged in a microcentrifuge to 
collect all liquid at the bottom of the tube, and incubated at 16°C for ≥ 16 h. 
A control reaction only consisting of vector DNA was also performed. Ratio of vector:insert  
was  increased from 1:3 to 1:10 if colonies were found to contain a high proportion of religated 
vector.  
 
3.3.9.2 High yield method (provided by A. Mohamed) 
 
Where a low number of colonies were obtained, the above reaction was repeated, replacing the 
incubation at 16°C for ≥ 16 h with the following. Vector and insert DNA, and water were 
incubated at 65°C for 15 min to denature any secondary structure in the DNA, then allowed to 
cool to 16°C. Ligase buffer and ligase were then added and  incubated at 16°C for 30 mins. 
Then the mixture was incubated at 4°C for >16h.  
 
3.3.10 Mutagenesis 
 
Point mutations were performed using the Stratagene Quik-Change Site-Directed Mutagenesis 
Kit (See “Commercially Available Kits” for protocol reference and supplier information). Each 
primer inserted a novel restriction enzyme site into the sequence near to the mutation (see 
Table: “Restriction enzymes used to screen for mutated clones.“ in “Restriction Enzyme” 
section) to allow screening of clones. Plasmids were then sequenced by DBS Genomics to 
ensure no point mutations had been produced and the mutated section subcloned back into the 
original plasmid.    
 
3.3.11 Sequencing  
 
Sequencing was performed by DBS Genomics, Durham University, or Eurofins MWG Operon, 
London.  
 
3.4 Protocols for preparation/use of RNA 
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3.4.1 RNA isolation  
 
Cells were washed with PBS, and then scraped from the bottom of the culture dish to remove 
adherent cells, or directly lysed in the appropriate volume of lysis buffer depending on the kit 
used. The cells were then resuspended and harvested according to the EZ-RNA protocol or the 
RNA Easy Kit (see “Commercially available Kits”, above). RNA was quantified and purity was 
measured using the Molecular Devices Spectramax Spectrophotometer (OD at 260nm, 
OD260/OD280 ratio) and concentrations confirmed by intensity of bands visible by RNA gel 
electrophoresis. 
 
3.4.2 RNA agarose gel electrophoresis 
 
RNA gels were prepared as DNA gels, above. The required amount of RNA was diluted 1:1:4 
RNA:RNA loading buffer with 0.5 µg/ml ethidium bromide:DEPC treated water and was added 
to the wells using a pipette. A DNA ladder marker (1Kbp DNA Ladder, Promega, 
Southampton, UK Code: G5711) was added to the first well of each gel at the same proportions 
as the RNA/Buffer/Water mix.  Field strengths of 1-1.5V/cm were applied to the gel. Once the 
RNA had migrated to the required distance (judged by migration of the loading dye), the RNA 
was visualized under a UV transilluminator (312nm, 0.120? J/cm
2
) for RNA bands.  
 
3.4.3 cDNA production from RNA 
 
cDNA was reverse transcribed from RNA using the first strand cDNA synthesis kit (Invitrogen, 
see Commercially available Kits”, above).  The following reaction was set up: 
 
1μl of oligo(dT)20 (See “vector sequencing and general primers”) or 1μl of mouse/CHO gene 
specific primer (See “RT-PCR primers”) or 250ng of random hexamers (See “Vector 
Sequencing and General Primers”).  
Up to 11μl of RNA dissolved in DEPC-treated Water (containing up to 5ug total RNA). 
1μl of 100mM RNase-free dNTPs (See “Solutions for RNA work”) 
DEPC-treated water to 13μl 
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The reaction mixture was heated to 65°C for 5 min and then cooled on ice to 4°C for > 1 min. 
The following components were then added: 
 
4μl 5x First Strand Buffer 
1μl 0.1M DTT 
1μl RNaseOUT or RNAsein  
1μl of Superscript III reverse transcriptase 
 
The reaction mixture was then incubated at 50°C for 50 min and then inactivated at 85°C for 15 
min.  
3.4.4 Reverse transcription (RT)-PCR Assays for Actin/XBP-1 splicing/IRE1α. 
 
Standard Reaction Mixture 
10μl 5x Promega GoTaq Buffer 
5μl 2mM dNTPs 
0.5μl forward primer  at 100µM 
0.5 μl reverse primer 100µM 
0.5μl Promega GoTaq HotStart Polymerase 
3μl 25mM MgCl2 
Xμl cDNA Reaction (from 3.3.3. “cDNA production from RNA”) 
Sterile H20 to 50μl  
3.4.4.1 RT-PCR for Mouse XBP-1/Actin 
Spliced and unspliced XBP-1 cDNA was amplified using primers covering the splice site (see 
“Primers”, above) and using conditions given in Table 3. 6, below. Actin cDNA was similarly 
amplified using primers listed above. Amplified DNA was analysed on 2%(w/v) agarose gel 
(see above) run for 1h 15min at 100 mV.  
 
The standard reaction mixture was set up, using the Actin or XBP-1 primers as listed in 
“Primers”, and either 1µl (actin) or 5µl (XBP-1) of cDNA mixture. It was subjected to the 
following PCR cycles:  
 
 137 
 
Table 3. 6 - Thermocycler conditions for (RT)-PCR for mouse XBP-1/Actin 
Temperature Time No. of Cycles 
95°C 2 min 1 
95°C 30 s 35 
 66°C 30 s 
72°C 15 s 
72°C 7 min 1 
 
3.4.4.2 Touchdown RT-PCR for mouse XBP-1/Actin 
 
The standard reaction mixture was set up, using the Actin or XBP-1 primers as listed in 
“Primers”, and either 1µl (actin) or 5µl (XBP-1) of cDNA mixture. It was subjected to the 
following PCR cycles:  
 
The reaction was subjected to the following PCR conditions, 
 
Table 3. 7 - Thermocycler conditions for touchdown (RT)-PCR for mouse XBP-1/Actin. 
Temperature Time No. of Cycles 
95°C 2 min 1 
95°C 30 s 22 
 72-50°C* 15 s 
72°C 15 s 
95°C 30 s 13 
50°C 15 s 
72°C 15 s 
72°C 7 min 1 
*Step down by one degree per cycle 
3.4.4.3 RT-PCR for CHO XBP-1/Actin using Promega Taq 
The standard reaction mixture was set up, using the CHO Actin or XBP-1 primers as listed in 
“Primers”, and either 1µl (actin) or 5µl (XBP-1/IRE1α) of cDNA mixture. It was subjected to 
the following PCR cycles:  
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The reaction was subjected to the PCR conditions in Table 3. 8, below. 
3.4.4.4 RT-PCR for CHO XBP-1/Actin using GE Illustra HotStart Taq 
25μl 2x GE Illustra Hot Start PCR Master Mix  
2μl CHO XBP-1/Actin Forward 2 primer at 100µM 
2μl CHO XBP-1/Actin Reverse 2 primer at 100µM 
5/1-2μl cDNA Reaction  
Sterile H20 to 50μl  
 
The reaction was subjected to the following PCR conditions in Table 3. 9, below. 
 
Table 3. 8 - Thermocycler conditions for (RT)-PCR for CHO XBP-1/Actin/IRE1α 
Temperature Time No. of Cycles 
95°C 2 min 1 
95°C 30 s 35 
 59°C XBP-1/Actin 56°C IRE1α 30 s 
72°C 15 s 
72°C 7 min 1 
 
3.4.5 PCR for Sequencing using the FirstChoice® RLM-RACE Kit 
The FirstChoice® RLM-RACE Kit was used according to the protocol listed above in 
“Commercially Available Kits”.  
 
The RACE PCR reaction was performed as listed in the RLM-RACE Kit manual, using the RT 
reaction from above and the degenerate primers combined with the 3’RACE outer primer from 
the RLM-RACE kit.  
 
1µl RT Reaction 
5µlAccuprime Taq buffer 
4µl dNTPs  
5µl 100µM Degenerate Primer  
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2uL 3’ RACE outer primer 
1µl/1.25U Accuprime Taq 
Nuclease-free water to 50µl 
 
The following PCR cycles were used:  
 
 
Temperature Time No. of Cycles 
94°C 2 min 1 
95°C 30 s 18  
 
 
 
68-50°C (Touchdown) 30 s 
72°C 2 min 
95°C 30 s 17 
50°C 30 s 
72°C 2 min 
72°C 7 min 1 
Table 3. 9 - Thermocycler conditions for 3’ RACE  PCR 
 
3.4.6 PCR for Sequencing using T-RACE PCR 
 
The protocol used for T-RACE (Targetted Rapid Amplification of cDNA ends) was from  
(Bower and Johnston 2010). T-RACE involves an additional second strand synthesis of cDNA 
and digestion of original templates, and an asymmetric PCR for cDNA ends.  
 
RNA was extracted as in “RNA Isolation” above.  First strand synthesis was performed similar 
to the cDNA production protocol above, but using the T-Race Adaptor A instead of OligoDT 
and replacing dNTPs with dNTP-UTPs. The following reaction was set up; 
 
0.5μl 100mM T-Race Adaptor A (1:40 dilution from 100mM stock for  2.5mM) 
11.5μl of RNA/DEPC Water (1ug total RNA). 
1μl of  10mM dNTP-UTPs (See “Solutions for DNA Work”) 
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The reaction mixture was heated to 65°C for 5 min and then cooled on ice to 4°C for > 1 min. 
The following components were then added: 
 
4μl 5x First Strand Buffer 
1μl 0.1M DTT 
1μl RNaseOUT or RNAsein  
1μl of Superscript III reverse transcriptase 
 
The reaction mixture was then incubated at 42°C for 1h and then the following added: 
 
0.4μl of 100mM MnCl2  
1μl of 10µM T-Race Adaptor B (1:10 dilution of 100µM stock) 
 
And the reaction was incubated at 42°C for 15 min. The reaction was then heat inactivated at 
70°C for 10 min.  The reaction was purified with a QIAquick PCR Purification Kit and eluted 
in 30μl elution solution.  Second strand synthesis was performed in a 50μl reaction containing: 
 
10μl 5x GoTaq Buffer 
2.5μl of  10mM dNTP-UTPs 
2.5μl of 10mM T-Race Primer A 
2.5μl of 10mM T-Race Primer B 
5μl of 25mM MgCl2  
1μl (5u) of GoTaq 
2μl of purified First Strand Synthesis reaction. 
 
And subjected to the following thermocycler conditions. 
 
Table 3. 10 - Thermocycler conditions for T-RACE second strand synthesis 
Temperature Time No. of Cycles 
95°C 2 min 1 
95°C 30 s 21 
 60°C 30 s 
72°C 6 min 
4°C As required 1 
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The reaction was purified with a QIAquick PCR Purification Kit and eluted in 100μl elution 
solution.  Asymmetric PCR was performed using standard dNTPs and a gene specific primer 
towards the 5’ or 3’ ends of the required transcript. The following reaction was set up: 
 
0.5μl of Gene Specific Primer (See “CHO IRE1a Sequencing” Primers above) 
3.2μl 100mM  (NH4)2SO4 
1.3μl 1M TrisHCl  
2.4μl of 25mM MgCl2 
2.5 μl of 2mM dNTPs  
2μl of Second Strand Synthesis Reaction  
 
The reaction was heated to 95°C for 2 min 30s and one unit (0.2μl) GoTaq added. Then the 
reaction was subjected to the following PCR conditions.  
 
Table 3. 11 - Thermocycler conditions for T-RACE asymmetric PCR 
Temperature Time No. of Cycles 
95°C 30 s 20 
 60°C 30 s 
72°C 2-7 min* 
4°C As required 1 
 
*Dependent upon amplicon length, 1kb per min 
 
The reaction was purified with a QIAquick PCR Purification Kit and eluted in 11μl sterile 
water.  The original template was digested with Uracil DNA Glycosylase (UDG) in the 
following reaction: 
 
2μl GoTaq Buffer 
2μl/2 units of UDG 
2.4μl 25mM MgCl2 
10μl Asymmetric PCR Product 
1μl 10mM Nested Gene Specific Primer (5’ or 3’ of the primer used in Asymmetric PCR) 
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1μl 10mM  5’ or 3’ T-RACE primer 
0.6μl Sterile H20 
 
The reaction was incubated at 37°C for 30 min then heated to 95°C  for 2 min. 2μl of 10mM 
dNTPs  and 0.2μl of GoTaq added and a final T-RACE PCR performed according to the 
following PCR conditions. 
 
Table 3. 12 - Thermocycler conditions for T-RACE PCR 
Temperature Time No. of Cycles 
95°C 5 min 1 
95°C 30 s 35 
 60°C 30 s 
72°C 2-7 min* 
72°C 7 min 1 
4°C As required 1 
 
*Dependent upon amplicon length, 1kb per min 
 
The final amplified DNA was analysed on 1%(w/v) agarose gel.  
 
3.4.7 qPCR assay for XBP-1/IRE1α /Actin 
 
qPCR was performed on the Qiagen (Crawley, UK)/Corbett Research Rotorgene 3000 qPCR 
machine according to the instructions in the manual for that instrument (Manual version 6.1.7.1, 
2004 ). Specifics of the appropriate qPCR run for each gene are listed in the results section. The 
following mixture was set up for each reaction: 
 
2μl GoTaq Buffer 
2μl 2mM dNTPs 
1.2μl 25mM MgCl2 
0.3μl 10mM appropriate qPCR forward primer  
0.3μl 10mM appropriate qPCR reverse primer  
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0.4μl (2units) GoTaq 
0.3μl 8x Sybr Green 
1.0-4.0μl of cDNA template or diluted standard. 
Sterile/Nucleotide Free Water to 20μl 
 
Standards used were 500ng, 250ng, 125ng, 62.5ng and 31.25ng of cDNA produced from the 
appropriate organism’s RNA and Sterile/Nucleotide Free Water for no-template control.  
3.5 Western Blotting 
 
3.5.1 Protein isolation  
 
Mouse embryonic fibroblasts, HEK293 cells and adherent CHO cells were placed on ice, their 
growth medium was removed and then washed with PBS. Dependent upon experimental 
protocol, cells were either then scraped from the bottom of the culture dish to remove adherent 
cells and resuspended in 0.1-0.5ml of RIPA buffer, or lysed directly using the RIPA buffer.  
Suspension CHO cells were aspirated and centrifuged at 110 g, 2-5 min, RT, and then lysed 
directly using RIPA buffer. Protein lysates were centrifuged at 16,000g for 10 min and protein 
concentration assessed using the DC Protein Assay (See above, “Commercially Available 
Kits”). 
3.5.2 Production of Poly-acrylamide Gel 
 
The gel casting unit was assembled according to manufacturer’s instructions and appropriately 
sized plates inserted into the caster, which was sealed. 12% (w/v) SDS Poly-Acrylamide Gel 
was assembled as below. 
 
Separating Gel: 
 
4.5ml 30% (w/v) acrylamide, 0.8% (w/v) bisacrylamide 
2.18 ml 1 M Tris·HCl, pH 8.9 
3.9 ml H2O 
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75 µl 10% (w/v) SDS 
33.75 µl 10% (w/v) ammonium persulfate 
7.5 µl TEMED  
 
Stacking Gel: 
 
0.5 ml 30% (w/v) acrylamide, 0.8% (w/v) bisacrylamide 
0.94  ml 1 M Tris·HCl, pH 8.9 
2.32 ml H2O 
9.4 µl 10% (w/v) SDS 
16.9 µl 10% (w/v) ammonium persulfate 
5.6 µl TEMED  
 
Components of the separating gel were mixed together and pipetted between the glass plates of 
the gel caster. H2O saturated butanol was pipetted on top of the gel to ensure the top level of the 
gel was even. The gel was left to polymerise for >30 min. Once the separating gel was set, the 
butanol was removed and the gel washed with water before the stacking gel was pipetted on top 
of the separating gel and left to polymerise for > 30 min.  
3.5.3 SDS-PAGE 
 
An electrophoresis unit (Biorad, Hemel Hempstead, UK) was assembled and buffer reservoirs 
were filled with 1 x SDS-PAGE running buffer. Samples were mixed on ice with 5 µl of 6 x 
SDS-PAGE sample buffer, and centrifuged for ~15 s at 12,000 g at room temperature. Samples 
were then boiled for 5 min at 100ºC and then centrifuged again for ~15 s at 12,000 g at room 
temperature to collect the whole sample at the bottom of the tube. Samples were loaded onto 
SDS-Poly-acrylamide Gel using gel loading pipette tips. The SDS-PAGE electrophoresis unit 
was closed and a voltage of 100mV was applied for >1hr. The gel was run until the 
bromophenol blue dye front eluted from the gel.  The gel was then removed from the 
electrophoresis unit and the plates disassembled. The stacking gel was removed using a ruler 
and a scalpel. 
 
3.5.4 Electrotransfer by Wet Transfer 
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The gel was transferred into 100 ml of 4ºC electrotransfer buffer and incubated with gentle 
agitation for 1 h at 4ºC. PVDF membrane  (See “Specialist Equipment”) and two pieces of filter 
paper were cut to the dimensions of the gel. Filter papers were soaked in ice-cold transfer 
buffer. PVDF membrane was placed into 50 mL methanol and soaked until completely wetted 
and then transferred into electrotransfer buffer and soaked for >15 min. Filter papers, gel, and 
membrane were placed between fibre pads in a Bio-Rad (Biorad, Hemel Hempstead, UK) 
electrotransfer cassette, which was closed, locked and placed in the Bio-Rad electrotransfer unit 
with 2.5-3 L electrotransfer buffer. 30 mV was applied to the electrotransfer unit and the 
assembly was incubated  overnight with stirring. After this time, the electrotransfer unit was 
disassembled and the membrane removed. 
3.5.5 Electrotransfer by Semi-Dry Transfer 
A pre-run SDS-PAGE gel was removed from its cassette and soaked in a container with 
sufficient chilled 1x Semi-Dry Transfer Buffer to cover the gel. The gel was measured and a 
suitable size of PVDF membrane was cut to cover it, along with eight pieces of laboratory filter 
paper of the same size. The laboratory filter paper was allowed to soak in 1x Semi-Dry Transfer 
Buffer. The PVDF membrane was wetted in methanol and then rinsed in 1x Semi-Dry Transfer 
Buffer. The surface of the semi-dry transfer apparatus was cleaned and the gel stack assembled 
as in Figure 3. 1 - Semi-Dry Transfer Stack Setup below. Bubbles and excess buffer were 
removed from the stack by rolling a sterile pipette across it. 
 
Figure 3. 1 - Semi-Dry Transfer Stack Setup 
 
 
 
 
Amperage on the Semi-Dry Transfer apparatus (Model AE6675, Atto Corporation, Tokyo, 
Japan) was set to 2mA/cm
2 
and transfer was set to a duration of 1h 15 min. Once transfer was 
complete the electrotransfer unit was disassembled and the membrane removed. 
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3.5.6 Electrotransfer by Dry Transfer  
Dry protein transfer was performed according to the iBlot (Invitrogen, Paisley UK) manual, 
Revision 21 Nov 2010. The iBlot stack was setup up as described in the iBlot manual with gel 
and PVDF membrane between anode and cathode stack. Protocol 9 (20V for 2 min, 5V for 3 
min, 5V for 3 min) was used to transfer the protein to the PVDF membrane.  
3.5.7 Antibody Immunoblotting 
PVDF membrane with protein samples were stained by incubating 5 min at room temperature 
in 0.5% (w/v) Ponceau S, 1% (v/v) HOAc to visualise proteins, then destained by washing for 
12 min in H2O.  Membranes were transferred into plastic trays containing ≥ 0.75 ml/cm
2
 TBST 
+ 5% (w/v) non-fat dry milk powder or 5% bovine serum albumin (Sigma-Aldrich, Gillingham, 
UK) and were incubated 1 h at room temperature with shaking (~50-60 rpm) to block. They 
were then washed three times with TBST. The membranes were transferred into a 50 ml 
centrifuge tube or hybridization bottle and any air bubbles caught between the tube walls and 
the membrane removed, then incubated overnight in 5% milk or 5% BSA (w/v) TBST 
containing the appropriate concentration of primary antibody (see “Antibodies”, above). The 
membranes were then transferred into plastic trays containing ≥ 0.75 ml/cm2 TBST and rinsed 
twice. The TBST was replaced and the membranes were incubated for 5 min at RT with 
shaking (~50-60 rpm). This replacement and incubation was repeated three times. The 
membranes were transferred into a 50 ml centrifuge tube or hybridization bottle and any air 
bubbles caught between the tube walls and the membrane removed, then incubated for 1 h in 
TBST containing 50 μl/cm2 TBST + 5% (w/v)  solution of non-fat dry milk and the appropriate 
concentration of secondary antibody (see “Antibodies”, above)  
 
Alternatively TBSTriton (Lonza Wash Buffer) was used for washing steps and TBSTriton with 
Casein (Lonza Blocking Buffer) was used for blocking and antibody incubation steps.  
3.5.8 Visualisation 
The membranes were washed again three times in TBST or TBSTriton and chemiluminescence 
detected with the ECL Plus detection kit  (see “Commercially Available Kits”, above) 
according to the manufacturer’s protocol,  by exposing to Kodak BioMax MS film (See 
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“Specialist Equipment”) in an exposure cassette for 30 seconds – overnight, and developed on 
an Xograph Compact 4 (Xograph Healthcare, Tetbury, UK). 
 
3.5.9 Dephosphorylation of samples 
Where required for phosphorylation analysis, a 50μl sample of lysate in RIPA buffer containing 
10-50ug of protein was treated with 100 units of lambda phosphatase for 20 min at 30 ºC.  
 
3.6 Southern Blotting 
 
3.6.1 Transfer 
 
Genomic DNA extracts were prepared using the DNA component of the EZ RNA kit and 
digested with the appropriate restriction enzyme chosen for the genomic DNA. The digest was 
run on a 1%(w/v) agarose DNA gel to separate out the genomic DNA for blotting. The 
following transfer stack was set up. A stack of paper towels 5cm high was used for a base and 
two basins of 20x SSC set up either side. Four pieces of filter paper were placed on top of the 
paper towels and sealed with film to prevent short-circuiting between the gel and filter 
papers/towels. A fifth filter paper was wetted with 20x SSC and placed on top of the other four. 
The membrane was wetted with sterile water and placed on top of the filter paper stack then 
flattened out by rolling a sterile pipette over it. The gel was then placed on top of the 
membrane, taking care to not extend the gel over the edges of the membrane. Three pieces of 
filter paper were soaked in 20x SSC and placed on top of the gel, then one long piece of filter 
paper was soaked in SSC and hung across the top of the filter papers with each end in the basins 
of 20x SSC so as to retain the 20x SSC in the filter paper. Air bubbles were removed by rolling 
with a sterile pipette. The apparatus was sealed to prevent evaporation with cling film and 
weighed down with a glass plate. The DNA was transferred overnight (>16h), then the 
apparatus was disassembled with forceps. The membrane was placed, nucleic acid side up onto 
a piece of filter paper and crosslinked to the membrane using the UVP ultraviolet crosslinker 
(Upland, CA, USA, manual reference 81-0112-01 Rev F) with 120mJ of UV light.  
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Figure 3. 2 - Southern Blot Transfer Setup 
 
 
 
 
3.6.2 Hybridisation 
 
The membrane was transferred into a hybridisation bottle and wetted with 6 x SSC. The membrane 
was then prehybridized at 42°C with 20 ml hybridization solution/bottle for ≥ 3 h. During this 
incubation the DNA probe was prepared using the Rediprime labelling kit (See “Commercially 
Available Kits”). A PCR product polymerised from the pFRT/lacZeo plasmid using the lacZ 
probe primers (see “Primers”, above) was diluted to 25ng in 45μl of TE then denatured by 
heating for 5 min at 95-100°C.The probe was then chilled on ice and centrifuged at 13,000 rpm. 
Denatured DNA was then added to the Rediprime reaction tubes and dissolved by flipping the 
tube. The solution was collected at the bottom of the tube by briefly centrifuging and then 5μl 
of Redivue [-32P]-dCTP, 3000 Ci/mmol, ~10 μCi/μl (Amersham Biosciences/GE Healthcare, 
Chalfont St. Giles, UK) was added and the tube mixed by flipping. The solution was incubated 
at 37˚C for 10 minutes. After this, the reaction was halted by adding 5 µl of 0.2 M EDTA. A 
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microspin S300 HR column was prepared by vortexing, and placed in a 1.5ml microcentrifuge 
tube, then centrifuged at 735g for 1 min.  The column was then transferred to a new 1.5ml 
microcentrifuge tube and the sample carefully added to the top-centre of the resin without 
disturbing the resin. The tube was recapped loosely and centrifuged at 735g for 2 min. The 
prepared labeled probe was denatured by boiling for 5 min and then added to the pre-hybridised 
membrane at 2ng/ml along with 1 mg/ml denatured salmon sperm solution and 5ml 
hybridisation solution per hybridisation bottle and hybridised overnight.  After hybridisation, 
the membrane was washed three times for 5 min at room temperature with ~ 200 ml 2 x SSC + 
0.1% (w/v) SDS. Then the membrane was washed again with 0.2 x SSC + 0.1% (w/v) SDS for 
5 min at room temperature. The membrane was transferred into a clean hybridisation bottle and 
washed again for 15 min at 42°C with ~ 50 ml 0.2 x SSC + 0.1% (w/v) SDS. Finally, the 
membrane was rinsed in 2x SSC and the excess liquid blotted off. The membrane was then 
visualised either by placing it in an exposure cassette overnight and imaging the irradiated 
insert from the cassette on a Typhoon 9400 Variable Mode Imager (GE Healthcare, Chalfont 
St. Giles, UK) or by exposing the membrane to Kodak BioMax MS film at -80°C in an 
exposure cassette fitted with intensifying screens overnight and developing the film on an 
Xograph Compact 4 (Xograph Healthcare, Tetbury, UK). 
 
3.7 Spectrophotometric assays 
 
3.7.1 Sandwich ELISA for assembled IgG cB72.3 
 
The Sandwich ELISA was performed according to a protocol provided by Lonza Biologics, 
Slough. ELISA plates (See “Specialist Equipment”) were coated with goat anti-human IgG 
diluted 1:1200 (10μl in 12ml) in ELISA coating buffer by dispensing 100μl of the dilution into 
each well and incubating overnight at  4˚C.  Plates were sealed with Abgene adhesive plate 
seals (See “Specialist Equipment”) during this and every following incubation step.  After the 
incubation period, each well was then washed with 300μl of ELISA wash buffer and excess 
buffer tapped out onto a paper towel. The plates were then blocked by dispensing 100μl of 
ELISA blocking buffer into each well and incubating >1 h with shaking. The wash step with 
300μl of wash buffer was repeated. The assembled cB72.3 antibody ELISA standard (provided 
by Lonza Biologics, Slough, UK) was diluted to 200ng/μl from the stock in ELISA 
sample/conjugate buffer and serial dilutions 1:2 down to 3.91 ng/μl made for a calibration 
curve. Samples of medium clarified by centrifugation at 110 g, 5 min, room temperature were 
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diluted 1:100-1:1000 as required by the experiment in ELISA sample/conjugate buffer. ELISA 
sample/conjugate buffer was used as a negative control and a standard dilution of one standard 
used as an interassay control. 100μl each of samples, standards and controls were dispensed 
into wells in duplicate. The plate was incubated at room temperature with shaking for 1h. 
 
After the incubation period, each well was then washed with 300μl of ELISA wash buffer and 
excess buffer tapped out onto a paper towel. Goat anti-Human IgG (kappa chain specific) HRP 
conjugate was diluted 1:8000 in ELISA sample/conjugate buffer and 100μl was dispensed into 
each well, before incubating for 1h with shaking.  After the incubation period, each well was 
then washed twice with 300μl of ELISA wash buffer and excess buffer tapped out onto a paper 
towel. TMB Liquid Substrate System was allowed to equilibriate to room temperature and then 
100μl added to each well of the plate. The plate was shaken at 220 rpm at room temperature for 
10-45 min until the 2000ng/μl standard had reached a mid- to dark blue. The reaction was 
stopped by the addition of 50μl of ELISA stop solution, changing the colour of the wells from 
blue to yellow. The absorbance of the plate at 450nm was immediately read on a Molecular 
Devices Spectramax Spectrophotometer.  
 
Optimisation of Goat anti-Human IgG (kappa chain specific) HRP conjugate antibody was 
performed as recommended by Lonza with concentration ranges of conjugate antibody used 
from 1:8000 to 1:100,000. The 1:8000 dilution passed the acceptance criteria of OD 1.0< x >3.0 
for the 200ng/µl standard and was used for future assays. 
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3.7.2 β-Gal Assay for pcDNA integration. 
 
β-galactosidase standard was prepared by adding 1 μl 1 U/μl β-galactosidase to 99 μl ice-
cold 1 x RLB, mixed, and the tube placed on ice. The standard was then diluted again 10μl 
in 990 μl ice-cold 1 x RLB, mix, and the final 0.1 mU/μl solution placed on ice. A 96-well 
plate was set up with the following dilutions in duplicate of the β -galactosidase solution in 
1 x RLB buffer for a standard curve.  
 
 
Table 3. 13 - β-galactosidase Assay Standards 
β-galactosidase standard 
[mU/50 μl] 
volume of 0.1 mU/μl 
β -galactosidase solution (step 2) 
volume of 1 x RLB 
0.0 0 μl 50 μl 
1.0 10 μl 40 μl 
2.0 20 μl 30 μl 
3.0 30 μl 20 μl 
4.0 40 μl 10 μl 
5.0 50 μl 0 μl 
 
50μl of each sample was added to the 96 well plate in duplicate. If required, 1:50 dilutions were 
also assayed. 50μl of 2x assay buffer was then added to each well and mixed by pipetting up 
and down. The plate was covered with parafilm (Pechiny Plastic Packaging Company/Camlab, 
Over, UK) or a plate sealer (ThermoFisher Scientific, Waltham, USA) and incubated at 37°C 
for 30 min or until a faint yellow colour developed (up to 3 h). The reaction was stopped by 
adding 150 μl 1 M Na2CO3 and bubbles removed with a pipette tip. Absorbance of samples was 
read at 405-420 nm on the Molecular Devices Spectramax Spectrophotometer.  
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4. RESULTS 
 
4.1 Cloning of IRE1α and IRE1β mutant plasmids 
 
4.1.1 Rationale 
 
Testing used to isolate the effect of IRE1α mutant constructs created in this study on 
mammalian cells required the use of mammalian expression vectors. Vectors used for 
expression of IRE1 wild type and mutants were gifts from R. Kaufman, University of 
Michigan, USA (pEDΔC-hIRE1α) and K. Kohno, Nara Institute of Science and Technology, 
Japan (pCAG-hIRE1β) . Both vectors had been previously tested and shown to produce 
functional IRE1 product visible at 110 KDa (Tirasophon, Welihinda et al. 1998; Iwawaki, 
Hosoda et al. 2001). Both vectors were fully sequenced and the DNA and translated protein 
sequences compared against those in the Genbank databases (IRE1α/ERN1 - NM_001433, 
IRE1β/ERN2 NM_033266.3). During sequencing of mutated vectors, a point mutation was 
found in the donated pEDΔC-hIRE1α –K599A which altered an amino acid (R->L) at the 
beginning of the open reading frame of hIRE1α. As a result, the cloning strategy was adjusted 
to ensure this mutation was removed before the pEDΔC-hIRE1α plasmid was used for 
cloning double mutants. Sequencing of the pCAG-hIRE1β plasmid was impeded by a GC 
rich region in the rabbit β-globin which appeared to possibly be stalling sequencing 
polymerases – sequencing across the region was only achieved by designing primers with 
small gaps between them against the rabbit β-globin gene itself. Bioinformatic sequence 
alignments were performed using the sequences of yeast Ire1p, and hIRE1 α and β to 
ascertain the equivalent residues to those used in (Mori, Ma et al. 1993; Tirasophon, 
Welihinda et al. 1998; Tirasophon 2000; Iwawaki, Hosoda et al. 2001; Papa, C. et al. 2003; 
Lin, Li et al. 2007; Imagawa, Hosoda et al. 2008) to select for mutagenesis.  These residues 
are K599, I642, D711 and K907A in the α isoform of hIRE1 and K547, L590, D659 and 
K855 in the β.  
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4.1.2 Mutagenesis Strategy: IRE1α constructs 
 
Based upon the predicted restriction enzyme sites in the sequenced pEDΔC-hIRE1α  plasmid, 
the following restriction enzymes were selected to use to screen for mutagenesis and 
incorporated into the sequences used: EcoRI, EcoRV, EagI, NgoMIV. 
 
Mutagenesis was performed using the Stratagene QuikChange® II XL Site-Directed 
Mutagenesis Kit according to the protocol described in the manual for that kit. Primers (listed 
in Materials and Methods – Primers) were designed to produce the appropriate point-
mutation substitutions to give the desired effect and used in the Quik-change reactions with 
pEDΔC-hIRE1α as a template. Where mutagenesis had not introduced a new restriction 
enzyme site for screening, a second point mutation was also included in the primers to aid in 
later screening for transformants. The kinase-dead mutant K599A and the RNAse dead 
mutant K907A had already been obtained from R. Kaufman, University of Michigan, USA, 
and the K599A was also used as a template for double mutants, as were D711A and K599R 
once they had been produced. The alterations to be made using the primers are listed in Table 
4.1. 1. 
 
Table 4.1. 1 - Mutagenesis schemes, IRE1 α – [EcoRV]: Restriction enzyme sites. 
Substitutions in italics mark mutagenesis codon changes, those in bold mark conservative 
substitutions which add a restriction enzyme site for screening.  
Mutant Alterations to Sequence 
K599R ATGTTTGACA ACCGCGACGT GGCCGTGAAG AGGATCCTCC CCGAGTGTTT  
M  F  D  N   R  D  V   A  V  K   R  I  L  P   E  C  F   
                                  [EcoRI] 
ATGTTTGACA ACCGCGACGT GGCCGTGAGG AGAATTCTCC CCGAGTGTTT  
M  F  D  N   R  D  V   A  V  R   R  I  L  P   E  C  F   
D711A GCAAGATCAA GGCCATGATC TCCGACTTTG GCCTCTGCAA GAAGCTGGCA 
  K  I  K   A  M  I   S  D  F  G   L  C  K   K  L  A    
                 [EcoRV] 
GCAAGATCAA GGCCATGATA TCCGCCTTTG GCCTCTGCAA GAAGCTGGCA 
  K  I  K   A  M  I   S  A  F  G   L  C  K   K  L  A    
I642A  AGGACCGGCA ATTCCAGTAC ATTGCCATCG AGCTGTGTGC AGCCACCCTG 
  D  R  Q   F  Q  Y   I  A  I  E   L  C  A   A  T  L    
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                          [EagI] 
AGGACCGGCA ATTCCAGTAC ATTGCGGCCG AGCTGTGTGC AGCCACCCTG 
  D  R  Q   F  Q  Y   I  A  A  E   L  C  A   A  T  L    
I642G AGGACCGGCA ATTCCAGTAC ATTGCCATCG AGCTGTGTGC AGCCACCCTG 
  D  R  Q   F  Q  Y   I  A  I  E   L  C  A   A  T  L    
                        [NgoMIV] 
AGGACCGGCA ATTCCAGTAC ATTGCCGGCG AGCTGTGTGC AGCCACCCTG 
  D  R  Q   F  Q  Y   I  A  G  E   L  C  A   A  T  L   
 
Figure 4.1. 1 - Mutagenesis of pEDΔC-hIRE1α. Mutagenesis primers anneal to site of 
mutation on denatured plasmid. Proof-reading PfuTurbo polymerase polymerises in direction 
of arrows around the plasmid.  
 
 
 
 
 
4.1.3 Screening of Transformants for Insertion of Mutation 
 
Original methylated and unmutated template DNA was digested with DpnI leaving the 
mutated plasmid, which was then transformed into XL-Blue supercompetent cells and plated 
out on LB-ampicillin plates.  Transformants plated out on LB-ampicillin plates were counted 
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for number of colonies. If transformation efficiency/plasmid yield was low and ≤ eight 
colonies had grown on the plate, all colonies were used. If yield was sufficient and  >8 
colonies were counted, eight transformants were selected from random sites across the plate. 
Colonies were grown up (see Materials and Methods - “Preparation from E.coli culture by 
Mini/ Midi/ Maxi/ Gigaprep and Ethanol Precipitation of Nucleic Acids”) overnight and 
minipreped to harvest the mutated plasmid. 5μl of each miniprep was digested overnight with 
the appropriate restriction enzyme in a 10μl reaction (see Materials and Methods - Restriction 
Enzyme Digestion, 10μl Reaction). This digest reaction was run on an agarose gel side by 
side with the undigested plasmid to ascertain whether the extra restriction enzyme site had 
been successfully mutagenised. Selected clones that digested correctly were sequenced to 
check the correct mutations and if these were present, preparations of the clones were frozen 
in 30% glycerol and stored for recloning (See Appendix 3 – Sequencing results from 
mutagenesis of IRE1 constructs).  
 
4.1.4 Recloning into pEDΔc-hIRE1α Plasmid 
 
Although proofreading Pfu polymerase was used for mutagenesis cloning, there was a risk of 
unwanted base-pair substitutions in the plasmid constructs. Therefore, the section between 
the restriction enzyme sites for BstZ17I, and SnaBI was sequenced in each plasmid and then 
excised and subcloned back into the original, fully sequenced plasmid. This was performed 
for all mutants apart from the K907A which was already fully sequenced. For this reason, the 
SnaBI site was acceptable, despite the desired product of digesting using BstZ17I, and SnaBI 
excluding the K907 site.  
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Figure 4.1. 2 - Subcloning of pEDΔc-hIRE1α mutants into original plasmid. 
 
 
 
 
For each of the clones produced by mutagenesis and for the original pEDΔc-hIRE1α plasmid, 
10-50ug of a midiprep were digested in a 50μl double digest enzyme reaction with 1μl each 
of BstZ17I and SnaBI and using the New England Bioscience Buffer 4.  Each reaction was 
run on a 1% agarose gel and the band for the BstZ17I-SnaBI fragment (2050bp), or that for 
the larger -SnaBI -BstZ17I fragment (6935bp) in the case of the original pEDΔc-hIRE1α 
vector, excised (see below) and purified using the GenElute™ Gel Extraction Kit. Each 
mutant’s fragment was ligated to the original plasmid’s larger fragment using the standard 
method reaction as described in Materials and Methods “DNA Ligation with T4 DNA ligase” 
and the resulting ligant chemically transformed into competent E. coli and plated out. 
Resulting colonies were minipreped and screened for completed ligation by redigesting with 
BstZ17I and SnaBI.  
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Figure 4.1. 3 – Example of digests of pEDΔc-hIRE1α with BstZ17I and SnaBI to ensure 
correct religation and re-insertion of mutated hIRE1α sequence. Ladder – DNA Ladder. Un-
Dig./Digested – religated pEDΔc-hIRE1α plasmid.  
 
 
 
Bands appear in digested plasmid at ~6000 (predicted 6935), and ~2400 (predicted 2050).   
E. coli clones with correctly religated plasmids were frozen in 30% glycerol and stored. 
Large scale preparations were made of each mutant using an endotoxin-free maxiprep kit 
(EndoFree Plasmid Maxi Kit) to produce plasmid suitable for mammalian transfection.   
 
4.1.5 Mutagenesis and Cloning Strategy: IRE1β 
 
Based upon the predicted restriction enzyme sites in the sequenced pCAG-hIRE1β plasmid, 
the following restriction enzymes were selected to use to screen for mutagenesis and 
incorporated into the sequences used: NaeI, HindIII NheI and AflII. 
 
As with the IRE1α mutants, mutagenesis was performed using the Stratagene QuikChange® 
II XL Site-Directed Mutagenesis Kit according to the protocol described in the manual for 
that kit. Primers (listed in Materials and Methods – Primers) were designed to produce the 
appropriate point-mutation substitutions to give the desired effect and used in the Quik-
change reactions with pCAG-hIRE1β as a template. Where mutagenesis had not introduced a 
new restriction enzyme site for screening, a second point mutation was also included in the 
primers to aid in later screening for transformants. The kinase-dead mutant K547A had 
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already been obtained from K. Kohno, NAIST, Japan, and this was also used as a template 
for double mutants, as were D659A and K547R once they had been produced. The alterations 
to be made using the primers are listed in Table 4.1. 2. 
 
Mutant Alterations to Sequence 
K547R TTTGAGGGAC GGGCAGTGGC TGTCAAGCGG CTCCTCCGCG AGTGCTTTGG 
F  E  G  R   A  V  A   V  K  R   L  L  R  E   C  F  G 
                           [NaeI] 
TTTGAGGGAC GGGCAGTGGC TGTCCGCCGG CTCCTCCGCG AGTGCTTTGG 
F  E  G  R   A  V  A   V  R  R   L  L  R  E   C  F  G 
D659A TGGGCAGAGT GGTGCTCTCA GACTTCGGCC TCTGCAAGAA GCTGCCTGCT 
  G  R  V   V  L  S   D  F   G  L   C  K  K   L  P  A    
                                        [HindIII] 
TGGGCAGAGT GGTGCTCTCA GCCTTCGGCC TCTGCAAGAA GCTTCCTGCT 
  G  R  V   V  L  S   A  F  G  L   C  K  K   L  P  A    
L590A     
GACCCCAGTT CCACTACATT GCCCTGGAGC TCTGCCGGGC CTCCTTGCAG 
  P  Q  F   H  Y  I   A  L  E  L   C  R  A   S  L  Q    
                                           [HindIII] 
GACCCCAGTT CCACTACATT GCCGCGGAGC TCTGCCGGGC AAGCTTGCAG 
  P  Q  F   H  Y  I   A  A  E  L   C  R  A   S  L  Q    
L590G GACCCCAGTT CCACTACATT GCCCTGGAGC TCTGCCGGGC CTCCTTGCAG 
  P  Q  F   H  Y  I   A  L  E  L   C  R  A   S  L  Q    
                                          [NheI] 
GACCCCAGTT CCACTACATT GCCGGGGAGC TCTGCCGGGC TAGCTTGCAG 
  P  Q  F   H  Y  I   A  G  E  L   C  R  A   S  L  Q    
K855A GCGAGACCTG CTCCGTGCTG TGAGGAACAA GAAGCACCAC TACAGGGAGC 
 R  D  L   L  R  A  V   R  N  K   K  H  H   Y  R  E   
         [AflII] 
GCGAGACCTC TTAAGAGCTG TGAGGAACGC GAAGCACCAC TACAGGGAGC 
 R  D  L   L  R  A  V   R  N  A   K  H  H   Y  R  E   
Table 4.1. 2 - Mutagenesis schemes, IRE1 β – [NaeI]: Restriction enzyme sites. Substitutions 
in italic mark mutagenesis codon changes, those in bold mark conservative substitutions 
which add a restriction enzyme site for screening.  
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Figure 4.1. 4 - Mutagenesis of pCAG-hIRE1β. Mutagenesis primers anneal to site of 
mutation on denatured plasmid. Proof-reading PfuTurbo polymerase polymerises in direction 
of arrows around the plasmid to form mutagenised form.  
 
 
 
Original methylated and unmutated template was digested with DpnI leaving the mutated 
plasmid, which was then transformed into XL-Blue supercompetent cells and plated out on 
LB-ampicillin plates. 
 
4.1.6 Screening of Transformants for Mutagenesis 
 
Mutagenesis reactions were attempted as above, but either did not result in colonies on the 
plates or resulted in very few colonies which did not digest correctly, indicating the 
mutagenesis was unsuccessful. It is likely that the presence of the GC rich region in the rabbit 
β-globin gene was stalling the polymerase, as occurred during sequencing of the plasmid. 
Therefore, the IRE1β gene required subcloning out of the pCAG plasmid. The pUC18 vector 
was used for this, as it possessed a suitable cloning site (EcoRI) and is a short vector, 
therefore increasing the likelihood of successful readthrough of the polymerase across its 
length.  
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Figure 4.1. 5 – Unsuccessful mutagenesis of pCAG-hIRE1β.  
 
 
 
500ng-1ug of minipreped plasmid clone was digested for 1hr with 10 units of the labeled 
restriction enzyme or no enzyme was used (undigested). Resulting preparations were run on a 
1% agarose gel.  Digestion of clone from mutagenesis reaction, shows linearised band 
indicating the second NaeI or HindIII site has not been integrated into the plasmid.  
 
4.1.7 Requirement and Strategy for Cloning into puc18 
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Mutation of pCAG-hIRE1β proved difficult due to the aforementioned heavily GC-rich rabbit 
β-globin gene, which may have been stalling the polymerases used. To overcome this, 
hIRE1β was digested with EcoRI and the resulting fragment ligated into the EcoRI site within 
the multi-cloning site of the pUC18 plasmid, producing pUC18-hIRE1β. 
 
Figure 4.1. 6- Cloning strategy for puc18-hIRE1β. The constructed plasmid comprises the 
entirety of the pUC18 vector (left-hand arrows) and the IRE1β gene (right-hand arrows).  
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4.1.8 Mutagenesis on pUC18-hIRE1β 
 
Mutagenesis reactions were attempted as above upon the pUC18-hIRE1β plasmid, and 
screened using the same restriction enzymes. This shorter plasmid without the GC rich region 
of pCAG-hIRE1β gave a higher number of correct clones, examples of which can be seen in 
the sequencing results in Appendix 3. Selected clones that digested correctly were sequenced 
to check the correct mutations and if these were present, preparations of the clones were 
frozen in 30% glycerol and stored for recloning (See Appendix 3 – Sequencing results from 
mutagenesis of IRE1 constructs). 
 
4.1.9 Recloning of IRE1β constructs into pCAG Plasmids 
 
As with the pEDΔc plasmid, although proofreading Pfu polymerase was used for mutagenesis 
cloning, there was a risk of unwanted base-pair substitutions in the plasmid constructs. 
Therefore, the section between the two restriction enzyme sites for EcoRI was sequenced in 
each plasmid and then excised and subcloned back into the original, fully sequenced pCAG 
plasmid. For each of the pUC18-hIRE1β  clones produced by mutagenesis and for the 
original pCAG plasmid, 10-50ug of a midiprep were digested in a 50μl double digest enzyme 
reaction with 1μl(10units) of EcoRI and using the Fermentas EcoRI buffer.  Each reaction 
was run on a 1% agarose gel and the band for the IRE1 EcoRI-EcoRI fragment (2847bp), or 
that for the larger EcoRI-EcoRI fragment from pCAG-hIRE1β (4794bp) in the case of the 
original vector, excised from the gel and purified using the GenElute™ Gel Extraction Kit. 
As the two bands in the pUC18-hIRE1β were very close to one another in size (2847 and 
2685), it was necessary to use an extra restriction site to distinguish between the fragments. 
Double digests were performed with EcoRI and DraI in Fermentas Tango buffer with DraI in 
excess at a1:2 ratio, to divide the 2685 fragment into four fragments, at 1115, 859, 692, 19bp 
(19bp fragment too small to be visible on gel). Test digest was performed for one hour on 
500ng of pUC18-hIRE1β, large scale digests overnight on 10ug (Figure 4.1.7).   
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Figure 4.1. 7 – Digests of pUC18-hIRE1β. A) Restriction sites. B) Test digest of pUC18-
hIRE1β-L590A with EcoRI and DraI 1-Ladder, 2-Undigested, 3- Digested.  
 
 
A 
B 
 
 
 
 
 
 
 
 
 
 
 
 
            1          2          3  
 
 
 
  
Each mutant’s fragment was ligated to the original plasmid’s larger fragment using the 
standard method reaction as described in Materials and Methods “DNA Ligation with T4 
DNA ligase” and the resulting ligant chemically transformed into competent E. coli and 
plated out. Resulting colonies were minipreped and screened for completed ligation by 
redigesting with SnaBI, which digests twice, once in the predicted insert, once in the pCAG 
vector yielding bands at 3180 and 4460 bp. An incorrect alignment of the insert would result 
in bands at 5232 and 2408. 
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Figure 4.1. 8 – Screening of pCAG-hIRE1β. A) Digestion sites for screening enzyme (SnaBI) 
B) Correct orientation of insert. C) Screening of pCAG-hIRE1β with SnaBI.  
 
In Figure 4.1. 8 above, Clones 2 and 3 have aligned successfully. E. coli clones with correctly 
religated plasmids were frozen in 30% glycerol and stored. Large scale preparations were 
made of each mutant using an endotoxin-free maxiprep kit (EndoFree Plasmid Maxi Kit) to 
produce plasmid suitable for mammalian transfection.   
  
4.1.10 Cloning Strategy for Addition of HA Tag into pCAG Plasmids 
 
 
 
A  
B 
 
 L-Ladder,  
A-D659A/L590A Clone 1, 
Undigested  
B-D659A/L590A Clone 1, 
Digested with SnaBI  
C- D659A/L590A Clone 2, 
Undigested  
D- D659A/L590A Clone 2, 
Digested with SnaBI 
E- D659A/L590G Clone 3,  
Undigested 
F- D659A/L590G Clone 3,  
Digested with SnaBI 
G- D659A/L590G Clone 3,  
Undigested 
H- D659A/L590G Clone 3,  
Digested with SnaBI 
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As at the time of cloning, no antibody was available to perform a Western blot for the 
hIRE1β protein that could detect the product of the pCAG-hIRE1β, therefore it was 
determined to use the HA tag in the plasmid provided by K. Kohno, Nara Institute of Science 
and Technology, Japan to permit detection by Western blot, and clone this tag into all the 
pCAG-hIRE1β mutant expressing plasmids. The two MscI sites flanking the HA tag end of 
the pCAG-hIRE1β-HA plasmid were chosen to clone the HA tag into the pCAG-hIRE1β 
mutants, but this required screening of the clones by digest with EcoRI to ensure the HA tag 
had been cloned in the correct orientation. pCAG-hIRE1β-HA was digested with MscI and 
run on a gel and the 320 bp insert containing the HA tag excised from the gel and purified 
using the GenElute™ Gel Extraction Kit.  pCAG-hIRE1β mutants were digested with MscI 
and the vector 7364bp similarly purified. The two fragments were religated the standard 
method reaction as described in Materials and Methods “DNA Ligation with T4 DNA ligase” 
and the resulting ligant chemically transformed into competent E. coli and plated out. 
Resulting colonies were minipreped and screened for completed ligation by redigesting with 
EcoRI. 
 
Figure 4.1. 9 - HA Tag Cloning into pCAG vectors. 
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After digest of clones by EcoRI, the resulting samples were run on 1% agarose gel. 
Correctly orientated religated plasmid gave bands at 4794 and 2890bp, reversed insert 
gave bands at 5063 and 2621 (see  
Figure 4.1. 9).  
 
Figure 4.1. 10 - Successful and unsuccessful pCAG-hIRE1β HA-tag clones.  Representative 
examples of digests, each pair of lanes LH lane undigested, RH lane digested with EcoRI. 
Mutants in lanes A-C- D659A/L590A, D-D659A/L590G, E-F – K547A/L590A, G-
K547A/L590G.  
 
                           
 
  
Lanes A and G show bands at 4794 and 2890, correct orientation, Lanes C,D and E are the 
incorrect 5063 and 2621 orientation, Lanes B and F have not sufficiently digested 
(linearised).  
 
4.1.11 Summary  
 
After mutagenesis, successful mutant plasmids were produced for all the required mutants of 
the IRE1 kinase pocket. Enzymes were selected to use to screen for each mutagenesis and 
mutagenesis primers successfully designed. After mutagenesis the mutated IRE1 sequence 
was subcloned into the original plasmid to reduce the risk of point mutations produced during 
mutagenesis affecting the plasmid. Problems encountered included the GC-heavy region of 
the rabbit β-globin gene which severely impeded sequencing and mutagenesis and forced 
subcloning into a shorter plasmid – the large size of both plasmids may have contributed to 
the low number of transformants in most mutagenesis reactions.  
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 Ideally it would have been better to test/check the availability of anti IRE1β antibody 
and perform all initial cloning steps in the HA tagged IRE1β plasmid rather than the 
untagged. This would have saved multiple cloning steps.  
 
 
4.2 Optimisation of IRE1α and IRE1β expression in ire1α-/- cells 
 
4.2.1 Rationale for Optimisation 
 
As described in Bertolotti (Bertolotti 2000), the IRE1β isoform is only expressed in 
gastrointestinal cells, and therefore an ire1α-/- mouse embryonic fibroblast cell line was 
considered adequate for testing putative analogue-sensitised IRE1 mutants, as α is the 
ubiquitous isoform. In order to isolate the optimum conditions for the expression of mutant 
constructs in this cell line, the optimum conditions for transfection, concentration of DNA 
and growth of cells required testing. Previous experiments by N. Strudwick in our laboratory 
indicated the optimum method for transfection of MEFs was by electroporation, as these cells 
were difficult to transfect by chemical methods. Transfection was performed using the pre-
optimised parameters used by N. Strudwick with the Digital Biotech/Invitrogen 
Electroporator, set to a single pulse at 1700mV, 20ms. All micrographs in this study are at 
10x magnification.  
 
4.2.2 Transfection Efficiency Assessment with GFP 
 
ire1α -/- mouse embryonic fibroblasts were grown to 80-90% confluency, trypsinised and 
centrifuged. 1x10
6
 cells per transfection were resuspended in 100μl of Neon® Transfection 
System Buffer R (Invitrogen Life Technologies Ltd, Paisley, UK), then electrotransfected 
using the above conditions and according to the protocol in Materials and Methods - 
“Transfection – Electroporation” with 2µg of pMAX-GFP plasmid. After transfection they 
were grown in a six well tissue culture plate (Sarstedt, Leicester, UK) for 24 hours in 
Dulbecco’s modified eagle’s medium with pyruvate and then visualised by UV and visible 
light confocal microscopy.  Transfection efficiency was high, 70-80%, and therefore it was 
determined this methodology was suitable for transfection. Untransfected cells show no 
visible background fluorescence under the UV filter. 
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4.2.3 Transfection of pEDΔc/pCAG plasmids to assess effect of IRE1 protein on 
viability of MEFs 
 
Once the efficiency of the transfection method had been established, preliminary 
transfections were performed with the wild-type and available mutant IRE1 plasmids and the 
empty pEDΔC and pCAG vectors provided by  R. Kaufman, University of Michigan, USA 
(pEDΔC) and K. Kohno, Nara Institute of Science and Technology, Japan (pCAG) to 
ascertain their effect on MEF viability.  ire1α -/- mouse embryonic fibroblasts were grown to 
80-90% confluency, trypsinised, centrifuged. 1x10
6
 cells per transfection were resuspended 
in 100μl of Buffer R, then electrotransfected by a single pulse at 1700mV, 20ms with 4ug of 
the listed plasmid. After transfection cells were seeded into a six well tissue culture plate 
(Sarstedt, Leicester, UK) and grown for 24 hours in Dulbecco’s Modified Eagle’s Medium 
with pyruvate. Cell growth was assessed by eye. 
  
Figure 4.2. 1 – Transfection efficiency of ire1α -/- mouse embryonic 
fibroblasts with pMAX-GFP. LH panel transfected cells with visible 
light, RH panel GFP fluorescence of same transfected cells with UV 
light.  
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Figure 4.2. 2 – Preliminary IRE1 transfections, percentage viability and example of 
micrograph showing non-adherent cells after transfection with pEDΔC-hIRE1α.  
 
Transfected Plasmid % 
Viability 
 
pMAX-GFP (Positive 
control) 
40-50% 
No plasmid (Negative 
control) 
40-50% 
pEDΔC-hIRE1α <5% 
pCAG-hIRE1β <5% 
pEDΔC 20-30% 
pCAG 10-20% 
pEDΔC-hIRE1α-K599A <10% 
pCAG-hIRE1β-K547A <10% 
pEDΔC-hIRE1α-K907A <5% 
No transfection 100% 
 
Initially, experiments using 4µg of DNA per transfection resulted in low viability of cells 
transfected with IRE1 plasmids, possibly due to triggering of apoptosis or ER stress from 
overexpressing the IRE1 protein. Iwawaki et al  report similar problems with viability in 
HeLa cells overexpressing transiently transfected IRE1(Iwawaki, Hosoda et al. 2001). 
Viability was lost both by transfection alone and by transfection with the empty vector but 
not to the same extent as that by either wild type or mutant IRE1. It was not possible to 
ascertain whether the loss of viability was due to the presence of IRE1 or due to 
overexpression of plasmid.   
 
To elucidate the role of the IRE1 plasmid in the loss of viability, further quantitative 
examination was made into the detrimental effect of transfection of the pEDΔC plasmids into 
cell death. As above ireα -/- mouse embryonic fibroblasts were grown and electrotransfected 
with 4µg of the listed plasmid in Table 4.2. 1. After transfection cells were grown for 24 
hours and cell viability assessed by trypsinising cells, resuspending and staining with trypan 
blue and then counting live/dead cells with an improved Neubauer haemocytometer 
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Table 4.2. 1 – Viable cell counts (cells in one 1mm2 square of haemocytometer, five replicates).  
Plasmid Dead 
   
Live 
   
% 
Viability 
     
 
1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 Mean SE 
pEDΔc-hIRE1α 20 19 14 11 17 33 20 21 29 29 62.3 51.3 60 72.5 63 61.81794 4.37 
pEDΔc (empty vector) 5 7 6 2 5 36 31 35 25 57 87.8 81.6 85.4 92.6 91.9 87.85555 2.66 
pEDΔc-hIRE1α-K599A 15 11 18 16 22 21 14 25 31 24 58.3 56 58.1 66 52.2 58.12085 2.9 
pEDΔc-hIRE1α-D711A 15 19 12 10 20 23 21 27 18 24 60.5 52.5 69.2 64.3 54.5 60.21765 3.97 
Untransfected 1 1 0 2 0 9 10 17 14 9 90 90.9 100 87.5 100 93.68182 3.19 
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Figure 4.2. 3 – Viability of cells transfected with pEDΔc constructs. 
 
 P =  <0.005 
 
In this experiment viability counts indicated no significant difference between the 
untransfected cells and the empty vector transfection, but a significant difference between 
untransfected and empty vector, and IRE1 constructs, demonstrating a role for the IRE1α 
protein in the loss of viability.  
 
4.2.4 Strategies for overcoming viability loss – reduced DNA in transfection 
   
The loss of viability due to the IRE1α construct expression was detrimental to further study 
of the protein, and was required to be overcome. To attempt to overcome this viability issue, 
varying concentrations of 0.1, 0.5, 1, 2 and 4 µg of DNA were transfected to ascertain if there 
was a level at which expression was detectable but cells were sufficiently viable. pMAX-GFP 
was used to assess plasmid expression. ire1α -/- mouse embryonic fibroblasts were grown to 
80-90% confluency, trypsinised and centrifuged. 1x10
6
 cells per transfection were 
resuspended in 100μl of Neon® Transfection System Buffer R, then electrotransfected using 
the above conditions and according to the protocol in Materials and Methods - “Transfection 
– Electroporation” with 2µg of either pEDΔC-hIRE1α,  pCAG-hIRE1β or pMAX-GFP 
plasmid. After transfection they were grown in a six well tissue culture plate (Sarstedt, 
Leicester, UK) for 24 hours in Dulbecco’s Modified Eagle’s Medium with pyruvate and then 
visualised by UV and visible light confocal microscopy. Viability was measured by 
0
20
40
60
80
100
120
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trypsinising cells, resuspending and staining with trypan blue and then counting live/dead 
cells with an Improved Neubauer haemocytometer. GFP expression was measured by UV 
fluorescence under confocal microscope.  
 
Table 4.2. 2 – Viable cell counts/Transfection efficiency in viability assessments.  
μg of plasmid/ 
transfection 
pEDΔC-hIRE1α pCAG-hIRE1β pMAX-GFP % GFP 
Fluorescence Live Dead % Live Dead % Live Dead % 
0.2 18 5 78.3 11 4 73.3 7 3 70 <1% 
0.5 18 8 30.5 21 14 60.0 13 5 72 3% 
1 26 0 0 5 10 33.3 17 11 60.7 10% 
2 21 0 0 3 19 13.6 4 5 44.4 40% 
4 20 0 0 0 15 0 2 11 15.3 80% 
 
Figure 4.2. 4 - Viability of ire1α-/- MEFs with varying concentrations of IRE1 plasmids and 
GFP expression plasmids.  
 
 
As seen in Figure 4.2. 4, viability of MEFs inverse correlation with transfection 
efficiency/DNA concentration, suggesting that transfection of cells may result in cell death 
and therefore there was unlikely to be a suitable concentration of plasmid which can be 
transfected which will produce suitable expression levels of IRE1 without also reducing 
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viability so far as to make harvesting of mRNA or protein in high enough concentrations for 
further analysis possible.  
 
4.2.5 Strategies for overcoming viability loss – Time Course for Expression  
 
Having eliminated the possibility of reducing the levels of DNA transfected, next the 
possibility of reducing the amount of time cells were expressing IRE1 was examined, to 
reduce the stress of constant high expression of the protein. MEFs were transfected with 2 µg 
of pMAX-GFP and inspected for expression at 0.5, 1, 2, 4, 8, and 12hrs. Fluorescence due to 
GFP expression was not found to occur until the 8 hr timepoint when most cells had adhered 
to the surface of the culture dish (Figure 4.2. 5), indicating a minimum of eight hours before 
plasmid expression could be detected. Having ascertained when GFP expression was 
occurring, MEFs were transfected with pEDΔC-hIRE1α and examined for viability at 4, 6, 8 
and 12h. After 4 h, some cells appeared to be adhering and growing, while most floated in the 
medium, either dead or unable to adhere. It is difficult to ascertain whether adherent cells 
were untransfected or not.  GFP fluorescence was not detectable until at least eight hours, 
after viability was already being lost in pEDΔC-hIRE1α transfection. 
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Figure 4.2. 5 - Expression of GFP Timecourse in ire1α-/-  MEFS. Bright field 
microscopy with fluorescence microscopy overlay where required.  
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4.2.6 Strategies for overcoming viability loss – transfection of traf2-/- cells to 
eliminate IRE1-induced cell death by the TRAF2 Pathway 
 
In order to ascertain whether cell death after transfection was via a TRAF2 dependent 
pathway as would be expected if expression of IRE1 was responsible (Urano, Bertolotti et al. 
2000), 1x10
6
 traf2
-/-
 MEFs (see Materials and Methods “Cell Lines”) were resuspended in 
100μl of transfection Buffer R and transfected with 4ug of pEDΔC-hIRE1α, kinase dead 
pEDΔC-hIRE1α-K599A, and empty vector pEDΔC. After 24 hrs, the cells were 
photographed by confocal microscopy and live vs. dead cells counted. Untransfected cells 
were also assessed as a control.  
Both empty vector and untransfected cells again showed similar viability, and both the wild 
type and the kinase dead IRE1α (rather than wild-type alone – a kinase-dead IRE1 should not 
be capable of inducing this pathway were TRAF2 to in fact be present for some reason) 
suffered loss of viability, suggesting that problems in viability may be due to a general 
overexpression of a transmembrane protein, which could potentially be overcome using a 
weaker promoter such as herpes simplex virus (HSV) thymidine kinase (TK) to express the 
IRE1 protein (Allen 1988; Nakamura, Watanabe et al. 2008). It is also possible that a point 
mutation in the K599A mutant (see “Cloning of IRE1α and IRE1β mutant plasmids”, above) 
may have been interfering with the results, and a corrected version of this mutant was 
produced by subcloning.  
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Figure 4.2. 6 – Effect of pEDΔC-hIRE1α on traf2-/- mouse embryonic fibroblasts. A) 
Live/Dead cell counts per haemocytometer square. B)  Light microscopy of cells 24 hours 
after transfection. C) % Viability of transfections/untransfected.  
 
A Replicate 1 2 3 4 5 Mean SE 
Plasmid Live Dead % L D % L D % L D % L D % 
pEDΔC-hIRE1α 0 6 0 0 2 0 0 5 0 0 9 0 0 6 0 0 0 
pEDΔC-hIRE1α-K599A 0 4 0 0 2 0 0 6 0 0 4 0 0 2 0 0 0.00 
pEDΔC 3 3 50 1 0 100 6 0 100 3 1 75 3 1 75 80 9.35 
Untransfectedlalalaalalala 3 4 43 4 0 100 2 0 100 2 0 100 6 0 100 88.57 11.43 
 
B 
 
 
C 
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4.2.7 Strategies for overcoming viability loss – weak promoter  
 
As the sequences driving the pEDΔC-hIRE1α and pCAG-hIRE1β plasmids were strong, 
adenoviral/ β-actin promoters, it was determined to ascertain whether the use of a weaker 
promoter would reduce the expression of IRE1α to levels suitable to retain viability. The 
herpes simplex thymidine kinase (an enzyme involved in DNA synthesis) promoter is a weak 
promoter with no tissue specificity whose sequence contains only 5’ flanking sequences 
associated with an early gene of herpes simplex virus. Its promoter sequences include a C-
AT-A-T-T-A-A sequence 31 nucleotides, and a G-G-C-G-A-A-T-T-C sequence frequently 
conserved in eukaryotic organisms 85 nucleotides upstream of the initiation codon(Wagner, 
Sharp et al. 1981; Allen 1988; Nakamura, Watanabe et al. 2008). The pDJB134 plasmid 
containing the HSV thymidine kinase promoter was a gift from the Marie Curie Research 
Insitute, Surrey.  
 
4.2.8 Cloning of thymidine kinase promoter 
  
The IRE1α sequence was cloned into the thymidine kinase plasmid by digesting pEDΔC-
hIRE1α with the restriction enzymes SpeI and XbaI to excise the IRE1 sequences and 
untranslated region. The pDJB134 plasmid was also digested with SpeI and XbaI to remove 
the CREB-H sequence. The IRE1 fragment was then ligated into the pDJB134 plasmid to 
produce pTK-HSV-BP2- hIRE1α (See Figure 4.2. 7). As SpeI and XbaI ends are compatible, 
the IRE1 fragment could ligate in either orientation, therefore transformants were minipreped 
and screened for the orientation of the plasmid which no longer digested with SpeI and XbaI 
as the sites had been destroyed by the cloning. 
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Figure 4.2. 7 – Cloning strategy for pTK-HSV-BP2-hIRE1α.  
 
 
The IRE1β sequence was cloned into the thymidine kinase plasmid by digesting pCAG-
hIRE1β overnight with the restriction enzymes SalI and XbaI to excise the strong chicken β-
actin promoter. The pDJB134 plasmid was digested with SalI and NheI, in recommended 
Fermentas Buffer AarI, to remove the thymidine kinase promoter. The 1162bp thymidine 
kinase promoter fragment was then ligated at a 1:3 vector:insert ratio into the pCAG-hIRE1β 
plasmid to produce pTKRG- hIRE1β .  The hIRE1β insert contains a single KpnI site in the 
middle of the IRE1β sequence. This was used to screen minipreped ligants for inserted 
hIRE1β. 
 
ire1α -/- mouse embryonic fibroblasts were grown to 80-90% confluency, trypsinised and 
centrifuged. 1x10
6
 cells per transfection were resuspended in 100μl of Buffer R, then 
electrotransfected using the above conditions and according to the protocol in Materials and 
Methods - “Transfection – Electroporation” with 4µg of either pTK-HSV-BP2-hIRE1α, 
pTKRG-hIRE1β (thymidine kinase promoter plasmids)  pEDΔC-hIRE1α,  pCAG-hIRE1β 
(strong promoter plasmids) or the empty vectors pEDΔC or pCAG. After transfection they 
were grown in a six well tissue culture plate (Sarstedt, Leicester,UK) for 24 hours in 
Dulbecco’s Modified Eagle’s Medium with Pyruvate. After 24 hours there was no visible 
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difference between the cell death due to the weak promoter thymidine kinase plasmids and 
the strong promoter plasmids suggesting that the weaker promoter was not sufficient to 
reduce the loss of viability. 
 
 
 
 
 
 
 
 
 
 
4.2.9 Strategies for overcoming viability loss – use of alternative transfection 
buffers   
 
Concomitantly with the production of the thymidine kinase plasmids, it was determined that 
since a certain amount of viability was lost by the transfection method alone, to attempt to 
use a transfection buffer which resulted in a higher viability. The transfection Buffer R used 
for electrotransfection of plasmids is described as a DPBS-based buffer in (Kim2008).  Patent 
WO/2008/134200 (Rubio and Terefe 2008) describes a set of high efficiency transfection 
buffers containing a number of additional components which could contribute to viability and 
transfection efficiency – a sugar to match cellular osmolarity, HEPES as a buffering agent, 
MgCl2 and EGTA to chelate halide salts, DMSO to render cells permeable, ATP to retain 
viability, glutathione to neutralise any free radicals, and pH adjustment with potassium salts 
rather than sodium to more closely mimic the intracellular environment.  Additionally, the 
Eppendorf Multiporator manual (Version 2006) recommends an electrical conductivity of 3.5 
mS/cm and not exceeding 10 mS/cm (http://www.eppendorf.com/script/cms-
newspic.php?id=1744&inline=1&col=DOWNLOADFILE) to be achieved by the addition of 
myo-inositol to approximately 90mOsmol/kg.  One of the buffers listed as most efficient in 
the patent WO/2008/134200 was prepared and tested under the same transfection conditions 
as the Invitrogen Buffer R. pMAX-GFP was used to assess plasmid expression. ireα -/- mouse 
Table 4.2. 3 – Viability comparison after transfection with weak/strong promoter plasmids. 
Plasmid  % Viability/Confluence 
pTK-HSV-BP2-hIRE1α <5% 
pTKRG-hIRE1β <5% 
pEDΔC-hIRE1α <5% 
pCAG-hIRE1β <5% 
pEDΔC 60-70% 
pCAG 60-70% 
No transfection 100% 
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embryonic fibroblasts were grown to 80-90% confluency, trypsinised and centrifuged. 1x10
6
 
cells per transfection were resuspended in 100μl of Neon® Transfection System Buffer R 
(Invitrogen Life Technologies Ltd, Glasgow, UK), or the Buffer to be tested then 
electrotransfected using the above conditions and according to the protocol in Materials and 
Methods - “Transfection – Electroporation” with 2µg of pMAX-GFP plasmid. After 
transfection they were grown in a six well tissue culture plate (Sarstedt, Leicester, UK) for 24 
hours in Dulbecco’s modified eagle’s medium with pyruvate and then visualised by UV and 
visible light confocal microscopy.   
 
Table 4.2. 4 - Transfection Buffer Recipes (from (Rubio and Terefe 2008)) and the Digital 
Biotech (Seoul, Korea)/Invitrogen Microporator protocol (Protocol Reference: MP-100 
Rev.M.03.51-11/07) 
Buffer 5 
250mM Trehalose 
5mM Potassium Phosphate 
25mM HEPES 
5mM MgCl2 
2mM EDTA 
pH 7.2-7.5 
PBS + Glucose 
1x PBS (see Materials and Methods) 
200mM Glucose 
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Observation of the electrotransfection apparatus during transfection appeared to indicate a 
difference in the conductivity of the buffer solutions, as when Buffer R was used, small 
bubbles of gas due to decomposition of water were emitted from the apparatus, but this did 
not occur with the other buffer solutions.  Measurement of the conductivity of Buffer R with 
a conductivity meter gave 14.71 mS/cm, similar to Dulbecco’s PBS, from which the buffer is 
derived (Kim, Cho et al. 2008) Addition of myo-inositol as recommended in the Eppendorf 
multiporator manual did not improve transfection efficiency over Buffer 5 alone (see Figure 
4.2. 8) 
Table 4.2. 5 - Conductivities of Electrotransfection Buffers 
Buffer Conductivity (mS/cm) 
Buffer R 14.71 
DPBS 14.00 
Buffer 5 3.09 
Buffer 5 + 300mM Myo-inositol 3.30 
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Figure 4.2. 8 - Transfection efficiency with electrotransfection buffers. Left-hand panels 
show visible light microscopy and right-hand GFP fluorescence with UV light. DPBS-based 
buffers exhibit high efficiency of transfection, as opposed to experimental buffers.  
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Preliminary experiments comparing buffers from the patent/literature to Buffer R using the 
standard conditions used for Buffer R did not produce an improvement in viability or 
transfection – therefore it was determined to perform the optimisation for transfection 
conditions using the methodology as listed in the microporator manual using Buffer 5 which 
appeared to produce the most fluorescence. The electrotransfection was repeated as above 
with Buffer 5, but the electrotransfection parameters were altered as in Table 4.2. 6. 
Conditions producing a viability and transfection efficiency equivalent to that of Buffer R 
were achieved (see Figure 4.2. 9) were no better than Buffer R and therefore did not 
contribute to improved RNA or protein yields (see later chapters). 
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Table 4.2. 6 - Optimisation of Electrotransfection Buffer 
Pulse Voltage 
(mV) 
Pulse Width 
(ms) 
Number of pulses Transfection 
efficiency 
Viability 
1400 20 1 80% 60% 
1500 20 1 80% 60% 
1600 20 1 80% 50% 
1700 20 1 80% 50% 
1100 30 1 60% 80% 
1200 30 1 40% 50% 
1300 30 1 40% 40% 
1400 30 1 50% 30% 
1000 40 1 30% 70% 
1100 40 1 40% 60% 
1200 40 1 30% 50% 
1100 20 2 50% 90% 
1200 20 2 50% 70% 
1300 20 2 20% 80% 
1400 20 2 10% 60% 
900 30 2 20% 100% 
1000 30 2 10% 90% 
1100 30 2 40% 80% 
1200 30 2 30% 50% 
1300 10 3 10% 40% 
1400 10 3 20% 30% 
1500 10 3 10% 30% 
1600 10 3 30% 20% 
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Figure 4.2. 9 - Buffer 5 Optimisation. Left-hand panels show visible light microscopy and 
right-hand GFP fluorescence with UV light. Upper panels represent previous optimized 
transfection conditions with Buffer R. Middle panels show a low voltage with low 
transfection efficiency. Lowest panels represent optimum conditions for Buffer 5, indicating 
this buffer requires a higher voltage.  
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4.2.10 Summary 
 
From the outset, viability issues with MEFs after IRE1 plasmid transfection impeded analysis 
after transfection. Reduction in transfection plasmid concentration did improve viability, but 
not to any useful extent and transfection efficiency was sacrificed as a result. Use of 
alternative buffers/transfection conditions did not improve viability in any way which was not 
again a tradeoff against transfection efficiency. As plasmid expression did not appear to occur 
to until eight hours after transfection, it was not possible to use an earlier timepoint in order 
to catch cells before they had completed apoptosis. The mechanism of IRE1 plasmid 
transfection-induced cell death is unclear – transfection alone was not the cause, as the use of 
a GFP expressing plasmid did not kill the cells to the same extent. Apoptosis induced via the 
IRE1-TRAF2 arm was unlikely, as cells without TRAF2 also suffered cell death from 
transfection. This left the possibility that overexpression of the IRE1 protein was causing 
lethal ER stress, therefore IRE1 constructs were produced with a low-copy thymidine kinase 
promoter. These constructs did not produce any improvement in viability over the stronger 
promoters.  
 .   
4.3 Testing of IRE1α constructs in IRE1α-/MEFs by transient transfection 
 
4.3.1 Rationale 
 
Before it was discovered that viability loss due to IRE1 transfection would severely impede 
the harvesting of sufficient RNA to allow reliable and repeatable analysis of XBP-1 splicing 
(Chapter 4.2), the transient transfection was thought to be a suitable method for testing the 
IRE1 wild type and mutant constructs for activity, as it allows for relatively simply 
performed, short-term expression of plasmid constructs, and should have provided usable 
results indicating IRE1 kinase and RNase function without the long complex procedures 
required to produce stable cell lines, and allow the testing of antibodies against IRE1 and 
JNK to permit examination of expression levels of IRE1 and activation of apoptosis.  
 
4.3.2 D711A mutant exhibits XBP-1 Splicing In MEFs Transiently Transfected 
with Mutant IRE1α 
 
 187 
 
In order to assess the effectiveness of the IRE1 expressing wild type and mutant plasmids in 
producing functional IRE1, splicing of the bZIP transcription factor XBP-1 in response to ER 
stress was used as a marker for function of IRE1’s RNase activity and therefore activation of 
a properly folded and functional protein.  Proportional spliced/unspliced XBP-1 was assessed 
by harvesting RNA from IRE1 transfected MEFs. RNA harvesting was performed according 
to the protocols in Materials and Methods “RNA isolation”. RNA thus harvested was 
analysed using the Molecular Devices Spectramax Spectrophotometer for RNA 
concentration. Total RNA was then reverse transcribed into DNA (see Materials and Methods 
– RNA - “cDNA Production from RNA”) and PCR was performed using primers flanking the 
splicing excision site (Figure 4.3. 1) in order to obtain products that would differ detectably 
when run on a 2%  electrophoresis gel (see Materials and Methods – RNA - “Reverse 
transcription (RT)-PCR Assay for Actin/XBP-1 splicing/IRE1α”). Products from unspliced 
XBP-1 run at 219bp, spliced at 193bp.  
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Figure 4.3. 1 - Sequence section from murine XBP-1. Red box – Forward primer flanking 
splicing excision site. Black box – 26 base pairs excised in spliced XBP-1. Blue box – 
Reverse primer flanking splicing excision site.  
 
  
 
 
 
 
As was explained in Section 4.2, it proved difficult to reliably produce viable transfected 
cells. Therefore several repeats of each XBP-1 splicing assay were required to produce 
sufficient data. ire1α-/- MEFS were transfected with 2µg of each pEDΔc-hIRE1α plasmid and 
grown for 24 hours. Those undergoing ER stress induction were then treated for two hours 
with 500nM thapsigargin (Tg). Both stressed and unstressed cells were also treated with 5µM 
1NM-PP1 for two hours to attempt to induce splicing bypassing the kinase pocket in 
analogue-sensitised I642A/G mutants. After treatment cells were harvested for RNA. Total 
RNA was reverse transcribed and Touchdown RT-PCR performed as described the Materials 
and Methods (“Touchdown RT-PCR for mouse XBP-1/Actin“) to obtain XBP-1 splicing 
PCR products.  As a negative control, ire1α-/- cells untransfected were used and as a positive 
wild type cells (wild type mouse embryonic fibroblasts, see Materials and Methods – “Cell 
Lines”) with or without 500nM thapsigargin treatment.  
 
In Figure 4.3. 2, although splicing can be seen in the wild-type IRE1α transient transfection, 
the level of splicing does not fully recapitulate to the splicing in wild type cells. Low levels of 
splicing can be seen in D711A, K599R and I642A/G mutants. As would be expected with the 
analogue sensitised mutant, this splicing was only clearly inducible by 1NM-PP1 in the case 
of the D711A/I642G mutant. No splicing could be seen in any of the K599A mutants, 
potentially because this is the least conservative mutation of K599 over the K599R. In this 
system no 1NM-PP1 induction was seen in the analogue sensitised mutants as in (Papa2003). 
As expected, no splicing can be seen in the K907A, untransfected and empty vector 
transfected samples. These data indicated a possible bypassing of the need for kinase function 
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of IRE1, but did not give clear or reliable results due to the irregular amounts of RNA 
obtained because of the viability issues. For this reason, the main methodology for obtaining 
material for assessing IRE1 function was changed to production of a stable cell line 
expressing the mutant constructs.  
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Figure 4.3. 2 – XBP-1 splicing in IRE1-construct expressing cells with/without ER stress 
induction/1NM-PP1 treatment. XBP1u – unspliced bands, XBP1s – spliced bands. 
 
 
 191 
 
 
 
4.3.3 Conclusion 
 
It was possible using these experiments to verify that the D711A and D711A double mutants, 
and to some extent the I642A and I642G mutants were capable of producing a low level of 
XBP-1 splicing and useful for further investigation. Whether this is a true reflection remained 
to be confirmed by a more appropriate method.  However, low viability lead to a low 
concentration of cells harvested after transfection and thus a low RNA yield, RNA being 
required for the XBP-1 splicing assay that is the standard marker of IRE1 activation. 
Optimisation of cDNA production by use of gene-specific primers, and of the PCR reaction 
by use of touchdown PCR and hot start polymerases gave some improvement in results (data 
not shown), but in some cases the starting concentration of RNA was too low for use in PCR 
detection.  It was determined part way through the attempts at producing sufficient RNA that 
an alternative strategy to transient transfection of IRE1 plasmids would be to construct a 
stable cell line of MEFs into which the IRE1 constructs could be stably transfected, thus 
allowing as much cell mass to be grown as was required for sufficient RNA. Attempts were 
also made to gain enough protein to test the transient system for JNK 
activation/phosphorylation and IRE1 expression by Western blotting, but this did not prove 
possible. With hindsight, the stable tranfection strategy would have been better started earlier 
and given greater priority as it was time-consuming, but ultimately successful, and completed 
earlier would have allowed more study of the resulting cell lines (see later).  
Difficulties in harvesting sufficient protein and RNA from transient transfection of IRE1α 
constructs precipitated the production of the stable cell lines as described in chapter 4. As 
XBP-1 splicing was successfully tested with sufficient RNA yield to give clear results in the 
ire1α-/- MEF cell lines thus constructed,  this method can be considered a success. The 
D711A mutant has also been confirmed to be capable of splicing as was seen in the yeast 
model in our hands and in (Chawla, Chakrabarti et al. 2011) – based on this information it 
was determined to continue and test this mutant in the CHO system, as will be detailed in the 
following chapters. However, although it was possible to test the apoptotic responses of the 
stable cell lines examined here, it was not possible due to issues with the phospho-IRE1α  
antibody to reliably confirm that differences in cell viability or JNK activation/expression 
were attributable to IRE1α phosphorylation and activation and not due to some other effect of 
the mutant, and that the D711A mutant had any impairment in IRE1α phosphorylation. If 
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more time were available, trying an alternative antibody, assay by immunoprecipitation or 
radioactive phosphate incorporation assay could be used to verify this. It is also evident from 
the high baseline XBP-1 splicing that a physiological UPR was no reconstituted by the stable 
expression system thanks to expression of the constructs occurring even without tetracycline 
induction. Tetracycline-free serum was obtained to eliminate this problem, but insufficient 
time was available to test this and ascertain whether it was tetracycline in the medium or 
leakiness of the construct that was responsible.  Due again to shortage of time, it was not 
possible to test any of the other constructs, - particularly valuable would have been the testing 
of the D711A/I642G construct with and without 1NM-PP1 to ascertain whether the enlarged 
kinase pocket could be used to bypass phosphorylation.  
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4.4 Construction of stable ireα-/-  MEF lines with FRT-IRE1 
 
4.4.1 Rationale 
 
As described in chapters two and three, the transient transfection system used initially proved too 
detrimental to the viability of the MEF cells to allow sufficient RNA and Protein to be harvested. 
Therefore, since no prepared stable transfection-competent ire
-/-
 cell line existed, it was necessary to 
produce one from the MEFs used for the transient system. It was determined to use the Invitrogen Flp-
In™ Core Kit stable cell line system as this had already been used successfully in our laboratory (see 
Materials and Methods – Commercially Available Kits).    
 
4.4.2 Flp-In™ System  
 
The Flp-In system involves the stable transfection of a number of plasmids containing a system that 
permits stable, controllable expression of a required construct. First, the pFRT/lacZeo plasmid is 
transfected into the cell line of interest – this transfection is then screened using a concentration of the 
antibiotic Zeocin which kills all cells in the cell line within two weeks against which the lacZeo fusion 
gene confers resistance. Those cells which remain after this time has elapsed have stably integrated the 
pFRT/lacZeo plasmid into their genome – the function of this plasmid can then be assessed by 
performing a beta-gal assay for the lac operon. This plasmid renders the cell line competent to accept 
the content of the pcDNA5™/FRT/TO, which contains a hygromycin resistance gene. The protein of 
interest is transferred into the pcDNA5™/FRT/TO plasmid – this vector if co-transfected with the 
pOG44 plasmid, which expresses the Flp recombinase that exchanges the two Flp sites, will transfer 
the protein sequence of interest into the stable integration site, exchanging zeocin resistance for 
hygromycin resistance. The third plasmid, which is stably transfected as is the pFRT/lacZeo, is the 
pcDNA6/TR tet repressor plasmid. This plasmid confers blasticidin resistance on cell lines into which 
is it stably transfected and is screened for with blasticidin as is the pFRT/lacZeo plasmid. Cells 
expressing the tet repressor protein from this plasmid suppress expression of the pcDNA5™/FRT/TO 
product, as this plasmid is preceded by two copies of the tetracycline operator. This allows expression 
from the pcDNA5™/FRT/TO plasmid to be induced by addition of tetracycline to growth 
medium/cells. This chapter describes the process of constructing a stable MEF cell line using this 
methodology.  
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4.4.3 Construction of pcDNA5/FRT/TO-hIRE1α and Mutants Thereof 
 
Before transfection, it was necessary to clone the protein of interest, IRE1 and its mutant forms into 
the pcDNA5/FRT/TO vector. This cloning was performed by our collaborator Sergej Seštak, 
Bratislava. Since the D711A/I642A construct did not exhibit clear splicing where the D711A/I642G 
did, possibly due to the greater difference in the size of the kinase pocket extension, only the I642G 
double mutants were produced.  
 
 
Figure 4.4. 1 – Plasmid map of pcDNA5/FRT/TO-hIRE1α. Plasmid contains the human IRE1 gene in 
a vector competent for transfer to a stable cell line using the FRT site.  
 
4.4.4 Testing of pcDNA5-FRT-TO-hIRE1α for successful IRE1α expression in T-Rex 
HEK293 Cells 
 
In order to ensure the pcDNA5 constructs containing the IRE1α for transfer into the stable cell line 
were expressing IRE1 at detectable levels, they were transfected into T-Rex HEK293 cells (Invitrogen, 
Glasgow, UK) which stably express the tet repressor required to control IRE1 expression from the 
pcDNA5/FRT/TO construct. 1x 10
6
 T-Rex HEK293 cells were transiently transfected using the 
Jetprime Method (see Materials and Methods “Transfection – JetPrime”), as this was the method 
optimised for this cell type in our laboratory, with 2µg of pcDNA5-FRT-TO-hIRE1α and grown for 24 
hours before treatment for a timecourse of 1,2,4,8 or 24 hours with 1µg/mL of tetracycline to induce 
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expression of IRE1α. After the required amount of time, the medium was removed and the cells lysed 
in situ with RIPA buffer (see Materials and Methods, Solutions for Protein Work) and harvested for 
protein. Protein levels were quantified using the DC protein assay on the Molecular Devices 
Spectramax. 50µg of protein was then run on an SDS-PAGE gel and a Western blot performed for 
IRE1α as described in Materials and Methods – Western Blotting (Figure 4.4. 2).  
 
 
Figure 4.4. 2 – Western blot for IRE1α in HEK293 Cells transiently  
transfected with pcDNA5-FRT-TO-hIRE1α construct and  
induced with tetracycline. 
 
 
 
Clear induction can be seen with the wild-type construct along with a consistent GAPDH control. 
However, induction is not as obvious in the mutant construct transfections, and the GAPDH result was 
missing or inconsistent in other samples, making it difficult to draw any conclusions about induction. 
IRE1 expression also occurs at 0 hours without tetracycline treatment – this may be due to either 
leakiness of the construct, tetracycline in the fetal calf serum used for tissue culture, or the HEK293’s 
own endogenous IRE1 expression – the Cell Signalling IRE1 α antibody reliably hybridises with 
human IRE1 in our hands, but does not detect MEF or CHO endogenous IRE1 α in cell lines. All 
constructs successfully expressed IRE1 in the T-Rex HEK293 cells. 
 
4.4.5 Stable Transfection with pFRT/lac/Zeo 
 
In order to produce stable transfection competent ire1α-/- cells, it was necessary to stably transfect the 
pFRT/lac/Zeo plasmid into the cells in order to render the cell line competent to accept the IRE1α 
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constructs from the pcDNA5 plasmid. In order to perform the selection procedure, as recommended in 
the Flp-In manual, the tolerance of the MEF cells for the antibiotic was ascertained (see Materials and 
Methods – Antibiotic Tolerance). The concentration 100µg/mL of Zeocin was chosen as suitable for 
the selection process, as the lowest concentration which caused total viability loss within seven days. 
Transfection was then performed according to the protocol in Materials and Methods – “Transfection 
with pFRT/lac/Zeo” and stably transfected clones selected by limited dilution cloning. Three stocks of 
each of the clones grown from a single cell were frozen as described above. In order to ensure the 
pFRT/lac/Zeo plasmid had been integrated, the clones were first analysed for β- gal activity as 
described in Materials and Methods “Beta Gal Assay for pcDNA integration”. Results of this analysis 
are given in (Table 4.4. 1) below. Clones 3 and 7 exhibited no or negligible β- gal activity, and were 
not considered suitable for progression in the stable cell line generation.  
 
Table 4.4. 1 – Beta-galactosidase activity in ire1 -/-  MEF clones stably transfected with pFRT/lac/Zeo 
 β- gal activity(munits/50µl) 
Clone 10x Dilution 2x Dilution 
1 5.88 6.735 
2 10.455 8.959 
3 -0.833 0.767 
4 14.148 10.774 
5 12.798 10.428 
6 5.021 4.068 
7 -1.577 0.071 
8 6.72 7.219 
 
To confirm the presence of the pFRT/lac/Zeo in the clones, Southern Blotting was performed using a 
primer pair against the lacZ gene in the plasmid. Cells from each clone were harvested and the 
genomic DNA extracted using the EZ RNA kit according to the protocol (Geneflow Ltd, Staffordshire, 
UK), digested with the restriction enzyme HindIII, run on a 1% agarose gel and Southern blotted as 
described in Materials and Methods – Southern Blotting (Figure 4.4. 3). Clones 1,7 and 8 did not 
contain a sequence that hybridised to the primer product and were not considered suitable for 
progression – clones 2 and 3 exhibit two bands and may indicate extra copies of the insert. Clones 4 
and 5 exhibited faint bands, and Clone 6 a clear single band. 
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Figure 4.4. 3 – Phosphoimage of Southern Blot for pFRT/lac/Zeo site. Lanes represent radioactive 
signal from Clones 1-8.   
 
Clone                         1     2     3     4     5     6     7     8       
 
 
 
 
Since it was still possible that multiple copies of the insert had integrated at the same site and this 
would not appear as a distinct band in the Southern blot, a PCR reaction was performed on the HindIII 
digested DNA prepared for the Southern blot using primers against the pFRT/lac/Zeo insert – if 
multiple copies of the insert had been integrated, the following size products would be produced see 
Figure 4.4. 4. Clones 1-3 did not successfully produce PCR products.  
 
Figure 4.4. 4 – Potential multiple insertions of the pFRT/lac/Zeo 
 
 
As no bands could be seen at 1100, 571 or 242 base pairs, there is no evidence to suggest that clones 4-
8 had multiple insertions of the pFRT/lac/Zeo sequence (Figure 4.4. 5).  
 
Figure 4.4. 5 - PCR for multiple insertions of pcDNA site 
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Based upon the results of the beta-gal assay, the southern blot and the PCR for insertion sites, Clones 
4,5 and 6 were selected for further analysis as the most likely clones to contain a single, functional 
pFRT/lac/Zeo insertion. Upon revival, however, clone 6 did not grow sufficiently and was not used in 
the following assays.  
 
4.4.6 Stable Transfection with Tet Repressor Plasmid pcDNA6⁄TR 
 
In order to produce stable transfection competent ire1α-/- cells, it was necessary to stably transfect a 
plasmid expressing the Tet Repressor, pcDNA6/TR (supplied with the Flp-In system). This plasmid 
was linearised and transfected into the cells and stable transfectants selected with blasticidin. In order 
to perform the selection procedure, as recommended in the Flp-In manual, the tolerance of the MEF 
cells for the antibiotic was ascertained (see Materials and Methods – Antibiotic Tolerance). A 
blasticidin concentration of 10µg/mL, which resulted in 100% loss by 10 days, was used for future 
selection. Transfection was then performed according to the protocol in Materials and Methods – 
“Transfection with pFRT/lac/Zeo” and stably transfected clones selected by limited dilution cloning. 
 
Three stocks of each of the clones obtained from a single cell were frozen as described above and 
tested for Tet repressor function. Those clones which had grown up fastest and exhibiting healthy 
morphology were chosen for further testing. This testing was performed by the transfection of an 
Fv2e-IRE1α construct produced by David Cox, University of Durham which contained a tet-inducible 
HA-tagged form of IRE1 which only dimerised/activated in the presence of the chemical AP20187. 
2ug of this plasmid was transfected by electroporation into two of the clones produced and the cells 
harvested for protein, run on an SDS page gel and a Western blot performed for the HA tag at a 
concentration of 1:1000 as recommended by the manufacturer (Sigma, Gillingham, UK) (Figure 4.4. 
6). Clone 4,3 produced a visible induction of the IRE1 product, indicating a functional tet-repressor in 
this clone. Clone 5,6 gave very low levels of induction, but also appeared to have a low GAPDH 
control, possibly indicating low protein levels in the sample. T-Rex HEK293 cells were used as a 
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positive control for Tet repressor function as these were used when testing the pcDNA5 constructs 
above, but only showed a low level of induction despite strong GAPDH signal.  
 
 
 
 
Figure 4.4. 6 - Transient transfection with FV2e-IRE1 for tetracycline induction 
 
 
4.4.7 Stable Transfection/Replacement with pcDNA5-FRT-TO-hIRE1α 
 
 ire1α-/- cells rendered competent to produce the tet repressor and shown to contain the FRT site, were 
next required to be transfected with the pcDNA5-FRT-TO-hIRE1α, which contained the hygromycin 
resistance site. Therefore, as above it was necessary to perform an antibiotic tolerance assay. In 
addition, as the cells had now been through several passages and procedures, a second β-Galactosidase 
assay was also performed to ensure the pFRT/Lac/Zeo site was still present in the cell line. Once this 
was verified, the clone selected for the final cell production was co-transfected with pcDNA5-FRT-
TO-hIRE1α and pOG44 as described in Materals and Methods – “Co-Transfection with pcDNA5-
FRT-TO-hIRE1α/ pOG44”. 
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4.4.8 Summary  
 
Using the methodology above, it proved possible to successfully produce a cell line competent for 
stable transfection of the IRE1α constructs, and to stably transfect those constructs to successfully 
produce the required cell lines. Certain aspects of the procedure could have been improved, for 
example, a repeat of the Southern blot to produce better confirmation of the presence of the FRT site, 
better blots for inducibility of the pcDNA5 IRE1 constructs, but otherwise the production process was 
satisfactory. Note: The recommended methodology for assessment of tet repressor function in the Flp-
In manual is transfection of a plasmid providing tetracycline-induced expression of chloramphenicol 
acetyl transferase (CAT) – in our hands this assay could not be made to function, therefore the Fv2e 
IRE1 construct was used instead.  
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4.5 Viability and unfolded protein response activation of stably transfected ireα-/- MEF 
lines with FRT-IRE1α 
 
4.5.1 Rationale 
 
The IRE1 constructs having been stably integrated into the genome of the ire1α-/- MEFs, and 
integrated into a site which permitted sufficient growth, the issues which made transient 
transfection unsuitable for characterising the mutant constructs (lack of viability, and 
concomitant insufficiencies in cell mass and therefore RNA and protein yields). Whereas 
previously the maximum cell limits of the transfection system constrained the amount of cell 
mass that could be obtained, larger 75cm
2
 plates could be used for the assay. Most further 
analyses in this chapter were performed at this scale of growth, and initially using the stably 
transfected cell lines expressing wild type, the kinase-dead K599A mutant and the D711A 
mutant which was of interest having exhibited splicing previously in our laboratory and in 
(Chawla, Chakrabarti et al. 2011), where it was proposed in yeast to be competent for 
splicing induction but not for the attenuation of the unfolded protein response. This being the 
case in the mammalian system it would be expected that there would be a difference or 
prolonged duration of splicing in cells expressing the D711A mutant.   
 
 
4.5.2 Verification of IRE1α expression in Stably Transfected IRE1 Reconstituted 
MEFS 
 
Successful transfection of the pcDNA5 IRE1 constructs was indicated in Chapter 4 by 
resistance to hygromycin, however, the expression of the IRE1 constructs under the control 
of the tet repressor required testing in order to verify the presence of a functional IRE1 and 
ensure consistent expression across different cell lines. 2x10
6 
cells of each cell line 
expressing the constructs were seeded into a 75cm
2
 tissue culture plate (Sarstedt, Leicester, 
UK) and grown for 24 hours until the plates reached 50-70% confluency to allow for the 
longest (24 hour) induction with tetracycline without the plates becoming overconfluent. 
Cells were then treated with 1μg/mL tetracycline for 1,2,4,8 or 24 hours before the medium 
was removed, the cells were washed with PBS and lysed directly in the culture plate with 
RIPA buffer, and then harvested for protein as described in the Materials and Methods. After 
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quantification by DC Protein Assay on the Molecular Devices Spectrophotometer, the protein 
lysate was run on an SDS-PAGE gel and blotted as described in Materials and Methods – 
“Western Blotting”, for IRE1α and GAPDH at 5% (w/v) casein (see Materials and Methods – 
Chemicals.  
 
 
Figure 4.5. 1 - IRE1 expression in Stably Transfected IRE1Reconstituted MEFS 
 
Stable and inducible expression of IRE1α can be seen in the Western blot indicating a 
functional tet repressor producing similar levels of expression across the different cell lines, 
and when compared to GAPDH as a housekeeping gene. As when the pcDNA constructs 
were tested in Chapter 4.4, there was some background IRE1 expression at 0 hours (no 
tetracycline treatment) indicating either leakiness/improper regulation of the construct or 
potentially expression due to tetracycline in the foetal calf serum used in the growth medium.   
 
4.5.3 D711A Mutant exhibits XBP-1 splicing in Stably Transfected ire1α-/- MEFS 
 
Having verified the expression of IRE1α in the stably transfected cell lines, it was then 
determined to examine XBP-1 splicing in the cell lines to confirm the presence of splicing in 
the D711A mutant already seen in the transient system. As above, 2x10
6
 cells of each cell 
line expressing the constructs was seeded into a 75cm
2
 tissue culture plate (Sarstedt, 
Leicester, UK). Cells were then treated with 1μg/mL tetracycline for 0,1,2,4,8 or 24 h before 
the medium was removed, the cells were washed with PBS. Cells were lysed directly in the 
dish using Solution A of the EZ-RNA kit (Geneflow, Staffordshire, UK). The cells were 
prepared for RNA using the kit, and 5µg of the harvested RNA used to produce cDNA as 
described in Materials and Methods – cDNA production from RNA. RT PCR was performed 
on the cDNA thus produced as described in Materials and Methods - “RT-PCR for Mouse 
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XBP-1/Actin”. Reactions were run on a 2% agarose gel and representative gels and graphs of 
averages of three biological repeats are shown in Figure 4.5. 2 
 
Figure 4.5. 2  – Tetracycline induction of XBP-1 splicing in IRE1 stably transfected ire1α-/- 
MEFs.  
 
 
 
 
As expected, the wild-type transfected cell line produced a clear induction of splicing in 
response to tetracycline induction of expression – this effect was also seen in response to 
overexpression in the transient system. The K599A did not induce splicing which is 
consistent with previous results in the transient system and the published literature 
(Tirasophon, Welihinda et al. 1998). The D711A mutant appeared to exhibit strong splicing 
(Figure 4.5. 2A), but upon analysis of replicates, the splicing was not shown to be different 
from the wild type (Figure 4.5. 2B).  
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4.5.4 D711A mutant exhibits similar growth characteristics to wild type IRE1α in 
stably transfected ire1α-/- mouse embryonic fibroblasts. 
 
Once expression and XBP-1 splicing had been established in the stably transfected cell lines, 
basic investigations were made into their growth and cell death characteristics and how these 
were affected by the particular mutant. Potentially, those mutants which did not possess 
kinase function, or which had a reduced kinase function could exhibit lower levels of cell 
death due to the inactivation of the TRAF2 arm, but equally the lack of XBP-1 splicing could 
be severely detrimental to the cell viability overall if it prevented the cell from dealing with 
high loads of unfolded protein.  As a basic indicator of cell viability, a visual inspection of 
adherent versus floating cells was used. As above, 2x10
6 
cells of each cell line expressing the 
constructs was seeded into a 75cm
2
 tissue culture plate and grown for 24 hours until the 
plates reached 50-70% confluency. As can be seen in Figure 4.5. 3, initial growth of the 
K599A and I642G mutants was slower than that of the wild-type and D711A mutants, 
suggesting these mutants are detrimental to the cell lines. As a result, the Wild Type and 
D711A mutants reached confluency faster and began to die off as can be seen in the 48 hour 
images which exhibit many floating cells.  
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Figure 4.5. 3 – Viability of ire1α-/- cells stably transfected with IRE1 constructs after 0-48 h 
tetracycline induction.  
 
 
4.5.5 D711A mutant improves survival of tunicamycin/thapsigargin-induced 
unfolded protein stress in stably transfected ire1α-/- MEFS 
 
Having established the base growth characteristics of the stably transfected cell lines, next 
they were exposed to varying concentrations of the ER stressors thapsigargin (an inhibitor of 
the SERCA pump which perturbs ER calcium homeostasis) and tunicamycin (an inhibitor of 
GlcNAc phosphotransferase which prevents the synthesis of N-linked glycoproteins). As 
above, 2x10
6 
of each cell line expressing the constructs was seeded into a 75cm
2
 tissue 
culture plate and grown for 24 hours until the plates reached 50-70% confluency. The K599A 
and I642G mutants appeared to exhibit slower growth characteristics than the Wild Type and 
D711A. Having established a baseline of growth, an experiment was set up with a low dose 
of tunicamycin (100ng/ml). As above, 2x10
6 
of each cell line expressing the constructs were 
seeded into a 75cm
2
 tissue culture plate and grown for 24 h until the plates reached 50-70% 
confluency. The K599A mutant did not appear to suffer from the low growth characteristics 
in this experiment, although the reason for this is unknown. Plates were first treated for 24 h 
with tetracycline to ensure strong expression of the IRE1 construct, and then treated with 
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100ng/ml tunicamycin and photographed at 24, 48, and 144h after treatment to examine the 
long term effects of low-level ER stress on the cell lines.  
 
 
 
 
Figure 4.5. 4 - Viability of ire1α-/- cells stably transfected with IRE1α constructs and treated 
with 100ng/ml tunicamycin – longer timecourse. 
 
 
Some differences could be seen between the growth and death characteristics of the mutants 
and the wild type transfected cells. Both the kinase-impaired mutants appeared to initially 
exhibit stronger growth up to 24h of tunicamycin treatment, whereas the wild type suffered a 
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gradual deterioration over time under unfolded protein stress, indicating a lack of cell death 
induction due to IRE1α in the kinase impaired mutants. After 48h of tunicamycin treatment, 
the K599A mutant began to suffer cell death more extensively than the D711A and by 144 
hours the cell death in these plates matched those in the wild type, whereas the D711A 
mutant cells died off more slowly. Whether this is due to the extent of the effect on kinase 
activity of the D711A mutant versus the K599A, or due to the splicing activity of the D711A 
mutant is unclear without kinase activity data, but the potential improvement in survival is 
promising for industrial cell productivity.  
 
4.5.6 K599A and D711A mutants exhibit increased PARP cleavage in Stably 
Transfected ire1α-/- MEFS 
 
Cleavage and inactivation of Poly ADP ribose polymerase (PARP), a DNA repair enzyme, by 
caspases into a 24kDa and 89kDa fragments occurs as part of apoptotic programmed cell 
death and is therefore a marker of the induction of the apoptotic programme (Oliver, de la 
Rubia et al. 1998). To investigate the induction of cell death in the IRE1α transfected cell 
lines, PARP cleavage over time was assessed as a marker of apoptotic induction.  0.5x10
6 
cells from each cell line expressing the constructs was seeded into a 75cm
2
 tissue culture 
plate. The lower cell density allowed for longer growth in the plates. Cells were then treated 
with 1μg/ml tetracycline for 0,1,2,3,4 or 7 days before the medium was removed, the cells 
were washed with PBS and lysed directly in the culture plate with RIPA buffer, and then 
harvested for protein as described in the Materials and Methods. After quantification by DC 
Protein Assay on the Molecular Devices Spectrophotometer, the protein lysate was run an 
SDS-PAGE gel (Bio-Rad, Hemel Hempstead, UK) and blotted as described in Materials and 
Methods – “Western Blotting”, using the antibodies and conditions described in Materials 
and Methods – “Antibodies” for PARP and GAPDH. 
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Figure 4.5. 5 – PARP Cleavage in IRE1α stably transfected ire1α-/- MEFs 
 
Seeded plates began to approach confluency at Day 4 and were overconfluent and therefore 
likely to be inducing apoptosis at Day 7. The untransfected host cell line was used as a 
negative control for the effect of IRE1α and the wild type cell line as a positive. Both these 
cell lines began to exhibit cleavage of PARP at confluency as would be expected. The wild 
type-transfected cell line appeared to exhibit similar levels of cleavage to controls, whereas 
the kinase-impaired K599A mutant showed slightly stronger 89kDa bands and reduced 
113kDa, suggesting it was more vulnerable to apoptosis, although it is difficult to verify this 
as general levels of PARP appeared to be lower in the wild type and controls (see below). 
The D711A mutant exhibited levels between the wild type and the K599A which is consistent 
with the results of Figure 4.5. 4 where the D711A phenotype appeared to have similar effects 
to the K599A but with a greater viability at higher cell density, a potentially useful effect for 
industrial biosynthesis where high biomass is required. Both kinase-impaired mutants 
appeared to have slight increases in PARP expression, although GAPDH control levels are 
similar – this could potentially indicate a response to an increase in DNA damage due to 
oxidative stress from poorly-controlled protein folding.  
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4.5.7 D711A Mutant appears to exhibit decreased JNK expression in Stably 
Transfected ire1α-/- MEFS 
 
As the PARP assay had indicated a potential difference in apoptotic responses between the 
mutant and the wild-type transfected cells, further investigation was made into markers of the 
apoptotic arm of the downstream effects of IRE1α activation. Protein obtained from the cells 
harvested for the PARP assay above was used to Western blot for both JNK phosphorylation 
and phospho-IRE1α (see next section). Although in the transient transfection system the 
phospho-JNK/JNK results were unsuitable for analysis, this may have been due to low 
protein yields, therefore these assays were retried with the stable cell protein lysates (data not 
shown). Lysate was run on an SDS-PAGE gel (Bio-Rad, Hemel Hempstead, UK) and blotted 
as described in Materials and Methods – “Western Blotting”, using the antibodies described 
in Materials and Methods – “Antibodies” for phospho JNK and total JNK.  
 
Figure 4.5. 6 – JNK Activation in IRE1α stably transfected ire1α-/- MEFs 
 
JNK activation in the experiment appeared to indicate an increase in JNK phosphorylation at 
the seven day mark when similar increases in PARP had indicated apoptosis due to 
overconfluence. No similar increase could be seen in the D711A mutant, however this may 
be due to a lower JNK concentration in these samples, as the total JNK result in these 
samples was also lower, where the GAPDH result was not altered (see Figure 4.5. 5 above), 
and the levels of total JNK were generally high – even a very short exposure (5 seconds) gave 
an overexposed signal. This may indicate some alteration of regulation of JNK itself in the 
D711A cells which could be contributing the lower cell death in Figure 4.5. 4.  
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4.5.8 IRE1α phosphorylation in Stably Transfected ire1α-/- MEFS 
 
Although the Abcam phospho-IRE1α had not given detectable results in the transient 
transfection system, and the phospho-JNK/JNK results were unsuitable for analysis, this may 
have been due to low protein yields, therefore these assays were retried with the stable cell 
protein lysates (data not shown) Disappointingly although a larger quantity of protein was 
used, the results for phospho-IRE1α remained inconclusive – no clear induction of phospho-
IRE1α could be seen over time, potentially due to non-specificity of the antibody. As a result 
it was not possible to directly confirm activation of the kinase domain of IRE1α. 
 
4.5.9 Summary 
 
Difficulties in harvesting sufficient protein and RNA from transient transfection of IRE1α 
constructs precipitated the production of the stable cell lines as described in chapter 4. As 
XBP-1 splicing was successfully tested with sufficient RNA yield to give clear results in the 
ire1-/- MEF cell lines thus constructed,  this method can be considered a success. The D711A 
mutant has also been confirmed to be capable of splicing as was seen in the yeast model in 
our hands and in (Chawla, Chakrabarti et al. 2011) – based on this information it was 
determined to continue and test this mutant in the CHO system, as will be detailed in the 
following chapters. However, although it was possible to test the apoptotic responses of the 
stable cell lines examined here, it was not possible due to issues with the phospho-IRE1α  
antibody to reliably confirm that differences in cell viability or JNK activation/expression 
were attributable to IRE1 phosphorylation and activation and not due to some other effect of 
the mutant, and that the D711A mutant had any impairment in IRE1 phosphorylation. If more 
time were available, trying an alternative antibody, assay by immunoprecipitation or 
radioactive phosphate incorporation assay could be used to verify this, but there was 
insufficient time for these analyses in this study. It is also evident from the high baseline 
XBP-1 splicing that a physiological UPR was not reconstituted by the stable expression 
system thanks to expression of the constructs occurring even without tetracycline induction. 
Tetracycline-free serum was obtained to eliminate this problem, but insufficient time was 
available to test this and ascertain whether it was tetracycline in the medium or leakiness of 
the construct that was responsible.  Due again to shortage of time, it was not possible to test 
any of the other constructs, - particularly valuable would have been the testing of the 
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D711A/I642G construct with and without 1NM-PP1 to ascertain whether the enlarged kinase 
pocket could be used to bypass phosphorylation.  
 
 
 
4.6 Cloning of CHO IRE1α 
 
4.6.1 Rationale 
 
Having seen in the analyses in the previous chapter that the D711A mutant exhibited XBP-1 
splicing and improvements in viability, this mutant was considered suitable to be brought 
forward into analysis on the working, industrial cell line, CHO (Chinese hamster ovary). As 
detailed in the introduction to this thesis, the CHO cell line is used for production of 
biopharmaceuticals, in particular the CHOK1 lines used by our industrial collaborator (de la 
Cruz Edmonds, Tellers et al. 2006).  However, unlike the MEF line used in the earlier 
chapters of this thesis, no CHO ire1α-/- cell line was available without its own endogenous 
IRE1α. Studies that have been performed using cell lines with their own IRE1α and transient 
transfection of mutant constructs appear to produce expression from the mutants so much 
greater than that of the endogenous IRE1α that it is sufficient to titrate out the effects of the 
endogenous and cause for example, the K599A mutant to have a dominant negative effect 
(e.g. Zhang 2005, Lipson2008), and so this approach was also tested (see Chapter 4.10). 
However, this is not an ideal approach, as it is impossible to completely rule out the effects of 
a small but physiological level of wild-type IRE1α forming heterodimers with the mutant 
constructs. Therefore concurrently to the titration strategy, it was determined to attempt to 
produce a transient knockdown by siRNA of the endogenous CHO IRE1α protein. Although 
currently there is a collaborative initiative to sequence the CHO genome, at the time of this 
work the genome was not available publicly. Therefore, in order to produce sequence to 
target the siRNA against, it was necessary to clone at least part of the sequence of the CHO 
IRE1α gene. Since the IRE1α protein sequences of other organisms (H. sapiens, M. musculus 
and R. norvegicus) are known, these were used as templates for a degenerate primer strategy.  
 
4.6.2 Degenerate primer design for CHO IRE1α 
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Degenerate primers intended for use against the CHO IRE1α sequence were derived by 
inserting the protein sequences listed in Genbank for R. norvegicus (XP_573211) M. 
Musculus (NP_076402) and H. sapiens (NP_001424) (aligned in Appendix 1) into the 
iCODEHOP program (http://dbmi-icode-01.dbmi.pitt.edu/i-codehop-context/Welcome) and 
selecting degenerate primers spanning approximately every 150 nucleotides/50 amino acids 
along the length of the sequence where there was good homology (primers listed in Materials 
and Methods – Primers – CHO IRE1α sequencing). See Appendix 1 for protein sequence 
alignment, iCODEHOP readout and primers selected.           
 
4.6.3 Harvesting of RNA from CHOK1SV Host Cells 
 
In order to produce cDNA for sequencing of CHO IRE1α, 1x107 cells from a culture of 
CHOK1SV donated by Lonza Biologics, Slough were harvested for RNA using the RNA 
Easy Mini Kit according to the kit protocol listed in Materials and Methods – Commercially 
Available Kits.  RNA concentration was measured by spectrophotometer: concentrations of 
0.9 and 1.4 µg/µl were obtained. To verify this 1uL of each sample were run on a 0.9% 
agarose gel (Figure 4.6. 1).  Clear, even bands on the electrophoresis gel indicated good 
quality RNA and therefore this RNA was used in further analysis.  
 
 
Figure 4.6. 1 -  RNA from CHOK1SV host cell line. 
 
 
4.6.4 Cloning Methods and RACE  
 
Initial cloning for CHO IRE1α sequences was performed using the FirstChoice® RLM-
RACE Kit, which uses a version of the Rapid Amplification of cDNA Ends methodology 
(Maruyama1994 Shaefer1995). Initially, 3’ RACE was performed on the RNA according to 
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the protocol version listed in Materials and Methods – Commercially Available Kits. 1µg 
total RNA was used in the reaction with murine moloney leukaemia virus reverse 
transcriptase and the 3’ RACE adaptor from the kit incubated at 42°C for 1h to produce 
cDNA which was used in sequencing reactions.  
 
The initial conditions used for RACE PCR did not appear to be sufficient to produce IRE1α 
sequence. The RLM-RACE manual recommended 60°C as an initial temperature, but that 
optimisation would be required. Therefore, a touchdown PCR method was used as with the 
XBP-1 splicing assay. The reaction was repeated as listed above, but the cycling altered as 
below, with an initial low and  potentially non-selective temperature of 50°C to ensure any 
possible products were visible. As predicted, due to the lower annealing temperature, a 
number of unselective bands were produced. It did not prove possible to selectively PCR any 
IRE1α products using a single degenerate primer, and therefore it was determined to attempt 
to increase selectivity by using two degenerate primers against IRE1α instead of the single 
primer and general 3’ RACE primer. This approach yielded single products of which two 
were the correct length for the primer positions in the IRE1α sequence, A49+A173 (~500bp) 
and B61+B161 (~600bp). Both products were TOPO vector cloned into competent cells and 
screened by colony PCR before sending those of the correct length A49+A173 (Clone 1) and 
B61+B161 (Clone 2) to be sequenced. Both products when run on the NCBI BLAST server 
had >90% homology with M. musculus IRE1α/ERN1 (NM_023913.2). The A49+A173 
matched base pairs 775-1403 and B61+B161 base pairs 2125- 2708 of this sequence. See 
Appendix 2 for full sequences from successful PCRs.  
 
4.6.5 T-RACE Methodology 
 
It did not prove possible in this study to successfully perform the RLM-RACE for 5’ and 3’ 
ends even with specific primers, an alternative methodology was tried, Targeted Rapid 
Amplification of cDNA Ends (Bower2010). This method involves A) Using a poly-A tail 
primer with an additional sequence to B) Using murine moloney leukaemia virus reverse 
transcriptase’s ability to add 2-4 cytosines to  the 5’ cap end of the cDNA and a cap finder 
primer (See Materials and Methods – T-RACE Primers) to place an additional sequence on 
the 5’ end and C) Then using the two extended ends for firstly a second-strand synthesis to 
increase the amount of cDNA and then as the non-specific primer binding site for 
amplification of cDNA ends. Asymmetric PCR is then performed using a gene-specific 
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primer, producing a sequence of unspecified length from the target gene. The first and second 
strand synthesis are performed with dUTP in excess over dTTP, allowing these cDNAs to be 
digested with uracil DNA glycosylase leaving only the dTTP-only asymmetric PCR products. 
Normal PCR is then performed with a nested gene specific primer and a T-RACE primer 
against one of the 3’ or 5’ end caps. When this methodology was used with gene specific 
primers against the CHO sequence, no products were obtained in the final reaction. To isolate 
where the issue was, a selection of primers known to have given products already in PCR 
reactions were used to PCR cDNAs from each stage of the process. As can be seen in Figure 
4.6. 2, both the first and second strand synthesis had produced cDNA and the second strand 
synthesis had produced an increased level, indicating that the 5’ and 3’ caps had attached and 
this synthesis was successful However, after the asymmetric PCR and UDG digestion stage 
no products were obtained, most likely indicating the asymmetric PCR was unsuccessful in 
yielding products. However, as the second strand synthesis had resulted in a better cDNA 
yield, this method was used in later experiments.   
 
 
Figure 4.6. 2 - T-RACE Synthesis 
 
 
4.6.6 Primers Designed using provided Assembly Sequences 
 
By this point in the study, early work had been done on a collaborative project from which 
our industrial sponsor, Lonza Biologics had obtained and donated to us a set of sequences 
from the CHO assembly. These sequences were aligned with those already obtained and used 
to design more gene specific primers at approx 500bp intervals which were used in PCRs as 
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above (in “PCR using standard primers designed from sequence”) to fill in any missing 
sequence and attempt to obtain the 3’ end and if this proved possible, the 5’ end. Although 
the sequences obtained from the 3’ end primers did not have any homology with IRE1α when 
investigated, the products from the 3000-3500 were successfully cloned. Products from these 
primers were sent off for sequencing and yielded sequences matching 2963 – 3264 and 3472- 
3868 of the M. musculus ERN1.   
 
4.6.7 Final CHO IRE1α assembly 
 
When sequences produced in this study were combined with those donated from the CHO 
assembly by Lonza, all but a predicted 29bp of the 3’end and 179 bp of the coding 5’ end 
were sequenced. The full sequence aligned against M. musculus and H.sapiens ERN1 
sequence and annotated with domains follows.  
 
Table 4.6. 1 – Final CHO IRE1α assembly. 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
 GCCTAGTCAGTTCTGCGTCCGCTGAGGCTCGGTCACCGCCTCGCTGTCGTCGCGGCGCCCC 
 ------------CCGTGTCCACCGATCCTCCGCCGGTGCCGCGCTGTCGTTGCGGCGCCCC 
 ------------------------------------------------------------- 
       
 
[5’ UTR 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
CGCCCCGTCCTCTGTCCG-------T-----ACCGCCC----------------
CCGGCGTCCAGCCCTCTGTTCGCGCGGGCTCCAGAACCGGCCGGCGGGGCCCGG 
 
 
 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
AGCCAGGGCCGAGTCCTCGCCATGCCGGCCCGGCGGCTGCTGCTGCTGCT   
AGTCAGGGCCACGTCCTGCC-ATGCCGGCCCGGTGGCTGTTGCTCCTGCT 
--------------------------------------------------- 
                     M  P  A  R  W  L  L  L  L  L 
 
  5’ UTR ][  Signal peptide -------------                                            
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H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
GACGCTGCTGCT------GCCCGGCCTCGGGATTTTTGGAAGTACCAGCAC 
GACGCTGCTGCTACCGCCGCCCGGCCCCGGGAGTTTTGGAAGAACCAGCAC 
------------------------------GAGTTTTGGAAGTGCCAGCAC 
A  L  L  L  P  P  P  G  P  G  S  F  G  R  T  S  T   
                              S  F  G  S  A  S  T 
-------------------------------]    [Luminal domain 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
AGTGACGCTTCCTGAAACCTTGTTGTTTGTGTCAACGCTGGATGGAAGTT 
AGTTACACTGCCTGAGACCTTGTTGTTTGTCTCGACCCTGGATGGAAGCT 
AGTAACACTGCCTGAAACCCTGTTGTTTGTTTCAACCCTGGATGGAAGTT 
V  T  L  P  E  T  L  L  F  V  S  T  L  D  G  S  L  
V  T  L  P  E  T  L  L  F  V  S  T  L  D  G  S  L 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
TGCATGCTGTCAGCAAGAGGACAGGCTCAATCAAATGGACTTTAAAAGAA 
TGCATGCTGTTAGCAAGAGGACGGGCTCCATCAAGTGGACTTTAAAAGAA 
TGCATGCTGTCAGCAAGAGGACAGGCTCGATCAAATGGACTTTAAAAGAA 
  H  A  V  S  K  R  T  G  S  I  K  W  T  L  K  E    
  H  A  V  S  K  R  T  G  S  I  K  W  T  L  K  E 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
GATCCAGTCCTGCAGGTCCCAACACATGTGGAAGAGCCTGCCTTTCTCCC 
GATCCAGTCCTGCAGGTCCCAACACACGTGGAAGAGCCGGCTTTCCTCCC 
GATCCAGTCCTGCAGGTTCCAACACACGTGGAAGAGCCTGCTTTCCTCCC 
 D  P  V  L  Q  V  P  T  H  V  E  E  P  A  F  L  P    
 D  P  V  L  Q  V  P  T  H  V  E  E  P  A  F  L  P 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
AGATCCTAATGATGGCAGCCTGTATACGCTTGGAAGCAAGAATAATGAAG 
AGATCCCAATGATGGCAGTCTGTACACACTTGGAGGCAAGAACAACGAAG 
AGATCCCAATGATGGCAGTCTGTACACACTTGGAGGCAAAAACAACGAAG 
 D  P  N  D  G  S  L  Y  T  L  G  G  K  N  N  E  G    
 D  P  N  D  G  S  L  Y  T  L  G  G  K  N  N  E  G 
 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
GCCTGACGAAACTTCCTTTTACCATCCCAGAATTGGTGCAGGCATCCCCA 
GCCTGACGAAACTTCCCTTTACCATCCCAGAATTGGTTCAGGCCTCCCCA 
GCCTGACGAAACTTCCCTTTACCATCCCAGAATTAGTCCAAGCATCTCCA 
 L  T  K  L  P  F  T  I  P  E  L  V  Q  A  S  P      
 L  T  K  L  P  F  T  I  P  E  L  V  Q  A  S  P 
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H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
TGCCGAAGTTCAGATGGAATCCTCTACATGGGTAAAAAGCAGGACATCTG   
TGCCGAAGTTCAGATGGAATCCTCTACATGGGTAAAAAGCAAGATATTTG 
TGCCGAAGTTCAGATGGAATCCTCTACATGGGTAAAAAGCAGGACATCTG 
C  R  S  S  D  G  I  L  Y  M  G  K  K  Q  D  I  W     
C  R  S  G  D  G  I  L  Y  M  G  K  K  Q  D  I  W 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
GTATGTTATTGACCTCCTGACCGGAGAGAAGCAGCAGACTTTGTCATCGG 
GTATGTTATCGACCTCCTGACTGGCGAGAAGCAGCAGACTTTGTCATCGG 
GTATGTTATCGACCTCCTGACTGGAGAGAAGCAGCAGACTTTGTCATCGG 
Y  V  I  D  L  L  T  G  E  K  Q  Q  T  L  S  S  A    
Y  V  I  D  L  L  T  G  E  K  Q  Q  T  L  S  S  A 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
CCTTTGCAGATAGTCTCTGCCCATCAACCTCTCTTCTGTATCTTGGGCGA   
CCTTTGCTGATAGTCTCTGCCCATCAACTTCCCTTCTATATCTTGGACGG 
CCTTTGCAGATAGTCTCTGCCCATCAACTTCCCTGCTGTATCTTGGACGG 
F  A  D  S  L  C  P  S  T  S  L  L  Y  L  G  R      
F  A  D  S  L  C  P  S  T  S  L  L  Y  L  G  R 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
ACAGAATACACCATCACCATGTACGACACCAAAACCCGAAAGCTCCGGTG 
ACAGAATACACCATCACCATGTATGACACCAAGACCCGGGAGCTCCGCTG 
ACAGAATATACCATCACTATGTATGACACCAAGACCCGAGAACTTCGTTG  
 T  E  Y  T  I  T  M  Y  D  T  K  T  R  E  L  R  W     
 T  E  Y  T  I  T  M  Y  D  T  K  T  R  E  L  R  W 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
GAATGCCACCTACTTTGACTATGCGGCCTCACTGCCTGAGGACGACGTGG   
GAATGCCACCTATTTTGACTATGCAGCCTCACTGCCGGAAGACGACGTGG 
GAACGCCACCTATTTTGACTATGCAGCCTCACTGCCCGAGGATGATGTGG 
 N  A  T  Y  F  D  Y  A  A  S  L  P  E  D  D  V  D    
 N  A  T  Y  F  D  Y  A  A  S  L  P  E  D  D  V  D 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
ACTACAAGATGTCCCACTTTGTGTCCAATGGTGATGGGCTGGTGGTGACT    
ACTACAAGATGTCCCACTTTGTGTCCAATGGCGATGGACTGGTGGTAACT 
ACTACAAGATGTCCCACTTTGTGTCCAATGGCGATGGACTAGTGGTAACT 
 Y  K  M  S  H  F  V  S  N  G  D  G  L  V  V  T      
 Y  K  M  S  H  F  V  S  N  G  D  G  L  V  V  T 
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H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
GTGGACAGTGAATCTGGGGACGTCCTGTGGATCCAAAACTACGCCTCCCC   
GTGGACAGTGAATCTGGGGATGTCCTGTGGATCCAAAACTATGCCTCTCC 
GTGGACAGTGATTCTGGGGATGTCTTGTGGATCCAAAACTATGCCTCTCC 
 V  D  S  E  S  G  D  V  L  W  I  Q  N  Y  A  S  P     
 V  D  S  D  S  G  D  V  L  W  I  Q  N  Y  A  S  P 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
TGTGGTGGCCTTTTATGTCTGGCAGCGGGAGGGTCTGAGGAAGGTGATGC  
TGTGGTGGCCTTCTACGTCTGGCAGGGGGAGGTCCTGAGAAAGGTGGTGC 
TGTGGTAGCCTTCTATGTCTGGCAGCGGGAGGGCCTGAGAAAGGTGATGC 
 V  V  A  F  Y  V  W  Q  G  E  V  L  R  K  V  V  H    
 V  V  A  F  Y  V  W  Q  R  E  G  L  R  K  V  M  H 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
ACATCAATGTCGCTGTGGAGACCCTGCGCTATCTGACCTTCATGTCTGGG  
ACATCAACGTTGCTGTGGAGACTCTACGCTACTTGACCTTCATGTCTGGG 
ACATCAACGTCGCTGTGGAGACTCTCCGCTACCTGACCTTCATGTCTGGG 
 I  N  V  A  V  E  T  L  R  Y  L  T  F  M  S  G      
 I  N  V  A  V  E  T  L  R  Y  L  T  F  M  S  G 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
GAGGTGGGGCGCATCACAAAGTGGAAGTACCCGTTCCCCAAGGAGACAGA 
GAAGTGGGGCGCATCACCAAGTGGAAGTATCCATTCCCCAAGGAGACAGA 
GAAGTGGGGCGCATCACCAAGT~~AAGTATCCGTTC~CCAAGGAGACAGA 
E  V  G  R  I  T  K  W  K  Y  P  F  P  K  E  T  E     
E  V  G  R  I  T  K  -  K  Y  P  F  -  K  E  T  E 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
GGCCAAGAGCAAGCTGACGCCCACTCTGTATGTTGGGAAATACTCTACCA 
GGCCAAGAGCAAGCTAACGCCTACTCTGTATGTTGGGAAGTATTCCACCA 
GGCCAAGAGCAAGCTGACGCCTACCCTGTACGTTGGGAAGTACTCAACCA 
 A  K  S  K  L  T  P  T  L  Y  V  G  K  Y  S  T  S    
 A  K  S  K  L  T  P  T  L  Y  V  G  K  Y  S  T  S 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
GCCTCTATGCCTCTCCCTCAATGGTACACGAGGGGGTTGCTGTCGTGCCC  
GCCTCTATGCCTCTCCCTCAATGGTGCATGAGGGGGTTGCTGTCGTGCCT 
GCCTCTATGCCTCTCCATCAATGGTGCACGAGGGGGTTGCTGTAGTGCCC 
   L  Y  A  S  P  S  M  V  H  E  G  V  A  V  V  P      
   L  Y  A  S  P  S  M  V  H  E  G  V  A  V  V  P 
       Luminal domain][Linker domain 
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H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
CGCGGCAGCACACTTCCTTTGCTGGAAGGGCCCCAGACTGATGGCGTCAC 
CGAGGCAGCACTCTTCCTTTGCTGGAAGGCCCCCAGACAGATGGCGTCAC 
CGAGGAAGCACTCTTCCTTTGCTGGAAGGTCCCCAGACAGATGGTGTCAC  
 R  G  S  T  L  P  L  L  E  G  P  Q  T  D  G  V  T     
 R  G  S  T  L  P  L  L  E  G  P  Q  T  D  G  V  T 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
CATTGGGGACAAGGGGGAGTGTGTGATCACGCCCAGCACGGACGTCAAGT 
CATTGGAGACAAAGGAGAGTGTGTGATCACTCCCAGCACAGACCTCAAGT 
CATTGAAGACAAAGGAGAGTGTGTGATCACCCCCAGCACAGACCTCAAGT 
  I  G  D  K  G  E  C  V  I  T  P  S  T  D  L  K  F    
  I  E  D  K  G  E  C  V  I  T  P  S  T  D  L  K  F 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
TTGATCCCGGACTCAAAAGCAAGAACAAGCTCAACTACTTGAGGAATTAC 
TTGACCCTGGACTCAAAGGGAAGAGCAAGCTGAACTACTTGAGGAATTAC 
TTGACCCTGGACTCAAAGGGAAGAGCAAGCTGAACTACTTGAGGAATTAC 
  D  P  G  L  K  G  K  S  K  L  N  Y  L  R  N  Y      
  D  P  G  L  K  G  K  S  K  L  N  Y  L  R  N  Y 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
TGGCTTCTGATAGGACACCATGAAACCCCACTGTCTGCGTCTACCAAGAT 
TGGCTTCTCATAGGACACCATGAAACTCCTCTGTCTGCATCCACCAAGAT 
TGGCTTCTCATAGGACACCATGAAACTCCTCTGTCTGCATCTACCAAGAT 
 W  L  L  I  G  H  H  E  T  P  L  S  A  S  T  K  M     
 W  L  L  I  G  H  H  E  T  P  L  S  A  S  T  K  M 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
GCTGGAGAGATTTCCCAACAATCTACCCAAACATCGGGAAAATGTGATTC 
GCTGGAGAGATTTCCTAACAACCTGCCCAAACATCGAGAAAATGTGATTC 
GCTGGAGAGATTCCCCAACAACCTGCCCAAACATCGGGAAAATGTGATTC 
 L  E  R  F  P  N  N  L  P  K  H  R  E  N  V  I  P    
 L  E  R  F  P  N  N  L  P  K  H  R  E  N  V  I  P 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
CTGCTGATTCAGAGAAAAAGAGCTTTGAGGAAGTTATCAACCTGGTTGAC 
CTGCTGATTCAGAAAAAAGGAGCTTTGAGGAAGTTATCAACATAGTTGGC 
CTGCTGATTCGGAAAAAAGGAGCTTTGAGAAAGTTATCAACATGGTTGAC 
  A  D  S  E  K  R  S  F  E  E  V  I  N  I  V  G      
  A  D  S  E  K  R  S  F  E  K  V  I  N  M  V  D 
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H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
CAGACTTCAGAAAACGCACCTACCACCGTGTCTCGGGATGTGGAGGAGAA 
CAGACTTCAGACAACACACCGACCACCGTATCTCAGGATGTGGAGGAGAA 
CAGACTTCAGAAAACACACCATCCACTGTGTCTCAGGCCGTGGAAGAGAA 
 Q  T  S  D  N  T  P  T  T  V  S  Q  D  V  E  E  K     
 Q  T  S  E  N  T  P  S  T  V  S  Q  A  V  E  E  K 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
GCCCGCCCAT GCCCCTGCCC GGCCCGAGGC CCCCGTGGAC TCCATGCTTA  
GCTCGCTCGC GCCCCTGCCA AGCCTGAGGC CCCCGTGGAC TCCATGCTCA 
GCTGGTCCAT GCCCCCGCCA AGCCTGAGGC CCCCGTTGAC TCCATGCTCA 
 L  A  R   A  P  A  K   P  E  A   P  V  D   S  M  L  K    
 L  V  H   A  P  A  K   P  E  A   P  V  D   S  M  L  K 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
AGGACATGGCTACCATCATCCTGAGCACCTTCCTGCTGATTGGCTGGGTG 
AGGACATGGCTACCATTATCCTGAGCACCTTCCTGCTGGTTGGATGGGTG 
AGGACATGGCTACTATTATCCTGAGCACCTTCCTGCTGGTTGGATGGGTG 
  D  M  A  T  I  I  L  S  T  F  L  L  V  G  W  V      
  D  M  A  T  I  I  L  S  T  F  L  L  V  G  W  V 
   Linker domain][Transmembrane domain 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
GCCTTCATCATCACCTATCCCCTGAGCATGCATCAGCAGCAGCAGCTCCA 
GCGTTCATCATCACTTACCCCCTGAGCGTGCATCAGCAGCGTCAGCTCCA 
GCCTTCATCATCACTTACCCCCTGAGCATGCATCAGCAGCGCCAGCTCCA 
A  F  I  I  T  Y  P  L  S  V  H  Q  Q  R  Q  L  Q     
A  F  I  I  T  Y  P  L  S  M  H  Q  Q  R  Q  L  Q 
               transmembrane domain][Poly Q region 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
GCACCAGCAGTTCCAGAAGGAACTGGAGAAGATCCAGCTCCTGCAGCAGC 
GCACCAACAGTTCCAGAAGGAGCTGGAGAAGATTCAGCTCCTGCAGCAGC 
GCACCAGCAGTTCCAGAAGGAACTGGAGAAAATTCAGCTCCTGCAGCAGC 
 H  Q  Q  F  Q  K  E  L  E  K  I  Q  L  L  Q  Q  Q    
 H  Q  Q  F  Q  K  E  L  E  K  I  Q  L  L  Q  Q  Q 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
AGCAGCAGCAGCTGCCCTTCCACCCACCTGGAGACACGGCTCAGGACGGCGAGCTC  
AGCAG------CTGCCCTTCCACCCACACGGAGACCTTACCCAGGACCCTGAGTTC 
AGCAG------CTGCCCTTCCACCCACATGGAGACCTTACTCAGGACCCCGAGTTT 
Q        L  P  F  H  P  H  G  D  L  T  Q  D  P  E  F      
Q  Q  Q  L  P  F  H  P  H  G  D  L  T  Q  D  P  E  F 
Poly Q] 
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H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
CTGGACACGTCTGGCCCGTACTCAGAGAGCTCGGGCACCAGCAGCCCCAG  
CTGGATTCATCTGGCCCCTTCTCAGAGAGCTCTGGCACCAGCAGCCCCAG 
CTGGATTCATCTGGTC~CTTCTCAGAGAGCTCAGGCACCAGCAGCTCCAG 
L  D  S  S  G  P  F  S  E  S  S  G  T  S  S  P  S     
L  D  S  S  G  X  F  S  E  S  S  G  T  S  S  S  S 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
CACGTCCCCCAGGGCCTCCAACCACTCGCTCTGCTCCGGCAGCTCTGCCT----  
CCCATCCCCCAGAGCCTCCAACCACTCCCTCCACCCCAGCAGCTCTGCCT---- 
CCCATCCCCCAGAGCCTCCAACCACTCACTCCACTCCAGCAGCTCTGCCTCCAA 
P  S  P  R  A  S  N  H  S  L  H  P  S  S  S  A  S  -  
P  S  P  R  A  S  N  H  S  L  H  S  S  S  S  A  S  N 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
CCAAGGCTGGCAGCAGCCCCTCCCTGGAACAAGACGATGGAGATGAGGAA---  
CCAGGGCCGGCACCAGCCCCTCTCTGGAGCAGGATGATGAGGATGAGGAA---                     
CCAAGACTGGCACCAACCCTTCCCTGGAGCAGGATGATGAGGATGAGGAAACT 
  R  A  G  T  S  P  S  L  E  Q  D  D  E  D  E  E  -   
  Q  T  G  T  N  P  S  L  E  Q  D  D  E  D  E  E  T 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
ACCAGCGTGGTGATAGTTGGGAAAATTTCCTTCTGTCCCAAGGATGTCCT 
ACCAGAATGGTGATTGTTGGGAAAATTTCATTCTGCCCCAAGGATGTCCT 
ACTAGAATGGTGATTGTTGGGAAAATTTCATTCTGCCCCAAGGATGTCCT 
 T  R  M  V  I  V  G  K  I  S  F  C  P  K  D  V  L     
 T  R  M  V  I  V  G  K  I  S  F  C  P  K  D  V  L 
                                 [Kinase domain 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
GGGCCATGGAGCTGAGGGCACAATTGTGTACCGGGGCATGTTTGACAACC 
GGGTCATGGAGCTGAGGGCACAATTGTATACAAAGGTATGTTTGACAACC 
GGGCCATGGAGCTGAGGGCACAATTGTATACAAAGGCATGTTTGACAACC 
 G  H  G  A  E  G  T  I  V  Y  K  G  M  F  D  N  R    
 G  H  G  A  E  G  T  I  V  Y  K  G  M  F  D  N  R 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
GCGACGTGGCCGTGAAGAGGATCCTCCCCGAGTGTTTTAGCTTCGCAGAC 
GAGATGTGGCCGTGAAGAGGATCCTCCCTGAGTGTTTTAGCTTTGCCGAC 
GTGATGTGGCAGTGAAGAGGATCCTCCCTGAGTGTTTTAGCTTTGCAGAC 
   D  V  A  V  K  R  I  L  P  E  C  F  S  F  A  D      
   D  V  A  V  K  R  I  L  P  E  C  F  S  F  A  D 
               K599 
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H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
CGTGAGGTCCAGCTGTTGCGAGAATCGGATGAGCACCCGAACGTGATCCG1951 
CGTGAGGTCCAGCTGCTTCGAGAATCAGACGAGCACCCAAATGTGATCCG 
CGTGAGGTCCAGCTGCTTCGAGAATCAGACGAGCATCCAAACGTGATCCG 
R  E  V  Q  L  L  R  E  S  D  E  H  P  N  V  I  R     
R  E  V  Q  L  L  R  E  S  D  E  H  P  N  V  I  R 
       
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
CTACTTCTGCACGGAGAAGGACCGGCAATTCCAGTACATTGCCATCGAGC 
CTACTTTTGCACAGAGAAGGACCGGCAGTTCCAGTACATTGCTATCGAGC 
CTACTTTTGCACAGAGAAGGACCGGCAGTTCCAATACATTGCTATTGAAT 
 Y  F  C  T  E  K  D  R  Q  F   Q  Y  I  A  I  E  L    
 Y  F  C  T  E  K  D  R  Q  F   Q  Y  I  A  I  E  L 
                                            I642 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
TGTGTGCAGCCACCCTGCAAGAGTATGTGGAGCAGAAGGACTTTGCGCAT        
TGTGTGCAGCCACCCTACAAGAGTATGTGGAGCAGAAGGACTTTGCCCAC 
TGTGTGCAGCCACTCTGCAAGAGTATGTGGAGCAGAAGGACTTTGCCCAC 
 C  A  A  T  L  Q  E  Y  V  E  Q  K  D  F  A  H      
 C  A  A  T  L  Q  E  Y  V  E  Q  K  D  F  A  H 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
CTCGGCCTGGAGCCCATCACCTTGCTGCAGCAGACCACCTCGGGCCTGGC  
CTTGGCCTCGAGCCCATCACCCTGCTTCATCAGACCACCTCAGGCCTGGC 
CTTGGCCTGGAGCCCATCACCTTGCTTCAGCAGACCACCTCAGGCCTGGC 
 L  G  L  E  P  I  T  L  L  H  Q  T  T  S  G  L  A     
 L  G  L  E  P  I  T  L  L  Q  Q  T  T  S  G  L  A 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
CCACCTCCACTCCCTCAACATCGTTCACAGAGACCTAAAGCCACACAACA  
ACACCTGCATTCTCTCAACATTGTTCACAGAGACCTGAAGCCCCACAACA 
ACACCTGCACTCTCTCAACATAGTTCACAGAGACCTGAAACCCCACAACA 
 H  L  H  S  L  N  I  V  H  R  D  L  K  P  H  N  I    
 H  L  H  S  L  N  I  V  H  R  D  L  K  P  H  N  I 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
GACTTTGGCCTCTGCAAGAAGCTGGCAGTGGGCAGACACAGTTTCAGCCG 
GACTTTGGCCTCTGCAAGAAGCTGGCAGTGGGCAGGCACAGTTTCAGCCG 
GACTTTGGCCTCTGCAAGAAGCTGGCAGTGGGTAGGCACAGTTTCAGCCG 
D  F  G  L  C  K  K  L  A  V  G  R  H  S  F  S  R     
D  F  G  L  C  K  K  L  A  V  G  R  H  S  F  S  R      
D711 <              Activation loop      S1     S2 
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H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
TCCTCATATCCATGCCCAATGCACACGGCAAGATCAAGGCCATGATCTCC 
TTCTCCTCTCCATGCCCAACGCACATGGCAGGATCAAGGCGATGATCTCT 
TTCTCCTCTCCATGCCCAACGCACATGGCAAGATCAAGGCCATGATCTCT 
   L  L  S  M  P  N  A  H  G  R  I  K  A  M  I  S      
   L  L  S  M  P  N  A  H  G  K  I  K  A  M  I  S 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
CCGATCTGGGGTGCCTGGCACAGAAGGCTGGATCGCTCCAGAGATGCTGA 
CCGTTCAGGGGTACCTGGCACTGAAGGGTGGATCGCCCCAGAGATGCTGA 
TCGTTCAGGGGTACCTGGCACTGAAGGCTGGATCGCCCCAGAGATGTTGA 
 R  S  G  V  P  G  T  E  G  W  I  A  P  E  M  L  S    
 R  S  G  V  P  G  T  E  G  W  I  A  P  E  M  L  S 
   S3                                         > 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
GCGAAGACTGTAAGGAGAACCCTACCTACACGGTGGACATCTTTTCTGCA 
GTGAAGACTGTAAGGACAACCCTACCTACACGGTGGACATCTTTTCTGCA 
GTGAAGACTGCAAGGAAAACCCTACCTACACAGTGGACATCTTCTCTGCA 
  E  D  C  K  D  N  P  T  Y  T  V  D  I  F  S  A      
  E  D  C  K  E  N  P  T  Y  T  V  D  I  F  S  A 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
GGCTGCGTCTTTTACTACGTAATCTCTGAGGGCAGCCACCCTTTTGGCAA  
GGCTGTGTCTTTTACTATGTCATCTCTGAGGGCAACCATCCTTTTGGCAA 
GGCTGTGTTTTTTACTATGTCATCTCTGAGGGCAACCATCCTTTTGGCAA 
 G  C  V  F  Y  Y  V  I  S  E  G  N  H  P  F  G  K     
 G  C  V  F  Y  Y  V  I  S  E  G  N  H  P  F  G  K 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
GTCCCTGCAGCGGCAGGCCAACATCCTCCTGGGTGCCTGCAGCCTTGACT  
ATCCTTGCAGCGGCAGGCCAACATCCTCCTGGGCGCCTGCAACCTTGACT 
GTCCTTGCAGCGGCAGGCCAACATCCTCCTGGGCGCCTGCAGCCTTGACT 
  S  L  Q  R  Q  A  N  I  L  L  G  A  C  N  L  D     
  S  L  Q  R  Q  A  N  I  L  L  G  A  C  S  L  D  
 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
GCTTGCACCCAGAGAAGCACGAAGACGTCATTGCACGTGAATTGATAGAG 
GTTTCCACTCAGACAAGCATGAGGACGTCATTGCTCGTGAATTGATAGAG 
GCTTCCACTCAGACAAGCATGAGGACGTCATTGCTCGTGAATTGATAGAG 
C  F  H  S  D  K  H  E  D  V  I  A  R  E  L  I  E      
C  F  H  S  D  K  H  E  D  V  I  A  R  E  L  I  E 
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H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
AAGATGATTGCGATGGATCCTCAGAAACGCCCCTCAGCGAAGCATGTGCT 
AAAATGATTGCTATGGATCCCCAGCAGCGTCCCTCTGCAAAGCACGTGCT 
AAGATGATTGCTATGGATCCCCAGCAACGGCCCTCTGCAAAGCATGTGCT 
 K  M  I  A  M  D  P  Q  Q  R  P  S  A  K  H  V  L     
 K  M  I  A  M  D  P  Q  Q  R  P  S  A  K  H  V  L  
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
CAAACACCCGTTCTTCTGGAGCCTAGAGAAGCAGCTCCAGTTCTTCCAGG 
GAAACACCCCTTCTTCTGGAGCCTGGAGAAGCAGCTCCAGTTTTTCCAGG 
AAAACACCCATTCTTCTGGAGCCTGGAAAAGCAGCTCCAGTTTTTCCAGG 
 K  H  P  F  F  W  S  L  E  K  Q  L  Q  F  F  Q  D    
 K  H  P  F  F  W  S  L  E  K  Q  L  Q  F  F  Q  D 
    Kinase domain ][ RNase domain 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
ACGTGAGCGACAGAATAGAAAAGGAATCCCTGGATGGCCCGATCGTGAAG         
ATGTAAGTGACCGAATAGAAAAGGAGGCCTTGGACGGTCCAATCGTACGG 
ATGTGAGTGACCGAATAGAAAAGGAGTCCTTGGATGGCCCGATAGTAAGA 
  V  S  D  R  I  E  K  E  A  L  D  G  P  I  V  R      
  V  S  D  R  I  E  K  E  S  L  D  G  P  I  V  R 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
CAGTTAGAGAGAGGCGGGAGAGCCGTGGTGAAGATGGACTGGCGGGAGAA 
CAGTTGGAGAGAGGCGGGAGAGCTGTGGTCAAGATGGACTGGCGGGAGAA 
CAGTTGGAGAGAGGCGGGAGAGCCGTGGTGAAGATGGACTGGCGGGAGAA 
Q  L  E  R  G  G  R  A  V  V  K  M  D  W  R  E  N     
Q  L  E  R  G  G  R  A  V  V  K  M  D  W  R  E  - 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
CATCACTGTCCCCCTCCAGACAGACCTGCGTAAATTCAGGACCTATAAAG  
CATCACTGTCCCCCTGCAGACAGATCTGCGCAAATTCAGAACCTACAAAG 
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~CAGAACCTACAAAG 
 I  T  V  P  L  Q  T  D  L  R  K  F  R  T  Y  K  G    
 -  -  -  -  -  -  -  -  -  -  -  -  R  T  Y  K  G 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
GTGGTTCTGTCAGAGATCTCCTCCGAGCCATGAGAAATAAGAAGCACCAC 
GTGGCTCTGTGAGAGACCTCCTCCGAGCCATGAGAAACAAGAAACACCAC 
GTGGCT~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~AGAAACACCAC 
   G  S  V  R  D  L  L  R  A  M  R  N  K   K  H  H     
   G  -  -  -  -  -  -  -  -  -  -  -  -   K  H  H 
           K907 
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H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
TACCGGGAGCTGCCTGCAGAGGTGCGGGAGACGCTGGGGTCCCTCCCCGA  
TACCGGGAGCTCCCCGTGGAGGTTCAGGAGACGCTGGGCTCCATCCCGGA 
TACCGAGAGCTCCCCATGGAGGTTCAGGAGACGCTGGGCTCCATCCCCGA 
 Y  R  E  L  P  V  E  V  Q  E  T  L  G  S  I  P  D     
 Y  R  E  L  P  M  E  V  Q  E  T  L  G  S  I  P  D  
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
Cgacttcgtgtgctacttcacatctcgcttcccccacctcctcgcacaca  
TGACTTTGTGCGCTACTTCACTTCCCGCTTCCCCCACCTCCTCTCTCACA 
Tgactttgtgcgctatttcacatcacgcttcccctacctcctctcacaca 
 D  F  V  R  Y  F  T  S  R  F  P  H  L  L  S  H  T   
 D  F  V  R  Y  F  T  S  R  F  P  Y  L  L  S  H  T 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
CCTACCGGGCCATGGAGCTGTGCAGCCACGAGAGACTCTTCCAGCCCTAC 
CCTACCAAGCCATGGAGCTGTGCAGACATGAGAGACTCTTTCAGACCTAC 
CCTACCGAGCCATGGAGCTCTGCAGACATGAGAGACTCTTCCAGACCTAC 
  Y  Q  A  M  E  L  C  R  H  E  R  L  F  Q  T  Y     
  Y  R  A  M  E  L  C  R  H  E  R  L  F  Q  T  Y 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
TACTTCCACGAGCCCCCAGAGCCCCAGCCCCCAGTGACTCCAGACGCCCT 
TACTGGCACGAGCCCACAGAACCCCAGCCTCCAGTGATTCCATATGCCCT 
TACTTGCACGAGCCCACAGAACCCCAGCCTCCAGTGACTCCAGATGCGCT 
 Y  W  H  E  P  T  E  P  Q  P  P  V  I  P  Y  A  L    
 Y  L  H  E  P  T  E  P  Q  P  P  V  T  P  D  A  L 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
CTGAGCGAGGGCGGCCCCTCTGTTCTGGTGGCCCCAGCTGT----GACTGAGGGC 
CTGAGCTAGGGCAGCCC-TCTGGTCTGGTGGCCCCA----ATAATGACCATGGGC 
CTGAGCCATGGCAGCCC-TCTAGTCTGGTGGCCCCAGCAGAGATTG~~CA~~GGC 
 *   
 *  
 RNase domain][3’ UTR  
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
CTGGTCACCACAATT-AGAGCTTGATGCCTCCCGGCTTTGCAGGGAGACCA 
CCGATCTCTGCAGTC-ATAGTTTGTTGCCTCTGGGATTAGCAGGAAGACTA 
CCAATCTCTGCAGTCTGTAGCTTGCTGCCTCTGGGATTAGCAGGAAGACTA 
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H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
GGCTTCCCAAACCAAGTGCCTTGAGCTGCCTGCTCTGCAGCCCACAGAGGA 
AGCTTCGCAAATCAAGTGCCTTGAGCT-GCTGATCTGCAGCCAGAAGAGGA 
AGCTTCTCAAACCAAGTGCCTTGAGCT-GCTGCCCTGCAGCCAGAAGAGGA 
 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
CAGTGCTGACCCCAGGAAGTGGGAGAAG-TGGCCCCTCGTGACCTACAGGG 
TAACGCTGATCCTAGGACGCAGGGGAAGATGGTCCCTCATGAC-TACAGAG 
CAGTGCTGACCCTAGGAAGTGGAAGAGGT-GGCCCCTCATGTC-TACAGAG 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
AACTGGGAAGATGCTGGCCCCAAAAGCCTTACGGTCATG-ATGTCTGCAAAG 
ACCTGAGGAGATGTGGCCCTGAAA--CCTTGTAGTGAAGGACGTCTACGAAG  
~~CTGAGGCGATGTAG~~~T~~~~--C~~~~~~~~~~AGGGCTGTCTACAAA 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
--GAGGGC--–CTCAGAGACAGCGCGAGTAGCACCCCCAGCCATCTACTGGA 
--GCAGCCTGTCCCAGAGGCTGCAAAGGAAACAGCATCAGCCTTTCACCGGA 
GGTGGGCCCATCCCAGAGGCTGCAAAAGGAGCAGCATCAGCCTCTCCCTGGA 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
TAAACTTGCT--------TCAGACTTTTTAAA-TTCCTGCTTAATGTCAG 
TGAGCTTGCTCCCACTTCTCTTTCTTTCTAAAATTCCTGTGGGATGGCAT 
TGAGCTTGCTT~CACTTCTTTTTCTTTCTAAAATTCCTGTGGGATGGCAT 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
TCTACAGG-CCTTTCAGGAAGGGAGAGGAG-GGAATCGTACATTTTGCTTGCGTGC 
TTTGGGGGGCCTTTCAGT----GAGAGTAGAGGAAT--TGG-TTTTGCCTGCATGG 
TTT-GGGGGCCTTTCAGTGAGGGAG~~TAGAGGAATCCTG~~TTTTGCCTG~~~~~ 
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H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
TGGGA-CAGCTAGGCTGAGATGCACCAAGTACAGCCTTCACTGG-AGACCGGA 
TGGAAGCAGCCTGGTTGGGGTATTGCATGTGCAGCCT---CTGATAGAAATGG 
----AGCAGCCTGGCTGGGGTGCAGCAAGAGCACCCT---CTGCTAGAAATGG 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
ATTGAGAGGTGGGGGATG--
CTGAGGAGGGGGAGGACGGAGTTCAGAGGGTGTCGTCCTGCAGTG 
TTTGAGAGATGTGGGGTG--CTAAGGAAG---AG-ATG—TTCAGAGG-TGT-------
TGCCATG 
TTTTTGAGAAGTACAGTGTGCTCAGGAAG---AG-GGC—TGCAGAAG-TGT-------
TGTCCTG 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
TGAGATTTCTCATTGATCACAGATGTGCCCAGAGTA 
GG------------GAT---AGGAG-GCACC---T— 
GA------------GAC---AGGAG-GCGCC---T— 
 
 
 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
GCCCAGGTCACTGTTAACTAGTGTTT-CTGCAGAGGCAG 
CCAAGTTACTGATA-GCCCGTGTTG-CCTCAT---GCAG 
CCAAGTTACTGGCA-GCCTGTGTTG-CCTTGT---GCA- 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
CAGGAGCCATGAGCATGAGGTGTGGCATTAGGG----
ACTGGTCAGCTATGCATGCTGGCAGGT 
CA—AGTTGTGAGAGTGGGTTGTGG------AG-----ACTCGTTAGCAATGC-
TGTGGACA-CT 
CA—AGTTGTGAGTGTGGAGCATGG-----
AGTTAAAGACTGGTTAGCCATGCATCTGGACAACT  
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
GGGGTTGTGTCTGCAGGTCTCAG-AAATGAAGAGGCTGCTCTGTTCTGGAGGC 
GACAT-GTG-CT-GTGGGTCTGGAAGATGAAGCAGACACTCAGTTCTGGATGT 
GAGGT-ATA-TCTGTGGGAAAGA~AAATGAAAAGGACA~TCAGTTCTGGGTGT 
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H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
AGCCGTGGCCCAGTGCCAGTGGCCAGAACAGTGGCCTTTGGTGGGTGTGTC 
GGTGCTGGCCCAGCACAGTGG-CCTAAATAGTGGCCCCTGATAGGTTGAAT 
GGTGCTGGCCCAACACAAGTGGCCTAAATAGTGGCCCCTGATAGACTGAAT 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
CCGGGCCATCTCGGGGTGGTGCTCAGGAGCGCCTGGGGCAAGAGGTAAA 
CCTGGCTAT------GTGG-----------GCC-------AGAGAT--- 
CCTGGCCAT------GTGA-----------GCC-------AGAGAT--- 
 
 
 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
GAGTTCCCTGGCCTTCAAGGAGAGCAGCGA 
GAGTTTCCTGGCCACCAG-GTG-GCAGCTA 
AAAGAGTTCCCTGACCAA-GAAGGCAGCTA 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
AGACCCAGACAGGGGC-----CAGCCT-TCAGGACCAGAGGGAGCCGCCGA 
AGACC-AGACAGGGACAGAGACAGATTGTCAGGGCCAGAGAGGAGCAACTA 
AGACC-AGACAGGGACAGAGACAGGTATTCAGGGCCAGAGGGGAGCAGCTA  
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
ATGGGACCCTCCTGGTCACCAGGAGAAAGCCCTGGGCCAGCGAGTAGGC-AGTCA 
GAGGGAGCTTCCCAGTCACTCAAAGATGC---TAAG--AACTAGAAGGTGAGTGA 
GAGGGAACCTCCCAGTCA TGTGGAGAGGC---TCAG—AACCAGA-AGGTAAGTGA  
 
 
H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
AAC—-TCCTTCGTCCCCA- AGGCCGGTGGAACAAGAGGCT 
TATGGTCCCTCTACCCCAGAGGCCAGCAGATTAGCGCATA 
TAGGGCCCCTCTGCCCCAGAGGC-----------------  
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H. sapiens (DNA) 
M. musculus (DNA)  
C. griseus (DNA) 
M. musculus(pro) 
C. griseus (pro) 
Annotations 
------------------------------------ 
GATTATGAATCAAGGCCCTGGGGGTAGAGAGCCAAG 
------------------------------------ 
 
                                                                     
3’ UTR] 
 
      
  
          
       
4.6.8 Summary 
  
The primary aim of this section of work was to produce sufficient sequence to design siRNA 
sequences targeted against CHO IRE1α (which will be discussed in chapter 4.8). The 
sequence obtained from this section was more than adequate for this – indeed the sequence 
obtained from one of the 900bp fragments was considered particularly suitable for the 
targeting of the siRNAs, as when the IRE1α sequence was subjected to a conserved domain 
search on the NCBI website (http://www.ncbi.nlm.nih.gov/Structure/cdd/cdd.shtml) the area 
upstream of the kinase domain was found to have no significant homology with other 
proteins (marked with an arrow on Figure 4.6. 3), making it a far better target for specific 
siRNAs than, for example, the highly conserved kinase domain. It is not surprising that this 
area was also the easiest section to sequence given again, the low homology with other 
sequences.  
 
 
Figure 4.6. 3 – Conserved domain analysis of H. sapiens ERN1/IRE1α. 
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The secondary outcome of this section was the production of a CHO IRE1α sequence for 
deposit in NCBI and general scientific use – this was for the main part successful, although 
unfortunately the most difficult 3’ and 5’ ends could not be sequenced due to non-specificity 
of primers. Sequences were returned to Lonza with annotations to be combined with 
assemblies from their project. If time had allowed, further work could have been attempted to 
clone these ends using nested primer combinations to reduce the non-specificity.    
A major impedance in this work was equipment contamination – upon sequencing of 
one of the constructs in the area of the kinase domain, human sequence was found instead of 
CHO (sequence was identical to human whereas previously CHO sequences had 
understandably better homology with mouse sequences). One of the cDNA samples had 
become contaminated with human IRE1α from one of the other constructs used in this thesis 
and needed to be discarded. All equipment used was thoroughly decontaminated and fresh 
cDNA produced, and all further sequences produced were found to be CHO.  
 
 
 
4.7 Production of Lonza vector pEE12.4-derived silencing vectors. 
 
4.7.1 Rationale 
 
RNA interference (RNAi) is a method of silencing genes by using the RNA-induced 
silencing complex and the enzyme Dicer. This pathway is used in the cell to destroy double-
stranded RNA from viruses and prevent their genes from being expressed – however, it can 
also be utilised to silence genes by inserting double-stranded RNA matching their sequence 
into the cell (Fire, Xu et al. 1998). RNAi delivery of siRNAs into the cell can be performed 
by simply inserting the siRNA sequences themselves directly into the cell, or by inserting a 
plasmid expressing a short hairpin RNA (shRNA) or a micro-RNA (miRNA) into the cell. 
These latter strategies gives a longer-lasting effect than the former (Fewell and Schmitt 
2006). The structures of the si/shRNAs used in this thesis will be discussed in greater detail 
in Chapter 4.8 – this chapter discusses the delivery vector plasmid developed for the shRNA.  
 
Certain criteria needed to be met by the delivery vector for potential future uses.  
1) That it contain a suitable promoter to drive shRNA expression, such as U6, CMV or H1.  
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2) That it be based on a Lonza-owned vector to avoid potential intellectual property conflicts 
(see below) and  
3) That it be competent for later addition of IRE1α constructs in order to co-express the 
shRNA and these contructs and perform knockdown in combination with expression. This 
combination of shRNA and cDNA was successfully used in (Li and Mahato 2009) by the 
insertion of an internal ribosome entry site (IRES) between the shRNA and the cDNA. In the 
following sections, the construction of this vector is described.  
 
 
4.7.2 Cloning Strategy – shRNA Polylinker 
 
The Lonza vector pEE12.4 was used to derive the shRNA vectors. This vector contains 
sequences in addition to the normal apparatus for selection and replication in E. coli which 
made it fit for purpose and for potential later applications: a CMV promoter which was used 
to drive the double gene expression the vector was designed for, which could be used to drive 
expression of the shRNA and the hygromycin resistance gene which would permit screening 
for potential. A U6 promoter driven vector was also designed in order that two vectors would 
be available, one RNA polymerase II dependent (CMV) and one RNA polymerase III 
dependent (U6), both of which have been used to drive shRNA production (Zhou, Xia et al. 
2005). The pEE12.4 vector contained suitable restriction enzyme sites (Figure 4.7. 1) to 
excise only the double gene insert (SacI/PvuII) or the double gene insert and the CMV 
promoter (AvrII/PvuII) to allow replacement with the U6 promoter.  
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Figure 4.7. 1 – Lonza pEE12.4 vector backbone. 
 
A polylinker was also designed to be cloned into the vector after either the CMV or U6 
promoter (Figure 4.7. 2B). The polylinker contains an EcoRI and an XhoI site to allow later 
cloning of the EMC-Leader/internal ribosome entry site already available in the pEDΔc-
hIRE1α plasmid, and a KasI and a HpaI site to allow cloning of the IRE1α sequence, also 
from this plasmid (Figure 4.7. 2A). Upstream of these cloning sites in the polylinker were 
several restriction enzyme sites that did not already exist in the pEE12.4 vector which 
permitted cloning in of the shRNA sequence itself (AgeI, XmaI, BssHII, NruI and BsiWI). 
The polylinker was designed with a PvuII site to permit ligation to the PvuII site at bp 4801 
in pEE12.4 (Figure 4.7. 1) and the appropriate restriction enzyme site (AvrII/SacI) for the 
CMV/U6 vector. However, as it did not prove possible to clone the CMV vector successfully, 
the following sections describe the cloning of the U6 promoter-driven vector.  
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Figure 4.7. 2 - Multiclone site insert. 
 
A 
 
 
B 
 
 
4.7.3 Cloning Strategy – U6 Promoter vector 
 
The U6 promoter drives the transcription of small nuclear RNA molecules (snRNA) in 
vertebrates. It consists of a TATA box (TATATA) and upstream of it a proximal sequence 
element, or PSE. Specificity of the sequence for RNA polymerase II or III is dependent upon 
the distances between the PSE and the TATA box (Goomer and Kunkel 1992). Sequences 
coding for the wild type human U6 promoter were taken from (Lin, Yang et al. 2004) and a 
polylinker consisting of the restriction enzyme site AvrII, followed by the U6 promoter (see 
Figure 4.7. 3), followed by the multiclone site designed above (Figure 4.7. 2) with sufficient 
gap (~29bp) between the TATA box and the multiclone site to cause the promoter to begin 
transcribing at the start of the shRNA once it was cloned in. This sequence was too long to 
order as a single primer pair, unlike the multiclone site alone, and therefore was ordered as 
four primer pairs.  
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4.7.4 Dilution of T4 Ligase in reaction to ensure a single copy of the polylinker 
was produced for cloning 
 
In order to produce a polylinker insert for cloning the U6 promoter into the Lonza vector, 
four primers were ordered overlapping to allow them to be annealed together (Eurofins 
MWG, London). Sequences can be found in Materials and Methods – Primers (“U6 Promoter 
+ MC site....”). An annealing protocol was used from (Sambrook, Fritsch et al. 1989) to 
adhere the primers to each other: initially, 1µl of each primer (100mM) was suspended in a 
standard Tris buffer as below: 
 
2µl Primer U6 Promoter + MC Site Short F 
2µl Primer U6 Promoter + MC Site Long F 
2µl Primer U6 Promoter + MC Site Long R 
2µl Primer U6 Promoter + MC Site Short R 
500µl 1M NaCl (500mM NaCl) 
200µl 1M Tris HCl (200mM TrisHCl) 
Nuclease-free water to 1ml  
 
A heating block was preheated to 70°C and used to heat the primer and buffer mixture for 5 
mins. The mixture was then allowed to cool to room temperature overnight and the 
complementary primers to anneal to each other. The annealed product was run on a 0.9% 
agarose gel and purified, and resuspended in 30µl of buffer after purification. The 
overlapping ends were ligated with T4 ligase in the following reaction: 
 
2µl Ligase Buffer 
1µl DNA Ligase (Promega, Southampton) 
7µl purified annealed product. 
Figure 4.7. 3 -  U6 Promoter Sequence (from Lin2004) 
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The ligation mixture was incubated overnight at 16°C to ligate and run on a 0.9% gel to 
check the length of the product. However, it appeared that multiple copies of the product had 
ligated together causing a range of different length constructs (Figure 4.7. 4, left panel). To 
attempt to ligate a single copy of the completed insert, a range of dilutions of the T4 ligase 
from 1:2 to 1:32 were used to perform the ligation reaction (Figure 4.7. 4, right panel) and 
products run on a gel as above. The lowest concentration produced inserts of the correct 
length (160bp), which were excised and purified from the gel. 
 
 
Figure 4.7. 4 - U6 Polylinker Annealing 
 
 
4.7.5 Ligation and Screening of vector with polylinker 
 
To produce the vector backbone for cloning in the insert produced above, pEE12.4 was 
digested with AvrII and PvuII in a standard 10µl reaction as described in Materials and 
Methods – Restriction Enzyme digestion.  Ligation of the U6 polylinker insert to the AvrII-
PvuII fragment of was performed as described in Materials and Methods - DNA Ligation 
with T4 DNA ligase and the ligation reaction was chemically transformed and the clones 
plated out. Four clones were screened by digestion with a selection of enzymes both within 
the multiclone site (e.g. AgeI) and within the vector backbone (e.g. PvuI). Digestions did not 
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appear to run to completion, however, a significant amount of linearization occurred with the 
HpaI enzyme, which only appeared in the multiclone site, indicating at least one copy of this 
site had been cloned in. PCR was performed on the clone using primers flanking the multi-
clone insertion site (Materials and Methods – Primers “MC Site II” and “Avr to MC Site”) 
and the product sequenced – sequencing revealed a single copy of the multiclone/U6 
construct in the correct site. The final pEE12.4-U6 vector is shown in Figure 4.7. 5.  
 
Figure 4.7. 5 – U6 Promoter Vector (pEE12.4-U6) 
 
4.7.6 Summary  
 
With some adjustments to the cloning methods it was possible to produce a U6 promoter-
driven vector competent for the introduction of the required shRNA sequences, and this 
vector was used to clone the shRNA sequences (See Chapter 4.8). This vector may be a 
useful tool for future shRNA studies. However, due potentially to improper digestion of the 
vector and to difficulties with PCR and sequencing, it was not possible to produce the CMV 
promoter-driven vector or to confirm whether it had been produced . What sequence could be 
gained by directly sequencing the clones gave confusing results, likely due to multiple CMV 
promoter sequences in the vector. Although it would have been useful to have this vector 
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available, as long as one vector existed that could be used, this was sufficient. Had more time 
been available, diagnostic digests could have been performed to ascertain whether SacI and 
PvuII had star activity under these conditions and this was the cause of the extra bands at 
~3500 and ~1800 or whether some sort of improper digest had occurred/extra enzyme site 
was present.    
 
 
 
 
 
4.8  Production of shRNA against CHO IRE1α   
 
4.8.1 Rationale 
 
As described in Chapter 4.7, RNAi Delivery of siRNAs into the cell can be performed by 
inserting a plasmid expressing a short hairpin RNA (shRNA) or a micro-RNA (miRNA) from 
a plasmid expressing in the cell. micro-RNAs utilise the microRNA pathway, an endogenous 
pathway to achieve gene silencing. The micro-RNA pathway begins with a primary miRNA 
transcript which is cleaved by the enzyme Drosha in the nucleus to create an intermediate, 
which is then transported into the cytoplasm where it is processed by the enzyme Dicer into 
siRNA sequences and activates the RNA induced silencing complex to silence the 
complementary gene (Fewell and Schmitt 2006). The mir-30 human miRNA construct has 
been used to successfully knock down HIV-1 (Boden, Pusch et al. 2004). The mir-30 scaffold 
is given below (Figure 4.8. 1), showing the hairpin structure of the short hairpin RNA, and 
the Drosha and Dicer processing sites. In the final construct, the area marked with “X”s is 
replaced with the passenger complementary (upper section) and siRNA sequence (lower 
section).  
 
 
Figure 4.8. 1 – miRNA scaffold – after (Chang, Elledge et al. 2006) 
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4.8.2 Design of shRNAs against choIRE1α 
 
In chapter 4.6 of this thesis, the sequencing of CHO IRE1α was described, and reference was 
made to the section upstream of the kinase domain which did not possess any significant 
homology to any other domain when subject to a conserved domain search on NCBI. Given 
this information, it was logical then to target any shRNAs to this section of the IRE1α 
sequence as this low homology to other sequences should also reduce the likelihood of off-
target effects of the shRNA. A number of studies exist in which an siRNA knockdown of 
IRE1α was performed (Hu, Han et al. 2006; Lipson, Fonseca et al. 2006; Rahmani, Davis et 
al. 2007; Hollien, Lin et al. 2009; Sha, He et al. 2009; Rahmani, Mayo et al.). Of these, the 
sequence #4 used in (Sha, He et al. 2009), which resulted in a reduction to <10% of control 
levels of IRE1α protein when stably transfected into 3T3-L1 cells was not only targeted 
against this area, but also had an identical sequence in CHO to the mouse sequence making it 
suitable as a candidate. Two more new shRNAs were designed by putting the low homology 
section’s sequence into the invitrogen RNAi designer 
(http://rnaidesigner.invitrogen.com/rnaiexpress/) and an eGFP sequence was used as an 
IRE1α negative shRNA. Sequences of siRNAs are listed in Table 4.8. 1, along with GC 
content of sequences as high GC content negatively correlates with shRNA efficiency of 
knockdown (Chan, Carmack et al. 2009).  
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Table 4.8. 1 – Anti-CHO IRE1α shRNAs 
Name Source G/C 
Content 
Sequences 
U6-IRE1α(-)4 (Sha, He 
et al. 
2009) 
50% 
 
Passenger – 5’ GGA   AGA  GCA  AGC TGA  
ACT  AC 3’ 
siRNA        -  3’ CCT    TCT  CGT  TCG  ACT  
TGA TG 5’ 
choIRE1a-sh-
01 
 
Designed 
from 
cloned 
sequence 
47.62% Passenger – 5’ GCTCAAGGACATGGCTACTAT 
3’ 
siRNA        - 3’  
CGAGTTCCTGTACCGATGATA 5’ 
choIRE1a-sh-
02 
Designed 
from 
cloned 
sequence 
47.62% Passenger – 5’ GGTGGCCTTCATCATCACTTA 
3’ 
siRNA        - 3’  
CCACCGGAAGTAGTAGTGAAT 5’ 
anti-eGFP Sigma 
(Dorset, 
UK) 
50% Passenger –     5’ 
GCAAGCTGACCCTGAAGTTCAT 3’ 
siRNA        -      3’ 
CGTTCGACTGGGACTTCAAGTA 5’ 
 
4.8.3 Cloning of shRNAs into U6 Vector 
 
Since it was not possible to clone the CMV driven vector within the time available for this 
study, the U6 vector constructed in Chapter 4.7 was used as the delivery system for the 
shRNA sequences. The shRNA sequences designed above, flanked by the restriction enzyme 
sites AgeI and NruI present in the multiclone site in the U6 were ordered from Eurogentec’s 
(Eurogentec, Southampton, UK) Custom Genes service in a puc57 vector ready for cloning 
into the pEE12.4 vector (Figure 4.8. 2).  
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Figure 4.8. 2 - Cloning of shRNAs into U6 Promoter Vector 
 
 
 
 
4.8.4 Cloning into pEE12.4-U6 
 
The custom gene insert site in the puc57 vector was flanked by two M13 priming sites, which 
could be used to clone a larger amount of the ~100bp shRNA inserts from the vector. PCR 
was performed using a proofreading polymerase to reduce the amount of inserted errors, 
according to the protocol in Materials and Methods – “Polymerase Chain Reaction (PCR) for 
insert construction” and the products run on a 1% agarose gel and purified. ShRNA inserts 
were then ligated into the 3827bp backbone from the pEE12.4-U6 vector using T4 ligase 
according the protocol in “DNA Ligation with T4 DNA ligase” and chemically transformed. 
A selection of clones were screened by digestion with NruI to ensure proper ligation of the 
shRNA insert. To confirm, a single clone of each construct that gave a band closest to 4kbp 
was sent for sequencing using the AvrII to MC Site Primer (Materials and Methods – 
Primers) as for the pEE12.4-U6 construction. The U6-IRE1α(-)4, sh01 and egfp sequences all 
showed correct integration into the pEE12.4-U6, whereas the clones with the sh02 insert had 
not been ligated correctly in any of these – all were religated vector. Attempts to retry this 
cloning were unfortunately unsuccessful within the time allocated for this study and only the 
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U6-IRE1α(-)4, sh01 and egfp were used in further applications. Clones of these were frozen 
down and retained for further use. 
 
4.8.5 Transient Transfection of shRNA Sequences into Cell Line 42 (High 
Producer) to produce cDNA for RT-PCR and qPCR knockdown analysis 
 
Once the shRNA vectors had been produced they were maxipreped from the retained clones 
using an endotoxin-free maxiprep kit suitable for mammalian transfection. Several CHOK1 
cell lines expressing a range of different yields of monoclonal antibody (see Chapters 4.9 and 
4.10) were donated by Lonza and the highest producer of these, Line 42, was selected for this 
experiment, as it would most likely be the line subjected to the most stress due to high protein 
throughput. Three 75cm
2
 plates for each vector were grown to 60-80% confluence and 2µg of 
each shRNA vector was transfected into the cells using the Lipofectamine method 
recommended by Lonza (see Materials and Methods - Transfection – Lipofectamine). 
Controls were also run – transfection only, 10mM DTT treatment to induce XBP-1 splicing 
and no transfection. After 24 hours, the cells were harvested and RNA extracted using the EZ 
RNA kit as with the MEF system. Yields of RNA were 1-2µg/µl and therefore suitable for 
use in RT-PCR.  
 
4.8.6 qPCR for XBP-1, Actin 
 
In order to perform qPCR for XBP, it was first necessary to isolate suitable primers for this 
analysis. The actin primers donated by Lonza had already been used successfully in qPCR by 
Lonza. The XBP-1 splicing primers used for RT-PCR for CHO XBP-1 were unsuitable for 
qPCR as they did not give a single product – these primers span the site that is excised by 
IRE1α and therefore give two lengths of product to determine spliced vs unspliced XBP-1. 
Therefore, to gauge the amount of spliced XBP-1, primers were designed against the site 
formed when the intron is removed and religated, which would therefore only prime against 
spliced XBP-1. Several primers were ordered and tested with two available primers from the 
3’ end already used in RT-PCR (Figure 4.8. 3, LH panel) using the protocol as in Materials 
and Methods – “RT-PCR for CHO XBP-1/Actin using Promega Taq” but with a lower 
annealing temperature of 52°C. The primer combination of Splice Junction Primer 2 (SJ2 
below) and Gene Specific Primer 2 (GSP2 below) was found to give the clearest band at the 
correct length (~130bp). A temperature optimisation with variable annealing temperatures 
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was performed (RH panel) and 66°C was chosen as this temperature suffered no reduction in 
product and no non-specific banding.  
 
Figure 4.8. 3 - Splice junction primer test. 
 
 
qPCR was performed using the the Qiagen/Corbett Research Rotorgene 3000 qPCR machine 
as described in Materials and Methods – “qPCR assay for XBP-1/IRE1α/Actin”. qPCR 
efficiency of spliced XBP-1 and Actin calculated from controls can be seen in Figure 4.8. 5 
and Figure 4.8. 6. Despite multiple repeats a better qPCR efficiency than 0.9 for XBP-1 and 
0.83 for Actin could not be achieved.  
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Data derived from these analyses can be seen in Figure 4.8. 6 and Table 4.8. 2. The 
normalisation was done using the Pfaffl method (Equation 1) using actin as the housekeeping 
gene and normalising to the “no transfection control”. No significant up or downregulation 
could be seen with the shRNAs, which when taken with the RT-PCR results above indicated 
that the shRNAs did not produce knockdown.  
 
Equation 1 – Pfaffl Method (Pfaffl 2001). 
 
 
Figure 4.8. 5 – Spliced XBP-1 qPCR Efficiency 
Figure 4.8. 4 - Actin qPCR Efficiency 
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Table 4.8. 2 – CT values from qPCR Analysis 
shRNA Vector/Treatment XBP-1 Actin 
U6-IRE1α(-)4 26.57 19.1 
choIRE1a-sh-01 21.78 16 
anti-eGFP 25.7 17.19 
Transfection only 20.19 13.11 
No transfection 22.14 13.61 
10mM DTT 19.87 13.2 
 
 
Figure 4.8. 6 - qPCR for IRE1α  knockdown 
 
4.8.7 Summary 
 
Although it was possible to successfully clone the shRNA sequences into the pEE12.4-U6 
vector, upon examination by RT-PCR and qPCR, the shRNA vectors did not appear to be 
producing knockdown. However, it is uncertain whether the samples used were suitable, as 
there was no increase in XBP-1 splicing with DTT as would have been expected. Were 
further time available, it would be advisable to repeat the transfection experiment. Given that 
it was not possible to tell whether the lack of knockdown was due to a non-functional shRNA 
or due to the shRNA vectors not functioning properly, it would be useful to either test the 
shRNAs by producing simple siRNA sequences and testing them transiently, or by cloning a 
known sequence which had produced knockdown previously in CHO cells into the shRNA 
vector and assessing the level of knockdown when expression was driven by the U6 
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promoter.  RT-PCR primers were ordered which spanned at least one of the sites in IRE1α 
(U6-IRE1α(-)4) as this had already been shown to work in M. musculus cells in (Sha, He et 
al. 2009).  However, there was insufficient time to test these primers. 
 
4.9 Characterisation of the UPR and its correlation with mAb Production in CHOK1SV  
 
4.9.1 Rationale 
 
One of the principles of this thesis is that an improved or adjusted function of the unfolded 
protein response could potentially increase throughput of proteins in the secretory pathway 
and therefore increase biopharmaceutical yields. This is indicated by the fact that increases in 
gene copy number, mRNA and intracellular protein concentration do not improve the 
productivities of individual cells (Schroder 2008) – most improvements in biopharmaceutical 
production titres have been due to increases in viable cell mass. It is therefore possible that 
cell lines used for industrial biomanufacture may suffer from chronic or abnormal unfolded 
protein response activation. To examine the role of the unfolded protein response in cell lines 
used for industrial biomanufacture, several different cell lines from a panel of stable 
transformants donated by Lonza producing a range of different titres of the assembled 
monoclonal antibody cB72.3 were analysed, along with host/null cells expressing no 
antibody. Actual values of productivity in batch culture were not provided for all cell lines, 
but were calculated by Lonza according to their industrial criteria.   
 
Table 4.9. 1 - Cell line specific productivities of lines used in this thesis (donated by Lonza) 
Cell Line Productivity in Batch Culture 
33 Low  
41 Low  
137 Medium 
159 Medium 
42 High  
 
 
 
4.9.2 Spliced and unspliced XBP-1 levels are not significantly different between 
cell lines of differing mAb production capacity 
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XBP-1 splicing in cB72.3 monoclonal antibody-producing cells was assessed by RT-PCR as 
in the MEF and CHO shRNA studies. As this assay was being run at the same time as the 
shRNA studies in Chapter 4.8, initially primers were designed using the sequences from same 
locus as those used in the MEF system (labelled in Materials and Methods – Primers as 
“CHO XBP-1 Forward 1” and “CHO XBP-1 Reverse 1”, “CHO Actin Forward”, “CHO 
Actin Reverse”).  CHO cells producing different levels of antibody were grown to stationary 
phase, as this was when harvesting of product would normally occur, and one flask for each 
of the cell lines studied was treated by the addition of 10mM DTT (which induces the 
unfolded protein response by preventing proper formation of disulphide bonds during 
folding)  two hours before harvesting by centrifugation. Harvested cells were prepared for 
RNA and cDNA produced as described in the materials and methods. RT PCR was 
performed on the cDNA as in “RT-PCR for CHO XBP-1/Actin using Promega Taq”. Three 
replicates each of all five available cell lines were subjected to the same growth and DTT 
treatment as above. All samples from each cell line seemed to have a low level of splicing 
under non-stressed conditions (Figure 4.9. 1), unlike the MEF system, indicating that none of 
the cell lines, of any level of production were splicing XBP-1 to maximum capacity, and 
therefore there was potential for further activation of the unfolded protein response. However, 
there was no significant difference that could be detected between the levels of splicing in 
different producers, when the samples were quantified and analysed by ANOVA, indicating 
potentially a low level of splicing is sufficient for output in these cells (Figure 4.9. 2).  
 
Figure 4.9. 1 - RT-PCR for XBP-1 Splicing in producer cell lines after optimisation. 
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Figure 4.9. 2 - Quantification and statistical analysis of XBP-1 Splicing in producer cell lines 
after optimization. 
 
4.9.3 Addition of serum to culture medium alters mAb Production and XBP-1 
splicing in different levels of mAb Producer  
 
As examination of the levels of XBP-1 splicing in the different cell lines in a single incidence 
after treatment with DTT having produced no clear differences, it was determined to 
investigate differences between cB72.3 mAb output of the varied cell lines in the laboratory 
conditions, and how this correlated with XBP-1 splicing both in the adherent, serum fed state 
used in the lab and the serum-starved suspension growth (as required by animal-component 
free biomanufacture) used at Lonza. cB72.3 analysis required the setup of the Lonza 
Sandwich ELISA (see Materials and Methods – “Sandwich ELISA for assembled IgG 
cB72.3” for full details).  
 
A null cell line without the monoclonal antibody was used as a control. Cells were seeded at 
0.2x10
6
 cells in 2.5mLs of either CD-CHO or Dulbecco’s Modified Eagle’s Medium without 
pyruvate  in 6cm cell culture dishes and grown for 8 days, with one set of cells harvested at 4 
days, during growth phase, and one at 8 days (normal harvesting time in batch culture). Cells 
were collected, and a sample stained 1:2 with trypan blue (Sigma, Dorset) and counted with 
an Improved Neubauer haemocytometer. Remaining cell samples were centrifuged to collect 
cells for RNA/RT-PCR and to clarify the medium to analyse for assembled cB72.3 antibody. 
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Using the samples of medium taken from the Day 4 and Day 8 samples above, the levels of 
assembled cB72.3 monoclonal antibody were assessed using the Sandwich ELISA for 
assembled IgG cB72.3 listed in Materials and Methods (Figure 4.9. 3). Cell line 42 seems to 
have performed consistently, if not necessarily as the highest expressing of the cell lines. The 
low expressing lines produced consistently low levels. However, the medium expressors 
exhibited a differing profile, giving higher expression later on rather than consistently.  
 
 
Figure 4.9. 3 - Monoclonal antibody expression during cell viability time course. 
 
 
Finally, RT-PCR was performed using the protocol listed in the materials and methods “CHO 
XBP-1 and Actin” to compare Day 4 samples with and without serum (Figure 4.9. 4). A clear 
difference can be seen between cells grown with serum and without, even in the null cell line 
indicating that cells grown in serum-starved conditions are undergoing higher levels of ER 
stress. This is consistent with the idea that nutrient starvation induces ER stress, particularly 
in nutrient starved tumour cells (Wang, Hua et al. 2008).  The null and cell line 42 samples at 
the earlier Day 4 timepoint appear to show a lower level of XBP-1 splicing in the serum 
treated samples, and the low producer 33 slightly more, although as shown previously in the 
single timepoint samples there is no clear difference between the non-serum grown cells, 
apart from the medium producer cell line 159, which appears to have a slightly stronger 
spliced band than unspliced. This may indicate that the high producer cell line induced less 
unfolded protein response than the other cell lines. The stronger splicing in the 159 line 
correlates with the high production of antibody in the 4hr no serum result. Taken together, 
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these results may indicate adaptations by producer cell lines in their unfolded protein 
response that permit them to deal with fluctuations in viability caused by unfolded protein 
stress and to control XBP-1 splicing in response to unfolded protein stress, although further 
investigation and repeats would be required to verify this conclusion.  
 
 
Figure 4.9. 4 - RT-PCR for XBP-1 splicing during cell viability time course. 
 
 
4.9.4 Summary 
 
Analysing the production characteristics and XBP-1 splicing in several producer cell lines 
indicates two things – That growth in serum-free medium appears to induce XBP-1 splicing 
and potentially ER stress, and that there is no clear correlation between productivity and 
increased XBP-1 splicing.  Unfortunately there was insufficient time in this study to perform 
any further examinations – a full time course correlating product, XBP-1 splicing and 
viability would have been useful, as would other investigations into the unfolded protein 
response such as peIF2α levels. Time could have been saved in these assays by switching to 
new primers for XBP-1 earlier on in the investigations, as with the shRNA analysis. 
Furthermore, cell counting by the Neubauer haemocytometer counting method while useful 
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for transfection was insufficiently accurate to allow correlation of monoclonal antibody 
output with viable cell density. It would be have been preferable to perform these counts with 
the ViCell counter used at Lonza, but this was not available during the later work.   
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4.10 Effect of IRE1α mutant constructs on viability and productivity in CHOK1SV 
industrial cell lines. 
 
4.10.1 Rationale 
 
Having examined the correlations between product yield, and XBP-1 splicing, next it was 
determined to ascertain the effect of the IRE1α mutants on these parameters in industrial cell 
lines. Constructs used for transfection were pEDΔc-hIRE1α with wild type IRE1α, kinase 
dead K599A, RNAse dead K907A and the D711A and D711A/I642A mutants which had 
exhibited splicing in transient and stable transfection respectively. These constructs were 
selected in order to test a range of IRE1α responses in a normal state, in wild type states and 
in states predicted to be without kinase or RNase activity (K599A), with only kinase activity 
(K907A), or with only RNAse activity (D711A) and therefore provide information on the 
effect of each function of IRE1α on parameters affecting industrial biomanufacture. Although 
it was not proven possible to knock down CHO IRE1α  during the time allotted to this study, 
there is evidence that a transfection of mutant IRE1α is dominant negative over the 
endogenous (Zhang, Kenski et al. 2005; Lipson, Ghosh et al. 2008) and therefore transient 
transfection of mutant constructs could give some information as to the effect of the mutants.  
 
4.10.1 Transient Transfection of kinase deficient IRE1α plasmids reduces viability 
in CHOK1SIV cells 
 
In order to test the usefulness of the mutant constructs in improving protein throughput it was 
determined to assess the effect of the constructs on the unfolded protein response/XBP-1 
splicing, viability and product yield as markers for potential use in improving product 
throughput. Transfection was performed with IRE1α plasmids as described in the Materials 
and Methods – “Transfection – Lipofectamine”. After 24 hours, the cells were harvested and 
RNA extracted using the RNA easy kit (Promega, Southampton). cDNA was synthesised and 
RT-PCR performed as described in Materials and Methods. Although RNA was of a 
reasonable quality and concentration, it was not possible to achieve clear XBP-1 splicing 
results within the time allocated to this study – an expanded experiment that was attempted 
using tunicamycin, thapsigargin and DTT yielded even less RNA than the smaller one (data 
not shown). Given the similar issues in the MEF system that had necessitated the production 
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of a stable cell line, and the irregular transient IRE1α expression shown in the Western blot 
above, it was determined not to investigate the XBP-1 splicing any further in the transient 
transfection, and proceed directly to producing a stable CHO cell line if possible as it was 
unlikely that better quality results would be obtained (see later). However, it was possible to 
quantify the viability of transfectants using the Beckman Coulter Vi-Cell counter available at 
Lonza, which automates the standard Trypan Blue assay by taking an average of 50 images of 
stained cells to calculate the average viability. Cell samples from the transfections above 
were counted with the Vi-Cell counter. Although there is not a great deal of different between 
viabilities, it is notable that the mutant transfected samples suffer apparent drops in viability, 
particularly when stressed with DTT and that the largest reductions are in the K907A mutant, 
concomitant with the possible dysregulation of IRE1α expression. This effect is potentially 
detrimental, and appears to contradict the findings in Chapter 4.5 where the D711A improved 
viability of the cells. However, it is not clear whether this effect is due to the confounding 
effects of the wild type endogenous CHO IRE1α. 
 
Table 4.10. 1 – Viabilities of Mutant Transfected CHOK1SV (by ViCell count) 
DNA 10mM DTT Viability 
pEDΔc-hIRE1α Y 73.3 
N 77.8 
pEDΔc-hIRE1α-K599A 
 
Y 56.4 
N 69.3 
pEDΔc-hIRE1α-D711A 
 
Y 68.6 
N 69.5 
pEDΔc-hIRE1α-D711A/I642A Y 58.1 
N 69.5 
pEDΔc-hIRE1α-K907A 
 
Y 54.2 
N 63.6 
No transfection 
 
Y 75.2 
N 77.1 
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Figure 4.10. 1 - Viability of CHOK1 cells after transient transfection with IRE1α plasmids 
 
4.10.2 Transient transfection with D711A mutant improves mAb yield in 
CHOK1SV cells 
 
Having investigated the effect of the mutant constructs on viability, as in the previous section, 
the effect on product output of the cell lines was next examined. CHOK1SV cells (three 
replicates for each transfection) were grown for 24 hours before transfection as described in 
Materials and Methods “Transfection – Lipofectamine”.  Medium was harvested after 48 
hours and assayed by ELISA for assembled IgG cB72.3. Normally after eight hours 
Lipofectamine + Optimem medium was replaced with DMEM growth medium for further 
cell growth, however to do this discarded much of the antibody produced during this time, 
and therefore samples were taken with and without this replacement of medium. Results can 
be seen in Figure 4.10. 2. Differences between transfectants and untransfected controls are 
clearer in those samples which retain their medium from the earliest time points post 
transfection. As would be expected, the wild type transfection is the same with or without 
medium change as the wild type is expressing at all time points, whereas it would be 
expected that there would be less expression of the mutant plasmids over time as the plasmid 
was rejected by the cells. Without medium replacement, the D711A and D711A/I642G 
mutants appeared to have similar levels of production to the wild type, whereas the K599A, 
I642G and K907A had reduced production. However, the no plasmid control also had similar 
low production, possibly indicating this was not a significant difference despite the statistics. 
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Figure 4.10. 2 - Monoclonal Antibody Production in High Producer Cell transiently  
transfected with human IRE1α mutants – cumulative production vs production with medium 
change. Error bars represent +/- SEM.  
 
 
In Figure 4.10. 3, the experiment was repeated with a time course of four hours, eight hours 
and 48 hours (after medium change) to compare the results from the same biological set of 
transfections. However, in the pre-medium change samples there is significant difference 
between the D711A and wild type samples, but none between the K599A and D711A or wild 
type samples. Results from D711A/I642G, I642G and K907A samples are mainly lower than 
D711A in the earlier samples before the plasmid would have been removed from the cells. 
Again, there is less difference after the medium change, and results for no plasmid and no 
transfection controls indicate that the differences between transfected samples may not be 
significant. Figure 4.10. 4 shows a Western blot against human IRE1α. As seen in  transient 
transfection of this mutant in the MEF system and previous CHO transfections (data not 
shown) K907A expression is greater, potentially due to self-dysregulation of IRE1α, but 
generally when compared to GAPDH expression, expression of the IRE1α constructs is 
consistent, ruling out the possibility of varied IRE1α expression being the cause of any 
differences in product yield.  
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Figure 4.10. 3 - Monoclonal Antibody Production in High Producer Cell transiently 
transfected with human IRE1α mutants at timecourse after transfection. 
 
 
 
 
 
 
0
5000
10000
15000
20000
25000
4hr 8hr 48hrs
m
A
b
   
m
g/
L
Wild Type
K599A
D711A
D711A/I642G
I642G
K907A
No plasmid
No lipofectamine
 256 
 
Figure 4.10. 4 – IRE1α expression after transient transfection. Each marked lane is three 
biological replicates.  
 
 
4.10.3 Construction of stable CHO cell line 
 
Given the issues with harvesting enough RNA for XBP-1 splicing analysis in the transient 
transfections, work was begun on an additional CHO cell line that could be stably transfected 
with IRE1α constructs as the MEF line was. Lonza provided an Invitrogen FLP-CHO cell 
line in which the pFRT/lac/Zeo site was already present, but still required the insertion of the 
pcDNA6⁄TR tet repressor plasmid. A blasticidin tolerance curve was performed for the FLP-
CHO cells as described in the Materials and Methods – “Antibiotic Tolerance” and 
“Transfection with  pcDNA6⁄TR”. Three stocks of each of the clones obtained from the 
transfection were frozen as described above and tested for tet repressor function as in the 
MEF system in chapter 4.5, using a tet-inducible HA-tagged form of IRE1α which only 
dimerised/activated in the presence of the chemical AP20187. 2µg of this plasmid was 
transfected by Lipofectamine methodology into three of the clones produced and the cells 
harvested for protein, run on an SDS page gel and Western blots performed for the HA tag. 
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Figure 4.10. 5- Transient transfection of FV2e-IRE1α to verify presence of tet repressor. 
 
 
The fastest growing clones 1,5 and 6 all gave strong bands at the appropriate length, which 
increased in strength upon addition of 1μg/mL tetracycline, however induction of Fv2e-
IRE1α was not as clear-cut as in the MEF system most likely because expression was so 
strong, (even a low exposure resulted in strong bands). Had there been sufficient time, this 
experiment would have been repeated with a lower strength detection reagent. Unfortunately 
there was insufficient time to perform the transfection/replacement with pcDNA5-FRT-TO-
hIRE1α plasmids or stable transfection of the plasmid expressing the assembled IgG cB72.3 
and examine XBP-1 splicing in CHO cells. However, this cell line may now be used with tet-
inducible promoters and will provide a tool for future examination of industrial 
bioproduction.  
 
4.10.4 Summary  
 
From the results of the above experiments, it would be possible to draw the conclusion that 
the D711A mutant improves monoclonal antibody output in CHOK1SV cells whilst reducing 
their viability. However, it is potentially possible that the K599A, D711A and other mutants 
may simply have dysregulated IRE1α’s control over protein synthesis (which would be 
consistent with(Rubio, Pincus et al. 2011)) and this may account for either the extra 
production or lower production dependent on experiment as protein production either 
continues uncontrolled or quickly results in the induction of other control mechanisms. From 
these results it is difficult to ascertain whether, however, given the additional evidence for a 
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reduction in viability, it is probable that dysregulation of IRE1α by mutation may cost more 
in cells lost to apoptosis than would be gained in product output. This is consistent with the 
necessity in (Becker, Florin et al. 2009) to combine a suppressor of apoptosis with 
overexpression of spliced XBP-1 to prevent viability loss, which would be a potential 
strategy if this investigation were to be continued. Once again, transient transfection of 
IRE1α plasmids did not yield sufficient quality of RNA for analysis of XBP-1, although 
curiously there was no difference between the wild type and untransfected viabilities when 
counted with the Vicell counter, in sharp contrast to the MEF system where the wild type 
transfection resulted in more cell death – this is likely attributable to the CHO cells still 
possessing their own endogenous IRE1α. Work on a stable cell line for CHO cells was begun 
to overcome the viability issue in a similar manner to the MEF  but there was insufficient 
time to complete it.  It was, however, possible to transfect and detect the mutant plasmids in 
the CHO system and examine their effect on viability and product output.  
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5.  DISCUSSION 
 
5.1  IRE1α mechanisms and outputs 
 
Any strategy that can combine both control of apoptosis and improvement in cell-specific 
productivity is potentially useful for improving overall biopharmaceutical yield, and reducing 
input and cost of product appropriately – in this thesis it was attempted to use the dual 
outputs of IRE1α to produce a strategy that, via engineering of IRE1α structure, combined the 
upregulation of biopharmaceutical expression seen with increases in spliced XBP-1 
expression with reduction in IRE1α induced apoptosis. IRE1α is an ER transmembrane 
protein with both a serine/threonine kinase domain and an RNase domain (Tirasophon, 
Welihinda et al. 1998). Activation of IRE1α in response to unfolded protein induces trans-
autophosphorylation (Shamu and Walter 1996). The activated RNase domain removes a 26bp 
intron from XBP-1 mRNA producing a longer spliced isoform of XBP-1 which functions as a 
transcription factor to upregulate unfolded protein response genes which help the cell deal 
with unfolded protein stress (Calfon, Zeng et al. 2002).  The kinase domain is thought to be 
responsible for inducing apoptosis by binding to TRAF2. This pathway results in JNK 
activation by an unknown mechanism and activates the p38 apoptotic signalling cascade to 
upregulate apoptotic genes (Urano, Bertolotti et al. 2000). Together, these dual functions are 
thought to control the switch between survival and apoptosis in response to unfolded protein 
stress(Jager, Bertrand et al. 2012). Although the mechanisms of this switch are not fully 
understood, it was proven possible, in yeast, to activate the RNase domain without 
autophosphorylation by mutation of the conserved residue Leu
745
 to alanine or glycine. 
Normally these mutations would result in a loss of activity, but in the presence of the kinase 
pocket binding compound 1NM-PP1, function was rescued (Papa, C. et al. 2003). This thesis 
attempted to elucidate further the role of the kinase and RNase activities in mammalian cells 
by studying the mutations in the kinase and RNase domains and the effect of these mutations 
on IRE1α function and product yield.  
 
In order to fulfil this outcome the following mutants were chosen for investigation:  
D711A - Mutation of the aspartic acid in the conserved DFG motif in the activation loop of 
IRE1α produces a form of kinase pocket that cannot chelate the magnesium ion for MgATP 
(Hubbard, Mohammadi et al. 1998). The yeast orthologue of this mutant (D828A) possessed 
4% of wild type activity in a reporter assay (Mori, Ma et al. 1993) and is capable of binding 
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nucleotide (Chawla, Chakrabarti et al. 2011). Chawla et al found that this mutant appeared to 
be capable of activating but incapable of inactivating the unfolded protein response, which 
impaired survival under Tunicamycin ER stress. This mutant could resemble an active 
conformation for splicing, altering the alignment of the kinase’s activation loop to match or 
partially match that of a phosphorylated and active IRE1α – functionally a constitutively 
active form, and was therefore potentially a useful tool for improving protein throughput. 
 
 
 K599A - Mutation of the lysine residue that aligns the α and β phosphates of ATP in 
the kinase pocket to alanine – this produces a completely kinase-defective IRE1α 
(Tirasophon, Welihinda et al. 1998). This mutant has been used in many studies as a 
trans-dominant negative control capable of repressing endogenous IRE1α activity, as 
it cannot be phosphorylated or activated, and does not splice XBP-1 mRNA 
(Tirasophon 2000; Urano, Bertolotti et al. 2000; Lee, Tirasophon et al. 2002; Kaneko, 
Niinuma et al. 2003; Zhou, Liu et al. 2006; Imagawa, Hosoda et al. 2008; Han, Lerner 
et al. 2009; Lin, Li et al. 2009; Oikawa, Kimata et al. 2009; Uemura, Oku et al. 2009; 
Nakamura, Tsuru et al. 2010; Mao, Shao et al. 2011; Kato, Nakajima et al.).  
Figure 5. 1 – IRE1 kinase pocket, see Fig 1.8 for original.  
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 I642A/G - The analogue sensitized mutant I642A/G confers an enlarged kinase 
pocket on the IRE1α protein into which an enlarged ATP analogue such as 1NM-PP1 
can fit. In yeast, mutation of L745 to a smaller residue results in a 40% loss of activity 
in L745A and a 90% loss in L745G. This loss can be rescued by addition of 1NM-
PP1. Stable transfection of the I642G mutants into HEK293 cells did not impair 
IRE1α function, but did permit induction of XBP-1 splicing by the addition of 1NM-
PP1, without ER stress as in the yeast analogue (Lin, Li et al. 2007). No JNK 
activation was observed with this 1NM-PP1 only induction, indicating activation of 
the RNase domain only, and these mutants have a defect in autophosphorylation to the 
same level as the K599A (Han, Lerner et al. 2009). Addition of 1NM-PP1 to I642G 
expressing cells also enhanced survival (Lin, Li et al. 2009). This mutant represented 
a pharmacological way of bypassing the kinase function of IRE1α to potentially 
improve viability 
 
 K907A  - an RNase defective control – this mutant does not splice XBP-1 or exhibit 
RNase activity (Tirasophon 2000). The IRE1β form, K855A also exhibited no XBP-1 
splicing in HeLa cells (Imagawa, Hosoda et al. 2008). 
 
 
5.2  Observed effects of IRE1α mutants 
 
D711A 
 
 In our laboratory the D828A mutant was also found to retain HAC1 splicing activity 
whilst remaining unphosphorylated (Sestak et al, unpublished). In this thesis, in the stable 
transfection of the ire1α-/- MEFs the D711A had ~60% of the splicing activity of the wild 
type and also exhibited the same increase in viability as the K599A (Fig 4, Chapter 4.5). The 
results in this work agree with the possibility of a D828A/D711A as a constitutively active 
form – XBP-1 splicing results in Chapter 4.5  show a gradual increase in splicing with 
induction of the D711A mutant (Fig 2, Chapter 4.5), but do not agree with the viability loss 
resulting from it (Fig 4, Chapter 4.5). These differences may be accounted for by the 
mammalian versus yeast systems – other mechanisms such as PERK and ATF6 are available 
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in the mammalian system to modulate unfolded protein stress and these may adjust the 
life/death balance in such a way as to either compensate for IRE1α, or directly alter the 
active/inactive IRE1α equilibrium, particularly in cells that have already adapted to a lack of 
IRE1α such as the ire1α-/- MEFs.  
 
K599A 
 
In transient transfections in COS-1 cells, the K599A was found to express at a higher level 
than the endogenous (Tirasophon, Welihinda et al. 1998) – this did not occur in the stable 
MEF line created in this study (Figure 4.5. 1, Chapter 4.5). It was found not to induce XBP-1 
splicing or to restore it in ire1α-/- MEFS (Zhou, Liu et al. 2006) – a finding which again was 
replicated in this thesis in the stable MEF cell line, indicating that at least this lysine residue 
is required for RNase domain activation. Given the K599A mutant is both kinase-inactive 
with or without unfolded protein stress (Tirasophon 2000) and RNase-inactive it follows that 
it should also be incapable of inducing downstream apoptotic effects – this does appear to be 
the case, as cells stably expressing K599A had lower expression of CHOP and lower ER 
stress-induced NFκB activation, although there are conflicting accounts whether K599A 
mutant IRE1α does (Urano, Bertolotti et al. 2000) or does not (Kaneko, Niinuma et al. 2003) 
co-immunoprecipitate with TRAF2 and the requirements for kinase activity to induce this. In 
Figure 4.5. 4, ire1α-/- MEFs stably transfected with the K599A mutant exhibited stronger 
growth early in ER stress induction than the wild-type transfected, and longer lasting 
viability, as well as a slight reduction in early JNK activation, although in the transient CHO 
model they suffered the opposite - some loss of viability, which may be an artefact of the 
difference between endogenous IRE1α expression in the CHO and stably transfected in the 
MEF. Interestingly there was also slight upregulation of PARP in this mutant’s stable 
transfection (Figure 4.5. 5) - potentially indicating a response to increased reactive oxygen 
species from improper protein folding. It was unfortunately not possible within the time 
allotted to directly confirm kinase activity in the K599A stably transfected cells, although the 
evidence above indicates a reduction.  
 
I642A/G 
 
 In the transient MEF system in this work, low levels of splicing could be seen (0-
20%) in cells transiently transfected with these mutants, (Figure 4.3. 2) but possibly due to 
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the limitations of the transient system, no increase in splicing could be seen with the addition 
of 1NM-PP1 – had there been sufficient time, this assay would have been repeated with the 
stably transfected cells.  
 
K907A 
 
 In this work in both the transient MEF and transient CHO systems K907A mutants 
synthesized at much higher levels than the wild type - this could also be seen in Tirasophon  
(2000) (Tirasophon 2000) and may be due to impairment of IRE1α self-regulation. K907A in 
this thesis also resulted in no splicing (Figure 4.3. 2). K907A was capable of phosphorylating 
K599A, indicating a functional kinase domain. However, in INS-1 cells, interestingly this 
mutant does not induce apoptosis (Han, Lerner et al. 2009). This is consistent with the idea 
that XBP-1 splicing has some role in the apoptotic responses as well as the protective as 
indicated by (Becker, Florin et al. 2009), and that a functional kinase and a functional RNAse 
domain may be required for this response.  
 
Returning to the original aims, it was possible to fulfil the first two – to produce analogue 
sensitized and kinase mutants in both isoforms of IRE1, however, it was not possible to test 
both isoforms, only the IRE1α. Transfection into ire1-/- cells was not successful, and instead a 
stable cell line was produced which allowed assessment of expression, by Western blot and 
analysis of XBP-1 splicing and JNK activation and additionally analysis of visible cell death 
by loss of adherence and apoptosis by PARP cleavage. Analysis of kinase activity was not 
successful in this study, but the data produced from the XBP-1 splicing activity and the 
analysis of cell death by the above methods suggested that the D711A mutant was the most 
suitable for further investigation in industrial cell lines, exhibiting reduced cell death 
characteristics whilst retaining XBP-1 splicing.  
 
5.3  Improvements in industrial biopharmaceutical synthesis. 
 
Yield in industrial synthesis of biopharmaceuticals is dependent upon a combination of cell-
specific productivity and viable cell density. Mammalian cells are used for industrial 
biosynthesis because these cells are more likely to produce the correct post-translational 
modifications which affect the activity and immunogenicity of biopharmaceuticals (Wurm 
2004; Jones, Nivitchanyong et al. 2005). Because of the requirements for proper folding, 
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disulphide bond formation and post-translational modification of protein biopharmaceuticals 
such as monoclonal antibodies industrial synthesis of biopharmaceuticals is thought to have 
among its rate-limiting steps exit of the correctly folded polypeptide chain from the ER 
(Schroder 2008) – the final stages of which are regulated by the unfolded protein response.  A 
number of methods of improving cell-specific biopharmaceutical production have been 
attempted using unfolded protein response components and chaperones – overexpression of 
the chaperone Hsp70 improved monoclonal antibody production in NS0 hybridomas 
(Lasunskaia, Fridlianskaia et al. 2003), and constitutive expression or overexpression of the 
spliced and active version of the bZip transcription factor XBP-1 in CHO cells improved 
production of secreted digestive enzymes (Tigges and Fussenegger 2006), and expression of 
erythropoietin in CHO and NS0 cells (Ku, Ng et al. 2008). While these strategies can be used 
to improve cell-specific productivity, they can potentially be detrimental to the viable cell 
density component of biopharmaceutical synthesis, reducing survival over time (Becker, 
Florin et al. 2008) and necessitating additional control of apoptosis (Becker, Florin et al. 
2009). Improvement in biopharmaceutical cell mass can also be achieved by control of 
apoptosis, for example the use of anti-apoptotic supplements and peptides (Sunstrom, Gay et 
al. 2000; Zanghi, Renner et al. 2000; Jones, Nivitchanyong et al. 2005), nutrient control  
(Sanfeliu and Stephanopoulos 1999; deZengotita, Abston et al. 2002; Lengwehasatit and 
Dickson 2002; Mendonca, Arrozio et al. 2002),  anti-apoptotic Bcl family proteins and 
homologues (Mastrangelo, Hardwick et al. 2000; Jung, Cote et al. 2002; Boya, Roumier et al. 
2003; Figueroa, Sauerwald et al. 2003; Arden and Betenbaugh 2004) and caspases 
(Sauerwald, Betenbaugh et al. 2002; Sauerwald, Oyler et al. 2003). 
 
5.4  Effects of IRE1α mutants on monoclonal antibody productivity of CHOK1SV cells 
 
The second main aim of this study was to assess the effect of a mutant IRE1 construct 
produced with increased protective signaling and reduced apoptotic signalling on industrial 
protein yields. Although it is was not possible to produce a suitable knockdown of 
endogenous CHO IRE1α to remove this factor, or stable cell lines similar to those in the MEF 
system, results from the transient transfection of the D711A mutant into the CHO system 
agree with the “constitutively active mutant concept” of (Chawla, Chakrabarti et al. 2011) – a 
small potential increase in output due to an increase in folding capacity from the 
constitutively active IRE1α coupled with a viability loss, as in the yeast system. In the CHO 
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cells transient transfected with mutants known to be kinase deficient - D711A, K599A, 
K907A, viability was 5-10% lower than wild type or no DNA control (Figure 4.10. 1), in 
contrast to the MEF system where the D711A mutant exhibited better survival (chapter 4.5)  
potentially indicating some sort of detrimental effect on IRE1α regulation or alteration to the 
life/death switch. This effect may also be due, as stated above, to the presence of endogenous 
IRE1α in the CHO cells as opposed to the ire1α-/- MEFs.  
Overall, based on the data from the stable transfection it can be said that the K599A mutant 
would be unsuitable for increasing the output or viability in industrial biopharmaceutical 
manufacture, whereas the D711A mutant’s increases in viability in the MEF data and the 
improvements to monoclonal antibody yields in the CHO system indicate that it is worthy of 
further investigation both to characterize the effect on the unfolded protein response and to 
potentially produce an applied improvement in protein throughput and biopharmaceutical 
output.  
 
5.5 Methodologies 
 
 Given differences in viability found between the results in the stable MEF 
transfections and the transient MEF and CHO transfections, coupled with the potential 
increase it seems as if the either the presence of an endogenous IRE1α or the transfection 
itself renders the cell line used vulnerable to ER stress when transiently transfected with a 
mutant – an adapted stable cell line does not suffer the same issues as can be seen in the MEF 
system. It would have been preferable then to examine an ire1α-/- CHO cell line with stably 
transfected monoclonal antibody product and a D711A mutant, potentially adapted to ER 
stress from a lack of IRE1α to the point where the mutant can only improve its growth 
characteristics, and with a deregulated IRE1α constitutively activating the unfolded protein 
response  - unfortunately there was insufficient time for this, and it would be difficult to 
anticipate the extent XBP-1s apparent apoptotic effect would affect it.  
 The methodologies used for this thesis were of mixed provenance. A great deal of 
time was expended attempting to optimise the transient system in the MEFs (Chapter 4.2, 
4,3) when the viability issues were too severe and it would have been advisable from the 
outset to begin stable cell line production – this method progressed smoothly and what results 
were obtainable from it were of generally good quality (Figure 4.5. 1-Figure 4.5. 5). With 
more time having produced them earlier it might have been possible to characterise all the 
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mutants and examine the effect of 1NM-PP1 on those with the I642A analogue sensitised 
mutation. The CHO system suffered less from detriments due to transient transfection but did 
exhibit some of the flaws – low RNA concentrations, irregular expression of the IRE1α 
construct (Chapter 4.10, “Transient Transfection of kinase deficient IRE1α plasmids reduces 
viability in CHOK1SIV cells“ and also seen in (Tirasophon 2000)) making it difficult to draw 
conclusions about either the apparently detrimental effects of the mutants on viability or the 
positive effects, despite their agreeing with the results of other studies that used this arm of 
the UPR for industrial bio-output improvements (Becker, Florin et al. 2008; Becker, Florin et 
al. 2009). Production of the shRNA against IRE1α would have benefited from a multiple 
methodology strategy to verify why it did not function – transient knockdown with siRNA 
sequences could have been compared to control shRNAs to verify whether it was the vector 
design or the siRNA which was not functional (Chapter 4.9). 
 
6.  CONTINUATION OF WORK 
 
Most importantly for the continuation of this work, for completion of the results from the 
MEF system, it would definitely be necessary to produce some clear evidence of the presence 
or absence of kinase activity in at least the wild type, K599A and D711A mutants . Several 
strategies could be tried for this: alternative antibodies would be the simplest method. Failing 
this, radioactive phosphate incorporation could be tried. After this, the testing of the 
remaining mutants and the effect of 1NM-PP1 on those with analogue sensitization and the 
effect of this on XBP-1 splicing, viability and phosphorylation could be completed.  
 
In the CHO system as described above, the ideal line for testing of the mutants would be an 
ire1α-/- CHO cell line with stably transfected monoclonal antibody product. This would 
require either a functional knockdown or a knockout, neither of which are currently available 
and one of which would require animal work. The shRNA vector knockdown with controls 
for siRNA and vector function would need to be completed as described above. 
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APPENDIX 1 – iCODEHOP Results for mammalian IRE1α alignments 
 
Mammalian protein sequences for R. norvegicus (XP_573211), M. musculus (NP_076402) 
and H. sapiens  (NP_001424) were entered into the iCODEHOP programme, which then 
produced alignments of the protein sequences and identified suitable sites for degenerate 
primers. 
 
CLUSTAL 2.0.12 multiple sequence alignment 
 
 
XP_573211       ------------MRRCNDIQSFGRASTVTLPEALLFVSTLDGSLHAVSKRTGSIKWTLKE 
NP_076402       MPARWLLLLLALLLPPPGPGSFGRTSTVTLPETLLFVSTLDGSLHAVSKRTGSIKWTLKE 
NP_001424       --MPARRLLLLLTLLLPGLGIFGSTSTVTLPETLLFVSTLDGSLHAVSKRTGSIKWTLKE 
                                 .   ** :*******:*************************** 
 
XP_573211       DPVLQVPTHVEEPAFLPDPNDGSLYTLGGKNNEGLTKLPFTIPELVQASPCRSSDGILYM 
NP_076402       DPVLQVPTHVEEPAFLPDPNDGSLYTLGGKNNEGLTKLPFTIPELVQASPCRSSDGILYM 
NP_001424       DPVLQVPTHVEEPAFLPDPNDGSLYTLGSKNNEGLTKLPFTIPELVQASPCRSSDGILYM 
                ****************************.******************************* 
 
XP_573211       GKKQDIWYVIDLLTGEKQQTLSSAFADSLCPSTSLLYLGRTEYTITMYDTKTRELRWNAT 
NP_076402       GKKQDIWYVIDLLTGEKQQTLSSAFADSLCPSTSLLYLGRTEYTITMYDTKTRELRWNAT 
NP_001424       GKKQDIWYVIDLLTGEKQQTLSSAFADSLCPSTSLLYLGRTEYTITMYDTKTRELRWNAT 
                ************************************************************ 
 
XP_573211       YFDYAASLPEDDVDYKMSHFVSNGDGLVVTVDSESGDVLWIQNYASPVVAFYIWQREGLR 
NP_076402       YFDYAASLPEDDVDYKMSHFVSNGDGLVVTVDSESGDVLWIQNYASPVVAFYVWQGEVLR 
NP_001424       YFDYAASLPEDDVDYKMSHFVSNGDGLVVTVDSESGDVLWIQNYASPVVAFYVWQREGLR 
                ****************************************************:** * ** 
 
XP_573211       KVVHINVAVETLRYLTFMSGEVGRITKWKYPFPKETEAKSKLTPTLYVGKYSTSLYASPS 
NP_076402       KVVHINVAVETLRYLTFMSGEVGRITKWKYPFPKETEAKSKLTPTLYVGKYSTSLYASPS 
NP_001424       KVMHINVAVETLRYLTFMSGEVGRITKWKYPFPKETEAKSKLTPTLYVGKYSTSLYASPS 
                **:********************************************************* 
 
XP_573211       MVHEGVAVVPRGSTLPLLEGPQTDGVTIGDKGECVITPSTDLKFDPGLKGKSKLNYLRNY 
NP_076402       MVHEGVAVVPRGSTLPLLEGPQTDGVTIGDKGECVITPSTDLKFDPGLKGKSKLNYLRNY 
NP_001424       MVHEGVAVVPRGSTLPLLEGPQTDGVTIGDKGECVITPSTDVKFDPGLKSKNKLNYLRNY 
                *****************************************:*******.*.******** 
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XP_573211       WLLIGHHETPLSASTKMLERFPNNLPKHRENVIPADSEKRSFEEVINLVGQTSENTPTTV 
NP_076402       WLLIGHHETPLSASTKMLERFPNNLPKHRENVIPADSEKRSFEEVINIVGQTSDNTPTTV 
NP_001424       WLLIGHHETPLSASTKMLERFPNNLPKHRENVIPADSEKKSFEEVINLVDQTSENAPTTV 
                ***************************************:*******:*.***:*:**** 
 
XP_573211       SQDVEEKLPRAPAKPEAPVDSMLKDMATIILSTFLLVGWVAFIITYPLSMHQQRQLQHQQ 
NP_076402       SQDVEEKLARAPAKPEAPVDSMLKDMATIILSTFLLVGWVAFIITYPLSVHQQRQLQHQQ 
NP_001424       SRDVEEKPAHAPARPEAPVDSMLKDMATIILSTFLLIGWVAFIITYPLSMHQQQQLQHQQ 
                *:***** .:***:**********************:************:***:****** 
 
XP_573211       FQKELEKIQLLQQQQ--LPFHPHGDLTQDPDFLDSSGLFSESSGTSSPSPSPRASNHSLN 
NP_076402       FQKELEKIQLLQQQQ--LPFHPHGDLTQDPEFLDSSGPFSESSGTSSPSPSPRASNHSLH 
NP_001424       FQKELEKIQLLQQQQQQLPFHPPGDTAQDGELLDTSGPYSESSGTSSPSTSPRASNHSLC 
                ***************  ***** ** :** ::**:** :**********.*********  
 
XP_573211       SSSSASKAGTSPSLEPDDEDEETRMVIVGKISFCPKDVLGHGAEGTIVYKGMFDNRDVAV 
NP_076402       PSSSASRAGTSPSLEQDDEDEETRMVIVGKISFCPKDVLGHGAEGTIVYKGMFDNRDVAV 
NP_001424       SGSSASKAGSSPSLEQDDGDEETSVVIVGKISFCPKDVLGHGAEGTIVYRGMFDNRDVAV 
                ..****:**:***** ** **** :************************:********** 
 
XP_573211       KRILPECFSFADREVQLLRESDEHPNVIRYFCTEKDRQFQYIAIELCAATLQEYVEQKDF 
NP_076402       KRILPECFSFADREVQLLRESDEHPNVIRYFCTEKDRQFQYIAIELCAATLQEYVEQKDF 
NP_001424       KRILPECFSFADREVQLLRESDEHPNVIRYFCTEKDRQFQYIAIELCAATLQEYVEQKDF 
                ************************************************************ 
 
XP_573211       AHLGLEPITLLHQTTSGLAHLHSLNIVHRDLKPHNILLSMPNAHGRIKAMISDFGLCKKL 
NP_076402       AHLGLEPITLLHQTTSGLAHLHSLNIVHRDLKPHNILLSMPNAHGRIKAMISDFGLCKKL 
NP_001424       AHLGLEPITLLQQTTSGLAHLHSLNIVHRDLKPHNILISMPNAHGKIKAMISDFGLCKKL 
                ***********:*************************:*******:************** 
 
XP_573211       AVGRHSFSRRSGVPGTEGWIAPEMLSEDCKENPTYTVDIFSAGCVFYYVISEGNHPFGKS 
NP_076402       AVGRHSFSRRSGVPGTEGWIAPEMLSEDCKDNPTYTVDIFSAGCVFYYVISEGNHPFGKS 
NP_001424       AVGRHSFSRRSGVPGTEGWIAPEMLSEDCKENPTYTVDIFSAGCVFYYVISEGSHPFGKS 
                ******************************:**********************.****** 
 
XP_573211       LQRQANILLGACSLDCFHSDKHEDVIARELIEKMIAMDPQQRPSAKHVLKHPFFWSLEKQ 
NP_076402       LQRQANILLGACNLDCFHSDKHEDVIARELIEKMIAMDPQQRPSAKHVLKHPFFWSLEKQ 
NP_001424       LQRQANILLGACSLDCLHPEKHEDVIARELIEKMIAMDPQKRPSAKHVLKHPFFWSLEKQ 
                ************.***:*.:********************:******************* 
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XP_573211       LQFFQDVSDRIEKESLDGPIVRQLERGGRAVVKMDWRENITVPLQTDLRKFRTYKGGSVR 
NP_076402       LQFFQDVSDRIEKEALDGPIVRQLERGGRAVVKMDWRENITVPLQTDLRKFRTYKGGSVR 
NP_001424       LQFFQDVSDRIEKESLDGPIVKQLERGGRAVVKMDWRENITVPLQTDLRKFRTYKGGSVR 
                **************:******:************************************** 
 
XP_573211       DLLRAMRNKRHHYRELPLEVQETLGSIPDDFVRYFTSRFPHLLSHTYRAMELCRHERLFQ 
NP_076402       DLLRAMRNKKHHYRELPVEVQETLGSIPDDFVRYFTSRFPHLLSHTYQAMELCRHERLFQ 
NP_001424       DLLRAMRNKKHHYRELPAEVRETLGSLPDDFVCYFTSRFPHLLAHTYRAMELCSHERLFQ 
                *********:******* **:*****:***** **********:***:***** ****** 
 
XP_573211       TYYWHEPTEAQPPGIPDAL 
NP_076402       TYYWHEPTEPQPPVIPYAL 
NP_001424       PYYFHEPPEPQPPVTPDAL 
                .**:***.*.***  * ** 
 
Protein sequence alignment – IRE1α 
 
 
Primers used for sequencing of CHO IRE1α are circled. 
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     APPENDIX 2: Sequences obtained by PCR and their position relative to the M. Musculus sequence NM_023913.2 
 
 
Sequence of NM_023913 + CHO sequences where known with reading frame and annotation 
based on best sequences attainable from CHO assembly, sequencing done in this study and 
sequences input into Genbank    
 
 
> ref|NM_023913.2|  Mus musculus endoplasmic reticulum (ER) to nucleus 
signalling  
1 (Ern1), mRNA 
 dbj|AB031332.1|  Mus musculus ire1 alpha mRNA for protein 
kinase/endoribonuclease(IRE1)  
alpha, complete cds 
Length=3976 
 
 GENE ID: 78943 Ern1 | endoplasmic reticulum (ER) to nucleus signalling 1 
[Mus musculus] (Over 10 PubMed links) 
 
 
315-587 
AGCAGGGAAGTTGATGGGCAGAGACTATCTGCAAAGGCCGATGACAAAGTCTGCTGCTTCTCTCCAGTCAGGAGGTCGATAACATAC
CAGATGTCCTGCTTTTTACCCATGTAGAGGATTCCATCTGAACTTCGGCATGGAGATGCTTGGACTAATTCTGGGATGGTAAAGGGA
AGTTTCGTCAGGCCTTCGTTGTTTTTGCCTCCAAGTGTGTACAGACTGCCATCATTGGGATCTGGGGGAAAGCAGGCTCTTCCACGT
GTGTTGGAACCTGCAGGACTGGATCTTCTTTTAAAGTCC 
 
Query  15   AGCAGGGAAGTTGATGGGCAGAGACTATCTGCAAAGGCCGATGACAAAGTCTGCTGCTTC  74 
            || |||||||||||||||||||||||||| |||||||||||||||||||||||||||||| 
Sbjct  587  AGAAGGGAAGTTGATGGGCAGAGACTATCAGCAAAGGCCGATGACAAAGTCTGCTGCTTC  528 
 
Query  75   TCTCCAGTCAGGAGGTCGATAACATACCAGATGTCCTGCTTTTTACCCATGTAGAGGATT  134 
            || |||||||||||||||||||||||||| || || |||||||||||||||||||||||| 
Sbjct  527  TCGCCAGTCAGGAGGTCGATAACATACCAAATATCTTGCTTTTTACCCATGTAGAGGATT  468 
 
Query  135  CCATCTGAACTTCGGCATGGAGATGCTTGGACTAATTCTGGGATGGTAAAGGGAAGTTTC  194 
            |||||||||||||||||||| || || || || ||||||||||||||||||||||||||| 
Sbjct  467  CCATCTGAACTTCGGCATGGGGAGGCCTGAACCAATTCTGGGATGGTAAAGGGAAGTTTC  408 
 
Query  195  GTCAGGCCTTCGTTGTTTTTGCCTCCAAGTGTGTACAGACTGCCATCATTGGGATCTGGG  254 
            ||||||||||||||||| |||||||||||||||||||||||||||||||||||||||||| 
Sbjct  407  GTCAGGCCTTCGTTGTTCTTGCCTCCAAGTGTGTACAGACTGCCATCATTGGGATCTGGG  348 
 
Query  255  AGGAAAGCAGGCTCTTCCACGTGTGTTGGAACCTGCAGGACTGGATCTTCTTTTAAAGTC  314 
            |||||||| |||||||||||||||||||| |||||||||||||||||||||||||||||| 
Sbjct  347  AGGAAAGCCGGCTCTTCCACGTGTGTTGGGACCTGCAGGACTGGATCTTCTTTTAAAGTC  288 
 
Query  315  C  315 
 
 
405-1117 
 
CTCCTTNGTCTTCAANGGGTGGACACCAATCCTGNTCTGAGGGACCTTCCAGCAAAGGAAGAGTGCTTCCTCGGGGCACTACAGGCA
ACCCCCTCGNTGCACCATTGATGGAGAGGCATAGAGGCTGGTTGAGTACTTCCCAACGTACAGGGTAGGCGTCAGCTTGCTCTTGGC
CTCTGTCTCCTTGGNGAACGGATACTTNAACTTGGTGATGCGCCCCACTTCCCCAGACATGAAGGTCAGGTAGCGGAGAGTCTCCAC
AGCGACGTTGATGTGCATCACCTTTCTCAGGCCCTCCCGCTGCCAGACATAGAAGGCTACCACAGGAGAGGCATAGTTTTGGATCCA
CAAGACATCCCCAGAATCACTGTCCACAGTTACCACTAGTCCATCGCCATTGGACACAAAGTGGGACATCTT 
 290 
 
GTAGTCCACATCATCCTCGGGCAGTGAGGCTGCATAGTCAAAATAGGTGGCGTTCCAACGAAGTTCTCGGGTCTTGGTGTCATACAT
AGTGATGGTATATTCTGTCCGTCCAAGATACAGCAGGGAAGTTGATGGGCAGAGACTATCTGCAAAGGCCGATGACAAAGTCTGCTG
CTTCTCTCCAGTCAGGAGGTCGATAACATACCANATGTCCTGCTTTTTACCCATGTAGAGGATTCCATCTGAACTTCGGCATGGAGA
TGCTTGGACTAATTCTGGGATGGTAAAGGGAAGTTTCNTCAGGCCTTCNTTGTTTTTGCCTCCAANTGTGTACAGACTGCCATCATT
GGGATCTGGGAN 
 
Query  12    CTCCTTNGTCTTCAANGGGTGGACACCAATCCTGNTCTGAGGGACCTTCCAGCAAAGGAA  71 
             |||||| |||| ||| ||   ||| |||   ||| |||| ||| |||||||||||||||| 
Sbjct  1117  CTCCTTTGTCTCCAATGGT--GACGCCAT--CTG-TCTGGGGG-CCTTCCAGCAAAGGAA  1064 
 
Query  72    GAGTGCTTCCTCGGGGCACTACAGGCAACCCCCTCGNTGCACCATTGATGGAGAGGCATA  131 
             ||||||| ||||| ||||| |||| ||||||||||  ||||||||||| ||||||||||| 
Sbjct  1063  GAGTGCTGCCTCGAGGCACGACAG-CAACCCCCTC-ATGCACCATTGAGGGAGAGGCATA  1006 
 
Query  132   GAGGCTGGTTGAGTACTTCCCAACGTACAGGGTAGGCGTCAGCTTGCTCTTGGCCTCTGT  191 
             ||||||||| || ||||||||||| ||||| |||||||| |||||||||||||||||||| 
Sbjct  1005  GAGGCTGGTGGAATACTTCCCAACATACAGAGTAGGCGTTAGCTTGCTCTTGGCCTCTGT  946 
 
Query  192   CTCCTTGGNGAACGGATACTTNAACTTGGTGATGCGCCCCACTTCCCCAGACATGAAGGT  251 
             |||||||| ||| ||||||||  ||||||||||||||||||||||||||||||||||||| 
Sbjct  945   CTCCTTGGGGAATGGATACTTCCACTTGGTGATGCGCCCCACTTCCCCAGACATGAAGGT  886 
 
Query  252   CAGGTAGCGGAGAGTCTCCACAGCGACGTTGATGTGCATCACCTTTCTCAGGCCCTCCCG  311 
             || |||||| |||||||||||||| ||||||||||||| ||||||||||||| ||||||  
Sbjct  885   CAAGTAGCGTAGAGTCTCCACAGCAACGTTGATGTGCACCACCTTTCTCAGGACCTCCCC  826 
 
Query  312   CTGCCAGACATAGAAGGCTACCACAGGAGAGGCATAGTTTTGGATCCACAAGACATCCCC  371 
             ||||||||| |||||||| ||||||||||||||||||||||||||||||| ||||||||| 
Sbjct  825   CTGCCAGACGTAGAAGGCCACCACAGGAGAGGCATAGTTTTGGATCCACAGGACATCCCC  766 
 
Query  372   AGAATCACTGTCCACAGTTACCACTAGTCCATCGCCATTGGACACAAAGTGGGACATCTT  431 
             ||| |||||||||||||||||||| ||||||||||||||||||||||||||||||||||| 
Sbjct  765   AGATTCACTGTCCACAGTTACCACCAGTCCATCGCCATTGGACACAAAGTGGGACATCTT  706 
 
Query  432   GTAGTCCACATCATCCTCGGGCAGTGAGGCTGCATAGTCAAAATAGGTGGCGTTCCAACG  491 
             ||||||||| || || || |||||||||||||||||||||||||||||||| ||||| || 
Sbjct  705   GTAGTCCACGTCGTCTTCCGGCAGTGAGGCTGCATAGTCAAAATAGGTGGCATTCCAGCG  646 
 
Query  492   AAGTTCTCGGGTCTTGGTGTCATACATAGTGATGGTATATTCTGTCCGTCCAAGATACAG  551 
              || || |||||||||||||||||||| |||||||| |||||||||||||||||||| || 
Sbjct  645   GAGCTCCCGGGTCTTGGTGTCATACATGGTGATGGTGTATTCTGTCCGTCCAAGATATAG  586 
 
Query  552   CAGGGAAGTTGATGGGCAGAGACTATCTGCAAAGGCCGATGACAAAGTCTGCTGCTTCTC  611 
              |||||||||||||||||||||||||| |||||||||||||||||||||||||||||||| 
Sbjct  585   AAGGGAAGTTGATGGGCAGAGACTATCAGCAAAGGCCGATGACAAAGTCTGCTGCTTCTC  526 
 
Query  612   TCCAGTCAGGAGGTCGATAACATACCANATGTCCTGCTTTTTACCCATGTAGAGGATTCC  671 
              |||||||||||||||||||||||||| || || |||||||||||||||||||||||||| 
Sbjct  525   GCCAGTCAGGAGGTCGATAACATACCAAATATCTTGCTTTTTACCCATGTAGAGGATTCC  466 
 
Query  672   ATCTGAACTTCGGCATGGAGATGCTTGGACTAATTCTGGGATGGTAAAGGGAAGTTTCNT  731 
             |||||||||||||||||| || || || || ||||||||||||||||||||||||||| | 
Sbjct  465   ATCTGAACTTCGGCATGGGGAGGCCTGAACCAATTCTGGGATGGTAAAGGGAAGTTTCGT  406 
 
Query  732   CAGGCCTTCNTTGTTTTTGCCTCCAANTGTGTACAGACTGCCATCATTGGGATCTGGGAN  791 
             ||||||||| ||||| |||||||||| ||||||||||||||||||||||||||||||||  
Sbjct  405   CAGGCCTTCGTTGTTCTTGCCTCCAAGTGTGTACAGACTGCCATCATTGGGATCTGGGAG  346 
 
 
 
683-1320 
 291 
 
GCCAGCTTCTCTTCCACGTCCTGAGACACAGTGGATGGTGTGTTTTCTGAAGTCTGGTCAACCATGTTGATAACTTTCTCAAAGCTC
CTTTTTTCCGAATCAGCAGGAATCACATTTTCCCGATGTTTGGGCAGGTTGTTGGGGAATCTCTCCAGCATCTTGGTAGATGCAGAC
AGAGGAGTTTCATGGTGTCCTATGAGAAGCCAGTAATTCCTCAAGTAGTTCAGCTTGCTCTTCCCTTTGAGTCCAGGGTCAAACTTG
AGGTCTGTGCTGGGGGTGATCACACACTCTCCTTTGTCTTCAATGGTGACACCATCTGTCTGGGGACCTTCCAGCAAAGGAAGAGTG
CTTCCTCGGGGCACTACAGCAACCCCCTCGTGCACCATTGATGGAGAGGCATAGAGGCTGGTTGAGTACTTC 
ACTACAGCAACCCCCTCGTGCACCATTGATGGAGAGGCATAGAGGCTGGTTGAGTACTTCCCAACGTACAGGGTAGGCGTTAGCTTG
CTCTTGGCCTCTGTCTCCTTGGGGAACGGATACACAGCGACGTTGATGTGCATCACCTTTCTCAGGCCCTCCCGCTGCCAGACATAG
AAGGCTACCACAGGAGAGGCATAATTCTGGATCCACAGCACGTC  
 
                                                    
Query  41    GCCAGCTTCTCTTCCACGTCCTGAGACACAGTGGATGGTGTGTTTTCTGAAGTCTGGTCA  100 
             || |||||||| ||||| |||||||| || ||||  |||||||| |||||||||||| || 
Sbjct  1320  GCGAGCTTCTCCTCCACATCCTGAGATACGGTGGTCGGTGTGTTGTCTGAAGTCTGGCCA  1261 
 
Query  101   ACCATGTTGATAACTTTCTCAAAGCTCCTTTTTTCCGAATCAGCAGGAATCACATTTTCC  160 
             || ||||||||||||| |||||||||||||||||| |||||||||||||||||||||||  
Sbjct  1260  ACTATGTTGATAACTTCCTCAAAGCTCCTTTTTTCTGAATCAGCAGGAATCACATTTTCT  1201 
 
Query  161   CGATGTTTGGGCAGGTTGTTGGGGAATCTCTCCAGCATCTTGGTAGATGCAGACAGAGGA  220 
             |||||||||||||||||||| || |||||||||||||||||||| ||||||||||||||| 
Sbjct  1200  CGATGTTTGGGCAGGTTGTTAGGAAATCTCTCCAGCATCTTGGTGGATGCAGACAGAGGA  1141 
 
Query  221   GTTTCATGGTGTCCTATGAGAAGCCAGTAATTCCTCAAGTAGTTCAGCTTGCTCTTCCCT  280 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1140  GTTTCATGGTGTCCTATGAGAAGCCAGTAATTCCTCAAGTAGTTCAGCTTGCTCTTCCCT  1081 
 
Query  281   TTGAGTCCAGGGTCAAACTTGAGGTCTGTGCTGGGGGTGATCACACACTCTCCTTTGTCT  340 
             ||||||||||||||||||||||||||||||||||| |||||||||||||||||||||||| 
Sbjct  1080  TTGAGTCCAGGGTCAAACTTGAGGTCTGTGCTGGGAGTGATCACACACTCTCCTTTGTCT  1021 
 
Query  341   TCAATGGTGACACCATCTGTCTGGGGACCTTCCAGCAAAGGAAGAGTGCTTCCTCGGGGC  400 
              |||||||||| |||||||||||||| ||||||||||||||||||||||| ||||| ||| 
Sbjct  1020  CCAATGGTGACGCCATCTGTCTGGGGGCCTTCCAGCAAAGGAAGAGTGCTGCCTCGAGGC  961 
 
Query  401   ACTACAGCAACCCCCTCGTGCACCATTGATGGAGAGGCATAGAGGCTGGTTGAGTACTTC  460 
             || |||||||||||||| ||||||||||| |||||||||||||||||||| || |||||| 
Sbjct  960   ACGACAGCAACCCCCTCATGCACCATTGAGGGAGAGGCATAGAGGCTGGTGGAATACTTC  901 
 
Query  461   CCAACGTACAGGGTAGGCGTTAGCTTGCTCTTGGCCTCTGTCTCCTTGGGGAACGGATAC  520 
             ||||| ||||| ||||||||||||||||||||||||||||||||||||||||| |||||| 
Sbjct  900   CCAACATACAGAGTAGGCGTTAGCTTGCTCTTGGCCTCTGTCTCCTTGGGGAATGGATAC  841 
 
Query  521   TTCCACTTGGTGATGCGCCCCACTTCCCCAGACATGAAGGTCAGGTAGCGGAGAGTCTCC  580 
             ||||||||||||||||||||||||||||||||||||||||||| |||||| ||||||||| 
Sbjct  840   TTCCACTTGGTGATGCGCCCCACTTCCCCAGACATGAAGGTCAAGTAGCGTAGAGTCTCC  781 
 
Query  581   ACAGCGACGTTGATGTGCATCACCTTTCTCAGGCCCTCCCGCTGCCAGACATAGAAGGCT  640 
             ||||| ||||||||||||| ||||||||||||| |||||| ||||||||| ||||||||  
Sbjct  780   ACAGCAACGTTGATGTGCACCACCTTTCTCAGGACCTCCCCCTGCCAGACGTAGAAGGCC  721 
 
Query  641   ACCACAGGAGAGGCATAATTCTGGATCCACAGCACGTC  678 
             ||||||||||||||||| || ||||||||||| || || 
Sbjct  720   ACCACAGGAGAGGCATAGTTTTGGATCCACAGGACATC  683 
 
 
888-1782 
CTTCATGTCTGGGGAAGTGGGGCGCATCACCAAGTGGAAGTATCCGTTCCCCAAGGAGACAGAGGCCAAGAGCAAGCTGACGCCTAC
CCTGTACGTTGGGAAGTACTCAACCAGCCTCTATGCCTCTCCATCAATGGTGCACGAGGGGGTTGCTGTAGTGCCCCGAGGAAGCAC
TCTTCCTTTGCTGGAAGGTCCCCAGACAGATGGTGTCACCATTGAAGACAAAGGAGAGTGTGTGATCACCCCCAGCACAGACCTCAA
GTTTGACCCTGGACTCAAAGGGAAGAGCAAGCTGAACTACTTGAGGAATTACTGGCTTCTCATAGGACACCATGAAACTCCTCTGTC
TGCATCTACCAAGATGCTGGAGAGATTCCCCAACAACCTGCCCAAACATCGGGAAAATGTGATTCCTGCTGA 
 292 
 
TTCGGAAAAAAGGAGCTTTGAGAAAGTTATCAACATGGTTGACCAGACTTCAGAAAACACACCATCCACTGTGTCTCAGGCCGTGGA
AGAGAAGCTGGTCCATGCCCCCGCCAAGCCTGAGGCCCCCGTTGACTCCATGCTCAAGGACATGGCTACTATTATCCTGAGCACCTT
CCTGCTGGTTGGATGGGTGGCCTTCATCATCACTTACCCCCTGAGCATGCATCAGCAGCGCCAGCTGGTTGGATGGGTGGCCTTCAT
CATCACTTACCCCCTGAGCATGCATCAGCAGCGCCAGCTCCAGCACCAGCAGTTCCAGAAGGAACTGGAGAAAATTCAGCTCCTGCA
GCAGCAGCAGCTGCCCTTCCACCCACATGGAGACCTTACTCAGGACCCCGAGTTTCTGGATTCATCTGGTCT 
CTTCTCAGAGAGCTCAGGCACCAGCAGCTCCAGCCCATCCCCCAGAGCCTCCAACCACTCACTCCACTCCAGCAGCTCTGCCTCCAA
GACTGGCACCAACCCTTCCCTGGAGCAG 
 
 
Query  53    CTTCATGTCTGGGGAAGTGGGGCGCATCACCAAGTGGAAGTATCCGTTCCCCAAGGAGAC  112 
             ||||||||||||||||||||||||||||||||||||||||||||| |||||||||||||| 
Sbjct  888   CTTCATGTCTGGGGAAGTGGGGCGCATCACCAAGTGGAAGTATCCATTCCCCAAGGAGAC  947 
 
Query  113   AGAGGCCAAGAGCAAGCTGACGCCTACCCTGTACGTTGGGAAGTACTCAACCAGCCTCTA  172 
             |||||||||||||||||| |||||||| ||||| ||||||||||| || ||||||||||| 
Sbjct  948   AGAGGCCAAGAGCAAGCTAACGCCTACTCTGTATGTTGGGAAGTATTCCACCAGCCTCTA  1007 
 
Query  173   TGCCTCTCCATCAATGGTGCACGAGGGGGTTGCTGTAGTGCCCCGAGGAAGCACTCTTCC  232 
             ||||||||| ||||||||||| |||||||||||||| ||||| ||||| ||||||||||| 
Sbjct  1008  TGCCTCTCCCTCAATGGTGCATGAGGGGGTTGCTGTCGTGCCTCGAGGCAGCACTCTTCC  1067 
 
Query  233   TTTGCTGGAAGGTCCCCAGACAGATGGTGTCACCATTGAAGACAAAGGAGAGTGTGTGAT  292 
             |||||||||||| |||||||||||||| |||||||||| ||||||||||||||||||||| 
Sbjct  1068  TTTGCTGGAAGGCCCCCAGACAGATGGCGTCACCATTGGAGACAAAGGAGAGTGTGTGAT  1127 
 
Query  293   CACCCCCAGCACAGACCTCAAGTTTGACCCTGGACTCAAAGGGAAGAGCAAGCTGAACTA  352 
             ||| |||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1128  CACTCCCAGCACAGACCTCAAGTTTGACCCTGGACTCAAAGGGAAGAGCAAGCTGAACTA  1187 
 
Query  353   CTTGAGGAATTACTGGCTTCTCATAGGACACCATGAAACTCCTCTGTCTGCATCTACCAA  412 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||| ||||| 
Sbjct  1188  CTTGAGGAATTACTGGCTTCTCATAGGACACCATGAAACTCCTCTGTCTGCATCCACCAA  1247 
 
Query  413   GATGCTGGAGAGATTCCCCAACAACCTGCCCAAACATCGGGAAAATGTGATTCCTGCTGA  472 
             ||||||||||||||| || |||||||||||||||||||| |||||||||||||||||||| 
Sbjct  1248  GATGCTGGAGAGATTTCCTAACAACCTGCCCAAACATCGAGAAAATGTGATTCCTGCTGA  1307 
 
Query  473   TTCGGAAAAAAGGAGCTTTGAGAAAGTTATCAACATGGTTGACCAGACTTCAGAAAACAC  532 
             ||| |||||||||||||||||| ||||||||||||| |||| |||||||||||| ||||| 
Sbjct  1308  TTCAGAAAAAAGGAGCTTTGAGGAAGTTATCAACATAGTTGGCCAGACTTCAGACAACAC  1367 
 
Query  533   ACCATCCACTGTGTCTCAGGCCGTGGAAGAGAAGCTGGTCCATGCCCCCGCCAAGCCTGA  592 
             |||  |||| || |||||||  ||||| |||||||| |  |  ||||| ||||||||||| 
Sbjct  1368  ACCGACCACCGTATCTCAGGATGTGGAGGAGAAGCTCGCTCGCGCCCCTGCCAAGCCTGA  1427 
 
Query  593   GGCCCCCGTTGACTCCATGCTCAAGGACATGGCTACTATTATCCTGAGCACCTTCCTGCT  652 
             ||||||||| |||||||||||||||||||||||||| ||||||||||||||||||||||| 
Sbjct  1428  GGCCCCCGTGGACTCCATGCTCAAGGACATGGCTACCATTATCCTGAGCACCTTCCTGCT  1487 
 
Query  653   GGTTGGATGGGTGGCCTTCATCATCACTTACCCCCTGAGCATGCATCAGCAGCGCCAGCT  712 
             ||||||||||||||| |||||||||||||||||||||||| ||||||||||||| ||||| 
Sbjct  1488  GGTTGGATGGGTGGCGTTCATCATCACTTACCCCCTGAGCGTGCATCAGCAGCGTCAGCT  1547 
 
Query  713   CCAGCACCAGCAGTTCCAGAAGGAACTGGAGAAAATTCAGCTCCTGCAGCAGCAGCAGCT  772 
             ||||||||| |||||||||||||| |||||||| |||||||||||||||||||||||||| 
Sbjct  1548  CCAGCACCAACAGTTCCAGAAGGAGCTGGAGAAGATTCAGCTCCTGCAGCAGCAGCAGCT  1607 
 
Query  773   GCCCTTCCACCCACATGGAGACCTTACTCAGGACCCCGAGTTTCTGGATTCATCTGGTCT  832 
             ||||||||||||||| ||||||||||| |||||||| ||||| |||||||||||||| |  
Sbjct  1608  GCCCTTCCACCCACACGGAGACCTTACCCAGGACCCTGAGTTCCTGGATTCATCTGGCCC  1667 
 
 293 
 
Query  833   CTTCTCAGAGAGCTCAGGCACCAGCAGCTCCAGCCCATCCCCCAGAGCCTCCAACCACTC  892 
             ||||||||||||||| |||||||||||| ||||||||||||||||||||||||||||||| 
Sbjct  1668  CTTCTCAGAGAGCTCTGGCACCAGCAGCCCCAGCCCATCCCCCAGAGCCTCCAACCACTC  1727 
 
Query  893   ACTCCACTCCAGCAGCTCTGCCTCCAAGACTGGCACCAACCCTTCCCTGGAGCAG  947 
              |||||| |||||||||||||||||| | | ||||||| ||| || ||||||||| 
Sbjct  1728  CCTCCACCCCAGCAGCTCTGCCTCCAGGGCCGGCACCAGCCCCTCTCTGGAGCAG  1782 
 
 
1322 - 2221 
 
CGTTTNNCATGGAGAGGAGAATGTTGTGGGGTTTCAGGTCTCTGTGAACTATGTTGAGAGAGTGCAGGTGTGCCAGGCCTGAGGTGG
TCTGCTGAAGCAAGGTGATGGGCTCCAGGCCAAGGTGGGCAAAGTCCTTCTGCTCCACATACTCTTGCAGAGTGGCTGCACACAATT
CAATAGCAATGTATTGGAACTGCCGGTCCTTCTCTGTGCAAAAGTAGCGGATCACGTTTGGATGCTCGTCTGATTCTCGAAGCAGCT
GGACCTCACGGTCTGCAAAGCTAAAACACTCAGGGAGGATCCTCTTCACTGCCACATCACGGTTGTCAAACATGCCTTTGTATACAA
TTGTGCCCTCAGCTCCATGGCCCAGGACATCCTTGGGGCAGAATGAAATTTTCCCAACAATCACCATTCTAG 
TTTCCTCATCCTCATCATCCTGCTCCAGGGAAGGGTTGGTGCCAGTCTTGGAGGCAGAGCTGCTGGAGTGGAGTGAGTGGTTGGAGG
CTCTGGGGGATGGGCTGGAGCTGCTGGTGCCTGAGCTCTCTGAGAAGAGACCAGATGAATCCAGAAACTCGGGGTCCTGAGTAAGGT
CTCCATGTGGGTGGAAGGGCAGCTGCTGTTGCTGCAGGAGCTGAATTTTCTCCAGTTCCTTCTGGAACTGCTGGTGCTGGAGCTGGC
GCTGCTGATGCATGCTCAGGGGGTAAGTGATGATGAAGGCCACCCATCCAACCAGCANGAAGGTGCTCAGGATAATAGTAGCCATGT
CCTTGAGCATGGAGTCAACGGGGGCCTCAGGCTTGGCGGGGGCATGGNCCAGCTTCTCTTCCACGGCCTGAG 
ACACAGTGGATGGCGTGTTTTCTGAAGTCTGGTCAACCATGTTTGATAACTTTCTCAAAGCTCNTTTTTTCCGAATCAGCAG        
 
Query  1     CGTTTNNCATGGAGAGGAGAATGTTGTGGGGTTTCAGGTCTCTGTGAACTATGTTGAGAG  60 
             ||||   |||||||||||||||||||||||| ||||||||||||||||| |||||||||| 
Sbjct  2221  CGTTGGGCATGGAGAGGAGAATGTTGTGGGGCTTCAGGTCTCTGTGAACAATGTTGAGAG  2162 
 
Query  61    AGTGCAGGTGTGCCAGGCCTGAGGTGGTCTGCTGAAGCAAGGTGATGGGCTCCAGGCCAA  120 
             | ||||||||||||||||||||||||||||| ||||||| |||||||||||| ||||||| 
Sbjct  2161  AATGCAGGTGTGCCAGGCCTGAGGTGGTCTGATGAAGCAGGGTGATGGGCTCGAGGCCAA  2102 
 
Query  121   GGTGGGCAAAGTCCTTCTGCTCCACATACTCTTGCAGAGTGGCTGCACACAATTCAATAG  180 
             |||||||||||||||||||||||||||||||||| || |||||||||||||  || |||| 
Sbjct  2101  GGTGGGCAAAGTCCTTCTGCTCCACATACTCTTGTAGGGTGGCTGCACACAGCTCGATAG  2042 
 
Query  181   CAATGTATTGGAACTGCCGGTCCTTCTCTGTGCAAAAGTAGCGGATCACGTTTGGATGCT  240 
             ||||||| ||||||||||||||||||||||||||||||||||||||||| ||||| |||| 
Sbjct  2041  CAATGTACTGGAACTGCCGGTCCTTCTCTGTGCAAAAGTAGCGGATCACATTTGGGTGCT  1982 
 
Query  241   CGTCTGATTCTCGAAGCAGCTGGACCTCACGGTCTGCAAAGCTAAAACACTCAGGGAGGA  300 
             |||||||||||||||||||||||||||||||||| ||||||||||||||||||||||||| 
Sbjct  1981  CGTCTGATTCTCGAAGCAGCTGGACCTCACGGTCGGCAAAGCTAAAACACTCAGGGAGGA  1922 
 
Query  301   TCCTCTTCACTGCCACATCACGGTTGTCAAACATGCCTTTGTATACAATTGTGCCCTCAG  360 
             |||||||||| |||||||| |||||||||||||| ||||||||||||||||||||||||| 
Sbjct  1921  TCCTCTTCACGGCCACATCTCGGTTGTCAAACATACCTTTGTATACAATTGTGCCCTCAG  1862 
 
Query  361   CTCCATGGCCCAGGACATCCTTGGGGCAGAATGAAATTTTCCCAACAATCACCATTCTAG  420 
             ||||||| |||||||||||||||||||||||||||||||||||||||||||||||||| | 
Sbjct  1861  CTCCATGACCCAGGACATCCTTGGGGCAGAATGAAATTTTCCCAACAATCACCATTCTGG  1802 
 
Query  421   TTTCCTCATCCTCATCATCCTGCTCCAGGGAAGGGTTGGTGCCAGTCTTGGAGGCAGAGC  480 
             |||||||||||||||||||||||||||| || ||| ||||||| | | |||||||||||| 
Sbjct  1801  TTTCCTCATCCTCATCATCCTGCTCCAGAGAGGGGCTGGTGCCGGCCCTGGAGGCAGAGC  1742 
 
Query  481   TGCTGGAGTGGAGTGAGTGGTTGGAGGCTCTGGGGGATGGGCTGGAGCTGCTGGTGCCTG  540 
             |||||| |||||| ||||||||||||||||||||||||||||||| |||||||||||| | 
Sbjct  1741  TGCTGGGGTGGAGGGAGTGGTTGGAGGCTCTGGGGGATGGGCTGGGGCTGCTGGTGCCAG  1682 
 
Query  541   AGCTCTCTGAGAAGAGACCAGATGAATCCAGAAACTCGGGGTCCTGAGTAAGGTCTCCAT  600 
             |||||||||||||| | |||||||||||||| ||||| |||||||| ||||||||||| | 
 294 
 
Sbjct  1681  AGCTCTCTGAGAAGGGGCCAGATGAATCCAGGAACTCAGGGTCCTGGGTAAGGTCTCCGT  1622 
 
Query  601   GTGGGTGGAAGGGCAGCTGCTGTTGCTGCAGGAGCTGAATTTTCTCCAGTTCCTTCTGGA  660 
             |||||||||||||||||||||| ||||||||||||||||| |||||||| |||||||||| 
Sbjct  1621  GTGGGTGGAAGGGCAGCTGCTGCTGCTGCAGGAGCTGAATCTTCTCCAGCTCCTTCTGGA  1562 
 
Query  661   ACTGCTGGTGCTGGAGCTGGCGCTGCTGATGCATGCTCAGGGGGTAAGTGATGATGAAGG  720 
             |||| |||||||||||||| ||||||||||||| |||||||||||||||||||||||| | 
Sbjct  1561  ACTGTTGGTGCTGGAGCTGACGCTGCTGATGCACGCTCAGGGGGTAAGTGATGATGAACG  1502 
 
Query  721   CCACCCATCCAACCAGCANGAAGGTGCTCAGGATAATAGTAGCCATGTCCTTGAGCATGG  780 
             |||||||||||||||||| |||||||||||||||||| |||||||||||||||||||||| 
Sbjct  1501  CCACCCATCCAACCAGCAGGAAGGTGCTCAGGATAATGGTAGCCATGTCCTTGAGCATGG  1442 
 
Query  781   AGTCAACGGGGGCCTCAGGCTTGGCGGGGGCATGGNCCAGCTTCTCTTCCACGGCCTGAG  840 
             |||| |||||||||||||||||||| |||||  |  | |||||||| |||||  |||||| 
Sbjct  1441  AGTCCACGGGGGCCTCAGGCTTGGCAGGGGCGCGAGCGAGCTTCTCCTCCACATCCTGAG  1382 
 
Query  841   ACACAGTGGATGGCGTGTTTTCTGAAGTCTGGTCAACCATGTTTGATAACTTTCTCAAAG  900 
             | || ||||  || ||||| |||||||||||| |||| ||| |||||||||| ||||||| 
Sbjct  1381  ATACGGTGGTCGGTGTGTTGTCTGAAGTCTGGCCAACTATG-TTGATAACTTCCTCAAAG  1323 
 
Query  901   CTCNTTTTTTCCGAATCAGCAG  922 
             ||| ||||||| |||||||||| 
Sbjct  1322  CTCCTTTTTTCTGAATCAGCAG  1301 
 
 
2125-2665 
 
CTTCACCAGACCACCTCCGGGTTGGCCCACCTCCACTCCCTCAACATCGTTCACAGAGACCTAAAGCCACACAACATCCTCATATCC
ATGCCCAATGCACACGGCAAGATCAAGGCCATGATATCCGCCTTTGGCCTCTGCAAGAAGCTGGCAGTGGGCAGACACAGTTTCAGC
CGCCGATCTGGGGTGCCTGGCACAGAAGGCTGGATCGCTCCAGAGATGCTGAGCGAAGACTGTAAGGAGAACCCTACCTACACGGTG
GACATCTTTTCTGCAGGCTGCGTCTTTTACTACGTAATCTCTGAGGGCAGCCACCCTTTTGGCAAGTCCCTGCAGCGGCAGGCCAAC
ATCCTCCTGGGTGCCTGCAGCCTTGACTGCTTGCACCCAGAGAAGCACGAAGACGTCATTGCACGTGAATTG 
ATAGAGAAGATGATTGCGATGGATCCTCAGAAACGCCCCTCAGCGAAGCACGTGCTCAGACACCCGTTCTTCTGGAGCCTAGAGAAG
CAGCTCCAGTTCTTCCAGGACGTGAGCGACAGAATAGAAAAGGAATCCCTGGACGGCCCGATCGTGAGGCAGCTGGA 
 
 
Query  41    CTTCACCAGACCACCTCCGGGTTGGCCCACCTCCACTCCCTCAACATCGTTCACAGAGAC  100 
             ||||| ||||||||||| ||  |||| ||||| || || |||||||| |||||||||||| 
Sbjct  2125  CTTCATCAGACCACCTCAGGCCTGGCACACCTGCATTCTCTCAACATTGTTCACAGAGAC  2184 
 
Query  101   CTAAAGCCACACAACATCCTCATATCCATGCCCAATGCACACGGCAAGATCAAGGCCATG  160 
             || ||||| |||||||| ||| | ||||||||||| ||||| |||| ||||||||| ||| 
Sbjct  2185  CTGAAGCCCCACAACATTCTCCTCTCCATGCCCAACGCACATGGCAGGATCAAGGCGATG  2244 
 
Query  161   ATATCCGCCTTTGGCCTCTGCAAGAAGCTGGCAGTGGGCAGACACAGTTTCAGCCGCCGA  220  < 
             || || | ||||||||||||||||||||||||||||||||| |||||||||||||||||  
Sbjct  2245  ATCTCTGACTTTGGCCTCTGCAAGAAGCTGGCAGTGGGCAGGCACAGTTTCAGCCGCCGT  2304 
 
Query  221   TCTGGGGTGCCTGGCACAGAAGGCTGGATCGCTCCAGAGATGCTGAGCGAAGACTGTAAG  280 
             || ||||| |||||||| ||||| |||||||| |||||||||||||| |||||||||||| 
Sbjct  2305  TCAGGGGTACCTGGCACTGAAGGGTGGATCGCCCCAGAGATGCTGAGTGAAGACTGTAAG  2364 
 
Query  281   GAGAACCCTACCTACACGGTGGACATCTTTTCTGCAGGCTGCGTCTTTTACTACGTAATC  340 
             || |||||||||||||||||||||||||||||||||||||| ||||||||||| || ||| 
Sbjct  2365  GACAACCCTACCTACACGGTGGACATCTTTTCTGCAGGCTGTGTCTTTTACTATGTCATC  2424 
 
Query  341   TCTGAGGGCAGCCACCCTTTTGGCAAGTCCCTGCAGCGGCAGGCCAACATCCTCCTGGGT  400 
             |||||||||| ||| ||||||||||| ||| ||||||||||||||||||||||||||||  
Sbjct  2425  TCTGAGGGCAACCATCCTTTTGGCAAATCCTTGCAGCGGCAGGCCAACATCCTCCTGGGC  2484 
 295 
 
 
Query  401   GCCTGCAGCCTTGACTGCTTGCACCCAGAGAAGCACGAAGACGTCATTGCACGTGAATTG  460 
             ||||||| ||||||||| || ||| |||| ||||| || ||||||||||| ||||||||| 
Sbjct  2485  GCCTGCAACCTTGACTGTTTCCACTCAGACAAGCATGAGGACGTCATTGCTCGTGAATTG  2544 
 
Query  461   ATAGAGAAGATGATTGCGATGGATCCTCAGAAACGCCCCTCAGCGAAGCACGTGCTCAGA  520 
             |||||||| |||||||| |||||||| ||| | || ||||| || ||||||||||| | | 
Sbjct  2545  ATAGAGAAAATGATTGCTATGGATCCCCAGCAGCGTCCCTCTGCAAAGCACGTGCTGAAA  2604 
 
Query  521   CACCCGTTCTTCTGGAGCCTAGAGAAGCAGCTCCAGTTCTTCCAGGACGTGAGCGACAGA  580 
             ||||| |||||||||||||| ||||||||||||||||| |||||||| || || ||| || 
Sbjct  2605  CACCCCTTCTTCTGGAGCCTGGAGAAGCAGCTCCAGTTTTTCCAGGATGTAAGTGACCGA  2664 
 
Query  581   ATAGAAAAGGAATCCCTGGACGGCCCGATCGTGAGGCAGCTGGA  624 
             |||||||||||  || ||||||| || |||||  ||||| |||| 
Sbjct  2665  ATAGAAAAGGAGGCCTTGGACGGTCCAATCGTACGGCAGTTGGA  2708 
 
 
2245-2665 
ATATCCGCCTTTGGCCTCTGCAAGAAGCTGGCAGTGGGCAGACACAGTTTCAGCCGCCGATCTGGGGTGCCTGGCACAGAAGGCTGG
ATCGCTCCAGAGATGCTGAGCGAAGACTGTAAGGAGAACCCTACCTACACGGTGGACATCTTTTCTGCAGGCTGCGTCTTTTACTAC
GTAATCTCTGAGGGCAGCCACCCTTTTGGCAAGTCCCTGCAGCGGCAGGCCAACATCCTCCTGGGTGCCTGCAGCCTTGACTGCTTG
CACCCAGAGAAGCACGAAGACGTCATTGCACGTGAATTGATAGAGAAGATGATTGCGATGGATCCTCAGAAACGCCCCTCAGCGAAG
CACGTGCTCAGACACCCGTTCTTCTGGAGCCTAGAGAAGCAGCTCCAGTTCTTCCAGGACGTGAGCGACAGA 
ATAGAAAAGGAATCCCTGGACGGCCCGATCGTGAGGCAGCTGGA 
Query  161   ATATCCGCCTTTGGCCTCTGCAAGAAGCTGGCAGTGGGCAGACACAGTTTCAGCCGCCGA  220 
             || || | ||||||||||||||||||||||||||||||||| |||||||||||||||||  
Sbjct  2245  ATCTCTGACTTTGGCCTCTGCAAGAAGCTGGCAGTGGGCAGGCACAGTTTCAGCCGCCGT  2304 
 
Query  221   TCTGGGGTGCCTGGCACAGAAGGCTGGATCGCTCCAGAGATGCTGAGCGAAGACTGTAAG  280 
             || ||||| |||||||| ||||| |||||||| |||||||||||||| |||||||||||| 
Sbjct  2305  TCAGGGGTACCTGGCACTGAAGGGTGGATCGCCCCAGAGATGCTGAGTGAAGACTGTAAG  2364 
 
Query  281   GAGAACCCTACCTACACGGTGGACATCTTTTCTGCAGGCTGCGTCTTTTACTACGTAATC  340 
             || |||||||||||||||||||||||||||||||||||||| ||||||||||| || ||| 
Sbjct  2365  GACAACCCTACCTACACGGTGGACATCTTTTCTGCAGGCTGTGTCTTTTACTATGTCATC  2424 
 
Query  341   TCTGAGGGCAGCCACCCTTTTGGCAAGTCCCTGCAGCGGCAGGCCAACATCCTCCTGGGT  400 
             |||||||||| ||| ||||||||||| ||| ||||||||||||||||||||||||||||  
Sbjct  2425  TCTGAGGGCAACCATCCTTTTGGCAAATCCTTGCAGCGGCAGGCCAACATCCTCCTGGGC  2484 
 
Query  401   GCCTGCAGCCTTGACTGCTTGCACCCAGAGAAGCACGAAGACGTCATTGCACGTGAATTG  460 
             ||||||| ||||||||| || ||| |||| ||||| || ||||||||||| ||||||||| 
Sbjct  2485  GCCTGCAACCTTGACTGTTTCCACTCAGACAAGCATGAGGACGTCATTGCTCGTGAATTG  2544 
 
Query  461   ATAGAGAAGATGATTGCGATGGATCCTCAGAAACGCCCCTCAGCGAAGCACGTGCTCAGA  520 
             |||||||| |||||||| |||||||| ||| | || ||||| || ||||||||||| | | 
Sbjct  2545  ATAGAGAAAATGATTGCTATGGATCCCCAGCAGCGTCCCTCTGCAAAGCACGTGCTGAAA  2604 
 
Query  521   CACCCGTTCTTCTGGAGCCTAGAGAAGCAGCTCCAGTTCTTCCAGGACGTGAGCGACAGA  580 
             ||||| |||||||||||||| ||||||||||||||||| |||||||| || || ||| || 
Sbjct  2605  CACCCCTTCTTCTGGAGCCTGGAGAAGCAGCTCCAGTTTTTCCAGGATGTAAGTGACCGA  2664 
 
Query  581   ATAGAAAAGGAATCCCTGGACGGCCCGATCGTGAGGCAGCTGGA  624 
             |||||||||||  || ||||||| || |||||  ||||| |||| 
Sbjct  2665  ATAGAAAAGGAGGCCTTGGACGGTCCAATCGTACGGCAGTTGGA  2708 
 
 
2671-2970 
AAGGATCCCTGGGATGGCCCGATCGTGA-
AGCAGTTAGAGAGAGGCGGGAGAGCCGTGGTGAAGATGGACTGGCGGGAGAACATCACTGTCCCCCTCCAGACAGACCTGCGTAAAT
 296 
 
TCAGGACCTATAAAGGTGGTTCTGTCAGAGATCTCCTCCGAGCCATGAGAAATAAGAAGCACCACTACCGGGAGCTGCCTGCAGAGG
TGCGGGAGACGCTGGGGTCCCTCCCCGACGACTTCGTGTGCTACTTCACGTCTCGCTTCCCCCACCTCCTCGCACACACCTACCGGG
CCATGGAGCTGTGCTACTTCACGTCTCGCTTCCCCCACCTCCTCGCACACACCTACCGGGCCATGGAGCTGTGCAGCCACGAGAGAC
TCTTCCAGCCCTACTACTGTCATGANCCCACCGAGCCCCAG 
 
Query  7     AAGGATCCCTGGGATGGCCCGATCGTGA-AGCAGTTAGAGAGAGGCGGGAGAGCCGTGGT  65 
             |||||  ||| ||| || || ||||| |  |||||| ||||||||||||||||| ||||| 
Sbjct  2671  AAGGAGGCCTTGGACGGTCCAATCGT-ACGGCAGTTGGAGAGAGGCGGGAGAGCTGTGGT  2729 
 
Query  66    GAAGATGGACTGGCGGGAGAACATCACTGTCCCCCTCCAGACAGACCTGCGTAAATTCAG  125 
              ||||||||||||||||||||||||||||||||||| |||||||| ||||| |||||||| 
Sbjct  2730  CAAGATGGACTGGCGGGAGAACATCACTGTCCCCCTGCAGACAGATCTGCGCAAATTCAG  2789 
 
Query  126   GACCTATAAAGGTGGTTCTGTCAGAGATCTCCTCCGAGCCATGAGAAATAAGAAGCACCA  185 
              ||||| |||||||| ||||| ||||| |||||||||||||||||||| ||||| ||||| 
Sbjct  2790  AACCTACAAAGGTGGCTCTGTGAGAGACCTCCTCCGAGCCATGAGAAACAAGAAACACCA  2849 
 
Query  186   CTACCGGGAGCTGCCTGCAGAGGTGCGGGAGACGCTGGGGTCCCTCCCCGACGACTTCGT  245 
             |||||||||||| || |  ||||| | |||||||||||| ||| |||| || ||||| || 
Sbjct  2850  CTACCGGGAGCTCCCCGTGGAGGTTCAGGAGACGCTGGGCTCCATCCCGGATGACTTTGT  2909 
 
Query  246   GTGCTACTTCACGTCTCGCTTCCCCCACCTCCTCGCACACACCTACCGGGCCATGGAGCT  305 
             | |||||||||| || |||||||||||||||||| | ||||||||||  ||||||||||| 
Sbjct  2910  GCGCTACTTCACTTCCCGCTTCCCCCACCTCCTCTCTCACACCTACCAAGCCATGGAGCT  2969 
 
Query  306   GTGCAGCCACGAGAGACTCTTCCAGCCCTACTACTGTCATGANCCCACCGAGCCCCAG  363 
             |||||| || ||||||||||| ||| |||||||||| || || ||||| || |||||| 
Sbjct  2970  GTGCAGACATGAGAGACTCTTTCAGACCTACTACTGGCACGAGCCCACAGAACCCCAG  3027 
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APPENDIX 3 – Sequencing results from mutagenesis of IRE1α/β constructs 
Sequences show the relevant section of sequences from the IRE1 plasmid constructs where sequencing reactions showed the mutagenesis to 
have worked correctly and mutagenised both the target amino acids and any additional conservative point mutations required for screening 
clones. Compare to Table 4.1. 1 and Table 4.1. 2 for appropriate sites.  
 
IRE1α 
Plasmid                     Position K599 I642 D711 
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IRE1β 
K547 
 
L590 
 
D659 
 
K855 
 
 
 
